Patent application title: SELECTED REACTION MONITORING ASSAYS
Inventors:
Paul Edward Kearney (Seattle, WA, US)
Paul Edward Kearney (Seattle, WA, US)
Xiao-Jun Li (Bellevue, WA, US)
Xiao-Jun Li (Bellevue, WA, US)
Clive Hayward (Seattle, WA, US)
Clive Hayward (Seattle, WA, US)
Miguel Dominguez Geeraerts (Pierrefonds, CA)
IPC8 Class: AG01N3368FI
USPC Class:
506 12
Class name: Combinatorial chemistry technology: method, library, apparatus method of screening a library by measuring a physical property (e.g., mass, etc.)
Publication date: 2015-11-12
Patent application number: 20150323545
Abstract:
Provided herein are methods for developing selected reaction monitoring
mass spectrometry (LC-SRM-MS) assays.Claims:
1. A composition comprising isolated synthetic peptides said composition
comprising ALQASALK (SEQ ID NO: 58), GFLLLASLR (SEQ ID NO: 1644),
LGGPEAGLGEYLFER (SEQ ID NO: 596), YVSELHLTR (SEQ ID NO: 878), or
YYIAASYVK (SEQ ID NO: 643).
2. A composition comprising at least 10 isolated synthetic peptides said composition comprising at least 2 isolated synthetic peptides of at least 5 proteins selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, KIT, GGH or GSLG1, and wherein the at least two isolated synthetic peptides are selected from ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK (SEQ ID NO: 58), QLLLTADDR (SEQ ID NO: 60), ADHHATNGVVHLIDK (SEQ ID NO: 136), DILATNGVIHYIDELLIPDSAK (SEQ ID NO: 137), LTLLAPLNSVFK (SEQ ID NO: 139), SPYQLVLQHSR (SEQ ID NO: 140), ADDILASPPR (SEQ ID NO: 331), AVGLAGTFR (SEQ ID NO: 332), TEAPSATGQASSLLGGR (SEQ ID NO: 335), GGSTSYGTGSETESPR (SEQ ID NO 554), NSLFEYQK (SEQ ID NO: 556), TVIGPDGHK (SEQ ID NO: 557), VQHIQLLQK (SEQ ID NO: 558), ALFQDIK (SEQ ID NO: 593), DDVALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ ID NO: 595), LGGPEAGLGEYLFER (SEQ ID NO: 596), LNQALLDLHALGSAR (SEQ ID NO: 597), MGDHLTNLHR (SEQ ID NO: 598), LYGSAGPPPTGEEDTAEK (SEQ ID NO: 663), TWNDPSVQQDIK (SEQ ID NO: 664), VYEGERPLTK (SEQ ID NO: 665), IIIQESALDYR (SEQ ID NO: 666), LDPALQDK (SEQ ID NO: 667), LIAQDYK (SEQ ID NO: 668), NDINILK (SEQ ID NO: 669), VAELSSDDFHLDR (SEQ ID NO: 670), ALPGTPVASSQPR (SEQ ID NO: 839), EVPLLQSLWLAHNEIR (SEQ ID NO: 840), LPGLPEGAFR (SEQ ID NO: 841), TVAAGALASLSHLK (SEQ ID NO: 843), ASHEEVEGLVEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO: 940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942), AALSGANVLTLIEK (SEQ ID NO: 958), TVLWPNGLSLDIPAGR (SEQ ID NO: 959), VFFTDYGQIPK (SEQ ID NO: 960), ADEGISFR (SEQ ID NO: 1321), ATAVMPDGQFK (SEQ ID NO: 1322), DISLSDYK (SEQ ID NO: 1323), GLFIIDDK (SEQ ID NO: 1324), IGHPAPNFK (SEQ ID NO: 1325), LVQAFQFTDK (SEQ ID NO: 1326), QGGLGPMNIPLVSDPK (SEQ ID NO: 1327), QITVNDLPVGR (SEQ ID NO: 1328), SVDETLR (SEQ ID NO: 1329), TIAQDYGVLK (SEQ ID NO: 1330), GGTLSTPQTGSENDALYEYLR (SEQ ID NO: 1588), LDTLAQEVALLK (SEQ ID NO: 1589), NWETEITAQPDGGK (SEQ ID NO: 1590), FQDLVDAVR (SEQ ID NO: 1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ ID NO: 1643), GFLLLASLR (SEQ ID NO: 1644), YVSELHLTR (SEQ ID NO: 878), YYIAASYVK (SEQ ID NO: 643) or GTSQNDPNWVVR (SEQ ID NO: 1645).
3. The composition of claim 2, wherein at least one of the isolated synthetic peptides is isotopically labeled.
4. The composition of claim 2, wherein the measured quantity of each of the at least 2 isolated synthetic peptides of at least 5 proteins is known.
5. The composition of claim 2, further comprising one or more polar solvents.
6. The composition of claim 2, further comprising an additional five isolated synthetic peptides of at least one protein selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, KIT, GGH or GSLG1.
7. The composition of claim 2, further comprising an additional five isolated synthetic peptides of at least one protein selected from APOE, BASP1, CD14, FOXA2 or HSPB1.
8. A composition comprising at least 25 isolated synthetic peptides said composition comprising at least five isolated synthetic peptides of at least five proteins selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, GSLG1, KIT or GGH wherein the at least five isolated synthetic peptides are selected from ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK (SEQ ID NO: 58), QLLLTADDR (SEQ ID NO: 60), ADHHATNGVVHLIDK (SEQ ID NO: 136), DILATNGVIHYIDELLIPDSAK (SEQ ID NO: 137), LTLLAPLNSVFK (SEQ ID NO: 139), SPYQLVLQHSR (SEQ ID NO: 140), ADDILASPPR (SEQ ID NO: 331), AVGLAGTFR (SEQ ID NO: 332), TEAPSATGQASSLLGGR (SEQ ID NO: 335), GGSTSYGTGSETESPR (SEQ ID NO 554), NSLFEYQK (SEQ ID NO: 556), TVIGPDGHK (SEQ ID NO: 557), VQHIQLLQK (SEQ ID NO: 558), ALFQDIK (SEQ ID NO: 593), DDVALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ ID NO: 595), LGGPEAGLGEYLFER (SEQ ID NO: 596), LNQALLDLHALGSAR (SEQ ID NO: 597), MGDHLTNLHR (SEQ ID NO: 598), LYGSAGPPPTGEEDTAEK (SEQ ID NO: 663), TWNDPSVQQDIK (SEQ ID NO: 664), VYEGERPLTK (SEQ ID NO: 665), IIIQESALDYR (SEQ ID NO: 666), LDPALQDK (SEQ ID NO: 667), LIAQDYK (SEQ ID NO: 668), NDINILK (SEQ ID NO: 669), VAELSSDDFHLDR (SEQ ID NO: 670), ALPGTPVASSQPR (SEQ ID NO: 839), EVPLLQSLWLAHNEIR (SEQ ID NO: 840), LPGLPEGAFR (SEQ ID NO: 841), TVAAGALASLSHLK (SEQ ID NO: 843), ASHEEVEGLVEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO: 940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942), AALSGANVLTLIEK (SEQ ID NO: 958), TVLWPNGLSLDIPAGR (SEQ ID NO: 959), VFFTDYGQIPK (SEQ ID NO: 960), ADEGISFR (SEQ ID NO: 1321), ATAVMPDGQFK (SEQ ID NO: 1322), DISLSDYK (SEQ ID NO: 1323), GLFIIDDK (SEQ ID NO: 1324), IGHPAPNFK (SEQ ID NO: 1325), LVQAFQFTDK (SEQ ID NO: 1326), QGGLGPMNIPLVSDPK (SEQ ID NO: 1327), QITVNDLPVGR (SEQ ID NO: 1328), SVDETLR (SEQ ID NO: 1329), TIAQDYGVLK (SEQ ID NO: 1330), GGTLSTPQTGSENDALYEYLR (SEQ ID NO: 1588), LDTLAQEVALLK (SEQ ID NO: 1589), NWETEITAQPDGGK (SEQ ID NO: 1590), FQDLVDAVR (SEQ ID NO: 1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ ID NO: 1643), GFLLLASLR (SEQ ID NO: 1644), YYIAASYVK (SEQ ID NO: 643), YVSELHLTR (SEQ ID NO: 878), or GTSQNDPNWVVR (SEQ ID NO: 1645).
9. The composition of claim 8, wherein the at least five isolated synthetic peptides are selected from GFLLLASLR (SEQ ID NO: 1644), AVGLAGTFR (SEQ ID NO: 332), ALPGTPVASSQPR (SEQ ID NO: 839), LDTLAQEVALLK (SEQ ID NO: 1589), LGGPEAGLGEYLFER (SEQ ID NO: 596), TWNDPSVQQDIK (SEQ ID NO: 664), ALQASALK (SEQ ID NO: 58), LTLLAPLNSVFK (SEQ ID NO: 139), VEIFYR (SEQ ID NO: 941), TVLWPNGLSLDIPAGR (SEQ ID NO: 959), NSLFEYQK (SEQ ID NO: 556), QITVNDLPVGR (SEQ ID NO: 1328), YYIAASYVK (SEQ ID NO: 643), YVSELHLTR (SEQ ID NO: 878), and IIIQESALDYR (SEQ ID NO: 666).
10. A composition comprising at least 5 transition ion pairs said composition comprising at least one transition ion pair of at least 5 proteins selected from ALDOA, TSP1, FRIL, KIT, and GGH, wherein the at least one transition ion pair consists of a precursor ion with a corresponding m/z and a fragment ion with a corresponding ion m/z, and wherein the transition ion pairs are selected from precursor ALQASALK (SEQ ID NO: 58) transition pair 401.25-260.2, 401.25-331.2, 401.25-489.3, or 401.25-617.4; precursor GFLLLASLR (SEQ ID NO: 1644) transition pair 495.31-318.2, 495.31-375.2, 495.31-446.3, or 495.31-559.4; precursor YYIAASYVK (SEQ ID NO: 643) transition pair 539.28-567.3, 539.28-638.40, 539.28-751.4, or 539.28-914.5; precursor LGGPEAGLGEYLFER (SEQ ID NO: 596) transition pair 804.41-451.2, 804.41-525.3, 804.41-564.3, or 804.41-913.4; and precursor YVSELHLTR (SEQ ID NO: 878) transition pair 373.21-263.1, 373.21-276.2, 373.21-526.3, or 373.21-639.4, wherein each of the precursor ions has a double or triple charge.
11. The composition of claim 10, further comprising an additional five transition ion pairs comprising one transition ion pair of at least one protein selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, KIT, GGH or GSLG1.
12. The composition of claim 11, further comprising an additional five transition ion pairs comprising one transition ion pair of at least one protein selected from APOE, BASP1, CD14, FOXA2 or HSPB1, wherein the additional one transition ion pair consists of a precursor ion with a corresponding m/z and a fragment ion with a corresponding m/z, and wherein the transition ion pairs are selected from precursor AATVGSLAGQPLQER (SEQ ID NO: 82) transition pair 479.4-600.3, 479.4-642.4, 479.4-827.4, or 479.4-898.5; precursor ALMDETMK (SEQ ID NO: 83) transition pair 469.72-508.2, 469.72-469.72, 469.72-508.2, 469.72-623.3, 469.72-754.3, or 469.72-867.4; precursor GEVQAMLGQSTEELR (SEQ ID NO: 85) transition pair 824.4-616.3, 824.4-729.4, 824.4-734.4, or 824.4-919.4; precursor LAVYQAGAR (SEQ ID NO: 86) transition pair 474.77-502.3, 474.77-665.3, 474.77-764.4, or 474.77-835.4; precursor LGPLVEQGR (SEQ ID NO: 87) transition pair 484.78-588.3, 484.78-701.4, 484.78-798.4, or 484.78-855.5; precursor SELEEQLTPVAEETR (SEQ ID NO: 88) transition pair 865.93-459.2, 865.93-801.4, 865.93-902.5, or 865.93-930.4; precursor SWFEPLVEDMQR (SEQ ID NO: 89) transition pair 768.86-274.1, 768.86-421.2, 768.86-678.3, or 768.86-987.5; precursor WELALGR (SEQ ID NO: 90) transition pair 422.74-316.1, 422.74-345.2, 422.74-529.3, or 422.74-658.4; precursor AAEAAAAPAESAAPAAGEEPSK (SEQ ID NO: 118) transition pair 983.97-414.2, 983.97-485.2, 983.97-556.3, or 983.97-885.4; precursor AEGAATEEEGTPK (SEQ ID NO: 119) transition pair 645.3-258.1, 645.3-789.4, 645.3-890.4, or 645.3-961.4; precursor APEQEQAAPGPAAGGEAPK (SEQ ID NO: 120) transition pair 592.62-629.3, 592.62-754.3, 592.62-825.4, or 592.62-951.5; precursor EKPDQDAEGK (SEQ ID NO: 122) transition pair 558.76-404.2, 558.76-647.3, 558.76-859.4, or 558.76-913.4; precursor ESEPQAAAEPAEAK (SEQ ID NO: 123) transition pair 714.34-515.3, 714.34-644.3, 714.34-786.4, or 714.34-857.4; precursor ETPAATEAPSSTPK (SEQ ID NO: 124) transition pair 693.84-616.3, 693.84-816.4, 693.84-917.5, or 693.84-988.5; precursor GYNVNDEK (SEQ ID NO: 125) transition pair 469.71-276.2, 469.71-505.2, 469.71-604.3, or 469.71-718.3; precursor SDGAPASDSKPGSSEAAPSSK (SEQ ID NO: 126) transition pair 644.96-260.1, 644.96-331.1, 644.96-418.2, or 644.96-586.2; precursor TEAPAAPAAQETK (SEQ ID NO: 127) transition pair 642.83-541.3, 642.83-744.4, 642.83-815.4, or 642.83-983.5; precursor AFPALTSLDLSDNPGLGER (SEQ ID NO: 206) transition pair 987-500.3, 987-628.3, 987-742.4, or 987-944.4; precursor ATVNPSAPR (SEQ ID NO: 207) transition pair 456.75-386.2, 456.75-430.2, 456.75-527.3, or 456.75-740.4; precursor ELTLEDLK (SEQ ID NO: 208) transition pair 480.77-260.2, 480.77-504.3, 480.77-617.4, or 480.77-718.4; precursor FPAIQNLALR (SEQ ID NO: 209) transition pair 571.84-714.4, 571.84-827.5, 571.84-898.5, or 571.84-995.6; precursor LTVGAAQVPAQLLVGALR (SEQ ID NO: 211) transition pair 593.03-416.3, 593.03-515.3, 593.03-628.4, or 593.03-740.4; precursor NVSWATGR (SEQ ID NO: 212) transition pair 445.73-301.2, 445.73-404.2, 5, 445.73-590.3, or 445.73-677.3; precursor STLSVGVSGTLVLLQGAR (SEQ ID NO: 213) transition pair 879.51-431.2, 879.51-544.3, 879.51-657.4, or 879.51-970.6; precursor SWLAELQQWLKPGLK (SEQ ID NO: 214) transition pair 599.67-274.1, 599.67-414.3, 599.67-542.4, or 599.67-841.5; precursor VDADADPR (SEQ ID NO: 215) transition pair 429.7-272.2, 429.7-573.3, 429.7-644.3, or 429.7-759.3; precursor AYEQVMHYPGYGSPMPGSLAMGPVTNK (SEQ ID NO: 577) transition pair 961.45-558.3, 961.45-615.3, 961.45-817.4, or 961.45-930.5; precursor EAAGAAGSGK (SEQ ID NO: 578) transition pair 409.7-348.2, 409.7-490.3, 409.7-547.3, or 409.7-618.3; precursor MHSASSMLGAVK (SEQ ID NO: 579) transition pair 406.87-374.2, 406.87-487.3, 406.87-601.2, or 406.87-732.3; precursor TGLDASPLAADTSYYQGVYSRPIMNSS (SEQ ID NO: 582) transition pair 955.45-387.2, 955.45-545.3, 955.45-648.3, or 955.45-826.4; precursor AQLGGPEAAK (SEQ ID NO: 731) transition pair 471.26-313.2, 471.26-427.2, 471.26-629.3, or 471.26-742.4; precursor DGVVEITGK (SEQ ID NO: 732) transition pair 459.25-305.2, 459.25-418.3, 459.25-547.3, or 459.25-646.4; precursor GPSWDPFR (SEQ ID NO: 733) transition pair 481.23-419.2, 481.23-534.3, 481.23-720.3, or 481.23-807.4; precursor LATQSNEITIPVTFESR (SEQ ID NO: 734) transition pair 953.5-639.3, 953.5-744.4, 953.5-835.4, or 953.5-857.4; precursor LFDQAFGLPR (SEQ ID NO: 735) transition pair 582.31-272.2; 582.31-442.3, 582.31-660.4, or 582.31-903.5; precursor QDEHGYISR (SEQ ID NO: 736) transition pair 368.84-262.2, 368.84-538.3, 368.84-595.3, 368.84-730.3, 368.84-504.3, 368.84-660.4, 368.84-747.4, or 368.84-834.4; precursor VPFSLLR (SEQ ID NO: 738) transition pair 416.26-488.3, 416.26-488.3, 416.26-635.4, or 416.26-732.4; or precursor VSLDVNHFAPDELTVK (SEQ ID NO: 739) transition pair 595.31-347.2, 595.31-460.3, 595.31-801.4, or 595.31-872.5, wherein each of the precursor ions has a double or triple charge.
13. The composition of claim 11, wherein the at least five transition ion pairs are selected from precursor GFLLLASLR (SEQ ID NO: 1644) transition pair 495.31-559.40, precursor LGGPEAGLGEYLFER (SEQ ID NO: 596) transition pair 804.40-913.40, precursor ALQASALK (SEQ ID NO: 58) transition pair 401.25-617.40, YYIAASYVK (SEQ ID NO: 643) transition pair 539.28-638.40, precursor LGGPEAGLGEYLFER (SEQ ID NO: 596) transition pair 804.41-451.2, 804.41-525.3, 804.41-564.3, 804.41-913.4, and precursor YVSELHLTR (SEQ ID NO: 878) transition pair 373.21-263.1, 373.21-276.2, 373.21-526.3, 373.21-639.4.
14. A method comprising analyzing the composition of claim 8 using mass spectrometry.
15. The method of claim 14, wherein the method uses selected reaction monitoring mass spectrometry.
16. A method comprising analyzing the composition of claim 8 using Enzyme-Linked Immunosorbent Assay (ELISA).
17. A multiplexed LC-SRM-MS assay for the measurement of a plurality of proteins in a single sample comprising: a) generating a set of peptides and corresponding transitions for each protein to be monitored; b) optimizing the collision energy for each transition such that interference among the transitions is avoided; c) selecting a set of transitions that have the greatest peak areas for each protein, and wherein the selected transitions do not interfere with the ions in the sample; d) measuring a plurality of proteins in a sample.
18. The assay according to claim 17 wherein the two best peptides per protein and the two best transitions per peptide are selected based on experimental data resulting from LC-SRM-MS analysis of one or more of the following experimental samples: a biological disease sample, a biological control sample, and a mixture of synthetic peptides.
19. The assay according to claim 18 wherein the biological disease and biological control samples are processed using an immunodepletion method prior to LC-SRM-MS analysis.
20. The assay according to claim 19, wherein the experimental samples contain internal standard peptides.
21. The assay according to claim 19, wherein the LC-SRM-MS analysis method specifies a maximum of 7000 transitions, including transitions of the internal standard peptides and transitions.
22. The Assay according to claim 17, wherein the top two transitions per peptide are selected according to one or more of the following criteria: (1) the transitions exhibit the largest peak areas measured in either of the two biological samples; (2) the transitions are not interfered with by other ions; (3) the transitions do not exhibit an elution profile that visually differs from those of other transitions of the same peptide; (4) the transitions are not beyond the detection limit of both of the two biological experimental samples; and (5) the transitions do not exhibit interferences.
23. The assay according to claim 17, wherein the top two peptides per protein are selected according to one or more of the following criteria: (1) one or more peptides exhibit two transitions according to claim 20 and represent the largest combined peak areas of the two transitions according to claim 20; and (2) one or more peptides exhibit one transition according to claim 20 and represent the largest combined peak areas of the two transitions according to claim 20.
24. An assay developed according to claim 17.
Description:
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 13/725,098 filed Dec. 21, 2012, which in turn claims priority and benefit of U.S. Provisional Application No. 61/578,718 filed Dec. 21, 2011, and U.S. Provisional Application No. 61/614,818 filed Mar. 23, 2012, the contents of each of which are incorporated herein by reference in their entireties.
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
[0002] The contents of the text file named "IDIA-004_C01US_ST25.txt", which was created on Jun. 11, 2015 and is 395,000 bytes in size, are hereby incorporated by reference in their entireties.
BACKGROUND
[0003] Liquid Chromatography Selected Reaction Monitoring Mass Spectrometry (LC-SRM-MS) has emerged as an alternative technology to immunoassays for quantification of target proteins in biological samples. LC-SRM-MS methods are highly desirable because LC-SRM-MS methods provide both absolute structural specificity for the target protein and relative or absolute measurement of the target protein concentration when suitable internal standards are utilized. In contrast to immunoassays, LC-SRM-MS does not involve the manufacturing of biologics. LC-SRM-MS protein assays can be rapidly and inexpensively developed in contrast to the development of immunoassays. LC-SRM-MS are highly multiplexed, with simultaneous assays for hundreds of proteins performed in a single sample analysis. Using LC-SRM-MS in contrast to other proteomic technologies allows for complex assays for the identification diagnostic proteins in complex diseases such as cancer, autoimmune, and metabolic disease. In particular, the development of a highly multiplexed LC-SRM-MS assay that reproducibly identifies a specific set of proteins relevant to a clinical disease presents diagnostic advantages and efficiencies. To date, proteomic techniques have not enabled such inventions to exist where hundreds of proteins can be accurately quantified within a single sample. The present invention provides accurate measurement of hundreds of lung cancer associated proteins within a single sample using multiplexed techniques.
SUMMARY OF THE INVENTION
[0004] The present invention comprises a LC-SRM-MS assay for the measurement proteins in a single sample and in a single LC-SRM-MS assay. The assay was optimized for protein quantification and minimal interference among proteins in the assay. This LC-SRM-MS assay is novel because measurement of a large number of proteins in a single sample specifically associated with lung cancer has not been accomplished. Simultaneous measurement of such a large number of proteins without interference among the proteins requires specific techniques to distinguish among the proteins. The current invention provides clinical utility as this assay was used for development of lung cancer diagnostic tests for the early detection of lung cancer, managing disease treatment, as well as testing for disease recurrence.
[0005] The object of the present invention is to provide improved methods for the use of LC-SRM-MS in the development of assays. Accordingly, provided herein is a method for developing peptides and transitions for a plurality of at least 200 proteins for a single sample selected reaction monitoring mass spectrometry (LC-SRM-MS) assay, including the steps of providing a set of 200 or more proteins; generating transitions for each protein; assessing LC-SRM-MS data by Mascot score; performing collision energy optimization on the transitions; selecting peptides with transitions showing the greatest peak areas of their transitions; selecting a set of transitions for each peptide, wherein the transitions for each peptide have one of the four most intense b or y transition ions; the transitions for each peptide have m/z values of at least 30 m/z above or below those of the precursor ion; the transitions for each peptide do not interfere with transitions from other peptides; and the transitions represent transitions due to breakage of peptide bond at different sites of the protein.
[0006] In one embodiment of the method, each selected peptide in the set of peptides has a monoisotopic mass of 700-5000 Da; and does not contain a cysteine or a methionine; or may contain cysteine or methionine. In another embodiment, the transitions for each peptide have one of the four most intense b or y transition ions; have m/z values of at least 30 m/z above or below those of a precursor ion; do not interfere with transitions from other peptides; and represent transitions due to breakage of peptide bond at different sites of the protein.
[0007] In another embodiment of the method, the peptides do not include any peptide that is bounded by KK, KR, RK or RR (either upstream or downstream) in the corresponding protein sequence. Specifically, the amino acid is charged at pH 7.0. These amino acids include arginine and lysine. In another embodiment, each peptide of said set of peptides is unique to the corresponding protein. In yet another embodiment, the peptides do not include peptides which were observed in post-translational modified forms. In still another embodiment, each set of peptides is prioritized according to one or more of the following ordered set of criteria: unique peptides first, then non-unique; peptides with no observed post-translational modifications first, then those observed with post-translational modifications; peptides within the mass range 800-3500 Da first, then those outside of 800-3500 Da; and sorted by decreasing number of variant residues. In certain embodiments, The peptides are unique in that they only appear once among the peptides run in a single assay.
[0008] In one embodiment, each set of peptides is prioritized according to all of the ordered set of criteria. In another embodiment, each prioritized set of peptides contains 1-5 peptides.
[0009] In certain embodiments of the preceding methods, the two best peptides per protein and the two best transitions per peptide are selected based on experimental data resulting from LC-SRM-MS analysis of one or more of the following experimental samples: a biological disease sample, a biological control sample, and a mixture of synthetic peptides of interest. In a particular embodiment, the biological disease and biological control samples are processed using an immunodepletion method prior to LC-SRM-MS analysis. In another embodiment, the experimental samples contain internal standard peptides. In yet another embodiment, the LC-SRM-MS analysis method specifies a maximum of 7000 transitions, including transitions of the internal standard peptides and transitions. In other embodiments the method specifies a maximum of between 1000-7000, 2000-6000, 3000-5000 and about 3500 transitions.
[0010] In one embodiment of the method, the top two transitions per peptide are selected according to one or more of the following criteria the transitions exhibit the largest peak areas measured in either of the two biological experimental samples; the transitions are not interfered with by other ions; the transitions do not exhibit an elution profile that visually differs from those of other transitions of the same peptide; or the transitions are not beyond the detection limit of both of the two biological experimental samples.
[0011] In another embodiment of the method, the top two peptides per protein are selected according to one or more of the following criteria: one or more peptides exhibit two transitions and represent the largest combined peak areas of the two transitions; or one or more peptides exhibit one transition and represent the largest combined peak areas of the two transitions.
[0012] In another aspect, provided herein is an assay developed according to the foregoing method, and embodiments thereof.
[0013] In yet another aspect provided herein is the use of an assay developed according to the foregoing method, and embodiments thereof, to detect a plurality of at least 200 proteins in a single biological sample.
[0014] In another aspect, provided herein is an assay developed according to the foregoing method, and embodiments thereof.
[0015] The disclosure provides a composition comprising at least five transition ions selected from the listing of transition ions in Table 2. In one embodiment of the assay each transition ion independently corresponds to a unique protein. The five transition ions corresponded to proteins selected from the group consisting of LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. (see: U.S. application Ser. No. 13/306,823 PCT/US11/62461). The composition can further include an additional five transition ions selected from the listing of transition ions in Table 2. The additional five transition ions can corresponded to the proteins APOE, BASP1, CD14, FOXA2 and HSPB1.
[0016] The disclosure provides a composition comprising at least five synthetic peptides selected from the listing of peptides and proteins in Table 2. In one embodiment, each peptide can independently correspond to a unique protein. At least one of the peptides was isotopically labeled. The amount of each of the at least five synthetic peptides is known. In another embodiment, the composition included one or more polar solvents. The five synthetic peptides can correspond to the proteins LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. The composition can also include an additional five synthetic peptides selected from the listing of peptides and proteins in Table 2. The additional five synthetic peptides can correspond to the proteins APOE, BASP1, CD14, FOXA2 and HSPB1.
[0017] The disclosure provides a use of a composition, as described above, for the development of an assay to detect a disease, disorder or condition in a mammal.
[0018] The disclosure provides a method comprising analyzing a composition, as described above, using mass spectrometry. The method can use selected reaction monitoring mass spectrometry.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] FIG. 1 depicts candidate protein cohort by source. 217 tissue proteins were identified using proteomics analysis. 319 proteins were identified by review of the literature. Between the two sources, there was an overlap of 148 proteins.
[0020] FIG. 2 is a bar diagram showing Pearson correlations for peptides from the same peptide, from the same protein and from different proteins.
DETAILED DESCRIPTION OF THE INVENTION
[0021] The present disclosure relates to methods for developing peptides and transitions for a single sample selected reaction monitoring mass spectrometry (LC-SRM-MS) assay, generally comprising the steps of providing a set of proteins; identifying representative proteolytic peptides for each protein according to a set of criteria; identifying representative transitions for each peptide according to another set of criteria; and selecting the optimum peptides per protein and the optimum transitions per peptide.
[0022] Selected reaction monitoring mass spectrometry is capable of highly sensitive and accurate protein quantification based on the quantification of proteolytic peptides. In terms of clinical utility, mass spectrometry-based assays are often compared to immunoassays (e.g., Enzyme-Linked Immunosorbent Assay, or ELISA), which have the ability to quantify specific analytes in large sample sets (e.g., 96 or 384 samples in parallel microtitre plate-based format). Until recently, mass spectrometry-based protein assays were not able to match these sample sizes or quantitative accuracy. Considerable time and expense is required to generate and characterize antibodies required for immunoassays. Increasingly efficient LC-SRM-MS assays, therefore, may surpass immunoassays such as ELISA in the rapid development of clinically useful, multiplexed protein assays.
[0023] LC-SRM-MS is a highly selective method of tandem mass spectrometry which has the potential to effectively filter out all molecules and contaminants except the desired analyte(s). This is particularly beneficial if the analysis sample is a complex mixture which may comprise several isobaric species within a defined analytical window. LC-SRM-MS methods may utilize a triple quadrupole mass spectrometer which, as is known in the art, includes three quadrupole rod sets. A first stage of mass selection is performed in the first quadrupole rod set, and the selectively transmitted ions are fragmented in the second quadrupole rod set. The resultant transition (product) ions are conveyed to the third quadrupole rod set, which performs a second stage of mass selection. The product ions transmitted through the third quadrupole rod set are measured by a detector, which generates a signal representative of the numbers of selectively transmitted product ions. The RF and DC potentials applied to the first and third quadrupoles are tuned to select (respectively) precursor and product ions that have m/z values lying within narrow specified ranges. By specifying the appropriate transitions (m/z values of precursor and product ions), a peptide corresponding to a targeted protein may be measured with high degrees of sensitivity and selectivity. Signal-to-noise ratio in LC-SRM-MS is often superior to conventional tandem mass spectrometry (MS/MS) experiments that do not selectively target (filter) particular analytes but rather aim to survey all analytes in the sample.
[0024] Accordingly, provided herein is a method for developing peptides and transitions for a plurality of proteins for use in selected reaction monitoring mass spectrometry (LC-SRM-MS) assay. In a preferred embodiment, the assay involves the analysis of a single sample containing all analytes of interest (e.g., a proteolytic digest of plasma proteins). As to the selection of the protease(s) used, trypsin, which cleaves exclusively C-terminal to arginine and lysine residues, is a preferred choice to generate peptides because the masses of generated peptides are compatible with the detection ability of most mass spectrometers (up to 2000 m/z), the number and average length of generated peptides, and also the availability of efficient algorithms for the generation of databases of theoretical trypsin-generated peptides. High cleavage specificity, availability, and cost are other advantages of trypsin. Other suitable proteases will be known to those of skill in the art. Miscleavage is a factor for failure or ambiguous protein identification. A miscleavage can be defined as partial enzymatic protein cleavages generating peptides with internal missed cleavage sites reflecting the allowed number of sites (targeted amino acids) per peptide that were not cut. The presence of post-translational modifications (PTMs) is also a potential contributor to the problem of miscleavages.
[0025] LC-SRM-MS mass spectrometry involves the fragmentation of gas phase ions and occurs between the different stages of mass analysis. There are many methods used to fragment the ions and these can result in different types of fragmentation and thus different information about the structure and composition of the molecule. The transition ions observed in an LC-SRM-MS spectrum result from several different factors, which include, but are not limited to, the primary sequence, the amount of internal energy, the means of introducing the energy, and charge state. Transitions must carry at least one charge to be detected. An ion is categorized as either a, b or c if the charge is on a transition comprising the original N terminus of the peptide, whereas the ion is categorized as either x, y or z if the charge is on a transition comprising the original C terminus of the peptide. A subscript indicates the number of residues in the transition (e.g., one peptide residue in x1, two peptide residues in y2, and three peptide residues in z3, etc.).
[0026] In a generic peptide repeat unit represented --N--C(O)--C--, an x ion and an a ion resulting from cleavage of the carbonyl-carbon bond (i.e., C(O)--C). The x ion is an acylium ion, and the a ion is an iminium ion. A y ion and a b ion result from cleavage of the carbonyl-nitrogen bond (i.e., C(O)--N, also known as the amide bond). In this case, the y ion is an ammonium ion and the b ion is an acylium ion. Finally, a z ion and a c ion result from cleavage of the nitrogen-carbon (i.e., C--N) bond. The z ion is a carbocation and the c ion is an ammonium ion.
[0027] Superscripts are sometimes used to indicate neutral losses in addition to the backbone fragmentation, for example, * for loss of ammonia and .sup.∘ for loss of water. In addition to protons, c ions and y ions may abstract an additional proton from the precursor peptide. In electrospray ionization, tryptic peptides may carry more than one charge.
[0028] Internal transitions arise from double backbone cleavage. These may be formed by a combination of b-type and y-type cleavage (i.e., cleavage producing b and y ions). Internal cleavage ions may also be formed by a combination of a-type and y-type cleavage. An internal transition with a single side chain formed by a combination of a-type and y-type cleavage is called an iminium ion (sometimes also referred to as an imonium or immonium ion). These ions are labeled with the one letter code for the corresponding amino acid.
[0029] Low energy CID (i.e., collision induced dissociation in a triple quadrupole or an ion trap) involves the fragmentation of a peptide carrying a positive charge, primarily along its backbone, to generate primarily a, b and y ions.
[0030] In one aspect, provided herein is a method for developing peptides and transitions for a plurality of proteins for a single sample selected reaction monitoring mass spectrometry (LC-SRM-MS) assay, by: (a) providing a panel of a plurality of proteins; (b) identifying a set of peptides for each protein, wherein (i) each peptide in the set of peptides corresponds to a transition of said protein; (ii) the peptides have a monoisotopic mass of 700-5000 Da; and (iii) the peptides do not contain a cysteine or a methionine; or may contain cysteine or methionine; (c) identifying a set of transitions for each peptide, wherein (i) the transitions for each peptide have one of the four most intense b or y transition ions; (ii) the transitions for each peptide have m/z values of at least 30 m/z above or below those of the precursor ion; (iii) the transitions for each peptide do not interfere with transitions from other peptides; and (iv) the transitions represent transitions due to breakage of peptide bond at different sites of the protein; and (d) selecting the peptides for each protein that best fit the criteria of step (b) and the transitions per peptide that best fit the criteria of step (c); thereby developing peptides and transitions for a LC-SRM-MS assay.
[0031] By plurality of proteins it is meant at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500 or more In certain embodiments, the plurality of proteins can encompass between 2 and 10. 10 and 20, 20 and 50, 50 and 100, 100 and 200, or 200 and 500 proteins. In other embodiments, the plurality of proteins can encompass between 250 and 450; or 300 and 400 proteins.
[0032] Trypsin-like proteases cleave peptide bonds following a positively charged amino acid (e.g., lysine (K) or arginine (R)). This specificity is driven by the residue which lies at the base of the enzyme's S1 pocket (generally a negatively charged aspartic acid or glutamic acid). Accordingly, in one embodiment of the method, the peptides do not include any peptide that is bounded by KK, KR, RK or RR, either upstream of downstream in the corresponding protein sequence. In another embodiment, each peptide of said set of peptides is unique to the corresponding protein.
[0033] Post-translational modification (PTM) is the chemical modification of a protein after its translation. It can include any modification following translation, including cleavage. It is one of the later steps in protein biosynthesis, and thus gene expression, for many proteins. It is desirable to avoid such peptides for the purpose of protein identification. Thus, in another embodiment, the peptides do not include peptides which were observed in post-translational modified forms.
[0034] In still another embodiment, each set of peptides is prioritized according to one or more of the following ordered set of criteria: (a) unique peptides first, then non-unique; (b) peptides with no observed post-translational modifications first, then those observed with post-translational modifications; (c) peptides within the mass range 800-3500 Da first, then those outside of 800-3500 Da; and (d) sorted by decreasing number of variant residues. In one embodiment, each set of peptides is prioritized according to all of the ordered set of criteria. In another embodiment, each prioritized set of peptides contains 1-5 peptides.
[0035] In certain embodiments, one or more liquid chromatography (LC) purification steps are performed prior to a subsequent LC-SRM-MS analysis step. Traditional LC analysis relies on the chemical interactions between sample components and column packing materials, where laminar flow of the sample through the column is the basis for separation of the analyte of interest from the test sample. The skilled artisan will understand that separation in such columns is a diffusional process. A variety of column packing materials are available for chromatographic separation of samples, and selection of an appropriate separation protocol is an empirical process that depends on the sample characteristics, the analyte of interest, the interfering substances present and their characteristics, etc. Various packing chemistries can be used depending on the needs (e.g., structure, polarity, and solubility of compounds being purified). In various embodiments the columns are polar, ion exchange (both cation and anion), hydrophobic interaction, phenyl, C-2, C-8, C-18 columns, polar coating on porous polymer, or others that are commercially available. During chromatography, the separation of materials is effected by variables such as choice of eluant (also known as a "mobile phase"), choice of gradient elution and the gradient conditions, temperature, etc. In certain embodiments, an analyte may be purified by applying a sample to a column under conditions where the analyte of interest is reversibly retained by the column packing material, while one or more other materials are not retained. In these embodiments, a first mobile phase condition can be employed where the analyte of interest is retained by the column, and a second mobile phase condition can subsequently be employed to remove retained material from the column, once the non-retained materials are washed through. Alternatively, an analyte may be purified by applying a sample to a column under mobile phase conditions where the analyte of interest elutes at a differential rate in comparison to one or more other materials. As discussed above, such procedures may enrich the amount of one or more analytes of interest relative to one or more other components of the sample.
[0036] The following parameters are used to specify an LC-SRM-MS assay of a protein under a particular LC-SRM-MS system: (1) a tryptic peptide of the protein; (2) the retention time (RT) of the peptide; (3) the m/z value of the peptide precursor ion; (4) the declustering potential used to ionize the precursor ion; (5) the m/z value of a fragment ion generated from the peptide precursor ion; and (6) the collision energy (CE) used to fragment the peptide precursor ion that is optimized for the particular peptide.
[0037] In certain embodiments of the preceding methods, the two best peptides per protein and the two best transitions per peptide are selected based on experimental data resulting from LC-SRM-MS analysis of one or more of the following experimental samples: a biological disease sample, a biological control sample, and a mixture of synthetic peptides of interest. Biological samples include body fluids, tissue samples and cell samples. Body fluid samples can include blood, serum, sputum, genital secretions, cerebrospinal fluid, sweat or excreta such as urine. Body tissue samples can include lung, skin, brain, spine, bone, muscle, epithelial, liver, kidney, pancreas, gastrointestinal tract, cardiovascular tissue, heart or nervous tissue. Biological disease samples can include cancer, benign tumors, infected tissue and tissue subject to trauma. In a particular embodiment, the biological disease and biological control samples are processed using an immunodepletion method prior to LC-SRM-MS analysis. Immunodepletion involves removal of one or more proteins through the use of antibodies. Numerous immunodepletion techniques are known to those of skill in the art. In another embodiment, the biological disease and biological control samples are processed using an immunocapture method prior to LC-SRM-MS analysis. Immunocapture involves selection of one or more proteins through the use of antibodies. Numerous immunocapture techniques are known to those of skill in the art.
[0038] To facilitate accurate quantification of the peptide transitions by the methods disclosed herein, a set of isotopically-labeled synthetic versions of the peptides of interest may be added in known amounts to the sample for use as internal standards. Since the isotopically-labeled peptides have physical and chemical properties identical to the corresponding surrogate peptide, they co-elute from the chromatographic column and are easily identifiable on the resultant mass spectrum. The addition of the labeled standards may occur before or after proteolytic digestion. Methods of synthesizing isotopically-labeled peptides will be known to those of skill in the art. Thus, in another embodiment, the experimental samples contain internal standard peptides. Other embodiments may utilize external standards or other expedients for peptide quantification.
[0039] In yet another embodiment, the LC-SRM-MS analysis method specifies a maximum of 7000 transitions, including transitions of the internal standard peptides and transitions. As used herein, the term "transition" refers to the specific pair of m/z (mass-to-charge) values associated with the precursor and transition ions corresponding to a specific peptide and, therefore, to a specific protein.
[0040] In one embodiment of the method, the top two transitions per peptide are selected according to one or more of the following criteria (A): (1) the transitions exhibit the largest peak areas measured in either of the two biological experimental samples; (2) the transitions are not interfered with by other ions; (3) the transitions do not exhibit an elution profile that visually differs from those of other transitions of the same peptide; (4) the transitions are not beyond the detection limit of both of the two biological experimental samples; (5) the transitions do not exhibit interferences.
[0041] For the mass spectrometric analysis of a particular peptide, the quantities of the peptide transitions in the sample may be determined by integration of the relevant mass spectral peak areas, as known in the prior art. When isotopically-labeled internal standards are used, as described above, the quantities of the peptide transitions of interest are established via an empirically-derived or predicted relationship between peptide transition quantity (which may be expressed as concentration) and the area ratio of the peptide transition and internal standard peaks at specified transitions.
[0042] In another embodiment of the method, the top two peptides per protein are selected according to one or more of the following criteria (B): (1) one or more peptides exhibit two transitions according to criteria (A) and represent the largest combined peak areas of the two transitions according to criteria (A); and (2) one or more peptides exhibit one transition according to criteria (A) and represent the largest combined peak areas of the two transitions according to criteria (A).
Assays
[0043] The methods of the present disclosure allow the quantification of high abundance and low abundance plasma proteins that serve as detectable markers for various health states (including diseases and disorders), thus forming the basis for assays that can be used to determine the differences between normal levels of detectable markers and changes of such detectable markers that are indicative of changes in health status. In one aspect of the invention, provided herein is an assay developed according to the foregoing method, and embodiments thereof. In another aspect, provided herein is the use of an assay developed according to the foregoing method, and embodiments thereof, to detect a plurality of at least 200, 300, or more proteins in a single sample. In a merely illustration embodiment, 388 proteins in the following table 1 are detected utilizing the method of present invention.
[0044] Of the 388 proteins, the 36 most cooperative proteins are listed in Table 2.
[0045] SRM assays for the 388 proteins were developed using standard synthetic peptide techniques. Of the 388 candidates, SRM assays were successfully developed for 371 candidates. The 371 SRM assays were applied to benign and lung cancer plasma samples to evaluate detection rate in blood. The summary of the SRM assay for these 371 proteins is listed in table 3 (see also Example III).
DEFINITIONS
[0046] As used herein, "transition" refers to a pair of m/z values associated with a peptide. Normally, labeled synthetic peptides are used as quality controls in SRM assays. However, for very large SRM assays such as the 371 protein lung cancer assay, labeled peptides are not feasible. However, correlation techniques (Kearney, Butler et al. 2008) were used to confirm the identity of protein transitions with high confidence. In FIG. 2 a histogram of the Pearson correlations between every pair of transitions in the assay is presented. The correlation between a pair of transitions is obtained from their expression profiles over all samples (143) in the training study detailed below. As expected, transitions from the same peptide are highly correlated. Similarly, transitions from different peptide fragments of the same protein are also highly correlated. In contrast, transitions from different proteins are not highly correlated. This methodology enables a statistical analysis of the quality of a protein's SRM assay. For example, if the correlation of transitions from two peptides from the same protein is above 0.5 then there is less than a 5% probability that the assay is false.
[0047] As used herein, a "tryptic peptide" refers to the peptide that is formed by the treatment of a protein with trypsin.
[0048] As used herein, "RT" refers to "retention time", the elapsed time between injection and elution of an analyte.
[0049] As used herein, "m/z" indicates the mass-to-charge ratio of an ion.
[0050] As used herein, "DP" refers to "declustering potential", a voltage potential to dissolvate and dissociate ion clusters. It is also known as "fragmentor voltage" or "ion transfer capillary offset voltage" depending on the manufacture.
[0051] As used herein, "CE" refers to "collision energy", the amount of energy precursor ions receive as they are accelerated into the collision cell.
[0052] As used herein, "LC-SRM-MS" is an acronym for "selected reaction monitoring" and may be used interchangeably with "LC-MRM-MS".
[0053] As used herein, "MS/MS" represents tandem mass spectrometry, which is a type of mass spectrometry involving multiple stages of mass analysis with some form of fragmentation occurring in between the stages.
[0054] As used herein, "ISP" refers to "internal standard peptides".
[0055] As used herein, "HGS" refers to "human gold standard", which is comprised of a pool of plasma from healthy individuals.
[0056] As used herein, "MGF" refers to "Mascot generic file". Mascot is a search engine that uses mass spectrometry data to identify proteins from primary sequence databases. A Mascot generic file is a plain text (ASCII) file containing peak list information and, optionally, search parameters.
[0057] Mascot is a web-based tool for deriving protein sequences from mass spectrometry data. This data can be acquired from any mass spectrometry technique including MALDI-TOF and MS/MS (including LC-SRM-MS) data. Mascot uses a `probability-based MOWSE` algorithm to estimate the significance of a match (i.e., that the observed transitions correspond to a particular protein). The total score is the absolute probability that the observed match is a random event. They are reported as -10×LOG 10(P), where P is the absolute probability. Lower probabilities, therefore, are reported as higher scores. For example, if the absolute probability that an observed match is random is 1×10-12, Mascot reports it as 120.
[0058] The disclosure also provides compositions. These compositions can include any of the transition ions described in Table 2. These transition ions exist while peptides derived from the proteins in Table 2 are undergoing analysis with LC-SRM-MS. In one embodiment, the composition includes any of the transition ions described in Table 2. In another embodiment, the composition includes any two transition ions described in Table 2. In other embodiments, the composition includes, any 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or 331 transition ions described in Table 2.
[0059] In another embodiment, the transition ions correspond with human proteins including LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. In another embodiment, the transition ions are derived from human proteins including LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. These proteins can further include transition ions corresponding with and/or derived from any number of additional proteins from Table 2. Thus, the composition can include, any additional 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or 331 transition ions described in Table 2.
[0060] In another embodiment, each of the transition ions in the composition corresponds and/or is derived from a different protein. In another embodiment, 90% of the transition ions in the composition correspond with and/or are derived from a protein that no other transition ion in the composition corresponds. In other embodiments, 80, 70, 60, 50, 40, 30, 20, 10 or 0% of the transition ions in the composition correspond and/or are derived from a protein that no other transition ion in the composition corresponds.
[0061] The compositions described herein included synthetic peptides. Synthetic peptides can be used as controls for the abundance of proteins they are derived from and/or correspond. In certain embodiments, the abundance of the synthetic peptides is defined and the results are compared to LC-SRM-MS results from a peptide found in a sample to the LC-SRM-MS results in the corresponding synthetic peptide. This allows for the calculation of the abundance of the peptide in the sample. In certain embodiments, by knowing the abundance of a peptide in a sample, the abundance of the protein it corresponded to is determined.
[0062] Synthetic peptides can be generated using any method known in the art. These methods can include recombinant expression techniques such as expression in bacteria or in vitro expression in eukaryotic cell lysate. These methods can also include solid phase synthesis.
[0063] In one embodiment, the composition includes synthetic peptides selected from any of the peptides described in Table 2. In another embodiment, the composition included any two peptides described in Table 2. In other embodiments, the composition included, any 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or more peptides described in Table 2.
[0064] In another embodiment, the peptides corresponded with human genes including LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1 as described in corresponding patent application. These genes can further include peptides corresponding with any number of additional genes from Table 2. Thus, the composition can include, any additional 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or more peptides described in Table 2.
[0065] In another embodiment, each of the peptides in the composition each corresponds with a different protein. In another embodiment, 90% of the peptides in the composition correspond with a protein that no other peptide in the composition corresponds with. In other embodiments, 80, 70, 60, 50, 40, 30, 20, 10 or 0% of the peptides in the composition correspond with from a protein that no other peptide in the composition corresponds with.
[0066] The peptides can be isotopically labeled. The isotopes with which they can be labeled include 13C, 2H, .sup.15N and 18O. The peptides can also include a polar solvent. Polar solvents can include water and mixtures of ethanol and water.
[0067] In certain embodiments, the samples described herein are taken from mammals. These mammals include rats, mice, rabbits, dogs, non-human primates and humans. Samples can be isolated from any tissue or organ or from any bodily fluid. Organs from which samples can be taken include skin, heart, lung, brain, kidney, liver, pancreas, spleen, testes, ovaries, gall bladder, thymus, thyroid, eye, ear, nose, mouth, tongue, penis, vagina, bladder or larynx. Tissues include nervous tissue, vascular tissue, muscle, bone, gastrointestinal tract, epithelial tissue, fibroblastic tissue, mucous membranes, hair, skin, reproductive tissue and connective tissue. Body fluids and excretions include, blood, serum, saliva, urine, semen, vaginal secretions, excrement, bile, tears, lymph, ear wax, mucous, shed skin, finger nails, toe nails, skin oils, sweat and dandruff.
[0068] The relative abundance of one or more of the proteins represented by the transition ions and synthetic peptides described above can be used to diagnose, determine likelihood of the presence of, develop prognoses for and/or stage various diseases and pathologies. Often the organ, tissue or bodily fluid or excretion from which the sample is taken is distinct from the organ, tissue or bodily fluid or excretion involved with the disease or pathology. For example, the presence of lung cancer can be determined from a sample taken from blood. Any type of body fluid may be used in the assays.
[0069] Diseases and pathologies that status, diagnosis, presence or prognosis can be found using the transition ions and/or synthetic peptides described herein include cancer, metabolic diseases, neurological disorders, infectious diseases and cardiovascular disorders.
Examples
Exemplary Standard Operating Procedure
Protein Selection
[0070] Proteins known to be over-expressed on the cell surface of lung cancer tumors were obtained (through literature searching, experimental data or proprietary databases). This was referred to as set `A`. Proteins known to be over-secreted by lung cancer tumor cells were obtained (through literature searching, experimental data or proprietary databases). This was referred to as set `B`. Proteins associated with lung cancer in the literature were mined. This was referred to as set `C`. Proteins of interest (sets A, B and C are merged resulting in over 700 proteins) were assembled. The set of proteins was reduced to a set of 388 proteins (see Table 4) by prioritizing those proteins that have been previously detected my LC-MS/MS in blood (serum or plasma).
[0071] Selected proteins were then identified by their UniProt protein name and accession, their Entrez gene symbol and gene name, the isoform accession and their amino acid sequence. The canonical isoform in UniProt was selected if a protein has more than one isoform.
Peptide Selection for Synthesis
[0072] The five best peptides per protein for LC-SRM-MS assay were selected for as follows. Fully tryptic peptides having a monoisotopic mass of 800-3500 mass units, without miscleavages, not containing a cysteine (C) or a methionine (M), without having high miscleavage probability were selected. Further, any peptide that was bounded by KK, KR, RK or RR (either upstream or downstream) in the corresponding protein sequence was not selected.
[0073] Peptides were selected that were unique to the protein of interest. Peptides were only selected that match only one protein or protein family including analogues of the one protein, when searched in protein databases. Further, peptides which were observed in post-translational modified forms were not selected. Databases were assessed that showed expression of the proteins from which the peptides were isolated in human blood. Also databases of good quality MS peptides were searched. Peptides that appeared in human blood and were good quality MS peptides were favored. If these methods did not result in a sufficient number of peptides, rules were relaxed in a step wise manner to allow a greater number of peptides until a sufficient number was reached. The purity of the synthesized peptides was >75% and the amount of material was ≧25 μg. Peptides did not need to be desalted.
[0074] The four best transitions per peptide are then selected and optimized based on experimental results from a mixture of synthetic peptides. LC-SRM-MS-triggered MS/MS spectra were acquired for each synthetic peptide, using a QTRAP 5500 instrument. One spectrum for the doubly- and one for the triply-charged precursor ion was collected for each peptide For the identified peptides (Mascot score≧15), retention time was recorded for the four most intense b or y transition ions. The selected transition ions possessed m/z values were at least 30 m/z above or below those of the precursor ions; they did not interfere with other synthetic peptides; and they were transition ions due to breakage of peptide bond at different sites.
[0075] If an insufficient percentage of the synthetic peptides were acquired, the steps were repeated. In some cases, the second transition with first with theoretical y+ ions with m/z values at least 30 m/z above those of the doubly charged precursor ion was selected if an insufficient percentage was acquired. Peptides that failed to trigger the acquisition of MS/MS spectrum were discarded.
[0076] Collision energy (CE) for each selected transition (See Table 4) was optimized.
Exemplary Protein List
[0077] The abundance of the following proteins can be assessed substantially simultaneously using the MS-LC-SRM-MS system described herein. Transitions from these proteins can be used to diagnose diseases including lung cancer when their abundance is measured in a biological specimen from a subject to be diagnosed for lung cancer. In one embodiment, the abundances of these proteins are measured in the blood serum of the subject.
TABLE-US-00001 TABLE 1 Sources of Subcellular Evidence for Gene Tissue Biomarkers Location Presence in UniProt Protein Protein Name Symbol Biomarkers in Literature (UniProt) Blood 1433B_HUMAN 14-3-3 YWHAB Secreted, LungCancers Cytoplasm. Literature, protein EPI Melanosome. Detection beta/alpha Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. 1433E_HUMAN 14-3-3 YWHAE ENDO LungCancers, Cytoplasm (By Literature, protein BenignNodules similarity). Detection epsilon Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. 1433S_HUMAN 14-3-3 SFN Secreted, LungCancers Cytoplasm. UniProt, protein EPI Nucleus (By Literature, sigma similarity). Detection Secreted. Note = May be secreted by a non-classical secretory pathway. 1433T_HUMAN 14-3-3 YWHAQ EPI LungCancers, Cytoplasm. Detection protein BenignNodules Note = In theta neurons, axonally transported to the nerve terminals. 1433Z_HUMAN 14-3-3 YWHAZ EPI LungCancers, Cytoplasm. Detection protein BenignNodules Melanosome. zeta/delta Note = Located to stage I to stage IV melanosomes. 6PGD_HUMAN 6-phosphogluconate PGD EPI, ENDO Cytoplasm (By Detection dehydrogenase, similarity). decarboxylating A1AG1_HUMAN Alpha-1- ORM1 EPI Symptoms Secreted. UniProt, acid Literature, glycoprotein 1 Detection, Prediction ABCD1_HUMAN ATP- ABCD1 ENDO Peroxisome Detection, binding membrane; Prediction cassette Multi-pass sub-family membrane D member 1 protein. ADA12_HUMAN Disintegrin ADAM12 LungCancers, Isoform 1: Cell UniProt, and BenignNodules, membrane; Detection, metalloproteinase Symptoms Single-pass Prediction domain- type I containing membrane protein 12 protein.|Isoform 2: Secreted.|Isoform 3: Secreted (Potential).|Isoform 4: Secreted (Potential). ADML_HUMAN ADM ADM LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction AGR2_HUMAN Anterior AGR2 EPI LungCancers Secreted. UniProt, gradient Endoplasmic Prediction protein 2 reticulum (By homolog similarity). AIFM1_HUMAN Apoptosis- AIFM1 EPI, ENDO LungCancers Mitochondrion Detection, inducing intermembrane Prediction factor 1, space. Nucleus. mitochondrial Note = Translocated to the nucleus upon induction of apoptosis. ALDOA_HUMAN Fructose- ALDOA Secreted, LungCancers, Literature, bisphosphate EPI Symptoms Detection aldolase A AMPN_HUMAN Aminopeptidase N ANPEP EPI, ENDO LungCancers, Cell membrane; UniProt, BenignNodules, Single-pass Detection Symptoms type II membrane protein. Cytoplasm, cytosol (Potential). Note = A soluble form has also been detected. ANGP1_HUMAN Angiopoietin-1 ANGPT1 LungCancers, Secreted. UniProt, BenignNodules Literature, Prediction ANGP2_HUMAN Angiopoietin-2 ANGPT2 LungCancers, Secreted. UniProt, BenignNodules Literature, Prediction APOA1_HUMAN Apolipoprotein A-I APOA1 LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction APOE_HUMAN Apolipoprotein E APOE EPI, ENDO LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction ASM3B_HUMAN Acid SMPDL3B EPI, ENDO Secreted (By UniProt, sphingomyelinase-like similarity). Prediction phosphodiesterase 3b AT2A2_HUMAN Sarcoplasmic/ ATP2A2 EPI, ENDO LungCancers, Endoplasmic Detection endoplasmic BenignNodules reticulum reticulum membrane; calcium Multi-pass ATPase 2 membrane protein. Sarcoplasmic reticulum membrane; Multi-pass membrane protein. ATS1_HUMAN A ADAMTS1 LungCancers, Secreted, UniProt, disintegrin BenignNodules, extracellular Literature, and Symptoms space, Prediction metalloproteinase with extracellular thrombospondin matrix (By motifs 1 similarity). ATS12_HUMAN A ADAMTS12 LungCancers Secreted, UniProt, disintegrin extracellular Detection, and space, Prediction metalloproteinase with extracellular thrombospondin matrix (By motifs 12 similarity). ATS19_HUMAN A ADAMTS19 LungCancers Secreted, UniProt, disintegrin extracellular Prediction and space, metalloproteinase with extracellular thrombospondin matrix (By motifs 19 similarity). BAGE1_HUMAN B BAGE LungCancers Secreted UniProt, melanoma (Potential). Prediction antigen 1 BAGE2_HUMAN B BAGE2 LungCancers Secreted UniProt, melanoma (Potential). Prediction antigen 2 BAGE3_HUMAN B BAGE3 LungCancers Secreted UniProt, melanoma (Potential). Prediction antigen 3 BAGE4_HUMAN B BAGE4 LungCancers Secreted UniProt, melanoma (Potential). Prediction antigen 4 BAGE5_HUMAN B BAGE5 LungCancers Secreted UniProt, melanoma (Potential). Prediction antigen 5 BASP1_HUMAN Brain acid BASP1 Secreted, Cell membrane; Detection soluble EPI Lipid-anchor. protein 1 Cell projection, growth cone. Note = Associated with the membranes of growth cones that form the tips of elongating axons. BAX_HUMAN Apoptosis BAX EPI LungCancers, Isoform Alpha: UniProt, regulator BenignNodules Mitochondrion Literature, BAX membrane; Prediction Single-pass membrane protein. Cytoplasm. Note = Colocalizes with 14- 3-3 proteins in the cytoplasm. Under stress conditions, redistributes to the mitochondrion membrane through the release from JNK- phosphorylated 14-3-3 proteins.|Isoform Beta: Cytoplasm.|Isoform Gamma: Cytoplasm.|Isoform Delta: Cytoplasm (Potential). BDNF_HUMAN Brain- BDNF BenignNodules, Secreted. UniProt, derived Symptoms Literature, neurotrophic Prediction factor BGH3_HUMAN Transforming TGFBI LungCancers, Secreted, UniProt, growth BenignNodules extracellular Detection factor-beta- space, induced extracellular protein ig- matrix. h3 Note = May be associated both with microfibrils and with the cell surface. BMP2_HUMAN Bone BMP2 LungCancers, Secreted. UniProt, morphogenetic BenignNodules, Literature protein 2 Symptoms BST1_HUMAN ADP- BST1 EPI Symptoms Cell membrane; Detection, ribosyl Lipid-anchor, Prediction cyclase 2 GPI-anchor. C163A_HUMAN Scavenger CD163 EPI Symptoms Soluble CD163: UniProt, receptor Secreted.|Cell Detection cysteine- membrane; rich type 1 Single-pass protein type I M130 membrane protein. Note = Isoform 1 and isoform 2 show a lower surface expression when expressed in cells. C4BPA_HUMAN C4b- C4BPA LungCancers, Secreted. UniProt, binding Symptoms Detection, protein Prediction alpha chain CAH9_HUMAN Carbonic CA9 LungCancers, Nucleus. UniProt anhydrase BenignNodules, Nucleus, 9 Symptoms nucleolus. Cell membrane;
Single-pass type I membrane protein. Cell projection, microvillus membrane; Single-pass type I membrane protein. Note = Found on the surface microvilli and in the nucleus, particularly in nucleolus. CALR_HUMAN Calreticulin CALR EPI Symptoms Endoplasmic UniProt, reticulum Literature, lumen. Detection, Cytoplasm, Prediction cytosol. Secreted, extracellular space, extracellular matrix. Cell surface. Note = Also found in cell surface (T cells), cytosol and extracellular matrix. Associated with the lytic granules in the cytolytic T- lymphocytes. CALU_HUMAN Calumenin CALU EPI Symptoms Endoplasmic UniProt, reticulum Detection, lumen. Prediction Secreted. Melanosome. Sarcoplasmic reticulum lumen (By similarity). Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. CALX_HUMAN Calnexin CANX Secreted, BenignNodules Endoplasmic UniProt, EPI, ENDO reticulum Literature, membrane; Detection Single-pass type I membrane protein. Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. CAP7_HUMAN Azurocidin AZU1 EPI Symptoms Cytoplasmic Prediction granule. Note = Cytoplasmic granules of neutrophils. CATB_HUMAN Cathepsin CTSB Secreted LungCancers Lysosome. Literature, B Melanosome. Detection, Note = Identified Prediction by mass spectrometry in melanosome fractions from stage I to stage IV. CATG_HUMAN Cathepsin CTSG Secreted, BenignNodules Cell surface. Detection, G ENDO Prediction CBPB2_HUMAN Carboxypeptidase CPB2 LungCancers, Secreted. UniProt, B2 BenignNodules, Detection, Symptoms Prediction CCL22_HUMAN C-C motif CCL22 LungCancers, Secreted. UniProt, chemokine 22 BenignNodules Prediction CD14_HUMAN Monocyte CD14 EPI LungCancers, Cell membrane; Literature, differentiation BenignNodules, Lipid-anchor, Detection, antigen Symptoms GPI-anchor. Prediction CD14 CD24_HUMAN Signal CD24 LungCancers, Cell membrane; Literature transducer BenignNodules Lipid-anchor, CD24 GPI-anchor. CD2A2_HUMAN Cyclin- CDKN2A LungCancers, Cytoplasm. Literature, dependent BenignNodules Nucleus.|Nucleus, Prediction kinase nucleolus inhibitor (By similarity). 2A, isoform 4 CD38_HUMAN ADP- CD38 EPI, ENDO Symptoms Membrane; UniProt, ribosyl Single-pass Literature cyclase 1 type II membrane protein. CD40L_HUMAN CD40 CD40LG LungCancers, Cell membrane; UniProt, ligand BenignNodules, Single-pass Literature Symptoms type II membrane protein.|CD40 ligand, soluble form: Secreted. CD44_HUMAN CD44 CD44 EPI LungCancers, Membrane; UniProt, antigen BenignNodules, Single-pass Literature, Symptoms type I Detection, membrane Prediction protein. CD59_HUMAN CD59 CD59 LungCancers, Cell membrane; UniProt, glycoprotein BenignNodules, Lipid-anchor, Literature, Symptoms GPI-anchor. Detection, Secreted. Prediction Note = Soluble form found in a number of tissues. CD97_HUMAN CD97 CD97 EPI, ENDO Symptoms Cell membrane; UniProt antigen Multi-pass membrane protein.|CD97 antigen subunit alpha: Secreted, extracellular space. CDCP1_HUMAN CUB CDCP1 LungCancers Isoform 1: Cell UniProt, domain- membrane; Prediction containing Single-pass protein 1 membrane protein (Potential). Note = Shedding may also lead to a soluble peptide.|Isoform 3: Secreted. CDK4_HUMAN Cell CDK4 LungCancers, Literature division Symptoms protein kinase 4 CEAM5_HUMAN Carcinoembryonic CEACAM5 EPI LungCancers, Cell membrane; Literature, antigen- BenignNodules, Lipid-anchor, Prediction related cell Symptoms GPI-anchor. adhesion molecule 5 CEAM8_HUMAN Carcinoembryonic CEACAM8 EPI LungCancers Cell membrane; Detection, antigen- Lipid-anchor, Prediction related cell GPI-anchor. adhesion molecule 8 CERU_HUMAN Ceruloplasmin CP EPI LungCancers, Secreted. UniProt, Symptoms Literature, Detection, Prediction CH10_HUMAN 10 kDa HSPE1 ENDO LungCancers Mitochondrion Literature, heat shock matrix. Detection, protein, Prediction mitochondrial CH60_HUMAN 60 kDa HSPD1 Secreted, LungCancers, Mitochondrion Literature, heat shock EPI, ENDO Symptoms matrix. Detection protein, mitochondrial CKAP4_HUMAN Cytoskeleton- CKAP4 EPI, ENDO LungCancers Endoplasmic UniProt associated reticulum-Golgi protein 4 intermediate compartment membrane; Single-pass membrane protein (Potential). CL041_HUMAN Uncharacterized C12orf41 ENDO Prediction protein C12orf41 CLCA1_HUMAN Calcium- CLCA1 LungCancers, Secreted, UniProt, activated BenignNodules extracellular Prediction chloride space. Cell channel membrane; regulator 1 Peripheral membrane protein; Extracellular side. Note = Protein that remains attached to the plasma membrane appeared to be predominantly localized to microvilli. CLIC1_HUMAN Chloride CLIC1 EPI Nucleus. UniProt, intracellular Nucleus Literature, channel membrane; Detection protein 1 Single-pass membrane protein (Probable). Cytoplasm. Cell membrane; Single-pass membrane protein (Probable). Note = Mostly in the nucleus including in the nuclear membrane. Small amount in the cytoplasm and the plasma membrane. Exists both as soluble cytoplasmic protein and as membrane protein with probably a single transmembrane domain. CLUS_HUMAN Clusterin CLU EPI, ENDO LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction CMGA_HUMAN Chromogranin-A CHGA LungCancers, Secreted. UniProt, BenignNodules Note = Neuro- Literature, endocrine and Detection, endocrine Prediction secretory granules.
CNTN1_HUMAN Contactin-1 CNTN1 LungCancers Isoform 1: Cell Detection, membrane; Prediction Lipid-anchor, GPI- anchor; Extracellular side.|Isoform 2: Cell membrane; Lipid-anchor, GPI- anchor; Extracellular side. CO4A1_HUMAN Collagen COL4A1 LungCancers Secreted, UniProt, alpha-1(IV) extracellular Detection, chain space, Prediction extracellular matrix, basement membrane. CO5A2_HUMAN Collagen COL5A2 LungCancers Secreted, UniProt, alpha-2(V) extracellular Detection, chain space, Prediction extracellular matrix (By similarity). CO6A3_HUMAN Collagen COL6A3 Secreted Symptoms Secreted, UniProt, alpha-3(VI) extracellular Detection, chain space, Prediction extracellular matrix (By similarity). COCA1_HUMAN Collagen COL12A1 ENDO LungCancers, Secreted, UniProt, alpha-1(XII) Symptoms extracellular Prediction chain space, extracellular matrix (By similarity). COF1_HUMAN Cofilin-1 CFL1 Secreted, LungCancers, Nucleus matrix. Detection, EPI BenignNodules Cytoplasm, Prediction cytoskeleton. Note = Almost completely in nucleus in cells exposed to heat shock or 10% dimethyl sulfoxide. COIA1_HUMAN Collagen COL18A1 LungCancers, Secreted, UniProt, alpha-1(XVIII) BenignNodules extracellular Literature, chain space, Detection, extracellular Prediction matrix (By similarity). COX5A_HUMAN Cytochrome COX5A Secreted, Mitochondrion Prediction c oxidase ENDO inner subunit 5A, membrane. mitochondrial CRP_HUMAN C-reactive CRP LungCancers, Secreted. UniProt, protein BenignNodules, Literature, Symptoms Detection, Prediction CS051_HUMAN UPF0470 C19orf51 ENDO Prediction protein C19orf51 CSF1_HUMAN Macrophage CSF1 LungCancers, Cell membrane; UniProt, colony- BenignNodules Single-pass Literature, stimulating membrane Detection factor 1 protein (By similarity).|Processed macrophage colony- stimulating factor 1: Secreted, extracellular space (By similarity). CSF2_HUMAN Granulocyte- CSF2 LungCancers, Secreted. UniProt, macrophage BenignNodules Literature, colony- Prediction stimulating factor CT085_HUMAN Uncharacterized C20orf85 LungCancers, Prediction protein BenignNodules C20orf85 CTGF_HUMAN Connective CTGF LungCancers, Secreted, UniProt, tissue BenignNodules extracellular Literature, growth space, Detection, factor extracellular Prediction matrix (By similarity). Secreted (By similarity). CYR61_HUMAN Protein CYR61 LungCancers, Secreted. UniProt, CYR61 BenignNodules Prediction CYTA_HUMAN Cystatin-A CSTA LungCancers Cytoplasm. Literature, Detection CYTB_HUMAN Cystatin-B CSTB Secreted Cytoplasm. Literature, Nucleus. Detection DDX17_HUMAN Probable DDX17 ENDO LungCancers, Nucleus. Detection, ATP- BenignNodules Prediction dependent RNA helicase DDX17 DEFB1_HUMAN Beta- DEFB1 LungCancers, Secreted. UniProt, defensin 1 BenignNodules Prediction DESP_HUMAN Desmoplakin DSP EPI, ENDO LungCancers Cell junction, Detection desmosome. Cytoplasm, cytoskeleton. Note = Innermost portion of the desmosomal plaque. DFB4A_HUMAN Beta- DEFB4A LungCancers, Secreted. UniProt defensin 4A BenignNodules DHI1L_HUMAN Hydroxysteroid HSD11B1L LungCancers Secreted UniProt, 11-beta- (Potential). Prediction dehydrogenase 1-like protein DMBT1_HUMAN Deleted in DMBT1 LungCancers, Secreted (By UniProt, malignant BenignNodules similarity). Detection, brain Note = Some Prediction tumors 1 isoforms may protein be membrane- bound. Localized to the lumenal aspect of crypt cells in the small intestine. In the colon, seen in the lumenal aspect of surface epithelial cells. Formed in the ducts of von Ebner gland, and released into the fluid bathing the taste buds contained in the taste papillae (By similarity). DMKN_HUMAN Dermokine DMKN LungCancers Secreted. UniProt, Detection, Prediction DPP4_HUMAN Dipeptidyl DPP4 EPI LungCancers, Dipeptidyl UniProt, peptidase 4 BenignNodules, peptidase 4 Detection Symptoms soluble form: Secreted.|Cell membrane; Single-pass type II membrane protein. DSG2_HUMAN Desmoglein-2 DSG2 ENDO Symptoms Cell membrane; UniProt, Single-pass Detection type I membrane protein. Cell junction, desmosome. DX39A_HUMAN ATP- DDX39A EPI Nucleus (By Prediction dependent similarity). RNA helicase DDX39A DX39B_HUMAN Spliceosome DDX39B EPI Nucleus. Prediction RNA Nucleus helicase speckle. DDX39B DYRK2_HUMAN Dual DYRK2 ENDO LungCancers Cytoplasm. Literature specificity Nucleus. tyrosine- Note = Translocates phosphorylation- into the regulated nucleus kinase 2 following DNA damage. EDN2_HUMAN Endothelin-2 EDN2 LungCancers Secreted. UniProt, Prediction EF1A1_HUMAN Elongation EEF1A1 Secreted, LungCancers, Cytoplasm. Detection factor 1- EPI BenignNodules alpha 1 EF1D_HUMAN Elongation EEF1D Secreted, LungCancers Prediction factor 1- EPI delta EF2_HUMAN Elongation EEF2 Secreted, Cytoplasm. Literature, factor 2 EPI Detection EGF_HUMAN Pro- EGF LungCancers, Membrane; UniProt, epidermal BenignNodules, Single-pass Literature growth Symptoms type I factor membrane protein. EGFL6_HUMAN Epidermal EGFL6 LungCancers Secreted, UniProt, growth extracellular Detection, factor-like space, Prediction protein 6 extracellular matrix, basement membrane (By similarity). ENOA_HUMAN Alpha- ENO1 Secreted, LungCancers, Cytoplasm. Cell Literature, enolase EPI, ENDO BenignNodules, membrane. Detection, Symptoms Cytoplasm, Prediction myofibril, sarcomere, M- band. Note = Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M-band.|Isoform MBP-1: Nucleus. ENOG_HUMAN Gamma- ENO2 EPI LungCancers, Cytoplasm (By Literature, enolase Symptoms similarity). Cell Detection, membrane (By Prediction similarity). Note = Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form (By similarity). ENOX2_HUMAN Ecto-NOX ENOX2 LungCancers Cell membrane. UniProt, disulfide- Secreted, Detection thiol extracellular exchanger space. 2 Note = Extracellular and plasma membrane- associated. ENPL_HUMAN Endoplasmin HSP90B1 Secreted, LungCancers, Endoplasmic Literature, EPI, ENDO BenignNodules, reticulum Detection,
Symptoms lumen. Prediction Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. EPHB6_HUMAN Ephrin EPHB6 LungCancers Membrane; UniProt, type-B Single-pass Literature receptor 6 type I membrane protein.|Isoform 3: Secreted (Probable). EPOR_HUMAN Erythropoietin EPOR LungCancers, Cell membrane; UniProt, receptor BenignNodules, Single-pass Literature, Symptoms type I Detection membrane protein.|Isoform EPOR-S: Secreted. Note = Secreted and located to the cell surface. ERBB3_HUMAN Receptor ERBB3 LungCancers, Isoform 1: Cell UniProt, tyrosine- BenignNodules membrane; Literature, protein Single-pass Prediction kinase type I erbB-3 membrane protein.|Isoform 2: Secreted. EREG_HUMAN Proepiregulin EREG LungCancers Epiregulin: UniProt Secreted, extracellular space. Proepiregulin: Cell membrane; Single-pass type I membrane protein. ERO1A_HUMAN ERO1-like ERO1L Secreted, Symptoms Endoplasmic Prediction protein EPI, ENDO reticulum alpha membrane; Peripheral membrane protein; Lumenal side. Note = The association with ERP44 is essential for its retention in the endoplasmic reticulum. ESM1_HUMAN Endothelial ESM1 LungCancers, Secreted. UniProt, cell- BenignNodules Prediction specific molecule 1 EZRI_HUMAN Ezrin EZR Secreted LungCancers, Apical cell Literature, BenignNodules membrane; Detection, Peripheral Prediction membrane protein; Cytoplasmic side. Cell projection. Cell projection, microvillus membrane; Peripheral membrane protein; Cytoplasmic side. Cell projection, ruffle membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Note = Localization to the apical membrane of parietal cells depends on the interaction with MPP5. Localizes to cell extensions and peripheral processes of astrocytes (By similarity). Microvillar peripheral membrane protein (cytoplasmic side). F10A1_HUMAN Hsc70- ST13 EPI Cytoplasm (By Detection, interacting similarity).|Cytoplasm Prediction protein (Probable). FAM3C_HUMAN Protein FAM3C EPI, ENDO Secreted UniProt, FAM3C (Potential). Detection FAS_HUMAN Fatty acid FASN EPI LungCancers, Cytoplasm. Literature, synthase BenignNodules, Melanosome. Detection Symptoms Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. FCGR1_HUMAN High FCGR1A EPI LungCancers, Cell membrane; UniProt affinity BenignNodules, Single-pass immunoglobulin Symptoms type I gamma Fc membrane receptor I protein. Note = Stabilized at the cell membrane through interaction with FCER1G. FGF10_HUMAN Fibroblast FGF10 LungCancers Secreted UniProt, growth (Potential). Prediction factor 10 FGF2_HUMAN Heparin- FGF2 LungCancers, Literature binding BenignNodules, growth Symptoms factor 2 FGF7_HUMAN Keratinocyte FGF7 LungCancers, Secreted. UniProt, growth BenignNodules Literature, factor Prediction FGF9_HUMAN Glia- FGF9 LungCancers Secreted. UniProt, activating Literature, factor Prediction FGFR2_HUMAN Fibroblast FGFR2 LungCancers, Cell membrane; UniProt, growth BenignNodules Single-pass Literature, factor type I Prediction receptor 2 membrane protein.|Isoform 14: Secreted.|Isoform 19: Secreted. FGFR3_HUMAN Fibroblast FGFR3 LungCancers Membrane; UniProt, growth Single-pass Literature, factor type I Prediction receptor 3 membrane protein. FGL2_HUMAN Fibroleukin FGL2 BenignNodules, Secreted. UniProt, Symptoms Detection, Prediction FHIT_HUMAN Bis(5'- FHIT LungCancers, Cytoplasm. Literature adenosyl)- BenignNodules, triphosphatase Symptoms FIBA_HUMAN Fibrinogen FGA LungCancers, Secreted. UniProt, alpha chain BenignNodules, Literature, Symptoms Detection, Prediction FINC_HUMAN Fibronectin FN1 Secreted, LungCancers, Secreted, UniProt, EPI, ENDO BenignNodules, extracellular Literature, Symptoms space, Detection, extracellular Prediction matrix. FKB11_HUMAN Peptidyl- FKBP11 EPI, ENDO Membrane; UniProt, prolyl cis- Single-pass Prediction trans membrane isomerase protein FKBP11 (Potential). FOLH1_HUMAN Glutamate FOLH1 ENDO LungCancers, Cell membrane; UniProt, carboxypeptidase Symptoms Single-pass Literature 2 type II membrane protein.|Isoform PSMA': Cytoplasm. FOLR1_HUMAN Folate FOLR1 LungCancers Cell membrane; UniProt receptor Lipid-anchor, alpha GPI-anchor. Secreted (Probable). FOXA2_HUMAN Hepatocyte FOXA2 LungCancers Nucleus. Detection, nuclear Prediction factor 3- beta FP100_HUMAN Fanconi C17orf70 ENDO Symptoms Nucleus. Prediction anemia- associated protein of 100 kDa FRIH_HUMAN Ferritin FTH1 EPI LungCancers, Literature, heavy BenignNodules Detection, chain Prediction FRIL_HUMAN Ferritin FTL Secreted, BenignNodules, Literature, light chain EPI, ENDO Symptoms Detection G3P_HUMAN Glyceralde- GAPDH Secreted, LungCancers, Cytoplasm. Detection hyde-3- EPI, ENDO BenignNodules, Cytoplasm, phosphate Symptoms perinuclear dehydrogenase region. Membrane. Note = Postnuclear and Perinuclear regions. G6PD_HUMAN Glucose-6- G6PD Secreted, LungCancers, Literature, phosphate EPI Symptoms Detection 1- dehydrogenase G6PI_HUMAN Glucose-6- GPI Secreted, Symptoms Cytoplasm. UniProt, phosphate EPI Secreted. Literature, isomerase Detection GA2L1_HUMAN GAS2-like GAS2L1 ENDO Cytoplasm, Prediction protein 1 cytoskeleton (Probable). GALT2_HUMAN Polypeptide N- GALNT2 EPI, ENDO Golgi UniProt, acetylgalactosaminyl- apparatus, Detection transferase 2 Golgi stack membrane; Single-pass type II membrane protein. Secreted. Note = Resides preferentially in the trans and medial parts of the Golgi stack. A secreted form also exists. GAS6_HUMAN Growth GAS6 LungCancers Secreted. UniProt, arrest- Detection, specific Prediction protein 6 GDIR2_HUMAN Rho GDP- ARHGDIB EPI Cytoplasm. Detection dissociation inhibitor 2 GELS_HUMAN Gelsolin GSN LungCancers, Isoform 2: UniProt, BenignNodules Cytoplasm, Literature, cytoskeleton.|Isoform Detection, 1: Secreted. Prediction GGH_HUMAN Gamma- GGH LungCancers Secreted, UniProt, glutamyl extracellular Detection, hydrolase space. Prediction
Lysosome. Melanosome. Note = While its intracellular location is primarily the lysosome, most of the enzyme activity is secreted. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. GPC3_HUMAN Glypican-3 GPC3 LungCancers, Cell membrane; UniProt, Symptoms Lipid-anchor, Literature, GPI-anchor; Prediction Extracellular side (By similarity).|Secreted glypican-3: Secreted, extracellular space (By similarity). GRAN_HUMAN Grancalcin GCA EPI Cytoplasm. Prediction Cytoplasmic granule membrane; Peripheral membrane protein; Cytoplasmic side. Note = Primarily cytosolic in the absence of calcium or magnesium ions. Relocates to granules and other membranes in response to elevated calcium and magnesium levels. GREB1_HUMAN Protein GREB1 ENDO Membrane; UniProt, GREB1 Single-pass Prediction membrane protein (Potential). GREM1_HUMAN Gremlin-1 GREM1 LungCancers, Secreted UniProt, BenignNodules (Probable). Prediction GRP_HUMAN Gastrin- GRP LungCancers, Secreted. UniProt, releasing Symptoms Prediction peptide GRP78_HUMAN 78 kDa HSPA5 Secreted, LungCancers, Endoplasmic Detection, glucose- EPI, ENDO BenignNodules reticulum Prediction regulated lumen. protein Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. GSLG1_HUMAN Golgi GLG1 EPI, ENDO BenignNodules Golgi apparatus UniProt apparatus membrane; protein 1 Single-pass type I membrane protein. GSTP1_HUMAN Glutathione GSTP1 Secreted LungCancers, Literature, S- BenignNodules, Detection, transferase Symptoms Prediction P GTR1_HUMAN Solute SLC2A1 EPI, ENDO LungCancers, Cell membrane; Literature carrier BenignNodules, Multi-pass family 2, Symptoms membrane facilitated protein (By glucose similarity). transporter Melanosome. member 1 Note = Localizes primarily at the cell surface (By similarity). Identified by mass spectrometry in melanosome fractions from stage I to stage IV. GTR3_HUMAN Solute SLC2A3 EPI Membrane; Detection carrier Multi-pass family 2, membrane facilitated protein. glucose transporter member 3 H2A1_HUMAN Histone HIST1H2AG Secreted Nucleus. Detection, H2A type 1 Prediction H2A1B_HUMAN Histone HIST1H2AB Secreted Nucleus. Detection, H2A type Prediction 1-B/E H2A1C_HUMAN Histone HIST1H2AC Secreted Nucleus. Literature, H2A type Detection, 1-C Prediction H2A1D_HUMAN Histone HIST1H2AD Secreted Nucleus. Detection, H2A type Prediction 1-D HG2A_HUMAN HLA class CD74 LungCancers, Membrane; UniProt, II BenignNodules, Single-pass Literature histocompatibility Symptoms type II antigen membrane gamma protein chain (Potential). HGF_HUMAN Hepatocyte HGF LungCancers, Literature, growth BenignNodules, Prediction factor Symptoms HMGA1_HUMAN High HMGA1 LungCancers, Nucleus. Literature mobility BenignNodules, group Symptoms protein HMG- I/HMG-Y HPRT_HUMAN Hypoxanthine- HPRT1 EPI Cytoplasm. Detection, guanine Prediction phosphoribosyl- transferase HPSE_HUMAN Heparanase HPSE LungCancers, Lysosome UniProt, BenignNodules, membrane; Prediction Symptoms Peripheral membrane protein. Secreted. Note = Secreted, internalised and transferred to late endosomes/ lysosomes as a proheparanase. In lysosomes, it is processed into the active form, the heparanase. The uptake or internalisation of proheparanase is mediated by HSPGs. Heparin appears to be a competitor and retain proheparanase in the extracellular medium. HPT_HUMAN Haptoglobin HP LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction HS90A_HUMAN Heat shock HSP90AA1 Secreted, LungCancers, Cytoplasm. Literature, protein EPI Symptoms Melanosome. Detection HSP 90- Note = Identified alpha by mass spectrometry in melanosome fractions from stage I to stage IV. HS90B_HUMAN Heat shock HSP90AB1 Secreted, LungCancers Cytoplasm. Literature, protein EPI Melanosome. Detection HSP 90- Note = Identified beta by mass spectrometry in melanosome fractions from stage I to stage IV. HSPB1_HUMAN Heat shock HSPB1 Secreted, LungCancers, Cytoplasm. Literature, protein EPI BenignNodules Nucleus. Detection, beta-1 Cytoplasm, Prediction cytoskeleton, spindle. Note = Cytoplasmic in interphase cells. Colocalizes with mitotic spindles in mitotic cells. Translocates to the nucleus during heat shock. HTRA1_HUMAN Serine HTRA1 LungCancers Secreted. UniProt, protease Prediction HTRA1 HXK1_HUMAN Hexokinase-1 HK1 ENDO Symptoms Mitochondrion Literature, outer Detection membrane. Note = Its hydrophobic N- terminal sequence may be involved in membrane binding. HYAL2_HUMAN Hyaluronidase-2 HYAL2 LungCancers Cell membrane; Prediction Lipid-anchor, GPI-anchor. HYOU1_HUMAN Hypoxia HYOU1 EPI, ENDO Symptoms Endoplasmic Detection up- reticulum regulated lumen. protein 1 IBP2_HUMAN Insulin-like IGFBP2 LungCancers Secreted. UniProt, growth Literature, factor- Detection, binding Prediction protein 2 IBP3_HUMAN Insulin-like IGFBP3 LungCancers, Secreted. UniProt, growth BenignNodules, Literature, factor- Symptoms Detection, binding Prediction protein 3 ICAM1_HUMAN Intercellular ICAM1 LungCancers, Membrane; UniProt, adhesion BenignNodules, Single-pass Literature, molecule 1 Symptoms type I Detection membrane protein. ICAM3_HUMAN Intercellular ICAM3 EPI, ENDO LungCancers, Membrane; UniProt, adhesion BenignNodules, Single-pass Detection molecule 3 Symptoms type I membrane protein. IDHP_HUMAN Isocitrate IDH2 Secreted, Mitochondrion. Prediction dehydrogenase ENDO [NADP], mitochondrial
IF4A1_HUMAN Eukaryotic EIF4A1 Secreted, Detection, initiation EPI, ENDO Prediction factor 4A-I IGF1_HUMAN Insulin-like IGF1 LungCancers, Secreted.|Secreted. UniProt, growth BenignNodules, Literature, factor I Symptoms Detection, Prediction IKIP_HUMAN Inhibitor of IKIP ENDO Symptoms Endoplasmic UniProt, nuclear reticulum Prediction factor membrane; kappa-B Single-pass kinase- membrane interacting protein. protein Note = Isoform 4 deletion of the hydrophobic, or transmembrane region between AA 45-63 results in uniform distribution troughout the cell, suggesting that this region is responsible for endoplasmic reticulum localization. IL18_HUMAN Interleukin-18 IL18 LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Prediction IL19_HUMAN Interleukin-19 IL19 LungCancers Secreted. UniProt, Detection, Prediction IL22_HUMAN Interleukin-22 IL22 LungCancers, Secreted. UniProt, BenignNodules Prediction IL32_HUMAN Interleukin-32 IL32 LungCancers, Secreted. UniProt, BenignNodules Prediction IL7_HUMAN Interleukin-7 IL7 LungCancers, Secreted. UniProt, BenignNodules Literature, Prediction IL8_HUMAN Interleukin-8 IL8 LungCancers, Secreted. UniProt, BenignNodules, Literature Symptoms ILEU_HUMAN Leukocyte SERPINB1 Secreted, Cytoplasm (By Detection, elastase EPI similarity). Prediction inhibitor ILK_HUMAN Integrin- ILK Secreted LungCancers, Cell junction, Literature, linked BenignNodules, focal adhesion. Detection protein Symptoms Cell membrane; kinase Peripheral membrane protein; Cytoplasmic side. INHBA_HUMAN Inhibin INHBA LungCancers, Secreted. UniProt, beta A BenignNodules Literature, chain Prediction ISLR_HUMAN Immunoglobulin ISLR LungCancers Secreted UniProt, superfamily (Potential). Detection, containing Prediction leucine- rich repeat protein ITA5_HUMAN Integrin ITGA5 EPI LungCancers, Membrane; UniProt, alpha-5 BenignNodules, Single-pass Literature, Symptoms type I Detection membrane protein. ITAM_HUMAN Integrin ITGAM EPI, ENDO LungCancers, Membrane; UniProt, alpha-M BenignNodules, Single-pass Literature Symptoms type I membrane protein. K0090_HUMAN Uncharacterized KIAA0090 EPI Symptoms Membrane; UniProt, protein Single-pass Prediction KIAA0090 type I membrane protein (Potential). K1C18_HUMAN Keratin, KRT18 Secreted LungCancers, Cytoplasm, Literature, type I BenignNodules perinuclear Detection, cytoskeletal 18 region. Prediction K1C19_HUMAN Keratin, KRT19 LungCancers, Literature, type I BenignNodules Detection, cytoskeletal 19 Prediction K2C8_HUMAN Keratin, KRT8 EPI LungCancers Cytoplasm. Literature, type II Detection cytoskeletal 8 KIT_HUMAN Mast/stem KIT LungCancers Membrane; UniProt, cell growth Single-pass Literature, factor type I Detection receptor membrane protein. KITH_HUMAN Thymidine TK1 LungCancers Cytoplasm. Literature, kinase, Prediction cytosolic KLK11_HUMAN Kallikrein-11 KLK11 LungCancers Secreted. UniProt, Literature, Prediction KLK13_HUMAN Kallikrein-13 KLK13 LungCancers Secreted UniProt, (Probable). Literature, Detection, Prediction KLK14_HUMAN Kallikrein-14 KLK14 LungCancers, Secreted, UniProt, Symptoms extracellular Literature, space. Prediction KLK6_HUMAN Kallikrein-6 KLK6 LungCancers, Secreted. UniProt, BenignNodules, Nucleus, Literature, Symptoms nucleolus. Detection, Cytoplasm. Prediction Mitochondrion. Microsome. Note = In brain, detected in the nucleus of glial cells and in the nucleus and cytoplasm of neurons. Detected in the mitochondrial and microsomal fractions of HEK-293 cells and released into the cytoplasm following cell stress. KNG1_HUMAN Kininogen-1 KNG1 LungCancers, Secreted, UniProt, BenignNodules, extracellular Detection, Symptoms space. Prediction KPYM_HUMAN Pyruvate PKM2 Secreted, LungCancers, Cytoplasm. Literature, kinase EPI Symptoms Nucleus. Detection isozymes Note = Translocates M1/M2 to the nucleus in response to different apoptotic stimuli. Nuclear translocation is sufficient to induce cell death that is caspase independent, isoform-specific and independent of its enzymatic actvity. KRT35_HUMAN Keratin, KRT35 ENDO Detection, type I Prediction cuticular Ha5 LAMB2_HUMAN Laminin LAMB2 ENDO LungCancers, Secreted, UniProt, subunit Symptoms extracellular Detection, beta-2 space, Prediction extracellular matrix, basement membrane. Note = S-laminin is concentrated in the synaptic cleft of the neuromuscular junction. LDHA_HUMAN L-lactate LDHA Secreted, LungCancers Cytoplasm. Literature, dehydrogenase EPI, ENDO Detection, A chain Prediction LDHB_HUMAN L-lactate LDHB EPI LungCancers Cytoplasm. Detection, dehydrogenase Prediction B chain LEG1_HUMAN Galectin-1 LGALS1 Secreted LungCancers Secreted, UniProt, extracellular Detection space, extracellular matrix. LEG3_HUMAN Galectin-3 LGALS3 LungCancers, Nucleus. Literature, BenignNodules Note = Cytoplasmic Detection, in adenomas and Prediction carcinomas. May be secreted by a non- classical secretory pathway and associate with the cell surface. LEG9_HUMAN Galectin-9 LGALS9 ENDO Symptoms Cytoplasm (By UniProt similarity). Secreted (By similarity). Note = May also be secreted by a non-classical secretory pathway (By similarity). LG3BP_HUMAN Galectin-3- LGALS3BP Secreted LungCancers, Secreted. UniProt, binding BenignNodules, Secreted, Literature, protein Symptoms extracellular Detection, space, Prediction extracellular matrix. LPLC3_HUMAN Long C20orf185 LungCancers Secreted (By UniProt, palate, lung similarity). Prediction and nasal Cytoplasm. epithelium Note = According to carcinoma- PubMed: 12837268 associated it is cytoplasmic. protein 3 LPLC4_HUMAN Long C20orf186 LungCancers Secreted (By UniProt, palate, lung similarity). Prediction and nasal Cytoplasm. epithelium carcinoma- associated protein 4 LPPRC_HUMAN Leucine- LRPPRC Secreted, LungCancers, Mitochondrion. Prediction rich PPR ENDO Symptoms Nucleus, motif- nucleoplasm. containing Nucleus inner protein, membrane. mitochondrial Nucleus outer membrane. Note = Seems to be predominantly mitochondrial. LRP1_HUMAN Prolow- LRP1 EPI LungCancers, Low-density UniProt, density Symptoms lipoprotein Detection lipoprotein receptor-related receptor- protein 1 85 related kDa subunit: protein 1 Cell membrane; Single-pass type I membrane protein. Membrane, coated pit.|Low- density lipoprotein receptor-related protein 1 515 kDa subunit:
Cell membrane; Peripheral membrane protein; Extracellular side. Membrane, coated pit.|Low- density lipoprotein receptor-related protein 1 intracellular domain: Cytoplasm. Nucleus. Note = After cleavage, the intracellular domain (LRPICD) is detected both in the cytoplasm and in the nucleus. LUM_HUMAN Lumican LUM Secreted, LungCancers, Secreted, UniProt, EPI BenignNodules, extracellular Detection, Symptoms space, Prediction extracellular matrix (By similarity). LY6K_HUMAN Lymphocyte LY6K LungCancers, Secreted. UniProt, antigen Symptoms Cytoplasm. Cell Prediction 6K membrane; Lipid- anchor, GPI-anchor (Potential). LYAM2_HUMAN E-selectin SELE LungCancers, Membrane; UniProt, BenignNodules, Single-pass Literature, Symptoms type I Detection membrane protein. LYAM3_HUMAN P-selectin SELP LungCancers, Membrane; UniProt, BenignNodules, Single-pass Literature, Symptoms type I Detection membrane protein. LYOX_HUMAN Protein- LOX LungCancers, Secreted, UniProt, lysine 6- BenignNodules extracellular Detection, oxidase space. Prediction LYPD3_HUMAN Ly6/PLAUR LYPD3 LungCancers Cell membrane; Detection, domain- Lipid-anchor, Prediction containing GPI-anchor. protein 3 MAGA4_HUMAN Melanoma- MAGEA4 LungCancers Literature, associated Prediction antigen 4 MASP1_HUMAN Mannan- MASP1 LungCancers, Secreted. UniProt, binding Symptoms Detection, lectin Prediction serine protease 1 MDHC_HUMAN Malate MDH1 Secreted Cytoplasm. Literature, dehydrogenase, Detection, cytoplasmic Prediction MDHM_HUMAN Malate MDH2 ENDO LungCancers Mitochondrion Detection, dehydrogenase, matrix. Prediction mitochondrial MIF_HUMAN Macrophage MIF Secreted LungCancers, Secreted. UniProt, migration BenignNodules, Cytoplasm. Literature, inhibitory Symptoms Note = Does not Prediction factor have a cleavable signal sequence and is secreted via a specialized, non- classical pathway. Secreted by macrophages upon stimulation by bacterial lipopolysaccharide (LPS), or by M. tuberculosis antigens. MLH1_HUMAN DNA MLH1 ENDO LungCancers, Nucleus. Literature mismatch BenignNodules, repair Symptoms protein Mlh1 MMP1_HUMAN Interstitial MMP1 LungCancers, Secreted, UniProt, collagenase BenignNodules, extracellular Literature, Symptoms space, Prediction extracellular matrix (Probable). MMP11_HUMAN Stromelysin-3 MMP11 LungCancers, Secreted, UniProt, Symptoms extracellular Literature, space, Prediction extracellular matrix (Probable). MMP12_HUMAN Macrophage MMP12 LungCancers, Secreted, UniProt, metalloelastase BenignNodules, extracellular Literature, Symptoms space, Prediction extracellular matrix (Probable). MMP14_HUMAN Matrix MMP14 ENDO LungCancers, Membrane; UniProt, metallopro- BenignNodules, Single-pass Literature, teinase-14 Symptoms type I Detection membrane protein (Potential). Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. MMP2_HUMAN 72 kDa MMP2 LungCancers, Secreted, UniProt, type IV BenignNodules, extracellular Literature, collagenase Symptoms space, Detection, extracellular Prediction matrix (Probable). MMP26_HUMAN Matrix MMP26 LungCancers Secreted, UniProt, metallopro- extracellular Prediction teinase-26 space, extracellular matrix. MMP7_HUMAN Matrilysin MMP7 LungCancers, Secreted, UniProt, BenignNodules, extracellular Literature, Symptoms space, Prediction extracellular matrix (Probable). MMP9_HUMAN Matrix MMP9 LungCancers, Secreted, UniProt, metallopro- BenignNodules, extracellular Literature, teinase-9 Symptoms space, Detection, extracellular Prediction matrix (Probable). MOGS_HUMAN Mannosyl- MOGS ENDO Endoplasmic UniProt, oligosaccharide reticulum Prediction glucosidase membrane; Single-pass type II membrane protein. MPRI_HUMAN Cation- IGF2R EPI, ENDO LungCancers, Lysosome UniProt, independent Symptoms membrane; Literature, mannose-6- Single-pass Detection phosphate type I receptor membrane protein. MRP3_HUMAN Canalicular ABCC3 EPI LungCancers Membrane; Literature, multispecific Multi-pass Detection organic membrane anion protein. transporter 2 MUC1_HUMAN Mucin-1 MUC1 EPI LungCancers, Apical cell UniProt, BenignNodules, membrane; Literature, Symptoms Single-pass Prediction type I membrane protein. Note = Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.|Isoform 5: Secreted.|Isoform 7: Secreted.|Isoform 9: Secreted.|Mucin-1 subunit beta: Cell membrane. Cytoplasm. Nucleus. Note = On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma- catenin at the nucleus. MUC16_HUMAN Mucin-16 MUC16 LungCancers Cell membrane; UniProt, Single-pass Detection type I membrane protein. Secreted, extracellular space. Note = May be liberated into the extracellular space following the phosphorylation of the intracellular C- terminus which induces the proteolytic cleavage and liberation of the extracellular domain. MUC4_HUMAN Mucin-4 MUC4 LungCancers, Membrane; UniProt BenignNodules Single-pass membrane protein (Potential). Secreted. Note = Isoforms lacking the Cys- rich region, EGF-like domains and transmembrane region are secreted. Secretion occurs by
splicing or proteolytic processing. Mucin- 4 beta chain: Cell membrane; Single- pass membrane protein.|Mucin- 4 alpha chain: Secreted.|Isoform 3: Cell membrane; Single-pass membrane protein.|Isoform 15: Secreted. MUC5B_HUMAN Mucin-5B MUC5B LungCancers, Secreted. UniProt, BenignNodules Detection, Prediction MUCL1_HUMAN Mucin-like MUCL1 LungCancers Secreted UniProt, protein 1 (Probable). Prediction Membrane (Probable). NAMPT_HUMAN Nicotinamide NAMPT EPI LungCancers, Cytoplasm (By Literature, phosphoribosyl- BenignNodules, similarity). Detection transferase Symptoms NAPSA_HUMAN Napsin-A NAPSA Secreted LungCancers Prediction NCF4_HUMAN Neutrophil NCF4 ENDO Cytoplasm. Prediction cytosol factor 4 NDKA_HUMAN Nucleoside NME1 Secreted LungCancers, Cytoplasm. Literature, diphosphate BenignNodules, Nucleus. Detection kinase A Symptoms Note = Cell- cycle dependent nuclear localization which can be induced by interaction with Epstein-barr viral proteins or by degradation of the SET complex by GzmA. NDKB_HUMAN Nucleoside NME2 Secreted, BenignNodules Cytoplasm. Literature, diphosphate EPI Nucleus. Detection kinase B Note = Isoform 2 is mainly cytoplasmic and isoform 1 and isoform 2 are excluded from the nucleolus. NDUS1_HUMAN NADH- NDUFS1 Secreted, Symptoms Mitochondrion Prediction ubiquinone ENDO inner oxidoreductase membrane. 75 kDa subunit, mitochondrial NEBL_HUMAN Nebulette NEBL ENDO Prediction NEK4_HUMAN Serine/threonine- NEK4 ENDO LungCancers Nucleus Prediction protein (Probable). kinase Nek4 NET1_HUMAN Netrin-1 NTN1 LungCancers, Secreted, UniProt, BenignNodules extracellular Literature, space, Prediction extracellular matrix (By similarity). NEU2_HUMAN Vasopressin- AVP LungCancers, Secreted. UniProt, neurophysin 2- Symptoms Prediction copeptin NGAL_HUMAN Neutrophil LCN2 EPI LungCancers, Secreted. UniProt, gelatinase- BenignNodules, Detection, associated Symptoms Prediction lipocalin NGLY1_HUMAN Peptide- NGLY1 ENDO Cytoplasm. Detection, N(4)-(N- Prediction acetyl-beta- glucosaminyl)as- paragine amidase NHRF1_HUMAN Na(+)/H(+) SLC9A3R1 EPI BenignNodules Endomembrane Detection exchange system; regulatory Peripheral cofactor membrane NHE-RF1 protein. Cell projection, filopodium. Cell projection, ruffle. Cell projection, microvillus. Note = Colocalizes with actin in microvilli-rich apical regions of the syncytiotrophoblast. Found in microvilli, ruffling membrane and filopodia of HeLa cells. Present in lipid rafts of T-cells. NIBAN_HUMAN Protein FAM129A EPI Cytoplasm. Literature, Niban Detection NMU_HUMAN Neuromedin-U NMU LungCancers Secreted. UniProt, Prediction NRP1_HUMAN Neuropilin-1 NRP1 LungCancers, Cell membrane; UniProt, BenignNodules, Single-pass Literature, Symptoms type I Detection, membrane Prediction protein.|Isoform 2: Secreted. ODAM_HUMAN Odontogenic ODAM LungCancers Secreted (By UniProt, ameloblast- similarity). Prediction associated protein OSTP_HUMAN Osteopontin SPP1 LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction OVOS2_HUMAN Ovostatin OVOS2 ENDO Secreted (By UniProt, homolog 2 similarity). Prediction P5CS_HUMAN Delta-1- ALDH18A1 ENDO Mitochondrion Prediction pyrroline-5- inner carboxylate membrane. synthase PA2GX_HUMAN Group 10 PLA2G10 Symptoms Secreted. UniProt secretory phospholipase A2 PAPP1_HUMAN Pappalysin-1 PAPPA LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Prediction PBIP1_HUMAN Pre-B-cell PBXIP1 EPI Cytoplasm, Prediction leukemia cytoskeleton. transcription Nucleus. factor- Note = Shuttles interacting between the protein 1 nucleus and the cytosol. Mainly localized in the cytoplasm, associated with microtubules. Detected in small amounts in the nucleus. PCBP1_HUMAN Poly(rC)- PCBP1 EPI, ENDO Nucleus. Detection, binding Cytoplasm. Prediction protein 1 Note = Loosely bound in the nucleus. May shuttle between the nucleus and the cytoplasm. PCBP2_HUMAN Poly(rC)- PCBP2 EPI Nucleus. Detection, binding Cytoplasm. Prediction protein 2 Note = Loosely bound in the nucleus. May shuttle between the nucleus and the cytoplasm. PCD15_HUMAN Protocadherin- PCDH15 ENDO Cell membrane; UniProt, 15 Single-pass Detection type I membrane protein (By similarity).|Isoform 3: Secreted. PCNA_HUMAN Proliferating PCNA EPI LungCancers, Nucleus. Literature, cell nuclear BenignNodules, Prediction antigen Symptoms PCYOX_HUMAN Prenylcysteine PCYOX1 Secreted LungCancers, Lysosome. Detection, oxidase 1 Symptoms Prediction PDGFA_HUMAN Platelet- PDGFA LungCancers Secreted. UniProt, derived Literature, growth Prediction factor subunit A PDGFB_HUMAN Platelet- PDGFB LungCancers, Secreted. UniProt, derived BenignNodules, Literature, growth Symptoms Detection, factor Prediction subunit B PDGFD_HUMAN Platelet- PDGFD LungCancers Secreted. UniProt, derived Prediction growth factor D PDIA3_HUMAN Protein PDIA3 ENDO LungCancers Endoplasmic Detection, disulfide- reticulum Prediction isomerase lumen (By A3 similarity). Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. PDIA4_HUMAN Protein PDIA4 Secreted, Endoplasmic Detection, disulfide- EPI, ENDO reticulum Prediction isomerase lumen. A4 Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. PDIA6_HUMAN Protein PDIA6 Secreted, Endoplasmic Detection, disulfide- EPI, ENDO reticulum Prediction isomerase lumen (By A6 similarity). Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. PECA1_HUMAN Platelet PECAM1 LungCancers, Membrane; UniProt, endothelial BenignNodules, Single-pass Literature, cell Symptoms type I Detection adhesion membrane molecule protein. PEDF_HUMAN Pigment SERPINF1 LungCancers, Secreted. UniProt, epithelium- Symptoms Melanosome. Literature, derived Note = Enriched Detection, factor in stage I Prediction melanosomes. PERM_HUMAN Myeloperoxidase MPO Secreted, LungCancers, Lysosome. Literature, EPI, ENDO BenignNodules, Detection, Symptoms Prediction PERP1_HUMAN Plasma PACAP EPI, ENDO Secreted UniProt, cell- (Potential). Detection, induced Cytoplasm. Prediction resident Note = In endoplasmic (PubMed: 11350957)
reticulum diffuse granular protein localization in the cytoplasm surrounding the nucleus. PGAM1_HUMAN Phosphoglycerate PGAM1 Secreted, LungCancers, Detection mutase 1 EPI Symptoms PLAC1_HUMAN Placenta- PLAC1 LungCancers Secreted UniProt, specific (Probable). Prediction protein 1 PLACL_HUMAN Placenta- PLAC1L LungCancers Secreted UniProt, specific 1- (Potential). Prediction like protein PLIN2_HUMAN Perilipin-2 ADFP ENDO LungCancers Membrane; Prediction Peripheral membrane protein. PLIN3_HUMAN Perilipin-3 M6PRBP1 EPI Cytoplasm. Detection, Endosome Prediction membrane; Peripheral membrane protein; Cytoplasmic side (Potential). Lipid droplet (Potential). Note = Membrane associated on endosomes. Detected in the envelope and the core of lipid bodies and in lipid sails. PLOD1_HUMAN Procollagen- PLOD1 EPI, ENDO Rough Prediction lysine, 2- endoplasmic oxoglutarate 5- reticulum dioxygenase 1 membrane; Peripheral membrane protein; Lumenal side. PLOD2_HUMAN Procollagen- PLOD2 ENDO BenignNodules, Rough Prediction lysine, 2- Symptoms endoplasmic oxoglutarate 5- reticulum dioxygenase 2 membrane; Peripheral membrane protein; Lumenal side. PLSL_HUMAN Plastin-2 LCP1 Secreted, LungCancers Cytoplasm, Detection, EPI cytoskeleton. Prediction Cell junction. Cell projection. Cell projection, ruffle membrane; Peripheral membrane protein; Cytoplasmic side (By similarity). Note = Relocalizes to the immunological synapse between peripheral blood T lymphocytes and antibody- presenting cells in response to costimulation through TCR/CD3 and CD2 or CD28. Associated with the actin cytoskeleton at membrane ruffles (By similarity). Relocalizes to actin-rich cell projections upon serine phosphorylation. PLUNC_HUMAN Protein PLUNC LungCancers, Secreted (By UniProt, Plunc BenignNodules similarity). Prediction Note = Found in the nasal mucus (By similarity). Apical side of airway epithelial cells. Detected in nasal mucus (By similarity). PLXB3_HUMAN Plexin-B3 PLXNB3 ENDO Membrane; UniProt, Single-pass Detection, type I Prediction membrane protein. PLXC1_HUMAN Plexin-C1 PLXNC1 EPI Membrane; UniProt, Single-pass Detection type I membrane protein (Potential). POSTN_HUMAN Periostin POSTN Secreted, LungCancers, Secreted, UniProt, ENDO BenignNodules, extracellular Literature, Symptoms space, Detection, extracellular Prediction matrix. PPAL_HUMAN Lysosomal ACP2 EPI Symptoms Lysosome UniProt, acid membrane; Prediction phosphatase Single-pass membrane protein; Lumenal side. Lysosome lumen. Note = The soluble form arises by proteolytic processing of the membrane- bound form. PPBT_HUMAN Alkaline ALPL EPI LungCancers, Cell membrane; Literature, phosphatase, BenignNodules, Lipid-anchor, Detection, tissue- Symptoms GPI-anchor. Prediction nonspecific isozyme PPIB_HUMAN Peptidyl- PPIB Secreted, Endoplasmic Detection, prolyl cis- EPI, ENDO reticulum Prediction trans lumen. isomerase Melanosome. B Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. PRDX1_HUMAN Peroxiredoxin- PRDX1 EPI LungCancers Cytoplasm. Detection, 1 Melanosome. Prediction Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV. PRDX4_HUMAN Peroxiredoxin- PRDX4 Secreted, Cytoplasm. Literature, 4 EPI, ENDO Detection, Prediction PROF1_HUMAN Profilin-1 PFN1 Secreted, LungCancers Cytoplasm, Detection EPI cytoskeleton. PRP31_HUMAN U4/U6 PRPF31 ENDO Nucleus Prediction small speckle. nuclear Nucleus, Cajal ribonucleo body. protein Note = Predominantly Prp31 found in speckles and in Cajal bodies. PRS6A_HUMAN 26S PSMC3 EPI BenignNodules Cytoplasm Detection protease (Potential). regulatory Nucleus subunit 6A (Potential). PSCA_HUMAN Prostate PSCA LungCancers Cell membrane; Literature, stem cell Lipid-anchor, Prediction antigen GPI-anchor. PTGIS_HUMAN Prostacyclin PTGIS EPI LungCancers, Endoplasmic UniProt, synthase BenignNodules reticulum Detection, membrane; Prediction Single-pass membrane protein. PTPA_HUMAN Serine/threonine- PPP2R4 ENDO Symptoms Detection, protein Prediction phosphatase 2A activator PTPRC_HUMAN Receptor- PTPRC Secreted, LungCancers Membrane; UniProt, type EPI, ENDO Single-pass Detection, tyrosine- type I Prediction protein membrane phosphatase C protein. PTPRJ_HUMAN Receptor- PTPRJ EPI LungCancers, Membrane; UniProt, type Symptoms Single-pass Detection, tyrosine- type I Prediction protein membrane phosphatase eta protein. PVR_HUMAN Poliovirus PVR Symptoms Isoform Alpha: UniProt, receptor Cell membrane; Detection, Single-pass Prediction type I membrane protein.|Isoform Delta: Cell membrane; Single-pass type I membrane protein.|Isoform Beta: Secreted.|Isoform Gamma: Secreted. RAB32_HUMAN Ras-related RAB32 EPI Mitochondrion. Prediction protein Rab-32 RAGE_HUMAN Advanced AGER Secreted LungCancers, Isoform 1: Cell UniProt, glycosylation BenignNodules membrane; Literature end product- Single-pass specific type I receptor membrane protein.|Isoform 2: Secreted. RAN_HUMAN GTP- RAN Secreted, LungCancers, Nucleus. Detection, binding EPI BenignNodules Cytoplasm. Prediction nuclear Melanosome. protein Ran Note = Becomes dispersed throughout the cytoplasm during mitosis. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. RAP2B_HUMAN Ras-related RAP2B EPI Cell membrane; Prediction protein Lipid-anchor; Rap-2b Cytoplasmic side (Potential). RAP2C_HUMAN Ras-related RAP2C EPI Cell membrane; Prediction protein Lipid-anchor; Rap-2c Cytoplasmic side (Potential). RCN3_HUMAN Reticulocalbin- RCN3 EPI Symptoms Endoplasmic Prediction 3 reticulum lumen (Potential). RL24_HUMAN 60S RPL24 EPI Prediction
ribosomal protein L24 S10A1_HUMAN Protein S100A1 Symptoms Cytoplasm. Literature, S100-A1 Prediction S10A6_HUMAN Protein S100A6 Secreted LungCancers Nucleus Literature, S100-A6 envelope. Detection, Cytoplasm. Prediction S10A7_HUMAN Protein S100A7 LungCancers Cytoplasm. UniProt, S100-A7 Secreted. Literature, Note = Secreted Detection, by a non- Prediction classical secretory pathway. SAA_HUMAN Serum SAA1 Symptoms Secreted. UniProt, amyloid A Literature, protein Detection, Prediction SCF_HUMAN Kit ligand KITLG LungCancers, Isoform 1: Cell UniProt, Symptoms membrane; Literature Single-pass type I membrane protein (By similarity). Secreted (By similarity). Note = Also exists as a secreted soluble form (isoform 1 only) (By similarity).|Isoform 2: Cell membrane; Single-pass type I membrane protein (By similarity). Cytoplasm, cytoskeleton (By similarity). SDC1_HUMAN Syndecan-1 SDC1 LungCancers, Membrane; UniProt, BenignNodules, Single-pass Literature, Symptoms type I Detection membrane protein. SEM3G_HUMAN Semaphorin-3G SEMA3G LungCancers Secreted (By UniProt, similarity). Prediction SEPR_HUMAN Seprase FAP ENDO Symptoms Cell membrane; UniProt, Single-pass Literature, type II Detection membrane protein. Cell projection, lamellipodium membrane; Single-pass type II membrane protein. Cell projection, invadopodium membrane; Single-pass type II membrane protein. Note = Found in cell surface lamellipodia, invadopodia and on shed vesicles. SERPH_HUMAN Serpin H1 SERPINH1 Secreted, LungCancers, Endoplasmic Detection, EPI, ENDO BenignNodules reticulum Prediction lumen. SFPA2_HUMAN Pulmonary SFTPA2 Secreted LungCancers, Secreted, UniProt, surfactant- BenignNodules extracellular Prediction associated space, protein A2 extracellular matrix. Secreted, extracellular space, surface film. SFTA1_HUMAN Pulmonary SFTPA1 Secreted LungCancers, Secreted, UniProt, surfactant- BenignNodules, extracellular Prediction associated Symptoms space, protein A1 extracellular matrix. Secreted, extracellular space, surface film. SG3A2_HUMAN Secretoglobin SCGB3A2 LungCancers, Secreted. UniProt, family BenignNodules Prediction 3A member 2 SGPL1_HUMAN Sphingosine-1- SGPL1 ENDO Endoplasmic UniProt, phosphate reticulum Prediction lyase 1 membrane; Single-pass type III membrane protein. SIAL_HUMAN Bone IBSP LungCancers Secreted. UniProt, sialoprotein Literature, 2 Prediction SLPI_HUMAN Antileukopro- SLPI LungCancers, Secreted. UniProt, teinase BenignNodules Literature, Detection, Prediction SMD3_HUMAN Small SNRPD3 Secreted BenignNodules Nucleus. Prediction nuclear ribonucleo protein Sm D3 SMS_HUMAN Somatostatin SST LungCancers Secreted. UniProt, Literature, Prediction SODM_HUMAN Superoxide SOD2 Secreted LungCancers, Mitochondrion Literature, dismutase BenignNodules, matrix. Detection, [Mn], Symptoms Prediction mitochondrial SORL_HUMAN Sortilin- SORL1 EPI LungCancers, Membrane; UniProt, related Symptoms Single-pass Detection receptor type I membrane protein (Potential). SPB3_HUMAN Serpin B3 SERPINB3 LungCancers, Cytoplasm. Literature, BenignNodules Note = Seems to Detection also be secreted in plasma by cancerous cells but at a low level. SPB5_HUMAN Serpin B5 SERPINB5 LungCancers Secreted, UniProt, extracellular Detection space. SPON2_HUMAN Spondin-2 SPON2 LungCancers, Secreted, UniProt, BenignNodules extracellular Prediction space, extracellular matrix (By similarity). SPRC_HUMAN SPARC SPARC LungCancers, Secreted, UniProt, BenignNodules, extracellular Literature, Symptoms space, Detection, extracellular Prediction matrix, basement membrane. Note = In or around the basement membrane. SRC_HUMAN Proto- SRC ENDO LungCancers, Literature oncogene BenignNodules, tyrosine- Symptoms protein kinase Src SSRD_HUMAN Translocon- SSR4 Secreted, Endoplasmic UniProt, associated ENDO reticulum Prediction protein membrane; subunit Single-pass delta type I membrane protein. STAT1_HUMAN Signal STAT1 EPI LungCancers, Cytoplasm. Detection transducer BenignNodules Nucleus. and Note = Translocated activator of into the transcription nucleus in 1-alpha/beta response to IFN-gamma- induced tyrosine phosphorylation and dimerization. STAT3_HUMAN Signal STAT3 ENDO LungCancers, Cytoplasm. Prediction transducer BenignNodules, Nucleus. and Symptoms Note = Shuttles activator of between the transcription nucleus and the 3 cytoplasm. Constitutive nuclear presence is independent of tyrosine phosphorylation. STC1_HUMAN Stanniocalcin- STC1 LungCancers, Secreted. UniProt, 1 Symptoms Prediction STT3A_HUMAN Dolichyl- STT3A EPI Symptoms Endoplasmic Literature diphosphooligosac- reticulum charide--protein membrane; glycosyltransferase Multi-pass subunit membrane STT3A protein. TAGL_HUMAN Transgelin TAGLN EPI LungCancers Cytoplasm Literature, (Probable). Prediction TARA_HUMAN TRIO and TRIOBP ENDO Nucleus. Detection, F-actin- Cytoplasm, Prediction binding cytoskeleton. protein Note = Localized to F-actin in a periodic pattern. TBA1B_HUMAN Tubulin TUBA1B EPI LungCancers Detection alpha-1B chain TBB2A_HUMAN Tubulin TUBB2A EPI LungCancers, Detection, beta-2A BenignNodules Prediction chain TBB3_HUMAN Tubulin TUBB3 EPI LungCancers, Detection beta-3 BenignNodules chain TBB5_HUMAN Tubulin TUBB EPI LungCancers, Detection beta chain BenignNodules TCPA_HUMAN T-complex TCP1 EPI Cytoplasm. Prediction protein 1 subunit alpha TCPD_HUMAN T-complex CCT4 EPI Cytoplasm. Detection, protein 1 Melanosome. Prediction subunit Note = Identified delta by mass spectrometry in melanosome fractions from stage I to stage IV. TCPQ_HUMAN T-complex CCT8 Secreted, Cytoplasm. Prediction protein 1 EPI subunit theta TCPZ_HUMAN T-complex CCT6A Secreted, Cytoplasm. Detection protein 1 EPI subunit zeta TDRD3_HUMAN Tudor TDRD3 ENDO Cytoplasm. Prediction domain- Nucleus. containing Note = Predominantly protein 3 cytoplasmic. Associated with actively translating
polyribosomes and with mRNA stress granules. TENA_HUMAN Tenascin TNC ENDO LungCancers, Secreted, UniProt, BenignNodules, extracellular Literature, Symptoms space, Detection extracellular matrix. TENX_HUMAN Tenascin-X TNXB ENDO LungCancers, Secreted, UniProt, Symptoms extracellular Detection, space, Prediction extracellular matrix. TERA_HUMAN Transitional VCP EPI LungCancers, Cytoplasm, Detection endoplasmic BenignNodules cytosol. reticulum Nucleus. ATPase Note = Present in the neuronal hyaline inclusion bodies specifically found in motor neurons from amyotrophic lateral sclerosis patients. Present in the Lewy bodies specifically found in neurons from Parkinson disease patients. TETN_HUMAN Tetranectin CLEC3B LungCancers Secreted. UniProt, Literature, Detection, Prediction TF_HUMAN Tissue F3 LungCancers, Membrane; UniProt, factor BenignNodules, Single-pass Literature Symptoms type I membrane protein. TFR1_HUMAN Transferrin TFRC Secreted, LungCancers, Cell membrane; UniProt, receptor EPI, ENDO BenignNodules, Single-pass Literature, protein 1 Symptoms type II Detection membrane protein. Melanosome. Note = Identified by mass spectrometry in melanosome fractions from stage I to stage IV.|Transferrin receptor protein 1, serum form: Secreted. TGFA_HUMAN Protransforming TGFA LungCancers, Transforming UniProt, growth BenignNodules growth factor Literature factor alpha alpha: Secreted, extracellular space.|Protransforming growth factor alpha: Cell membrane; Single-pass type I membrane protein. THAS_HUMAN Thromboxane- TBXAS1 EPI, ENDO LungCancers, Membrane; Prediction A BenignNodules, Multi-pass synthase Symptoms membrane protein. THY1_HUMAN Thy-1 THY1 EPI Symptoms Cell membrane; Detection, membrane Lipid-anchor, Prediction glycoprotein GPI-anchor (By similarity). TIMP1_HUMAN Metalloproteinase TIMP1 LungCancers, Secreted. UniProt, inhibitor 1 BenignNodules, Literature, Symptoms Detection, Prediction TIMP3_HUMAN Metalloproteinase TIMP3 LungCancers, Secreted, UniProt, inhibitor 3 BenignNodules extracellular Literature, space, Prediction extracellular matrix. TLL1_HUMAN Tolloid- TLL1 ENDO Secreted UniProt, like protein (Probable). Prediction 1 TNF12_HUMAN Tumor TNFSF12 LungCancers, Cell membrane; UniProt necrosis BenignNodules Single-pass factor type II ligand membrane superfamily protein.|Tumor member 12 necrosis factor ligand superfamily member 12, secreted form: Secreted. TNR6_HUMAN Tumor FAS LungCancers, Isoform 1: Cell UniProt, necrosis BenignNodules, membrane; Literature, factor Symptoms Single-pass Prediction receptor type I superfamily membrane member 6 protein.|Isoform 2: Secreted.|Isoform 3: Secreted.|Isoform 4: Secreted.|Isoform 5: Secreted.|Isoform 6: Secreted. TPIS_HUMAN Triosephosphate TPI1 Secreted, Symptoms Literature, isomerase EPI Detection, Prediction TRFL_HUMAN Lactotransferrin LTF Secreted, LungCancers, Secreted. UniProt, EPI, ENDO BenignNodules, Literature, Symptoms Detection, Prediction TSP1_HUMAN Thrombospondin- THBS1 LungCancers, Literature, 1 BenignNodules, Detection, Symptoms Prediction TTHY_HUMAN Transthyretin TTR LungCancers, Secreted. UniProt, BenignNodules Cytoplasm. Literature, Detection, Prediction TYPH_HUMAN Thymidine TYMP EPI LungCancers, Literature, phosphorylase BenignNodules, Detection, Symptoms Prediction UGGG1_HUMAN UDP-glucose: UGGT1 Secreted, Endoplasmic Detection, glycoprotein ENDO reticulum Prediction glucosyltransferase lumen. 1 Endoplasmic reticulum-Golgi intermediate compartment. UGGG2_HUMAN UDP-glucose: UGGT2 ENDO Endoplasmic Prediction glycoprotein reticulum glucosyltransferase lumen. 2 Endoplasmic reticulum-Golgi intermediate compartment. UGPA_HUMAN UTP-- UGP2 EPI Symptoms Cytoplasm. Detection glucose-1- phosphate uridylyltransferase UPAR_HUMAN Urokinase PLAUR LungCancers, Isoform 1: Cell UniProt, plasminogen BenignNodules, membrane; Literature, activator Symptoms Lipid-anchor, Prediction surface GPI- receptor anchor.|Isoform 2: Secreted (Probable). UTER_HUMAN Uteroglobin SCGB1A1 LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms Detection, Prediction VA0D1_HUMAN V-type ATP6V0D1 EPI Prediction proton ATPase subunit d 1 VAV3_HUMAN Guanine VAV3 ENDO Prediction nucleotide exchange factor VAV3 VEGFA_HUMAN Vascular VEGFA LungCancers, Secreted. UniProt, endothelial BenignNodules, Note = VEGF12 Literature, growth Symptoms 1 is acidic and Prediction factor A freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell- associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. VEGFC_HUMAN Vascular VEGFC LungCancers, Secreted. UniProt, endothelial BenignNodules Literature, growth Prediction factor C VEGFD_HUMAN Vascular FIGF LungCancers Secreted. UniProt, endothelial Literature, growth Prediction factor D VGFR1_HUMAN Vascular FLT1 LungCancers, Isoform Flt1: UniProt, endothelial BenignNodules, Cell membrane; Literature, growth Symptoms Single-pass Detection, factor type I Prediction receptor 1 membrane protein.|Isoform sFlt1: Secreted. VTNC_HUMAN Vitronectin VTN ENDO Symptoms Secreted, UniProt, extracellular Literature, space. Detection, Prediction VWC2_HUMAN Brorin VWC2 LungCancers Secreted, UniProt, extracellular Prediction space, extracellular matrix, basement membrane (By similarity). WNT3A_HUMAN Protein WNT3A LungCancers, Secreted, UniProt, Wnt-3a Symptoms extracellular Prediction space, extracellular matrix. WT1_HUMAN Wilms WT1 LungCancers, Nucleus. Literature, tumor BenignNodules, Cytoplasm (By Prediction protein Symptoms similarity). Note = Shuttles between nucleus and cytoplasm (By similarity).|Isoform 1: Nucleus speckle.|Isoform 4: Nucleus, nucleoplasm. ZA2G_HUMAN Zinc-alpha- AZGP1 LungCancers, Secreted. UniProt, 2- Symptoms Literature, glycoprotein Detection, Prediction ZG16B_HUMAN Zymogen ZG16B LungCancers Secreted UniProt, granule (Potential). Prediction protein 16
homolog B
SRM Assay
[0078] SRM assays for 388 targeted proteins were developed based on synthetic peptides, using a protocol similar to those described in the literature (Lange, Picotti et al. 2008, Picotti, Rinner et al. 2010, Huttenhain, Soste et al. 2012). Up to five SRM suitable peptides per protein were identified from public sources such as the PeptideAtlas, Human Plasma Proteome Database or by proteotypic prediction tools (Mallick, Schirle et al. 2007) and synthesized. SRM triggered MS/MS spectra were collected on an ABSciex 5500 QTrap for both doubly and triply charged precursor ions. The obtained MS/MS spectra were assigned to individual peptides using MASCOT (cutoff score≧15) (Perkins, Pappin et al. 1999). Up to four transitions per precursor ion were selected for optimization. The resulting corresponding optimal retention time, declustering potential and collision energy were assembled for all transitions. Optimal transitions were measured on a mixture of all synthetic peptides, a pooled sample of benign patients and a pooled sample of cancer patients. Transitions were analyzed in batches, each containing up to 1750 transitions. Both biological samples were immuno-depleted and digested by trypsin. All three samples were analyzed on an ABSciex 5500 QTrap coupled with a reversed-phase (RP) high-performance liquid chromatography (HPLC) system. The obtained SRM data were manually reviewed to select the two best peptides per protein and the two best transitions per peptide. Transitions having interference with other transitions were not selected. Ratios between intensities of the two best transitions of peptides in the synthetic peptide mixture were also used to assess the specificity of the transitions in the biological samples. The intensity ratio was considered as an important metric defining the SRM assays. The complete transition table is shown below in Table 2.
TABLE-US-00002 Lengthy table referenced here US20150323545A1-20151112-T00001 Please refer to the end of the specification for access instructions.
Exemplary Protein Detection
[0079] The following 164 proteins and their peptides were detected simultaneously in a large-scale experiment of 158 samples using the MS-LC-SRM-MS system described herein.
TABLE-US-00003 TABLE 3 SEQ Protein Peptide ID Detec- Detec- Protein Peptide NO: tion tion 1433E_HUMAN EDLVYQAK 7 16 16 1433E_HUMAN IISSIEQK 9 16 0 1433T_HUMAN AVTEQGAELSNEER 16 127 0 1433T_HUMAN TAFDEAIAELDTLNED 19 127 127 SYK 1433Z_HUMAN FLIPNASQAESK 21 157 157 1433Z_HUMAN SVTEQGAELSNEER 23 157 0 6PGD_HUMAN AGQAVDDFIEK 25 90 0 6PGD_HUMAN LVPLLDTGDIIIDGGNS 27 90 90 EYR A1AG1_HUMAN WFYIASAFR 32 157 0 A1AG1_HUMAN YVGGQEHFAHLLILR 33 157 157 ABCD1_HUMAN DAGIALLSITHRPSLWK 34 9 0 ABCD1_HUMAN GLQAPAGEPTQEASGVA 36 9 0 AAK ABCD1_HUMAN NLLTAAADAIER 37 9 9 ADML_HUMAN LAHQIYQFTDK 44 27 27 ADML_HUMAN SPEDSSPDAAR 45 27 0 AIFM1_HUMAN ELWFSDDPNVTK 53 158 158 AIFM1_HUMAN GVIFYLR 54 158 0 ALDOA_HUMAN ADDGRPFPQVIK 57 158 141 ALDOA_HUMAN ALQASALK 58 158 17 AMPN_HUMAN ALEQALEK 62 158 158 AMPN_HUMAN DHSAIPVINR 63 158 0 APOA1_HUMAN AKPALEDLR 78 158 158 APOA1_HUMAN ATEHLSTLSEK 79 158 0 APOE_HUMAN AATVGSLAGQPLQER 82 158 158 APOE_HUMAN LGPLVEQGR 87 158 0 BGH3_HUMAN LTLLAPLNSVFK 139 158 0 BGH3_HUMAN SPYQLVLQHSR 140 158 158 BST1_HUMAN GEGTSAHLR 149 157 0 BST1_HUMAN GFFADYEIPNLQK 150 157 157 C163A_HUMAN INPASLDK 153 158 11 C163A_HUMAN LEVFYNGAWGTVGK 154 158 49 C163A_HUMAN TSYQVYSK 155 158 98 CALU_HUMAN EQFVEFR 172 120 120 CALU_HUMAN TFDQLTPEESK 174 120 0 CATB_HUMAN LPASFDAR 188 62 62 CATB_HUMAN TDQYWEK 190 62 0 CATG_HUMAN NVNPVALPR 192 14 0 CATG_HUMAN SSGVPPEVFTR 193 14 14 CBPB2_HUMAN DTGTYGFLLPER 198 158 158 CBPB2_HUMAN EAFAAVSK 199 158 0 CD14_HUMAN ATVNPSAPR 207 158 0 CD14_HUMAN SWLAELQQWLKPGLK 214 158 158 CD44_HUMAN FAGVFHVEK 227 158 158 CD44_HUMAN YGFIEGHVVIPR 231 158 0 CD59_HUMAN AGLQVYNK 232 156 156 CD59_HUMAN TVLLLVTPFLAAAWSLHP 233 156 0 CDCP1_HUMAN EEGVFTVTPDTK 239 157 0 CDCP1_HUMAN LSLVLVPAQK 241 157 157 CEAM8_HUMAN LFIPNITTK 256 79 79 CEAM8_HUMAN TLTLLSVTR 257 79 0 CERU_HUMAN GAYPLSIEPIGVR 258 158 0 CERU_HUMAN GPEEEHLGILGPVIWAEV 259 158 158 GDTIR CERU_HUMAN NNEGTYYSPNYNPQSR 261 158 0 CH1O_HUMAN GGEIQPVSVK 265 158 0 CH1O_HUMAN VLLPEYGGTK 266 158 158 CLIC1_HUMAN FSAYIK 288 137 8 CLIC1_HUMAN LAALNPESNTAGLDIFAK 290 137 129 CLIC1_HUMAN NSNPALNDNLEK 291 137 0 CLUS_HUMAN ASSIIDELFQDR 293 158 0 CLUS_HUMAN EIQNAVNGVK 294 158 158 CNTN1_HUMAN AHSDGGDGWSQVK 303 158 157 CNTN1_HUMAN DGEYWEVR 304 158 1 CO6A3_HUMAN IGDLHPQIVNLLK 319 158 0 CO6A3_HUMAN VAVVQYSDR 321 158 158 CO6A3_HUMAN WYYDPNTK 322 158 0 COF1_HUMAN EILVGDVGQTVDDPYA 328 127 0 TFVK COF1_HUMAN LGGSAVISLEGKPL 329 127 0 COF1_HUMAN YALYDATYETK 330 127 127 COIA1_HUMAN AVGLAGTFR 332 158 37 COIA1_HUMAN TEAPSATGQASSLLGGR 335 158 121 CRP_HUMAN APLTKPLK 341 153 21 CRP_HUMAN ESDTSYVSLK 342 153 132 CRP_HUMAN YEVQGEVFTKPQLWP 343 153 0 CSF1_HUMAN FNSVPLTDTGHER 351 134 113 CSF1_HUMAN ISSLRPQGLSNPSTLSAQ 352 134 21 PQLSR CYTB_HUMAN SQLEEK 372 100 0 CYTB_HUMAN SQVVAGTNYFIK 373 100 100 DESP_HUMAN YGDGIQLTR 384 131 131 DMKN_HUMAN QVPGFGVADALGNR 395 128 0 DMKN_HUMAN VSEALGQGTR 397 128 128 DSG2_HUMAN GQIIGNFQAFDEDTGLP 404 158 1 AHAR DSG2_HUMAN ILDVNDNIPVVENK 405 158 157 EF1A1_HUMAN IGGIGTVPVGR 423 158 158 EF1A1_HUMAN QTVAVGVIK 426 158 0 EF2_HUMAN FSVSPVVR 439 125 125 EF2_HUMAN GVQYLNEIK 441 125 0 ENOA_HUMAN AVEHINK 452 156 0 ENOA_HUMAN YISPDQLADLYK 455 156 156 ENOA_HUMAN YNQLLR 456 156 0 ENPL_HUMAN SGTSEFLNK 469 158 1 ENPL_HUMAN SGYLLPDTK 470 158 157 EPHB6_HUMAN RPHFDQLVAAFDK 472 157 0 EPHB6_HUMAN WAAPEVIAHGK 476 157 157 ERBB3_HUMAN GESIEPLDPSEK 483 105 0 ERBB3_HUMAN LAEVPDLLEK 484 105 105 EREG_HUMAN VAQVSITK 487 115 115 EREG_HUMAN VTSGDPELPQV 488 115 0 ERO1A_HUMAN AVLQWTK 489 121 0 ERO1A_HUMAN LLESDYFR 491 121 0 ERO1A_HUMAN NLLQNIH 492 121 0 ERO1A_HUMAN VLPFFERPDFQLFTGNK 493 121 121 F10A1_HUMAN AIDLFTDAIK 501 35 0 F10A1_HUMAN LQKPNAAIR 503 35 35 FAM3C_HUMAN GINVALANGK 505 97 88 FAM3C_HUMAN SALDTAAR 507 97 9 FAM3C_HUMAN TGEVLDTK 509 97 0 FCGR1_HUMAN HLEEELK 517 39 0 FCGR1_HUMAN VFTEGEPLALR 519 39 39 FIBA_HUMAN GGSTSYGTGSETESPR 554 147 108 FIBA_HUMAN NSLFEYQK 556 147 39 FINC_HUMAN SYTITGLQPGTDYK 561 154 135 FINC_HUMAN VPGTSTSATLTGLTR 562 154 19 FKB11_HUMAN ANYWLK 565 23 0 FKB11_HUMAN DPLVIELGQK 566 23 23 FOLH1_HUMAN GVILYSDPADYFAPGVK 569 138 0 FOLH1_HUMAN LGSGNDFEVFFQR 570 138 138 FRIL_HUMAN DDVALEGVSHFFR 594 151 0 FRIL_HUMAN LGGPEAGLGEYLFER 596 151 151
G3P_HUMAN GALQNIIPASTGAAK 599 150 149 G3P_HUMAN LISWYDNEFGYSNR 600 150 1 G6PD_HUMAN DGLLPENTFIVGYAR 603 43 43 G6PD_HUMAN GGYFDEFGIIR 604 43 0 G6PI_HUMAN AVLHVALR 608 39 6 G6PI_HUMAN TLAQLNPESSLFIIASK 610 39 33 GDIR2_HUMAN DIVSGLK 629 158 158 GDIR2_HUMAN LNYKPPPQK 630 158 0 GELS_HUMAN AQPVQVAEGSEPDGFWEA 634 158 0 LGGK GELS_HUMAN TASDFITK 637 158 158 GGH_HUMAN NLDGISHAPNAVK 640 158 158 GGH_HUMAN YYIAASYVK 643 158 0 GRP78_HUMAN TWNDPSVQQDIK 664 158 90 GRP78_HUMAN VYEGERPLTK 665 158 68 GSLG1_HUMAN IIIQESALDYR 666 158 158 GSLG1_HUMAN LDPALQDK 667 158 0 GSLG1_HUMAN LIAQDYK 668 158 0 GSLG1_HUMAN NDINILK 669 158 0 GSTP1_HUMAN ALPGQLKPFETLLSQNQ 672 123 123 GGK GSTP1_HUMAN YISLIYTNYEAGK 675 123 0 HPSE_HUMAN LPYPFSNK 714 49 0 HPSE_HUMAN SVQLNGLTLK 715 49 49 HPT_HUMAN VGYVSGWGR 719 158 0 HPT_HUMAN VTSIQDWVQK 720 158 158 HS90A_HUMAN SLTNDWEDHLAVK 724 32 32 HS90B_HUMAN ADHGEPIGR 726 121 0 HS90B_HUMAN IDIIPNPQER 728 121 121 HS90B_HUMAN NPDDITQEEYGEFYK 730 121 0 HSPB1_HUMAN DGVVEITGK 732 30 0 HSPB1_HUMAN GPSWDPFR 733 30 30 HTRA1_HUMAN LHRPPVIVLQR 741 40 40 HTRA1_HUMAN LPVLLLGR 742 40 0 HTRA1_HUMAN VTAGISFAIPSDK 744 40 0 HXK1_HUMAN FLLSESGSGK 747 117 17 HXK1_HUMAN LVDEYSLNAGK 749 117 47 HXK1_HUMAN SANLVAATLGAILNR 750 117 53 HYOU1_HUMAN FPEHELTFDPQR 757 156 0 HYOU1_HUMAN LPATEKPVLLSK 760 156 156 IBP2_HUMAN AEVLFR 762 158 0 IBP2_HUMAN ELAVFR 763 158 158 IBP2_HUMAN LIQGAPTIR 765 158 0 IBP3_HUMAN FHPLHSK 768 158 0 IBP3_HUMAN FLNVLSPR 769 158 0 IBP3_HUMAN YGQPLPGYTTK 771 158 158 ICAM1_HUMAN ASVSVTAEDEGTQR 772 114 0 ICAM1_HUMAN VELAPLPSWQPVGK 776 114 114 ICAM3_HUMAN IALETSLSK 780 158 0 ICAM3_HUMAN TFVLPVTPPR 783 158 158 IF4A1_HUMAN GYDVIAQAQSGTGK 792 58 0 IF4A1_HUMAN VLITTDLLAR 796 58 58 IGF1_HUMAN EGTEASLQIR 797 40 0 IGF1_HUMAN ISSLPTQLFK 798 40 40 IL18_HUMAN SDIIFFQR 807 45 45 IL18_HUMAN SVPGHDNK 808 45 0 ILEU_HUMAN EATTNAPFR 824 88 13 ILEU_HUMAN TYNFLPEFLVSTQK 828 88 75 ILK_HUMAN HSGIDFK 830 90 15 ILK_HUMAN QLNFLTK 832 90 75 ILK_HUMAN WQGNDIVVK 833 90 0 INHBA_HUMAN AEVWLFLK 834 32 0 INHBA_HUMAN EGSDLSVVER 835 32 32 ISLR_HUMAN ALPGTPVASSQPR 839 158 0 ISLR_HUMAN EVPLLQSLWLAHNEIR 840 158 0 ISLR_HUMAN LPGLPEGAFR 841 158 158 ITA5_HUMAN SLQWFGATVR 846 114 114 ITA5_HUMAN SSASSGPQILK 847 114 0 K1C18_HUMAN LASYLDR 861 72 0 K1C18_HUMAN LQLETEIEALK 862 72 72 K1C18_HUMAN VVSETNDTK 863 72 0 K1C19_HUMAN FGAQLAHIQALISGIEAQ 865 158 158 LGDVR K1C19_HUMAN FGPGVAFR 866 158 0 KIT_HUMAN QATLTISSAR 876 158 158 KIT_HUMAN YVSELHLTR 878 158 0 KLK14_HUMAN VLGSGTWPSAPK 889 27 27 KLK14_HUMAN VSGWGTISSPIAR 890 27 0 KPYM_HUMAN APIIAVTR 899 158 13 KPYM_HUMAN LDIDSPPITAR 903 158 145 LAMB2_HUMAN IQGTLQPHAR 910 69 0 LAMB2_HUMAN SLADVDAILAR 911 69 31 LAMB2_HUMAN VLELSIPASAEQIQHLAG 913 69 38 AIAER LDHA_HUMAN FIIPNVVK 915 157 0 LDHA_HUMAN LVIITAGAR 917 157 157 LDHB_HUMAN FIIPQIVK 920 158 157 LDHB_HUMAN GLTSVINQK 921 158 1 LEG1_HUMAN GEVAPDAK 925 146 0 LEG1_HUMAN LPDGYEFK 926 146 0 LEG1_HUMAN SFVLNLGK 927 146 146 LG3BP_HUMAN ASHEEVEGLVEK 938 158 158 LG3BP_HUMAN VEIFYR 941 158 0 LG3BP_HUMAN YSSDYFQAPSDYR 942 158 0 LRP1_HUMAN TVLWPNGLSLDIPAGR 959 158 158 LRP1_HUMAN VFFTDYGQIPK 960 158 0 LUM_HUMAN NIPTVNENLENYYLEVN 962 158 158 QLEK LUM_HUMAN SLEDLQLTHNK 964 158 0 LYOX_HUMAN HWFQAGYSTSR 975 121 0 LYOX_HUMAN TPILLIR 977 121 121 MASP1_HUMAN APGELEHGLITFSTR 991 158 151 MASP1_HUMAN TGVITSPDFPNPYPK 994 158 7 MDHC_HUMAN LGVTANDVK 997 130 130 MDHC_HUMAN VLVTGAAGQIAYSLLYSI 999 130 0 GNGSVFGK MDHM_HUMAN VDFPQDQLTALTGR 1002 158 158 MDHM_HUMAN VSSFEEK 1004 158 0 MMP12_HUMAN FLLILLLQATASGALP 1021 158 158 LNSSTSLEK MMP12_HUMAN GIQSLYGDPK 1022 158 0 MMP12_HUMAN IDAVFYSK 1023 158 0 MMP2_HUMAN AFQVWSDVTPLR 1031 153 152 MMP2_HUMAN IIGYTPDLDPETVDDA 1033 153 1 FAR MMP7_HUMAN LSQDDIK 1042 102 102 MMP7_HUMAN NANSLEAK 1043 102 0 MMP9_HUMAN AFALWSAVTPLTFTR 1044 158 50 MMP9_HUMAN FQTFEGDLK 1046 158 108 MMP9_HUMAN SLGPALLLLQK 1048 158 0 MPRI_HUMAN GHQAFDVGQPR 1055 158 23 MPRI_HUMAN TYHSVGDSVLR 1056 158 4 MPRI_HUMAN VPIDGPPIDIGR 1057 158 131 NCF4_HUMAN AEALFDFTGNSK 1095 138 43 NCF4_HUMAN DAEGDLVR 1096 138 0 NCF4_HUMAN DIAVEEDLSSTPLLK 1097 138 0 NCF4_HUMAN GATGIFPLSFVK 1098 138 95 NDKB_HUMAN DRPFFPGLVK 1105 24 0 NDKB_HUMAN NIIHGSDSVK 1107 24 24 NRP1_HUMAN FVSDYETHGAGFSIR 1149 158 0
NRP1_HUMAN FVTAVGTQGAISK 1150 158 158 NRP1_HUMAN SFEGNNNYDTPELR 1152 158 0 OSTP_HUMAN AIPVAQDLNAPSDWDSR 1156 108 108 OSTP_HUMAN DSYETSQLDDQSAETH 1157 108 0 SHK OSTP_HUMAN YPDAVATWLNPDPSQK 1160 108 0 PCBP2_HUMAN IANPVEGSTDR 1189 52 0 PCBP2_HUMAN IITLAGPTNAIFK 1190 52 52 PCYOX_HUMAN IAIIGAGIGGTSAAYYLR 1207 37 0 PCYOX_HUMAN IFSQETLTK 1208 37 37 PCYOX_HUMAN TLLETLQK 1209 37 0 PDGFB_HUMAN SFDDLQR 1216 111 99 PDGFB_HUMAN SHSGGELESLAR 1217 111 12 PDIA3_HUMAN ELSDFISYLQR 1225 129 129 PDIA3_HUMAN SEPIPESNDGPVK 1227 129 0 PDIA4_HUMAN FDVSGYPTIK 1231 81 81 PDIA4_HUMAN FHHTFSTEIAK 1232 81 0 PECA1_HUMAN SELVTVTESFSTPK 1241 77 0 PECA1_HUMAN STESYFIPEVR 1242 77 77 PEDF_HUMAN LQSLFDSPDFSK 1246 158 0 PEDF_HUMAN TVQAVLTVPK 1248 158 158 PGAM1_HUMAN HGESAWNLENR 1259 14 14 PLIN2_HUMAN DAVTTTVTGAK 1264 138 0 PLIN2_HUMAN EVSDSLLTSSK 1265 138 138 PLSL_HUMAN IGNFSTDIK 1284 158 0 PLSL_HUMAN ISFDEFIK 1285 158 158 PLXB3_HUMAN ELPVPIYVTQGEAQR 1294 77 0 PLXB3_HUMAN GPVDAVTGK 1296 77 77 PLXC1_HUMAN FWVNILK 1299 158 0 PLXC1_HUMAN LNTIGHYEISNGSTIK 1300 158 158 POSTN_HUMAN GFEPGVTNILK 1302 158 158 POSTN_HUMAN IIDGVPVEITEK 1303 158 0 POSTN_HUMAN IIHGNQIATNGVVHVIDR 1304 158 0 PPIB_HUMAN VIFGLFGK 1319 158 0 PPIB_HUMAN VYFDLR 1320 158 158 PRDX1_HUMAN IGHPAPNFK 1325 158 116 PRDX1_HUMAN QITVNDLPVGR 1328 158 42 PROF1_HUMAN STGGAPTFNVTVTK 1338 158 157 PROF1_HUMAN TFVNITPAEVGVLVGK 1339 158 1 PRS6A_HUMAN VDILDPALLR 1349 13 13 PTGIS_HUMAN DPEIYTDPEVFK 1352 158 0 PTGIS_HUMAN LLLFPFLSPQR 1357 158 158 PTPA_HUMAN FGSLLPIHPVTSG 1361 103 103 PTPA_HUMAN TGPFAEHSNQLWNISAVP 1363 103 0 SWSK PTPA_HUMAN VDDQIAIVFK 1364 103 0 PTPA_HUMAN WIDETPPVDQPSR 1365 103 0 PTPRJ_HUMAN AVSISPTNVILTWK 1372 158 0 PTPRJ_HUMAN VITEPIPVSDLR 1374 158 158 PVR_HUMAN SVDIWLR 1379 158 158 PVR_HUMAN VLAKPQNTAEVQK 1380 158 0 RAB32_HUMAN VHLPNGSPIPAVLLANK 1384 22 0 RAB32_HUMAN VLVIGELGVGK 1385 22 22 RAN_HUMAN FNVWDTAGQEK 1391 116 2 RAN_HUMAN LVLVGDGGTGK 1392 116 114 RAN_HUMAN NVPNWHR 1393 116 0 RAP2B_HUMAN EVSYGEGK 1395 145 0 RAP2B_HUMAN VDLEGER 1397 145 145 S10A1_HUMAN DVDAVDK 1408 128 128 S10A1_HUMAN ELLQTELSGFLDAQK 1409 128 0 S10A6_HUMAN ELTIGSK 1411 154 154 S10A6_HUMAN LQDAEIAR 1412 154 0 SAA_HUMAN EANYIGSDK 1414 143 0 SAA_HUMAN SFFSFLGEAFDGAR 1416 143 143 SCF_HUMAN LFTPEEFFR 1418 143 143 SCF_HUMAN LVANLPK 1419 143 0 SEM3G_HUMAN DYPDEVLQFAR 1426 155 0 SEM3G_HUMAN LFLGGLDALYSLR 1428 155 155 SIAL_HUMAN AYEDEYSYFK 1449 19 19 SIAL_HUMAN TTSPPFGK 1452 19 0 SODM_HUMAN GDVTAQIALQPALK 1460 154 151 SODM_HUMAN NVRPDYLK 1462 154 3 SPON2_HUMAN WSQTAFPK 1478 63 0 SPON2_HUMAN YSITFTGK 1479 63 63 STAT1_HUMAN TELISVSEVHPSR 1494 38 29 STAT1_HUMAN YTYEHDPITK 1496 38 9 TBA1B_HUMAN AVFVDLEPTVIDEVR 1519 119 119 TBA1B_HUMAN EIIDLVLDR 1520 119 0 TBB3_HUMAN ISVYYNEASSHK 1533 158 158 TBB3_HUMAN YLTVATVFR 1535 158 0 TCPA_HUMAN IHPTSVISGYR 1540 158 4 TCPA_HUMAN SSLGPVGLDK 1542 158 154 TCPQ_HUMAN DIDEVSSLLR 1550 48 0 TCPQ_HUMAN NVGLDIEAEVPAVK 1553 48 48 TCPZ_HUMAN GIDPFSLDALSK 1557 6 6 TCPZ_HUMAN GLVLDHGAR 1558 6 0 TENA_HUMAN GLEPGQEYNVLLTAEK 1570 140 140 TENA_HUMAN TVSGNTVEYALTDLEPA 1572 140 0 TEYTLR TENX_HUMAN DAQGQPQAVPVSGDLR 1574 158 158 TENX_HUMAN YEVTVVSVR 1578 158 0 TERA_HUMAN GILLYGPPGTGK 1579 106 94 TERA_HUMAN LDQLIYIPLPDEK 1582 106 12 TETN_HUMAN GGTLSTPQTGSENDALY 1588 158 118 EYLR TETN_HUMAN LDTLAQEVALLK 1589 158 40 TFR1_HUMAN LTVSNVLK 1598 157 0 TFR1_HUMAN SSGLPNIPVQTISR 1600 157 157 TIMP1_HUMAN GFQALGDAADIR 1610 151 151 TIMP1_HUMAN SEEFLIAGK 1611 151 0 TNF12_HUMAN AAPFLTYFGLFQVH 1621 156 156 TNF12_HUMAN INSSSPLR 1622 156 0 TPIS_HUMAN VVFEQTK 1634 157 157 TPIS_HUMAN VVLAYEPVWAIGTGK 1635 157 0 TRFL_HUMAN FQLFGSPSGQK 1637 48 22 TRFL_HUMAN LRPVAAEVYGTER 1638 48 4 TRFL_HUMAN VPSHAVVAR 1639 48 5 TRFL_HUMAN YYGYTGAFR 1640 48 17 TSP1_HUMAN GFLLLASLR 1644 158 6 TSP1_HUMAN GTSQNDPNWVVR 1645 158 152 TTHY_HUMAN TSESGELHGLTTEEEFV 1646 27 27 EGIYK TTHY_HUMAN VEIDTK 1647 27 0 TYPH_HUMAN ALQEALVLSDR 1648 59 0 TYPH_HUMAN TLVGVGASLGLR 1651 59 59 UGGG1_HUMAN DLSQNFPTK 1653 58 58 UGGG1_HUMAN FTILDSQGK 1654 58 0 UGPA_HUMAN LVEIAQVPK 1669 97 97 UGPA_HUMAN NENTFLDLTVQQIEHLNK 1670 97 0 VA0D1_HUMAN LLFEGAGSNPGDK 1679 13 13 VA0D1_HUMAN NVADYYPEYK 1681 13 0 VEGFC_HUMAN DLEEQLR 1689 21 21 VEGFC_HUMAN EAPAAAAAFESGLDLSDA 1690 21 0 EPDAGEATAYASK VEGFC_HUMAN FAAAHYNTEILK 1692 21 0 VEGFC_HUMAN NQPLNPGK 1693 21 0 VTNC_HUMAN AVRPGYPK 1705 145 0 VTNC_HUMAN DVWGIEGPIDAAFTR 1707 145 145
ZA2G_HUMAN EIPAWVPFDPAAQITK 1724 158 158 ZA2G_HUMAN WEAEPVYVQR 1725 158 0
[0080] Exemplary Biomarker Protein
[0081] The following 36 proteins were identified as biomarker candidates in a large-scale experiment of 72 lung cancer samples and 71 benign lung nodule samples using the MS-LC-SRM-MS system described herein.
TABLE-US-00004 TABLE 4 Coeff- icient Coef- Pre- (Discov- ficient dicted Official Coop- Coef- ery) (Final) Concen- Protein Gene erative Partial ficient SEQ ID alpha = alpha = Tissue tration Category (UniProt) Name Score AUC CV Transition NO: 36.16 26.25 Candidate (ng/ml) Classifier TSP1_ THBS1 1.8 0.25 0.24 GFLLLASLR_ 1644 0.53 0.44 510 HUMAN 495.31_559.40 Classifier COIA1_ COL18A1 3.7 0.16 0.25 AVGLAGTFR_ 332 -1.56 -0.91 35 HUMAN 446.26_721.40 Classifier ISLR_ ISLR 1.4 0.32 0.25 ALPGTPVASSQPR_ 839 1.40 0.83 -- HUMAN 640.85_841.50 Classifier TETN_ CLEC3B 2.5 0.26 0.26 LDTLAQEVALLK_ 1589 -1.79 -1.02 58000 HUMAN 657.39_330.20 Classifier FRIL_ FTL 2.8 0.31 0.26 LGGPEAGLGEYLFER_ 596 0.39 0.17 Secreted, 12 HUMAN 804.40_913.40 Epi, Endo Classifier GRP78_ HSPA5 1.4 0.27 0.27 TWNDPSVQQDIK_ 664 1.41 0.55 Secreted, 100 HUMAN 715.85_260.20 Epi, Endo Classifier ALDOA_ ALDOA 1.3 0.26 0.28 ALQASALK_ 58 -0.80 -0.26 Secreted, 250 HUMAN 401.25_617.40 Epi Classifier BGH3_ TGFBI 1.8 0.21 0.28 LTLLAPLNSVFK_ 139 1.73 0.54 Epi 140 HUMAN 658.40_804.50 Classifier LG3BP_ LGALS3BP 4.3 0.29 0.29 VEIFYR_413.73_ 941 -0.58 -0.21 Secreted 440 HUMAN 598.30 Classifier LRP1_ LRP1 4.0 0.13 0.32 TVLWPNGLSLDIPAGR_ 959 -1.59 -0.83 Epi 20 HUMAN 855.00_400.20 Classifier FIBA_ FGA 1.1 0.31 0.35 NSLFEYQK_514.76 556 0.31 0.13 130000 HUMAN 714.30 Classifier PRDX1_ PRDX1 1.5 0.32 0.37 QITVNDLPVGR_ 1328 -0.34 -0.26 Epi 60 HUMAN 606.30_428.30 Classifier GSLG1_ GLG1 1.2 0.34 0.45 IIIQESALDYR_ 666 -0.70 -0.44 Epi, -- HUMAN 660.86_338.20 Endo Robust KIT_ KIT 1.4 0.33 0.46 8.2 HUMAN Robust CD14_ CD14 4.0 0.33 0.48 Epi 420 HUMAN Robust EF1A1_ EEF1A1 1.2 0.32 0.56 Secreted, 61 HUMAN Epi Robust TENX_ TNXB 1.1 0.30 0.56 Endo 70 HUMAN Robust AIFM1_ AIFM1 1.4 0.32 0.70 Epi, 1.4 HUMAN Endo Robust GGH_ GGH 1.3 0.32 0.81 250 HUMAN Robust IBP3_ IGFBP3 3.4 0.32 1.82 5700 HUMAN Robust ENPL_ HSP90B1 1.1 0.29 5.90 Secreted, 88 HUMAN Epi, Endo Non- ERO1A_ ERO1L 6.2 Secreted, -- Robust HUMAN Epi, Endo Non- 6PGD_ PGD 4.3 Epi, 29 Robust HUMAN Endo Non- ICAM1_ ICAM1 3.9 71 Robust HUMAN Non- PTPA_ PPP2R4 2.1 Endo 3.3 Robust HUMAN Non- NCF4_ NCF4 2.0 Endo -- Robust HUMAN Non- SEM3G_ SEMA3G 1.9 -- Robust HUMAN Non- 1433T_ YWHAQ 1.5 Epi 180 Robust HUMAN Non- RAP2B_ RAP2B 1.5 Epi -- Robust HUMAN Non- MMP9_ MMP9 1.4 28 Robust HUMAN Non- FOLH1_ FOLH1 1.3 -- Robust HUMAN Non- GSTP1_ GSTP1 1.3 Endo 32 Robust HUMAN Non- EF2_ EEF2 1.3 Secreted, 30 Robust HUMAN Epi Non- RAN_ RAN 1.2 Secreted, 4.6 Robust HUMAN Epi Non- SODM_ SOD2 1.2 Secreted 7.1 Robust HUMAN Non- DSG2_ DSG2 1.1 Endo 2.7 Robust HUMAN
TABLE-US-LTS-00001 LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20150323545A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).
Sequence CWU
1
1
1731114PRTArtificial SequenceSynthetic Polypeptide 1Ala Val Thr Glu Gln
Gly His Glu Leu Ser Asn Glu Glu Arg 1 5
10 222PRTArtificial SequenceSynthetic Polypeptide 2Asp
Asn Leu Thr Leu Trp Thr Ser Glu Asn Gln Gly Asp Glu Gly Asp 1
5 10 15 Ala Gly Glu Gly Glu Asn
20 36PRTArtificial SequenceSynthetic Polypeptide
3Ser Glu Leu Val Gln Lys 1 5 419PRTArtificial
SequenceSynthetic Polypeptide 4Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu
Asp Thr Leu Asn Glu Glu 1 5 10
15 Ser Tyr Lys 512PRTArtificial SequenceSynthetic Polypeptide
5Tyr Leu Ile Pro Asn Ala Thr Gln Pro Glu Ser Lys 1 5
10 619PRTArtificial SequenceSynthetic Polypeptide
6Ala Ala Phe Asp Asp Ala Ile Ala Glu Leu Asp Thr Leu Ser Glu Glu 1
5 10 15 Ser Tyr Lys
78PRTArtificial SequenceSynthetic Polypeptide 7Glu Asp Leu Val Tyr Gln
Ala Lys 1 5 812PRTArtificial
SequenceSynthetic Polypeptide 8His Leu Ile Pro Ala Ala Asn Thr Gly Glu
Ser Lys 1 5 10 98PRTArtificial
SequenceSynthetic Polypeptide 9Ile Ile Ser Ser Ile Glu Gln Lys 1
5 105PRTArtificial SequenceSynthetic Polypeptide 10Val
Phe Tyr Tyr Lys 1 5 1124PRTArtificial SequenceSynthetic
Polypeptide 11Asp Asn Leu Thr Leu Trp Thr Ala Asp Asn Ala Gly Glu Glu Gly
Gly 1 5 10 15 Glu
Ala Pro Gln Glu Pro Gln Ser 20
128PRTArtificial SequenceSynthetic Polypeptide 12Glu Ala Gly Asp Ala Glu
Ser Arg 1 5 1326PRTArtificial
SequenceSynthetic Polypeptide 13Leu Gly Leu Ala Leu Asn Phe Ser Val Phe
His Tyr Glu Ile Ala Asn 1 5 10
15 Ser Pro Glu Glu Ala Ile Ser Leu Ala Lys 20
25 149PRTArtificial SequenceSynthetic Polypeptide 14Ser
Asn Glu Glu Gly Ser Glu Glu Lys 1 5
158PRTArtificial SequenceSynthetic Polypeptide 15Val Leu Ser Ser Ile Glu
Gln Lys 1 5 1614PRTArtificial
SequenceSynthetic Polypeptide 16Ala Val Thr Glu Gln Gly Ala Glu Leu Ser
Asn Glu Glu Arg 1 5 10
179PRTArtificial SequenceSynthetic Polypeptide 17Glu Met Gln Pro Thr His
Pro Ile Arg 1 5 1818PRTArtificial
SequenceSynthetic Polypeptide 18Gln Thr Ile Asp Asn Ser Gln Gly Ala Tyr
Gln Glu Ala Phe Asp Ile 1 5 10
15 Ser Lys 1919PRTArtificial SequenceSynthetic Polypeptide
19Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu Asp Thr Leu Asn Glu Asp 1
5 10 15 Ser Tyr Lys
2012PRTArtificial SequenceSynthetic Polypeptide 20Tyr Leu Ile Ala Asn Ala
Thr Asn Pro Glu Ser Lys 1 5 10
2112PRTArtificial SequenceSynthetic Polypeptide 21Phe Leu Ile Pro Asn Ala
Ser Gln Ala Glu Ser Lys 1 5 10
2218PRTArtificial SequenceSynthetic Polypeptide 22Gly Ile Val Asp Gln Ser
Gln Gln Ala Tyr Gln Glu Ala Phe Glu Ile 1 5
10 15 Ser Lys 2314PRTArtificial SequenceSynthetic
Polypeptide 23Ser Val Thr Glu Gln Gly Ala Glu Leu Ser Asn Glu Glu Arg 1
5 10 2419PRTArtificial
SequenceSynthetic Polypeptide 24Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu
Asp Thr Leu Ser Glu Glu 1 5 10
15 Ser Tyr Lys 2511PRTArtificial SequenceSynthetic Polypeptide
25Ala Gly Gln Ala Val Asp Asp Phe Ile Glu Lys 1 5
10 2613PRTArtificial SequenceSynthetic Polypeptide 26His Glu
Met Leu Pro Ala Ser Leu Ile Gln Ala Gln Arg 1 5
10 2720PRTArtificial SequenceSynthetic Polypeptide
27Leu Val Pro Leu Leu Asp Thr Gly Asp Ile Ile Ile Asp Gly Gly Asn 1
5 10 15 Ser Glu Tyr Arg
20 2811PRTArtificial SequenceSynthetic Polypeptide 28Tyr Gly
Pro Ser Leu Met Pro Gly Gly Asn Lys 1 5
10 2915PRTArtificial SequenceSynthetic Polypeptide 29Asn Trp Gly Leu
Ser Val Tyr Ala Asp Lys Pro Glu Thr Thr Lys 1 5
10 15 3016PRTArtificial SequenceSynthetic
Polypeptide 30Ser Val Gln Glu Ile Gln Ala Thr Phe Phe Tyr Phe Thr Pro Asn
Lys 1 5 10 15
318PRTArtificial SequenceSynthetic Polypeptide 31Thr Glu Asp Thr Ile Phe
Leu Arg 1 5 329PRTArtificial
SequenceSynthetic Polypeptide 32Trp Phe Tyr Ile Ala Ser Ala Phe Arg 1
5 3315PRTArtificial SequenceSynthetic
Polypeptide 33Tyr Val Gly Gly Gln Glu His Phe Ala His Leu Leu Ile Leu Arg
1 5 10 15
3417PRTArtificial SequenceSynthetic Polypeptide 34Asp Ala Gly Ile Ala Leu
Leu Ser Ile Thr His Arg Pro Ser Leu Trp 1 5
10 15 Lys 3514PRTArtificial SequenceSynthetic
Polypeptide 35Glu Leu Glu Asp Ala Gln Ala Gly Ser Gly Thr Ile Gly Arg 1
5 10 3620PRTArtificial
SequenceSynthetic Polypeptide 36Gly Leu Gln Ala Pro Ala Gly Glu Pro Thr
Gln Glu Ala Ser Gly Val 1 5 10
15 Ala Ala Ala Lys 20 3712PRTArtificial
SequenceSynthetic Polypeptide 37Asn Leu Leu Thr Ala Ala Ala Asp Ala Ile
Glu Arg 1 5 10 3815PRTArtificial
SequenceSynthetic Polypeptide 38Tyr His Thr His Leu Leu Gln Phe Asp Gly
Glu Gly Gly Trp Lys 1 5 10
15 3919PRTArtificial SequenceSynthetic Polypeptide 39Ala Asp Glu Val
Val Ser Ala Ser Val Gly Ser Gly Asp Leu Trp Ile 1 5
10 15 Pro Val Lys 4013PRTArtificial
SequenceSynthetic Polypeptide 40Phe Gly Phe Gly Gly Ser Thr Asp Ser Gly
Pro Ile Arg 1 5 10
4110PRTArtificial SequenceSynthetic Polypeptide 41Leu Ile Glu Ile Ala Asn
His Val Asp Lys 1 5 10 429PRTArtificial
SequenceSynthetic Polypeptide 42Asn His Pro Glu Val Leu Asn Ile Arg 1
5 4311PRTArtificial SequenceSynthetic
Polypeptide 43Tyr Val Glu Leu Val Ile Val Ala Asp Asn Arg 1
5 10 4411PRTArtificial SequenceSynthetic
Polypeptide 44Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys 1
5 10 4511PRTArtificial SequenceSynthetic
Polypeptide 45Ser Pro Glu Asp Ser Ser Pro Asp Ala Ala Arg 1
5 10 4624PRTArtificial SequenceSynthetic
Polypeptide 46Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
Pro 1 5 10 15 Ser
Gly Ser Ala Pro His Phe Leu 20
4718PRTArtificial SequenceSynthetic Polypeptide 47Gly Trp Gly Asp Gln Leu
Ile Trp Thr Gln Thr Tyr Glu Glu Ala Leu 1 5
10 15 Tyr Lys 4811PRTArtificial SequenceSynthetic
Polypeptide 48His Leu Ser Pro Asp Gly Gln Tyr Val Pro Arg 1
5 10 4918PRTArtificial SequenceSynthetic
Polypeptide 49Ile Pro Val Ser Ala Phe Leu Leu Leu Val Ala Leu Ser Tyr Thr
Leu 1 5 10 15 Ala
Arg 5017PRTArtificial SequenceSynthetic Polypeptide 50Leu Ala Glu Gln Phe
Val Leu Leu Asn Leu Val Tyr Glu Thr Thr Asp 1 5
10 15 Lys 517PRTArtificial SequenceSynthetic
Polypeptide 51Leu Pro Gln Thr Leu Ser Arg 1 5
5213PRTArtificial SequenceSynthetic Polypeptide 52Ala Leu Gly Thr Glu Val
Ile Gln Leu Phe Pro Glu Lys 1 5 10
5312PRTArtificial SequenceSynthetic Polypeptide 53Glu Leu Trp Phe
Ser Asp Asp Pro Asn Val Thr Lys 1 5 10
547PRTArtificial SequenceSynthetic Polypeptide 54Gly Val Ile Phe
Tyr Leu Arg 1 5 5511PRTArtificial
SequenceSynthetic Polypeptide 55Leu Asn Asp Gly Ser Gln Ile Thr Tyr Glu
Lys 1 5 10 5614PRTArtificial
SequenceSynthetic Polypeptide 56Thr Gly Gly Leu Glu Ile Asp Ser Asp Phe
Gly Gly Phe Arg 1 5 10
5712PRTArtificial SequenceSynthetic Polypeptide 57Ala Asp Asp Gly Arg Pro
Phe Pro Gln Val Ile Lys 1 5 10
588PRTArtificial SequenceSynthetic Polypeptide 58Ala Leu Gln Ala Ser Ala
Leu Lys 1 5 5923PRTArtificial
SequenceSynthetic Polypeptide 59Gly Val Val Pro Leu Ala Gly Thr Asn Gly
Glu Thr Thr Thr Gln Gly 1 5 10
15 Leu Asp Gly Leu Ser Glu Arg 20
609PRTArtificial SequenceSynthetic Polypeptide 60Gln Leu Leu Leu Thr Ala
Asp Asp Arg 1 5 6122PRTArtificial
SequenceSynthetic Polypeptide 61Tyr Thr Pro Ser Gly Gln Ala Gly Ala Ala
Ala Ser Glu Ser Leu Phe 1 5 10
15 Val Ser Asn His Ala Tyr 20
628PRTArtificial SequenceSynthetic Polypeptide 62Ala Leu Glu Gln Ala Leu
Glu Lys 1 5 6310PRTArtificial
SequenceSynthetic Polypeptide 63Asp His Ser Ala Ile Pro Val Ile Asn Arg 1
5 10 6416PRTArtificial SequenceSynthetic
Polypeptide 64Glu Asn Ser Leu Leu Phe Asp Pro Leu Ser Ser Ser Ser Ser Asn
Lys 1 5 10 15
6512PRTArtificial SequenceSynthetic Polypeptide 65Glu Val Val Leu Gln Trp
Phe Thr Glu Asn Ser Lys 1 5 10
669PRTArtificial SequenceSynthetic Polypeptide 66Ser Ile Gln Leu Pro Thr
Thr Val Arg 1 5 6713PRTArtificial
SequenceSynthetic Polypeptide 67Asp Ala Pro His Val Glu Pro Asp Phe Ser
Ser Gln Lys 1 5 10
6814PRTArtificial SequenceSynthetic Polypeptide 68Leu Glu Ile Gln Leu Leu
Glu Asn Ser Leu Ser Thr Tyr Lys 1 5 10
6911PRTArtificial SequenceSynthetic Polypeptide 69Gln Leu
Leu Gln Gln Thr Asn Glu Ile Leu Lys 1 5
10 7014PRTArtificial SequenceSynthetic Polypeptide 70Gln Ser Ser Leu
Ile Leu His Gly Ala Asp Phe Ser Thr Lys 1 5
10 7110PRTArtificial SequenceSynthetic Polypeptide
71Gln Thr Tyr Ile Ile Gln Glu Leu Glu Lys 1 5
10 7212PRTArtificial SequenceSynthetic Polypeptide 72Asp Ala Pro Leu
Glu Tyr Asp Asp Ser Val Gln Arg 1 5 10
739PRTArtificial SequenceSynthetic Polypeptide 73Asp Gln Leu Gln
Val Leu Val Ser Lys 1 5 7414PRTArtificial
SequenceSynthetic Polypeptide 74Ile Ser Ser Ile Ser Gln Pro Gly Asn Asp
Phe Ser Thr Lys 1 5 10
7511PRTArtificial SequenceSynthetic Polypeptide 75Gln Ile Leu Asp Gln Thr
Ser Glu Ile Asn Lys 1 5 10
7613PRTArtificial SequenceSynthetic Polypeptide 76Ser Ser Ser Ser Pro Tyr
Val Ser Asn Ala Val Gln Arg 1 5 10
778PRTArtificial SequenceSynthetic Polypeptide 77Ala Glu Leu Gln
Glu Gly Ala Arg 1 5 789PRTArtificial
SequenceSynthetic Polypeptide 78Ala Lys Pro Ala Leu Glu Asp Leu Arg 1
5 7911PRTArtificial SequenceSynthetic
Polypeptide 79Ala Thr Glu His Leu Ser Thr Leu Ser Glu Lys 1
5 10 807PRTArtificial SequenceSynthetic
Polypeptide 80Leu Ala Glu Tyr His Ala Lys 1 5
817PRTArtificial SequenceSynthetic Polypeptide 81Leu His Glu Leu Gln Glu
Lys 1 5 8215PRTArtificial SequenceSynthetic
Polypeptide 82Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
1 5 10 15
838PRTArtificial SequenceSynthetic Polypeptide 83Ala Leu Met Asp Glu Thr
Met Lys 1 5 846PRTArtificial
SequenceSynthetic Polypeptide 84Phe Trp Asp Tyr Leu Arg 1 5
8515PRTArtificial SequenceSynthetic Polypeptide 85Gly Glu Val Gln
Ala Met Leu Gly Gln Ser Thr Glu Glu Leu Arg 1 5
10 15 869PRTArtificial SequenceSynthetic
Polypeptide 86Leu Ala Val Tyr Gln Ala Gly Ala Arg 1 5
879PRTArtificial SequenceSynthetic Polypeptide 87Leu Gly Pro
Leu Val Glu Gln Gly Arg 1 5
8815PRTArtificial SequenceSynthetic Polypeptide 88Ser Glu Leu Glu Glu Gln
Leu Thr Pro Val Ala Glu Glu Thr Arg 1 5
10 15 8912PRTArtificial SequenceSynthetic Polypeptide
89Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg 1 5
10 907PRTArtificial SequenceSynthetic Polypeptide
90Trp Glu Leu Ala Leu Gly Arg 1 5
9123PRTArtificial SequenceSynthetic Polypeptide 91Trp Val Gln Thr Leu Ser
Glu Gln Val Gln Glu Glu Leu Leu Ser Ser 1 5
10 15 Gln Val Thr Gln Glu Leu Arg 20
9223PRTArtificial SequenceSynthetic Polypeptide 92Glu Ile Glu
Pro Glu Pro Asp Phe Ile Leu Trp Thr Gly Asp Asp Thr 1 5
10 15 Pro His Val Pro Asp Glu Lys
20 9314PRTArtificial SequenceSynthetic Polypeptide
93Phe Trp His Ile Ala Asp Leu His Leu Asp Pro Asp Tyr Lys 1
5 10 9410PRTArtificial
SequenceSynthetic Polypeptide 94Ile Ala Gly Asp Gln Ser Thr Leu Gln Arg 1
5 10 9512PRTArtificial SequenceSynthetic
Polypeptide 95Leu Gly Glu Ala Ala Val Leu Glu Ile Val Glu Arg 1
5 10 9616PRTArtificial SequenceSynthetic
Polypeptide 96Val Ile Ala Gly Gln Phe Phe Gly His His His Thr Asp Ser Phe
Arg 1 5 10 15
9715PRTArtificial SequenceSynthetic Polypeptide 97Ala Glu Ile Gly Ile Ala
Met Gly Ser Gly Thr Ala Val Ala Lys 1 5
10 15 9813PRTArtificial SequenceSynthetic Polypeptide
98Ile Gly Ile Phe Gly Gln Asp Glu Asp Val Thr Ser Lys 1 5
10 9913PRTArtificial SequenceSynthetic
Polypeptide 99Asn Met Leu Phe Ser Gly Thr Asn Ile Ala Ala Gly Lys 1
5 10 10014PRTArtificial
SequenceSynthetic Polypeptide 100Ala Ser Phe Gly Ser Gly Pro Ala Val Glu
Trp Ile Pro Lys 1 5 10
10121PRTArtificial SequenceSynthetic Polypeptide 101Gly Ala Phe Tyr Leu
Leu Gly Glu Ala Tyr Phe Ile Gln Pro Leu Pro 1 5
10 15 Ala Ala Ser Glu Arg 20
10211PRTArtificial SequenceSynthetic Polypeptide 102Gly Ile Gly Tyr Phe
Phe Val Leu Gln Pro Lys 1 5 10
10313PRTArtificial SequenceSynthetic Polypeptide 103Gly Pro Glu Val Thr
Ser Asn Ala Ala Leu Thr Leu Arg 1 5 10
10412PRTArtificial SequenceSynthetic Polypeptide 104His Tyr Leu
Leu Thr Leu Phe Ser Val Ala Ala Arg 1 5
10 10513PRTArtificial SequenceSynthetic Polypeptide 105Glu Gly
Ser Gly Tyr Val Asp Ile Gly Leu Ile Pro Lys 1 5
10 10612PRTArtificial SequenceSynthetic Polypeptide
106Leu Ile Leu Leu Glu Glu Glu Glu Gln Gly Leu Lys 1 5
10 10713PRTArtificial SequenceSynthetic Polypeptide
107Gln Leu Gln Tyr Asp Pro Thr Pro Leu Thr Trp Ser Lys 1 5
10 10814PRTArtificial SequenceSynthetic
Polypeptide 108Gln Trp Gln Asp Ser Ser Thr Gln Pro Glu Leu Ser Ser Arg 1
5 10 10911PRTArtificial
SequenceSynthetic Polypeptide 109Trp Val Glu Thr Leu Val Val Ala Asp Thr
Lys 1 5 10 1109PRTArtificial
SequenceSynthetic Polypeptide 110Glu Gln Pro Ile Leu Leu Ser Glu Lys 1
5 11111PRTArtificial SequenceSynthetic
Polypeptide 111Gly Gln Asn Leu Gly Asp Val Ser Trp Ser Arg 1
5 10 11222PRTArtificial SequenceSynthetic
Polypeptide 112Leu Arg Pro Pro Pro Pro Ser Glu Gly Glu Glu Asp Glu Glu
Leu Glu 1 5 10 15
Ser Gln Glu Leu Pro Arg 20 1139PRTArtificial
SequenceSynthetic Polypeptide 113Asn Ile Ser Ile Val Asp Asn Glu Lys 1
5 11414PRTArtificial SequenceSynthetic
Polypeptide 114Ser Val Ala Pro Val Pro Leu Glu Glu Pro Val Glu Gly Arg 1
5 10 11514PRTArtificial
SequenceSynthetic Polypeptide 115Ala Val Phe Leu Ala Leu Ser Ala Gln Leu
Leu Gln Ala Arg 1 5 10
1169PRTArtificial SequenceSynthetic Polypeptide 116Glu Glu Ser Pro Val
Val Ser Trp Arg 1 5 11718PRTArtificial
SequenceSynthetic Polypeptide 117Glu Glu Ser Pro Val Val Ser Trp Trp Leu
Glu Pro Glu Asp Gly Thr 1 5 10
15 Ala Leu 11822PRTArtificial SequenceSynthetic Polypeptide
118Ala Ala Glu Ala Ala Ala Ala Pro Ala Glu Ser Ala Ala Pro Ala Ala 1
5 10 15 Gly Glu Glu Pro
Ser Lys 20 11913PRTArtificial SequenceSynthetic
Polypeptide 119Ala Glu Gly Ala Ala Thr Glu Glu Glu Gly Thr Pro Lys 1
5 10 12019PRTArtificial
SequenceSynthetic Polypeptide 120Ala Pro Glu Gln Glu Gln Ala Ala Pro Gly
Pro Ala Ala Gly Gly Glu 1 5 10
15 Ala Pro Lys 12128PRTArtificial SequenceSynthetic
Polypeptide 121Ala Gln Gly Pro Ala Ala Ser Ala Glu Glu Pro Lys Pro Val
Glu Ala 1 5 10 15
Pro Ala Ala Asn Ser Asp Gln Thr Val Thr Val Lys 20
25 12210PRTArtificial SequenceSynthetic Polypeptide
122Glu Lys Pro Asp Gln Asp Ala Glu Gly Lys 1 5
10 12314PRTArtificial SequenceSynthetic Polypeptide 123Glu Ser Glu
Pro Gln Ala Ala Ala Glu Pro Ala Glu Ala Lys 1 5
10 12414PRTArtificial SequenceSynthetic
Polypeptide 124Glu Thr Pro Ala Ala Thr Glu Ala Pro Ser Ser Thr Pro Lys 1
5 10 1258PRTArtificial
SequenceSynthetic Polypeptide 125Gly Tyr Asn Val Asn Asp Glu Lys 1
5 12621PRTArtificial SequenceSynthetic Polypeptide
126Ser Asp Gly Ala Pro Ala Ser Asp Ser Lys Pro Gly Ser Ser Glu Ala 1
5 10 15 Ala Pro Ser Ser
Lys 20 12713PRTArtificial SequenceSynthetic Polypeptide
127Thr Glu Ala Pro Ala Ala Pro Ala Ala Gln Glu Thr Lys 1 5
10 12813PRTArtificial SequenceSynthetic
Polypeptide 128Thr Gly Ala Leu Leu Leu Gln Gly Phe Ile Gln Asp Arg 1
5 10 1296PRTArtificial
SequenceSynthetic Polypeptide 129Val Pro Glu Leu Ile Arg 1
5 13010PRTArtificial SequenceSynthetic Polypeptide 130Val Val Ala
Leu Phe Tyr Phe Ala Ser Lys 1 5 10
1318PRTArtificial SequenceSynthetic Polypeptide 131Asp Ala Asp Leu Tyr
Thr Ser Arg 1 5 13222PRTArtificial
SequenceSynthetic Polypeptide 132Gly Leu Thr Ser Leu Ala Asp Thr Phe Glu
His Val Ile Glu Glu Leu 1 5 10
15 Leu Asp Glu Asp Gln Lys 20
13311PRTArtificial SequenceSynthetic Polypeptide 133Gly Gln Gly Gly Leu
Ala Tyr Pro Gly Val Arg 1 5 10
1347PRTArtificial SequenceSynthetic Polypeptide 134Gln Tyr Phe Tyr Glu
Thr Lys 1 5 13512PRTArtificial SequenceSynthetic
Polypeptide 135Thr His Gly Thr Leu Glu Ser Val Asn Gly Pro Lys 1
5 10 13615PRTArtificial SequenceSynthetic
Polypeptide 136Ala Asp His His Ala Thr Asn Gly Val Val His Leu Ile Asp
Lys 1 5 10 15
13722PRTArtificial SequenceSynthetic Polypeptide 137Asp Ile Leu Ala Thr
Asn Gly Val Ile His Tyr Ile Asp Glu Leu Leu 1 5
10 15 Ile Pro Asp Ser Ala Lys 20
13815PRTArtificial SequenceSynthetic Polypeptide 138Glu Gly Val
Tyr Thr Val Phe Ala Pro Thr Asn Glu Ala Phe Arg 1 5
10 15 13912PRTArtificial SequenceSynthetic
Polypeptide 139Leu Thr Leu Leu Ala Pro Leu Asn Ser Val Phe Lys 1
5 10 14011PRTArtificial SequenceSynthetic
Polypeptide 140Ser Pro Tyr Gln Leu Val Leu Gln His Ser Arg 1
5 10 14115PRTArtificial SequenceSynthetic
Polypeptide 141Ile Asn Ile Tyr Glu Ile Ile Lys Pro Ala Thr Ala Asn Ser
Lys 1 5 10 15
1428PRTArtificial SequenceSynthetic Polypeptide 142Leu Val Asn Gln Asn
Ala Ser Arg 1 5 14317PRTArtificial
SequenceSynthetic Polypeptide 143Ser Phe His His Glu Glu Ser Leu Glu Glu
Leu Pro Glu Thr Ser Gly 1 5 10
15 Lys 14424PRTArtificial SequenceSynthetic Polypeptide 144Ser
Leu His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu 1
5 10 15 Val Thr Phe Gly His Asp
Gly Lys 20 14521PRTArtificial
SequenceSynthetic Polypeptide 145Trp Thr Ala Gln Gly His Ala Asn His Gly
Phe Val Val Glu Val Ala 1 5 10
15 His Leu Glu Glu Lys 20 14614PRTArtificial
SequenceSynthetic Polypeptide 146Ala Gly Leu Ile Ile Pro Leu Phe Leu Val
Leu Ala Ser Arg 1 5 10
1478PRTArtificial SequenceSynthetic Polypeptide 147Ala Leu Leu Ser Pro
Glu Gln Arg 1 5 1486PRTArtificial
SequenceSynthetic Polypeptide 148Asp Ile Phe Leu Gly Arg 1
5 1499PRTArtificial SequenceSynthetic Polypeptide 149Gly Glu Gly
Thr Ser Ala His Leu Arg 1 5
15013PRTArtificial SequenceSynthetic Polypeptide 150Gly Phe Phe Ala Asp
Tyr Glu Ile Pro Asn Leu Gln Lys 1 5 10
15117PRTArtificial SequenceSynthetic Polypeptide 151Glu Ala Glu
Phe Gly Gln Gly Thr Gly Pro Ile Trp Leu Asn Glu Val 1 5
10 15 Lys 15211PRTArtificial
SequenceSynthetic Polypeptide 152Gly Glu Asn Leu Val His Gln Ile Gln Tyr
Arg 1 5 10 1538PRTArtificial
SequenceSynthetic Polypeptide 153Ile Asn Pro Ala Ser Leu Asp Lys 1
5 15414PRTArtificial SequenceSynthetic Polypeptide
154Leu Glu Val Phe Tyr Asn Gly Ala Trp Gly Thr Val Gly Lys 1
5 10 1558PRTArtificial
SequenceSynthetic Polypeptide 155Thr Ser Tyr Gln Val Tyr Ser Lys 1
5 15611PRTArtificial SequenceSynthetic Polypeptide
156Glu Asp Val Tyr Val Val Gly Thr Val Leu Arg 1 5
10 1579PRTArtificial SequenceSynthetic Polypeptide 157Gly
Tyr Ile Leu Val Gly Gln Ala Lys 1 5
1587PRTArtificial SequenceSynthetic Polypeptide 158Ile Ala His Gly His
Tyr Lys 1 5 15912PRTArtificial SequenceSynthetic
Polypeptide 159Leu Ser Leu Glu Ile Glu Gln Leu Glu Leu Gln Arg 1
5 10 1608PRTArtificial SequenceSynthetic
Polypeptide 160Thr Trp Tyr Pro Glu Val Pro Lys 1 5
16116PRTArtificial SequenceSynthetic Polypeptide 161Phe Pro Ala Glu
Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg 1 5
10 15 16215PRTArtificial
SequenceSynthetic Polypeptide 162Gly Gly Val Ser Tyr Arg Pro Ala Glu Val
Ala Glu Thr Gly Ala 1 5 10
15 16328PRTArtificial SequenceSynthetic Polypeptide 163Leu Glu Glu Ile
Ala Glu Glu Gly Ser Glu Thr Gln Val Pro Gly Leu 1 5
10 15 Asp Ile Ser Ala Leu Leu Pro Ser Asp
Phe Ser Arg 20 25
16415PRTArtificial SequenceSynthetic Polypeptide 164Val Ile Glu Ala Ser
Phe Pro Ala Gly Val Asp Ser Ser Pro Arg 1 5
10 15 1659PRTArtificial SequenceSynthetic Polypeptide
165Tyr Gly Gly Asp Pro Pro Trp Pro Arg 1 5
16621PRTArtificial SequenceSynthetic Polypeptide 166Asp Asp Glu Phe Thr
His Leu Tyr Thr Leu Ile Val Arg Pro Asp Asn 1 5
10 15 Thr Tyr Glu Val Lys 20
16713PRTArtificial SequenceSynthetic Polypeptide 167Asp Pro Asp Ala Ser
Lys Pro Glu Asp Trp Asp Glu Arg 1 5 10
1687PRTArtificial SequenceSynthetic Polypeptide 168Phe Tyr Gly
Asp Glu Glu Lys 1 5 1699PRTArtificial
SequenceSynthetic Polypeptide 169Gly Leu Gln Thr Ser Gln Asp Ala Arg 1
5 17011PRTArtificial SequenceSynthetic
Polypeptide 170Gly Gln Thr Leu Val Val Gln Phe Thr Val Lys 1
5 10 17116PRTArtificial SequenceSynthetic
Polypeptide 171Asp Trp Ile Leu Pro Ser Asp Tyr Asp His Ala Glu Ala Glu
Ala Arg 1 5 10 15
1727PRTArtificial SequenceSynthetic Polypeptide 172Glu Gln Phe Val Glu
Phe Arg 1 5 17316PRTArtificial SequenceSynthetic
Polypeptide 173Gly His Asp Leu Asn Glu Asp Gly Leu Val Ser Trp Glu Glu
Tyr Lys 1 5 10 15
17411PRTArtificial SequenceSynthetic Polypeptide 174Thr Phe Asp Gln Leu
Thr Pro Glu Glu Ser Lys 1 5 10
17522PRTArtificial SequenceSynthetic Polypeptide 175Val His Asn Asp Ala
Gln Ser Phe Asp Tyr Asp His Asp Ala Phe Leu 1 5
10 15 Gly Ala Glu Glu Ala Lys 20
1769PRTArtificial SequenceSynthetic Polypeptide 176Ala Glu Glu
Asp Glu Ile Leu Asn Arg 1 5
17716PRTArtificial SequenceSynthetic Polypeptide 177Ala Pro Val Pro Thr
Gly Glu Val Tyr Phe Ala Asp Ser Phe Asp Arg 1 5
10 15 17810PRTArtificial SequenceSynthetic
Polypeptide 178Gly Thr Leu Ser Gly Trp Ile Leu Ser Lys 1 5
10 17919PRTArtificial SequenceSynthetic Polypeptide
179Ile Pro Asp Pro Glu Ala Val Lys Pro Asp Asp Trp Asp Glu Asp Ala 1
5 10 15 Pro Ala Lys
1807PRTArtificial SequenceSynthetic Polypeptide 180Thr Gly Ile Tyr Glu
Glu Lys 1 5 18115PRTArtificial SequenceSynthetic
Polypeptide 181Asp Trp Ile Asp Gly Val Leu Asn Asn Pro Gly Pro Gly Pro
Ala 1 5 10 15
18225PRTArtificial SequenceSynthetic Polypeptide 182Glu Ala Asn Leu Thr
Ser Ser Val Thr Ile Leu Pro Leu Pro Leu Gln 1 5
10 15 Asn Ala Thr Val Glu Ala Gly Thr Arg
20 25 1837PRTArtificial SequenceSynthetic
Polypeptide 183Gly Pro Asp Phe Phe Thr Arg 1 5
18415PRTArtificial SequenceSynthetic Polypeptide 184Leu Thr Val Leu Ala
Leu Leu Ala Gly Leu Leu Ala Ser Ser Arg 1 5
10 15 18513PRTArtificial SequenceSynthetic
Polypeptide 185Gln Phe Pro Phe Leu Ala Ser Ile Gln Asn Gln Gly Arg 1
5 10 18614PRTArtificial
SequenceSynthetic Polypeptide 186His Tyr Gly Tyr Asn Ser Tyr Ser Val Ser
Asn Ser Glu Lys 1 5 10
18730PRTArtificial SequenceSynthetic Polypeptide 187Ile Leu Gly Trp Gly
Val Glu Asn Gly Thr Pro Tyr Trp Leu Val Ala 1 5
10 15 Asn Ser Trp Asn Thr Asp Trp Gly Asp Asn
Gly Phe Phe Lys 20 25 30
1888PRTArtificial SequenceSynthetic Polypeptide 188Leu Pro Ala Ser Phe
Asp Ala Arg 1 5 18918PRTArtificial
SequenceSynthetic Polypeptide 189Asn Gly Pro Val Glu Gly Ala Phe Ser Val
Tyr Ser Asp Phe Leu Leu 1 5 10
15 Tyr Lys 1907PRTArtificial SequenceSynthetic Polypeptide
190Thr Asp Gln Tyr Trp Glu Lys 1 5
1917PRTArtificial SequenceSynthetic Polypeptide 191His Pro Gln Tyr Asn
Gln Arg 1 5 1929PRTArtificial SequenceSynthetic
Polypeptide 192Asn Val Asn Pro Val Ala Leu Pro Arg 1 5
19311PRTArtificial SequenceSynthetic Polypeptide 193Ser Ser
Gly Val Pro Pro Glu Val Phe Thr Arg 1 5
10 1949PRTArtificial SequenceSynthetic Polypeptide 194Val Ser Ser
Phe Leu Pro Trp Ile Arg 1 5
19525PRTArtificial SequenceSynthetic Polypeptide 195Ala Ser Ala Ser Tyr
Tyr Glu Gln Tyr His Ser Leu Asn Glu Ile Tyr 1 5
10 15 Ser Trp Ile Glu Phe Ile Thr Glu Arg
20 25 19620PRTArtificial SequenceSynthetic
Polypeptide 196Ala Tyr Ile Ser Met His Ser Tyr Ser Gln His Ile Val Phe
Pro Tyr 1 5 10 15
Ser Tyr Thr Arg 20 19714PRTArtificial SequenceSynthetic
Polypeptide 197Asp His Glu Glu Leu Ser Leu Val Ala Ser Glu Ala Val Arg 1
5 10 19812PRTArtificial
SequenceSynthetic Polypeptide 198Asp Thr Gly Thr Tyr Gly Phe Leu Leu Pro
Glu Arg 1 5 10 1998PRTArtificial
SequenceSynthetic Polypeptide 199Glu Ala Phe Ala Ala Val Ser Lys 1
5 2009PRTArtificial SequenceSynthetic Polypeptide
200Ile His Ile Gly Ser Ser Phe Glu Lys 1 5
20120PRTArtificial SequenceSynthetic Polypeptide 201Leu Val Asp Phe Tyr
Val Met Pro Val Val Asn Val Asp Gly Tyr Asp 1 5
10 15 Tyr Ser Trp Lys 20
20215PRTArtificial SequenceSynthetic Polypeptide 202Gln Val His Phe Phe
Val Asn Ala Ser Asp Val Asp Asn Val Lys 1 5
10 15 2037PRTArtificial SequenceSynthetic Polypeptide
203Tyr Pro Leu Tyr Val Leu Lys 1 5
20427PRTArtificial SequenceSynthetic Polypeptide 204Tyr Thr His Gly His
Gly Ser Glu Thr Leu Tyr Leu Ala Pro Gly Gly 1 5
10 15 Gly Asp Asp Trp Ile Tyr Asp Leu Gly Ile
Lys 20 25 2056PRTArtificial
SequenceSynthetic Polypeptide 205Xaa Xaa Xaa Xaa Xaa Xaa 1
5 20619PRTArtificial SequenceSynthetic Polypeptide 206Ala Phe Pro
Ala Leu Thr Ser Leu Asp Leu Ser Asp Asn Pro Gly Leu 1 5
10 15 Gly Glu Arg 2079PRTArtificial
SequenceSynthetic Polypeptide 207Ala Thr Val Asn Pro Ser Ala Pro Arg 1
5 2088PRTArtificial SequenceSynthetic
Polypeptide 208Glu Leu Thr Leu Glu Asp Leu Lys 1 5
20910PRTArtificial SequenceSynthetic Polypeptide 209Phe Pro Ala Ile
Gln Asn Leu Ala Leu Arg 1 5 10
21021PRTArtificial SequenceSynthetic Polypeptide 210Ile Thr Gly Thr Met
Pro Pro Leu Pro Leu Glu Ala Thr Gly Leu Ala 1 5
10 15 Leu Ser Ser Leu Arg 20
21118PRTArtificial SequenceSynthetic Polypeptide 211Leu Thr Val Gly Ala
Ala Gln Val Pro Ala Gln Leu Leu Val Gly Ala 1 5
10 15 Leu Arg 2128PRTArtificial
SequenceSynthetic Polypeptide 212Asn Val Ser Trp Ala Thr Gly Arg 1
5 21318PRTArtificial SequenceSynthetic Polypeptide
213Ser Thr Leu Ser Val Gly Val Ser Gly Thr Leu Val Leu Leu Gln Gly 1
5 10 15 Ala Arg
21415PRTArtificial SequenceSynthetic Polypeptide 214Ser Trp Leu Ala Glu
Leu Gln Gln Trp Leu Lys Pro Gly Leu Lys 1 5
10 15 2158PRTArtificial SequenceSynthetic Polypeptide
215Val Asp Ala Asp Ala Asp Pro Arg 1 5
21624PRTArtificial SequenceSynthetic Polypeptide 216Ala Ala Gly Gly Ala
Leu Gln Ser Thr Ala Ser Leu Phe Val Val Ser 1 5
10 15 Leu Ser Leu Leu His Leu Tyr Ser
20 2176PRTArtificial SequenceSynthetic Polypeptide
217His Ser His Pro Thr Arg 1 5 2188PRTArtificial
SequenceSynthetic Polypeptide 218Val Phe Val Val His Ile Pro Arg 1
5 21911PRTArtificial SequenceSynthetic Polypeptide
219Asp Leu Ala His Gln Phe Thr Gln Val Gln Arg 1 5
10 2206PRTArtificial SequenceSynthetic Polypeptide 220Ile
Leu Leu Trp Ser Arg 1 5 2217PRTArtificial
SequenceSynthetic Polypeptide 221Asn Ile Tyr Arg Pro Asp Lys 1
5 22216PRTArtificial SequenceSynthetic Polypeptide 222Asn
Ser Thr Phe Gly Ser Val Glu Val His Asn Leu Gln Pro Glu Lys 1
5 10 15 22313PRTArtificial
SequenceSynthetic Polypeptide 223Val Gln Thr Leu Glu Ala Trp Val Ile His
Gly Gly Arg 1 5 10
22418PRTArtificial SequenceSynthetic Polypeptide 224Gly Asp Gln Asn Pro
Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser 1 5
10 15 Ser Lys 2258PRTArtificial
SequenceSynthetic Polypeptide 225Ser Gln Phe Glu Gly Phe Val Lys 1
5 22610PRTArtificial SequenceSynthetic Polypeptide
226Thr Thr Ser Val Leu Gln Trp Ala Glu Lys 1 5
10 2279PRTArtificial SequenceSynthetic Polypeptide 227Phe Ala Gly
Val Phe His Val Glu Lys 1 5
22825PRTArtificial SequenceSynthetic Polypeptide 228His Leu Ser Phe Ser
Gly Ser Gly Ile Asp Asp Asp Glu Asp Phe Ile 1 5
10 15 Ser Ser Thr Ile Ser Thr Thr Pro Arg
20 25 22911PRTArtificial SequenceSynthetic
Polypeptide 229Lys Pro Ser Gly Leu Asn Gly Glu Ala Ser Lys 1
5 10 23024PRTArtificial SequenceSynthetic
Polypeptide 230Thr Asn Pro Glu Asp Ile Tyr Pro Ser Asn Pro Thr Asp Asp
Asp Val 1 5 10 15
Ser Ser Gly Ser Ser Ser Glu Arg 20
23112PRTArtificial SequenceSynthetic Polypeptide 231Tyr Gly Phe Ile Glu
Gly His Val Val Ile Pro Arg 1 5 10
2328PRTArtificial SequenceSynthetic Polypeptide 232Ala Gly Leu Gln Val
Tyr Asn Lys 1 5 23318PRTArtificial
SequenceSynthetic Polypeptide 233Thr Val Leu Leu Leu Val Thr Pro Phe Leu
Ala Ala Ala Trp Ser Leu 1 5 10
15 His Pro 23422PRTArtificial SequenceSynthetic Polypeptide
234Glu Leu Asn Ser Pro Ile Leu Phe Ala Phe Ser His Leu Glu Ser Ser 1
5 10 15 Asp Gly Glu Ala
Gly Arg 20 2357PRTArtificial SequenceSynthetic
Polypeptide 235Phe Ile Pro Glu Asp Pro Lys 1 5
23613PRTArtificial SequenceSynthetic Polypeptide 236Thr Ser Ser Ala Glu
Val Thr Ile Gln Asn Val Ile Lys 1 5 10
23710PRTArtificial SequenceSynthetic Polypeptide 237Val Phe Gln
Gly Gln Gly Leu Ser Thr Arg 1 5 10
23817PRTArtificial SequenceSynthetic Polypeptide 238Tyr Ser Glu Phe Thr
Ser Thr Thr Ser Gly Thr Gly His Asn Gln Thr 1 5
10 15 Arg 23912PRTArtificial
SequenceSynthetic Polypeptide 239Glu Glu Gly Val Phe Thr Val Thr Pro Asp
Thr Lys 1 5 10
24010PRTArtificial SequenceSynthetic Polypeptide 240Ile Tyr Val Val Asp
Leu Ser Asn Glu Arg 1 5 10
24110PRTArtificial SequenceSynthetic Polypeptide 241Leu Ser Leu Val Leu
Val Pro Ala Gln Lys 1 5 10
24223PRTArtificial SequenceSynthetic Polypeptide 242Ser Pro Pro Glu Ser
Glu Ser Glu Pro Tyr Thr Phe Ser His Pro Asn 1 5
10 15 Asn Gly Asp Val Ser Ser Lys
20 24316PRTArtificial SequenceSynthetic Polypeptide 243Val
Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn Pro Glu Val Phe Lys 1
5 10 15 24412PRTArtificial
SequenceSynthetic Polypeptide 244Ala Pro Pro Pro Gly Leu Pro Ala Glu Thr
Ile Lys 1 5 10
24516PRTArtificial SequenceSynthetic Polypeptide 245Asp Leu Lys Pro Glu
Asn Ile Leu Val Thr Ser Gly Gly Thr Val Lys 1 5
10 15 24615PRTArtificial SequenceSynthetic
Polypeptide 246Ile Phe Asp Leu Ile Gly Leu Pro Pro Glu Asp Asp Trp Pro
Arg 1 5 10 15
24717PRTArtificial SequenceSynthetic Polypeptide 247Val Pro Asn Gly Gly
Gly Gly Gly Gly Gly Leu Pro Ile Ser Thr Val 1 5
10 15 Arg 24813PRTArtificial
SequenceSynthetic Polypeptide 248Val Thr Leu Val Phe Glu His Val Asp Gln
Asp Leu Arg 1 5 10
24920PRTArtificial SequenceSynthetic Polypeptide 249Glu Val Leu Leu Leu
Val His Asn Leu Pro Gln His Leu Phe Gly Tyr 1 5
10 15 Ser Trp Tyr Lys 20
25016PRTArtificial SequenceSynthetic Polypeptide 250Ile Asn Gly Ile Pro
Gln Gln His Thr Gln Val Leu Phe Ile Ala Lys 1 5
10 15 25114PRTArtificial SequenceSynthetic
Polypeptide 251Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly Lys 1
5 10 25221PRTArtificial
SequenceSynthetic Polypeptide 252Gln Ile Ile Gly Tyr Val Ile Gly Thr Gln
Gln Ala Thr Pro Gly Pro 1 5 10
15 Ala Tyr Ser Gly Arg 20 25313PRTArtificial
SequenceSynthetic Polypeptide 253Ser Asp Leu Val Asn Glu Glu Ala Thr Gly
Gln Phe Arg 1 5 10
25414PRTArtificial SequenceSynthetic Polypeptide 254Glu Val Leu Leu Leu
Val His Asn Leu Pro Gln Asp Pro Arg 1 5
10 2556PRTArtificial SequenceSynthetic Polypeptide
255Gly Tyr Asn Trp Tyr Lys 1 5 2569PRTArtificial
SequenceSynthetic Polypeptide 256Leu Phe Ile Pro Asn Ile Thr Thr Lys 1
5 2579PRTArtificial SequenceSynthetic
Polypeptide 257Thr Leu Thr Leu Leu Ser Val Thr Arg 1 5
25813PRTArtificial SequenceSynthetic Polypeptide 258Gly Ala
Tyr Pro Leu Ser Ile Glu Pro Ile Gly Val Arg 1 5
10 25923PRTArtificial SequenceSynthetic Polypeptide
259Gly Pro Glu Glu Glu His Leu Gly Ile Leu Gly Pro Val Ile Trp Ala 1
5 10 15 Glu Val Gly Asp
Thr Ile Arg 20 26010PRTArtificial
SequenceSynthetic Polypeptide 260Ile Tyr His Ser His Ile Asp Ala Pro Lys
1 5 10 26116PRTArtificial
SequenceSynthetic Polypeptide 261Asn Asn Glu Gly Thr Tyr Tyr Ser Pro Asn
Tyr Asn Pro Gln Ser Arg 1 5 10
15 26223PRTArtificial SequenceSynthetic Polypeptide 262Ser Val
Pro Pro Ser Ala Ser His Val Ala Pro Thr Glu Thr Phe Thr 1 5
10 15 Tyr Glu Trp Thr Val Pro Lys
20 2637PRTArtificial SequenceSynthetic
Polypeptide 263Asp Gly Asp Ile Leu Gly Lys 1 5
2646PRTArtificial SequenceSynthetic Polypeptide 264Asp Tyr Phe Leu Phe
Arg 1 5 26510PRTArtificial SequenceSynthetic
Polypeptide 265Gly Gly Glu Ile Gln Pro Val Ser Val Lys 1 5
10 26610PRTArtificial SequenceSynthetic Polypeptide
266Val Leu Leu Pro Glu Tyr Gly Gly Thr Lys 1 5
10 26714PRTArtificial SequenceSynthetic Polypeptide 267Val Leu Gln
Ala Thr Val Val Ala Val Gly Ser Gly Ser Lys 1 5
10 2687PRTArtificial SequenceSynthetic Polypeptide
268Gly Ile Ile Asp Pro Thr Lys 1 5
26912PRTArtificial SequenceSynthetic Polypeptide 269Gly Tyr Ile Ser Pro
Tyr Phe Ile Asn Thr Ser Lys 1 5 10
27025PRTArtificial SequenceSynthetic Polypeptide 270Leu Val Gln Asp Val
Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly 1 5
10 15 Thr Thr Thr Ala Thr Val Leu Ala Arg
20 25 27125PRTArtificial SequenceSynthetic
Polypeptide 271Thr Ala Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr
Thr Ala 1 5 10 15
Glu Val Val Val Thr Glu Ile Pro Lys 20 25
27212PRTArtificial SequenceSynthetic Polypeptide 272Thr Val Ile Ile Glu
Gln Ser Trp Gly Ser Pro Lys 1 5 10
27312PRTArtificial SequenceSynthetic Polypeptide 273Asp Phe Thr Ser Leu
Glu Asn Thr Val Glu Glu Arg 1 5 10
27412PRTArtificial SequenceSynthetic Polypeptide 274Ile Glu Thr Asn Glu
Asn Asn Leu Glu Ser Ala Lys 1 5 10
27519PRTArtificial SequenceSynthetic Polypeptide 275Leu Glu Gly Leu Gly
Ser Ser Glu Ala Asp Gln Asp Gly Leu Ala Ser 1 5
10 15 Thr Val Arg 2769PRTArtificial
SequenceSynthetic Polypeptide 276Leu Pro Pro Gln Asp Phe Leu Asp Arg 1
5 27716PRTArtificial SequenceSynthetic
Polypeptide 277Val Gln Ser Leu Gln Ala Thr Phe Gly Thr Phe Glu Ser Ile
Leu Arg 1 5 10 15
27823PRTArtificial SequenceSynthetic Polypeptide 278Ala Ser Ala Pro Leu
Ser Gln Ser Gly Leu Ala Thr Ala Asn Gly Lys 1 5
10 15 Pro Glu Pro Thr Ser Ile Ser
20 27919PRTArtificial SequenceSynthetic Polypeptide 279Gly
Asp Pro Asp Ser Glu Ala Asp Ser Ile Asp Ser Asp Gln Glu Asp 1
5 10 15 Pro Leu Lys
28022PRTArtificial SequenceSynthetic Polypeptide 280Ile Leu Asp Glu Asp
Ser Trp Ser Asp Gly Glu Gln Glu Pro Ile Thr 1 5
10 15 Val Asp Gln Thr Trp Arg 20
28112PRTArtificial SequenceSynthetic Polypeptide 281Thr Glu Leu
Gly Ser Gln Thr Pro Glu Ser Ser Arg 1 5
10 2829PRTArtificial SequenceSynthetic Polypeptide 282Tyr Gly
Val Glu Ala Leu Leu His Arg 1 5
28313PRTArtificial SequenceSynthetic Polypeptide 283Ala Ser Val Thr Ala
Leu Ile Glu Ser Val Asn Gly Lys 1 5 10
2848PRTArtificial SequenceSynthetic Polypeptide 284Ser Glu Ile
Ser Asn Ile Ala Arg 1 5 28530PRTArtificial
SequenceSynthetic Polypeptide 285Thr Ser Ser Gly Gly Ser Phe Val Ala Ser
Asp Val Pro Asn Ala Pro 1 5 10
15 Ile Pro Asp Leu Phe Pro Pro Gly Gln Ile Thr Asp Leu Lys
20 25 30 28617PRTArtificial
SequenceSynthetic Polypeptide 286Thr Val Thr Leu Glu Leu Leu Asp Asn Gly
Ala Gly Ala Asp Ala Thr 1 5 10
15 Lys 28712PRTArtificial SequenceSynthetic Polypeptide 287Trp
Gly Val Phe Asp Glu Tyr Asn Asn Asp Glu Lys 1 5
10 2886PRTArtificial SequenceSynthetic Polypeptide 288Phe
Ser Ala Tyr Ile Lys 1 5 2899PRTArtificial
SequenceSynthetic Polypeptide 289Gly Phe Thr Ile Pro Glu Ala Phe Arg 1
5 29018PRTArtificial SequenceSynthetic
Polypeptide 290Leu Ala Ala Leu Asn Pro Glu Ser Asn Thr Ala Gly Leu Asp
Ile Phe 1 5 10 15
Ala Lys 29112PRTArtificial SequenceSynthetic Polypeptide 291Asn Ser Asn
Pro Ala Leu Asn Asp Asn Leu Glu Lys 1 5
10 2928PRTArtificial SequenceSynthetic Polypeptide 292Tyr Leu
Ser Asn Ala Tyr Ala Arg 1 5
29312PRTArtificial SequenceSynthetic Polypeptide 293Ala Ser Ser Ile Ile
Asp Glu Leu Phe Gln Asp Arg 1 5 10
29410PRTArtificial SequenceSynthetic Polypeptide 294Glu Ile Gln Asn Ala
Val Asn Gly Val Lys 1 5 10
2959PRTArtificial SequenceSynthetic Polypeptide 295Ile Asp Ser Leu Leu
Glu Asn Asp Arg 1 5 29614PRTArtificial
SequenceSynthetic Polypeptide 296Leu Ala Asn Leu Thr Gln Gly Glu Asp Gln
Tyr Tyr Leu Arg 1 5 10
29723PRTArtificial SequenceSynthetic Polypeptide 297Val Thr Thr Val Ala
Ser His Thr Ser Asp Ser Asp Val Pro Ser Gly 1 5
10 15 Val Thr Glu Val Val Val Lys
20 29831PRTArtificial SequenceSynthetic Polypeptide 298Ala
Glu Gly Asn Asn Gln Ala Pro Gly Glu Glu Glu Glu Glu Glu Glu 1
5 10 15 Glu Ala Thr Asn Thr His
Pro Pro Ala Ser Leu Pro Ser Gln Lys 20 25
30 2999PRTArtificial SequenceSynthetic Polypeptide
299Glu Ala Val Glu Glu Pro Ser Ser Lys 1 5
30023PRTArtificial SequenceSynthetic Polypeptide 300Ser Glu Ala Leu Ala
Val Asp Gly Ala Gly Lys Pro Gly Ala Glu Glu 1 5
10 15 Ala Gln Asp Pro Glu Gly Lys
20 30110PRTArtificial SequenceSynthetic Polypeptide 301Ser
Gly Glu Leu Glu Gln Glu Glu Glu Arg 1 5
10 30220PRTArtificial SequenceSynthetic Polypeptide 302Tyr Pro Gly Pro
Gln Ala Glu Gly Asp Ser Glu Gly Leu Ser Gln Gly 1 5
10 15 Leu Val Asp Arg 20
30314PRTArtificial SequenceSynthetic Polypeptide 303Ala His Ser Asp Gly
Gly Asp Gly Val Val Ser Gln Val Lys 1 5
10 3049PRTArtificial SequenceSynthetic Polypeptide
304Asp Gly Glu Tyr Val Val Glu Val Arg 1 5
3059PRTArtificial SequenceSynthetic Polypeptide 305His Ser Ile Glu Val
Pro Ile Pro Arg 1 5 30623PRTArtificial
SequenceSynthetic Polypeptide 306Ser Thr Glu Ala Thr Leu Ser Phe Gly Tyr
Leu Asp Pro Phe Pro Pro 1 5 10
15 Glu Glu Arg Pro Glu Val Arg 20
30714PRTArtificial SequenceSynthetic Polypeptide 307Thr Thr Lys Pro Tyr
Pro Ala Asp Ile Val Val Gln Phe Lys 1 5
10 30811PRTArtificial SequenceSynthetic Polypeptide
308Gly Asp Pro Gly Thr Pro Gly Val Pro Gly Lys 1 5
10 30911PRTArtificial SequenceSynthetic Polypeptide 309Gly
Glu Pro Gly Val Gly Leu Pro Gly Leu Lys 1 5
10 31012PRTArtificial SequenceSynthetic Polypeptide 310Gly Pro Pro
Gly Gly Val Gly Phe Pro Gly Ser Arg 1 5
10 31121PRTArtificial SequenceSynthetic Polypeptide 311Gly Pro
Pro Gly Pro Gln Gly Pro Pro Gly Glu Ile Gly Phe Pro Gly 1 5
10 15 Gln Pro Gly Ala Lys
20 31216PRTArtificial SequenceSynthetic Polypeptide 312Ile Leu
Tyr His Gly Tyr Ser Leu Leu Tyr Val Gln Gly Asn Glu Arg 1 5
10 15 31319PRTArtificial
SequenceSynthetic Polypeptide 313Asp Gly Glu Val Gly Pro Ser Gly Pro Val
Gly Pro Pro Gly Leu Ala 1 5 10
15 Gly Glu Arg 31417PRTArtificial SequenceSynthetic
Polypeptide 314Gly Pro Glu Gly Pro Pro Gly Lys Pro Gly Glu Asp Gly Glu
Pro Gly 1 5 10 15
Arg 31517PRTArtificial SequenceSynthetic Polypeptide 315Gly Thr Gln Gly
Pro Pro Gly Ala Thr Gly Phe Pro Gly Ser Ala Gly 1 5
10 15 Arg 31622PRTArtificial
SequenceSynthetic Polypeptide 316Leu Gly Pro Leu Gly Ala Pro Gly Glu Asp
Gly Arg Pro Gly Pro Pro 1 5 10
15 Gly Ser Ile Gly Ile Arg 20
31721PRTArtificial SequenceSynthetic Polypeptide 317Val Gly Pro Pro Gly
Pro Ala Gly Ala Pro Gly Pro Ala Gly Pro Leu 1 5
10 15 Gly Glu Pro Gly Lys 20
31821PRTArtificial SequenceSynthetic Polypeptide 318Ala Leu Gly Ser Ala
Ile Glu Tyr Thr Ile Glu Asn Val Phe Glu Ser 1 5
10 15 Ala Pro Asn Pro Arg 20
31913PRTArtificial SequenceSynthetic Polypeptide 319Ile Gly Asp Leu His
Pro Gln Ile Val Asn Leu Leu Lys 1 5 10
32025PRTArtificial SequenceSynthetic Polypeptide 320Asn Ala Asp
Pro Ala Glu Leu Glu Gln Ile Val Leu Ser Pro Ala Phe 1 5
10 15 Ile Leu Ala Ala Glu Ser Leu Pro
Lys 20 25 3219PRTArtificial
SequenceSynthetic Polypeptide 321Val Ala Val Val Gln Tyr Ser Asp Arg 1
5 3228PRTArtificial SequenceSynthetic
Polypeptide 322Trp Tyr Tyr Asp Pro Asn Thr Lys 1 5
32316PRTArtificial SequenceSynthetic Polypeptide 323Gly Pro Gly Asp
Leu Glu Ala Pro Ser Asn Leu Val Ile Ser Glu Arg 1 5
10 15 32412PRTArtificial
SequenceSynthetic Polypeptide 324Ile Thr Val Asp Pro Thr Thr Asp Gly Pro
Thr Lys 1 5 10
32511PRTArtificial SequenceSynthetic Polypeptide 325Ser Leu Tyr Asp Asp
Val Asp Thr Gly Glu Lys 1 5 10
32610PRTArtificial SequenceSynthetic Polypeptide 326Ser Gln Asp Glu Val
Glu Ile Pro Ala Arg 1 5 10
32710PRTArtificial SequenceSynthetic Polypeptide 327Val Thr Asp Glu Thr
Thr Asp Ser Phe Lys 1 5 10
32820PRTArtificial SequenceSynthetic Polypeptide 328Glu Ile Leu Val Gly
Asp Val Gly Gln Thr Val Asp Asp Pro Tyr Ala 1 5
10 15 Thr Phe Val Lys 20
32914PRTArtificial SequenceSynthetic Polypeptide 329Leu Gly Gly Ser Ala
Val Ile Ser Leu Glu Gly Lys Pro Leu 1 5
10 33011PRTArtificial SequenceSynthetic Polypeptide
330Tyr Ala Leu Tyr Asp Ala Thr Tyr Glu Thr Lys 1 5
10 33110PRTArtificial SequenceSynthetic Polypeptide 331Ala
Asp Asp Ile Leu Ala Ser Pro Pro Arg 1 5
10 3329PRTArtificial SequenceSynthetic Polypeptide 332Ala Val Gly Leu
Ala Gly Thr Phe Arg 1 5
33324PRTArtificial SequenceSynthetic Polypeptide 333Asp Glu Leu Leu Phe
Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu 1 5
10 15 Gly Pro Leu Lys Pro Gly Ala Arg
20 33430PRTArtificial SequenceSynthetic Polypeptide
334Leu Ser Gly Val Gln Asp Gly His Gln Asp Ile Ser Leu Leu Tyr Thr 1
5 10 15 Glu Pro Gly Ala
Gly Gln Thr His Thr Ala Ala Ser Phe Arg 20
25 30 33517PRTArtificial SequenceSynthetic Polypeptide
335Thr Glu Ala Pro Ser Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly 1
5 10 15 Arg
33629PRTArtificial SequenceSynthetic Polypeptide 336Glu Ile Tyr Pro Tyr
Val Ile Gln Glu Leu Arg Pro Thr Leu Asn Glu 1 5
10 15 Leu Gly Ile Ser Thr Pro Glu Glu Leu Gly
Leu Asp Lys 20 25
3377PRTArtificial SequenceSynthetic Polypeptide 337Gly Leu Leu His Ser
Ala Arg 1 5 3387PRTArtificial SequenceSynthetic
Polypeptide 338Ile Ile Asp Ala Ala Leu Arg 1 5
3396PRTArtificial SequenceSynthetic Polypeptide 339Ile Leu Glu Val Val
Lys 1 5 34012PRTArtificial SequenceSynthetic
Polypeptide 340Thr Pro Gly Pro Ala Val Ala Ile Gln Ser Val Arg 1
5 10 3418PRTArtificial SequenceSynthetic
Polypeptide 341Ala Pro Leu Thr Lys Pro Leu Lys 1 5
34210PRTArtificial SequenceSynthetic Polypeptide 342Glu Ser Asp Thr
Ser Tyr Val Ser Leu Lys 1 5 10
34315PRTArtificial SequenceSynthetic Polypeptide 343Tyr Glu Val Gln Gly
Glu Val Phe Thr Lys Pro Gln Leu Trp Pro 1 5
10 15 34415PRTArtificial SequenceSynthetic
Polypeptide 344Ala Gln Ala Asp Leu Leu Ala His Leu Val Pro Glu Pro Asp
Arg 1 5 10 15
3459PRTArtificial SequenceSynthetic Polypeptide 345Asp Thr Gly Val Ala
Phe Glu Leu Arg 1 5 34625PRTArtificial
SequenceSynthetic Polypeptide 346Gly Tyr Trp Gly Asp Ile Ala Thr Gly Pro
Phe Val Ala Phe Gly Ile 1 5 10
15 Glu Ala Asp Asp Glu Ser Leu Leu Arg 20
25 34711PRTArtificial SequenceSynthetic Polypeptide 347Leu Glu
Glu Gln Leu Pro Trp Leu Ser Leu Arg 1 5
10 34815PRTArtificial SequenceSynthetic Polypeptide 348Thr Ala Gly
Glu Ile Thr Gln His Asn Val Thr Glu Leu Leu Arg 1 5
10 15 34918PRTArtificial SequenceSynthetic
Polypeptide 349Asp Asn Thr Pro Asn Ala Ile Ala Ile Val Gln Leu Gln Glu
Leu Ser 1 5 10 15
Leu Arg 3509PRTArtificial SequenceSynthetic Polypeptide 350Asp Pro Pro
Glu Pro Gly Ser Pro Arg 1 5
35113PRTArtificial SequenceSynthetic Polypeptide 351Phe Asn Ser Val Pro
Leu Thr Asp Thr Gly His Glu Arg 1 5 10
35223PRTArtificial SequenceSynthetic Polypeptide 352Ile Ser Ser
Leu Arg Pro Gln Gly Leu Ser Asn Pro Ser Thr Leu Ser 1 5
10 15 Ala Gln Pro Gln Leu Ser Arg
20 35312PRTArtificial SequenceSynthetic Polypeptide
353Thr Phe Tyr Glu Thr Pro Leu Gln Leu Leu Glu Lys 1 5
10 3546PRTArtificial SequenceSynthetic Polypeptide
354Ile Glu Leu Pro Glu Arg 1 5 3559PRTArtificial
SequenceSynthetic Polypeptide 355Ile Arg Pro Val Thr Pro Val Glu Lys 1
5 35619PRTArtificial SequenceSynthetic
Polypeptide 356Gln Asn Trp Pro Gln Asn Trp Gly Phe Leu Thr Thr Pro Phe
Glu Glu 1 5 10 15
Leu Ile Lys 3578PRTArtificial SequenceSynthetic Polypeptide 357Ser Ala
Val Pro Gly Leu Asn Lys 1 5
35818PRTArtificial SequenceSynthetic Polypeptide 358Val Phe Pro Ser Pro
Pro Val Pro Gln Thr Thr Gln Gly Phe Ile Gly 1 5
10 15 Trp Arg 35913PRTArtificial
SequenceSynthetic Polypeptide 359Asp Gln Thr Val Val Gly Pro Ala Leu Ala
Ala Tyr Arg 1 5 10
3609PRTArtificial SequenceSynthetic Polypeptide 360Thr Thr Thr Leu Pro
Val Glu Phe Lys 1 5 36113PRTArtificial
SequenceSynthetic Polypeptide 361Ala Leu Ala Leu Val Val Thr Leu Leu His
Leu Thr Arg 1 5 10
36213PRTArtificial SequenceSynthetic Polypeptide 362Glu Leu Gly Phe Asp
Ala Ser Glu Val Glu Leu Thr Arg 1 5 10
36310PRTArtificial SequenceSynthetic Polypeptide 363Ile Leu Tyr
Asn Pro Leu Gln Gly Gln Lys 1 5 10
3647PRTArtificial SequenceSynthetic Polypeptide 364Leu Phe Asn Asp Ile
His Lys 1 5 3659PRTArtificial SequenceSynthetic
Polypeptide 365Asn Asn Glu Leu Ile Ala Val Gly Lys 1 5
3667PRTArtificial SequenceSynthetic Polypeptide 366Leu Glu
Ala Val Gln Tyr Lys 1 5 36718PRTArtificial
SequenceSynthetic Polypeptide 367Ser Leu Pro Gly Gln Asn Glu Asp Leu Val
Leu Thr Gly Tyr Gln Val 1 5 10
15 Asp Lys 3687PRTArtificial SequenceSynthetic Polypeptide
368Thr Asn Glu Thr Tyr Gly Lys 1 5
36912PRTArtificial SequenceSynthetic Polypeptide 369Thr Gln Val Val Ala
Gly Thr Asn Tyr Tyr Ile Lys 1 5 10
3708PRTArtificial SequenceSynthetic Polypeptide 370Val Lys Pro Gln Leu
Glu Glu Lys 1 5 3717PRTArtificial
SequenceSynthetic Polypeptide 371His Asp Glu Leu Thr Tyr Phe 1
5 3726PRTArtificial SequenceSynthetic Polypeptide 372Ser Gln
Leu Glu Glu Lys 1 5 37312PRTArtificial
SequenceSynthetic Polypeptide 373Ser Gln Val Val Ala Gly Thr Asn Tyr Phe
Ile Lys 1 5 10
37421PRTArtificial SequenceSynthetic Polypeptide 374Val Phe Gln Ser Leu
Pro His Glu Asn Lys Pro Leu Thr Leu Ser Asn 1 5
10 15 Tyr Gln Thr Asn Lys 20
37512PRTArtificial SequenceSynthetic Polypeptide 375Val His Val Gly Asp
Glu Asp Phe Val His Leu Arg 1 5 10
3768PRTArtificial SequenceSynthetic Polypeptide 376Asp Trp Val Leu Asn
Glu Phe Arg 1 5 37717PRTArtificial
SequenceSynthetic Polypeptide 377Phe Val Ile Asn Tyr Asp Tyr Pro Asn Ser
Ser Glu Asp Tyr Val His 1 5 10
15 Arg 3789PRTArtificial SequenceSynthetic Polypeptide 378Leu
Ile Asp Phe Leu Glu Ser Gly Lys 1 5
37914PRTArtificial SequenceSynthetic Polypeptide 379Ser Ser Gln Ser Ser
Ser Gln Gln Phe Ser Gly Ile Gly Arg 1 5
10 38012PRTArtificial SequenceSynthetic Polypeptide
380Val Leu Glu Glu Ala Asn Gln Ala Ile Asn Pro Lys 1 5
10 38110PRTArtificial SequenceSynthetic Polypeptide
381Ile Gln Ser Gln Phe Thr Asp Ala Gln Lys 1 5
10 38215PRTArtificial SequenceSynthetic Polypeptide 382Ile Thr Asn
Leu Thr Gln Gln Leu Glu Gln Ala Ser Ile Val Lys 1 5
10 15 38312PRTArtificial SequenceSynthetic
Polypeptide 383Asn Met Pro Leu Gln His Leu Leu Glu Gln Ile Lys 1
5 10 3849PRTArtificial SequenceSynthetic
Polypeptide 384Tyr Gly Asp Gly Ile Gln Leu Thr Arg 1 5
3859PRTArtificial SequenceSynthetic Polypeptide 385Ala Leu
Pro Ser Leu Thr Asp Ser Lys 1 5
38612PRTArtificial SequenceSynthetic Polypeptide 386Gly Ser Leu Val Val
Val Ser Ser Leu Leu Gly Arg 1 5 10
38720PRTArtificial SequenceSynthetic Polypeptide 387Leu Gly Gly Leu Asp
Tyr Leu Val Leu Asn His Ile Gly Gly Ala Pro 1 5
10 15 Ala Gly Thr Arg 20
38817PRTArtificial SequenceSynthetic Polypeptide 388Asn Asp Gly His Leu
Glu Pro Val Thr Ala Trp Glu Val Gln Val Pro 1 5
10 15 Arg 38913PRTArtificial
SequenceSynthetic Polypeptide 389Val Pro Thr Ser Phe Ser Thr Pro Tyr Ser
Ala Ala Lys 1 5 10
39014PRTArtificial SequenceSynthetic Polypeptide 390Phe Gly Gln Gly Ser
Gly Pro Ile Val Leu Asp Asp Val Arg 1 5
10 3919PRTArtificial SequenceSynthetic Polypeptide
391Ile Asn Leu Gly Phe Ser Asn Leu Lys 1 5
39215PRTArtificial SequenceSynthetic Polypeptide 392Val Asp Val Val Leu
Gly Pro Ile Gln Leu Gln Thr Pro Pro Arg 1 5
10 15 39311PRTArtificial SequenceSynthetic
Polypeptide 393Gly Gly Val Ser Pro Ser Ser Ser Ala Ser Arg 1
5 10 39411PRTArtificial SequenceSynthetic
Polypeptide 394Leu Gly Phe Ile Asn Trp Asp Ala Ile Asn Lys 1
5 10 39514PRTArtificial SequenceSynthetic
Polypeptide 395Gln Val Pro Gly Phe Gly Val Ala Asp Ala Leu Gly Asn Arg 1
5 10 39617PRTArtificial
SequenceSynthetic Polypeptide 396Val Gly Glu Ala Ala His Ala Leu Gly Asn
Thr Gly His Glu Ile Gly 1 5 10
15 Arg 39710PRTArtificial SequenceSynthetic Polypeptide 397Val
Ser Glu Ala Leu Gly Gln Gly Thr Arg 1 5
10 39814PRTArtificial SequenceSynthetic Polypeptide 398Leu Gly Thr Phe
Glu Val Glu Asp Gln Ile Glu Ala Ala Arg 1 5
10 39910PRTArtificial SequenceSynthetic Polypeptide
399Met Leu Gln Asn Val Gln Met Pro Ser Lys 1 5
10 40011PRTArtificial SequenceSynthetic Polypeptide 400Trp Glu Tyr
Tyr Asp Ser Val Tyr Thr Glu Arg 1 5 10
40110PRTArtificial SequenceSynthetic Polypeptide 401Trp Ile Ser Asp His
Glu Tyr Leu Tyr Lys 1 5 10
40215PRTArtificial SequenceSynthetic Polypeptide 402Tyr Met Gly Leu Pro
Thr Pro Glu Asp Asn Leu Asp His Tyr Arg 1 5
10 15 40311PRTArtificial SequenceSynthetic
Polypeptide 403Gly Asn Asn Val Glu Lys Pro Leu Glu Leu Arg 1
5 10 40421PRTArtificial SequenceSynthetic
Polypeptide 404Gly Gln Ile Ile Gly Asn Phe Gln Ala Phe Asp Glu Asp Thr
Gly Leu 1 5 10 15
Pro Ala His Ala Arg 20 40514PRTArtificial
SequenceSynthetic Polypeptide 405Ile Leu Asp Val Asn Asp Asn Ile Pro Val
Val Glu Asn Lys 1 5 10
40611PRTArtificial SequenceSynthetic Polypeptide 406Asn Leu Asp Phe Ser
Val Ile Val Ala Asn Lys 1 5 10
40724PRTArtificial SequenceSynthetic Polypeptide 407Val Tyr Ala Pro Ala
Ser Thr Leu Val Asp Gln Pro Tyr Ala Asn Glu 1 5
10 15 Gly Thr Val Val Val Thr Glu Arg
20 40810PRTArtificial SequenceSynthetic Polypeptide
408Asp Phe Leu Leu Lys Pro Glu Leu Leu Arg 1 5
10 40922PRTArtificial SequenceSynthetic Polypeptide 409Phe Glu Val
Asn Val Ala Glu Leu Pro Glu Glu Ile Asp Ile Ser Thr 1 5
10 15 Tyr Ile Glu Gln Ser Arg
20 41014PRTArtificial SequenceSynthetic Polypeptide 410Gly
Leu Ala Ile Thr Phe Val Ser Asp Glu Asn Asp Ala Lys 1 5
10 4118PRTArtificial SequenceSynthetic
Polypeptide 411Ile Leu Asn Asp Val Gln Asp Arg 1 5
4126PRTArtificial SequenceSynthetic Polypeptide 412Leu Thr Pro His
Glu Lys 1 5 4138PRTArtificial SequenceSynthetic
Polypeptide 413Glu Leu Ala Phe Gln Ile Ser Lys 1 5
41422PRTArtificial SequenceSynthetic Polypeptide 414Phe Glu Val Asn
Ile Ser Glu Leu Pro Asp Glu Ile Asp Ile Ser Ser 1 5
10 15 Tyr Ile Glu Gln Thr Arg
20 4159PRTArtificial SequenceSynthetic Polypeptide 415Ala Pro
Glu Val Ile Leu Gly Ala Arg 1 5
41615PRTArtificial SequenceSynthetic Polypeptide 416Ala Ser Asn Ala Ala
Ala Ala Ala His Thr Ile Gly Gly Ser Lys 1 5
10 15 41714PRTArtificial SequenceSynthetic
Polypeptide 417Gln Leu Gln Ala Ser Pro Gly Leu Gly Ala Gly Ala Thr Arg 1
5 10 41817PRTArtificial
SequenceSynthetic Polypeptide 418Ser Gly Val Gly Thr Gly Pro Pro Ser Pro
Ile Ala Leu Pro Pro Leu 1 5 10
15 Arg 4199PRTArtificial SequenceSynthetic Polypeptide 419Thr
Gly Leu Pro Val Val Pro Glu Arg 1 5
42022PRTArtificial SequenceSynthetic Polypeptide 420Gly Gln Ala Ala Ala
Thr Leu Glu Gln Pro Ala Ser Ser Ser His Ala 1 5
10 15 Gln Gly Thr His Leu Arg 20
42111PRTArtificial SequenceSynthetic Polypeptide 421Thr Gly Ala
Thr Thr Gly Glu Leu Leu Gln Arg 1 5 10
42212PRTArtificial SequenceSynthetic Polypeptide 422Glu His Ala Leu Leu
Ala Tyr Thr Leu Gly Val Lys 1 5 10
42311PRTArtificial SequenceSynthetic Polypeptide 423Ile Gly Gly Ile Gly
Thr Val Pro Val Gly Arg 1 5 10
4248PRTArtificial SequenceSynthetic Polypeptide 424Leu Pro Leu Gln Asp
Val Tyr Lys 1 5 42511PRTArtificial
SequenceSynthetic Polypeptide 425Met Asp Ser Thr Glu Pro Pro Tyr Ser Gln
Lys 1 5 10 4269PRTArtificial
SequenceSynthetic Polypeptide 426Gln Thr Val Ala Val Gly Val Ile Lys 1
5 42710PRTArtificial SequenceSynthetic
Polypeptide 427Ser Thr Thr Thr Gly His Leu Ile Tyr Lys 1 5
10 42815PRTArtificial SequenceSynthetic Polypeptide
428Thr His Ile Asn Ile Val Val Ile Gly His Val Asp Ser Gly Lys 1
5 10 15 42924PRTArtificial
SequenceSynthetic Polypeptide 429Val Glu Thr Gly Val Leu Lys Pro Gly Met
Val Val Thr Phe Ala Pro 1 5 10
15 Val Asn Val Thr Thr Glu Val Lys 20
4307PRTArtificial SequenceSynthetic Polypeptide 430Tyr Ala Trp Val
Leu Asp Lys 1 5 43112PRTArtificial
SequenceSynthetic Polypeptide 431Tyr Tyr Val Thr Ile Ile Asp Ala Pro Gly
His Arg 1 5 10
43215PRTArtificial SequenceSynthetic Polypeptide 432Phe Glu Glu His Val
Gln Ser Val Asp Ile Ala Ala Phe Asn Lys 1 5
10 15 43312PRTArtificial SequenceSynthetic
Polypeptide 433Gly Val Val Gln Glu Leu Gln Gln Ala Ile Ser Lys 1
5 10 4346PRTArtificial SequenceSynthetic
Polypeptide 434Leu Asn Val Leu Glu Lys 1 5
43513PRTArtificial SequenceSynthetic Polypeptide 435Ser Ile Gln Leu Asp
Gly Leu Val Trp Gly Ala Ser Lys 1 5 10
43612PRTArtificial SequenceSynthetic Polypeptide 436Val Gly Thr
Asp Leu Leu Glu Glu Glu Ile Thr Lys 1 5
10 43712PRTArtificial SequenceSynthetic Polypeptide 437Asp Ser
Val Val Ala Gly Phe Gln Trp Ala Thr Lys 1 5
10 43812PRTArtificial SequenceSynthetic Polypeptide 438Glu Gly
Ile Pro Ala Leu Asp Asn Phe Leu Asp Lys 1 5
10 4398PRTArtificial SequenceSynthetic Polypeptide 439Phe Ser
Val Ser Pro Val Val Arg 1 5
44010PRTArtificial SequenceSynthetic Polypeptide 440Gly Glu Gly Gln Leu
Gly Pro Ala Glu Arg 1 5 10
4419PRTArtificial SequenceSynthetic Polypeptide 441Gly Val Gln Tyr Leu
Asn Glu Ile Lys 1 5 44214PRTArtificial
SequenceSynthetic Polypeptide 442Phe Ile Phe Trp Ser Ser Glu Val Ala Gly
Ser Leu Tyr Arg 1 5 10
44314PRTArtificial SequenceSynthetic Polypeptide 443Ile Asn Leu His Ser
Ser Phe Val Pro Leu Gly Glu Leu Lys 1 5
10 44422PRTArtificial SequenceSynthetic Polypeptide
444Leu Val Ile Ala Ser Ser Asp Leu Ile Trp Pro Ser Gly Ile Thr Ile 1
5 10 15 Asp Phe Leu Thr
Asp Lys 20 44511PRTArtificial SequenceSynthetic
Polypeptide 445Asn Gln Val Thr Pro Leu Asp Ile Leu Ser Lys 1
5 10 44612PRTArtificial SequenceSynthetic
Polypeptide 446Tyr Pro Ala Asn Val Ala Val Asp Pro Val Glu Arg 1
5 10 44711PRTArtificial SequenceSynthetic
Polypeptide 447Glu Asp Asp Phe Asp Trp Asn Pro Ala Asp Arg 1
5 10 4487PRTArtificial SequenceSynthetic
Polypeptide 448Gly Asp Val Phe Phe Pro Lys 1 5
44911PRTArtificial SequenceSynthetic Polypeptide 449Ile Gln Leu Tyr Gln
Gly Thr Asp Ala Thr Lys 1 5 10
45010PRTArtificial SequenceSynthetic Polypeptide 450Asn Ser Asn Asn Ala
Leu Ala Trp Glu Lys 1 5 10
45114PRTArtificial SequenceSynthetic Polypeptide 451Val Asn Leu Gln Pro
Phe Asn Tyr Glu Glu Ile Val Ser Arg 1 5
10 4527PRTArtificial SequenceSynthetic Polypeptide
452Ala Val Glu His Ile Asn Lys 1 5
45313PRTArtificial SequenceSynthetic Polypeptide 453Gly Asn Pro Thr Val
Glu Val Asp Leu Phe Thr Ser Lys 1 5 10
45410PRTArtificial SequenceSynthetic Polypeptide 454Ile Gly Ala
Glu Val Tyr His Asn Leu Lys 1 5 10
45512PRTArtificial SequenceSynthetic Polypeptide 455Tyr Ile Ser Pro Asp
Gln Leu Ala Asp Leu Tyr Lys 1 5 10
4566PRTArtificial SequenceSynthetic Polypeptide 456Tyr Asn Gln Leu Leu
Arg 1 5 45726PRTArtificial SequenceSynthetic
Polypeptide 457Asp Ala Thr Asn Val Gly Asp Glu Gly Gly Phe Ala Pro Asn
Ile Leu 1 5 10 15
Glu Asn Ser Glu Ala Leu Glu Leu Val Lys 20
25 45813PRTArtificial SequenceSynthetic Polypeptide 458Gly Asn Pro
Thr Val Glu Val Asp Leu Tyr Thr Ala Lys 1 5
10 45910PRTArtificial SequenceSynthetic Polypeptide 459Ile
Glu Glu Glu Leu Gly Asp Glu Ala Arg 1 5
10 46010PRTArtificial SequenceSynthetic Polypeptide 460Leu Gly Ala Glu
Val Tyr His Thr Leu Lys 1 5 10
46116PRTArtificial SequenceSynthetic Polypeptide 461Tyr Ile Thr Gly Asp
Gln Leu Gly Ala Leu Tyr Gln Asp Phe Val Arg 1 5
10 15 4628PRTArtificial SequenceSynthetic
Polypeptide 462Ala Leu Tyr Leu Ser Gly Tyr Arg 1 5
46315PRTArtificial SequenceSynthetic Polypeptide 463Glu Thr Glu Glu
Ser Ala Leu Val Ser Gln Ala Glu Ala Leu Lys 1 5
10 15 46414PRTArtificial SequenceSynthetic
Polypeptide 464Phe Ser Glu Ala Val Gln Thr Leu Leu Thr Trp Ile Glu Arg 1
5 10 46522PRTArtificial
SequenceSynthetic Polypeptide 465Gln Ala Leu Ser Gly Ile Leu Ile Gln Phe
Glu Gln Ile Val Ala Val 1 5 10
15 Tyr His Ser Ala Ser Lys 20
46615PRTArtificial SequenceSynthetic Polypeptide 466Trp Leu Trp Val Tyr
Glu Ile Gly Tyr Ala Ala Asp Asn Ser Arg 1 5
10 15 4678PRTArtificial SequenceSynthetic Polypeptide
467Glu Val Glu Glu Asp Glu Tyr Lys 1 5
46819PRTArtificial SequenceSynthetic Polypeptide 468Leu Ile Ser Leu Thr
Asp Glu Asn Ala Leu Ser Gly Asn Glu Glu Leu 1 5
10 15 Thr Val Lys 4699PRTArtificial
SequenceSynthetic Polypeptide 469Ser Gly Thr Ser Glu Phe Leu Asn Lys 1
5 4709PRTArtificial SequenceSynthetic
Polypeptide 470Ser Gly Tyr Leu Leu Pro Asp Thr Lys 1 5
4718PRTArtificial SequenceSynthetic Polypeptide 471Thr Asp
Asp Glu Val Val Gln Arg 1 5
47213PRTArtificial SequenceSynthetic Polypeptide 472Arg Pro His Phe Asp
Gln Leu Val Ala Ala Phe Asp Lys 1 5 10
4738PRTArtificial SequenceSynthetic Polypeptide 473Ser Phe Gly
Pro Leu Thr Gln Arg 1 5 47435PRTArtificial
SequenceSynthetic Polypeptide 474Val Asp Thr Ile Ala Ala Asp Glu Ser Phe
Pro Ser Ser Ser Ser Ser 1 5 10
15 Ser Ser Ser Ser Ser Ser Ala Ala Trp Ala Val Gly Pro His Gly
Ala 20 25 30 Gly
Gln Arg 35 47518PRTArtificial SequenceSynthetic Polypeptide 475Val Tyr
Phe Gln Thr Leu Pro Gln Gly Glu Leu Ser Ser Gln Leu Pro 1 5
10 15 Glu Arg 47611PRTArtificial
SequenceSynthetic Polypeptide 476Trp Ala Ala Pro Glu Val Ile Ala His Gly
Lys 1 5 10 47720PRTArtificial
SequenceSynthetic Polypeptide 477Ile Trp Pro Gly Ile Pro Ser Pro Glu Ser
Glu Phe Glu Gly Leu Phe 1 5 10
15 Thr Thr His Lys 20 47811PRTArtificial
SequenceSynthetic Polypeptide 478Leu Ala Asp Glu Ser Gly His Val Val Leu
Arg 1 5 10 47919PRTArtificial
SequenceSynthetic Polypeptide 479Val Ile His Ile Asn Glu Val Val Leu Leu
Asp Ala Pro Val Gly Leu 1 5 10
15 Val Ala Arg 4809PRTArtificial SequenceSynthetic Polypeptide
480Val Thr Ala Ala Ser Gly Ala Pro Arg 1 5
48116PRTArtificial SequenceSynthetic Polypeptide 481Tyr Glu Val Asp Val
Ser Ala Gly Asn Gly Ala Gly Ser Val Gln Arg 1 5
10 15 48217PRTArtificial SequenceSynthetic
Polypeptide 482Gly Ala Leu Gly Pro Gln Leu Leu Leu Asn Trp Gly Val Gln
Ile Ala 1 5 10 15
Lys 48312PRTArtificial SequenceSynthetic Polypeptide 483Gly Glu Ser Ile
Glu Pro Leu Asp Pro Ser Glu Lys 1 5 10
48410PRTArtificial SequenceSynthetic Polypeptide 484Leu Ala Glu Val
Pro Asp Leu Leu Glu Lys 1 5 10
48518PRTArtificial SequenceSynthetic Polypeptide 485Ser Leu Glu Ala Thr
Asp Ser Ala Phe Asp Asn Pro Asp Tyr Trp His 1 5
10 15 Ser Arg 48621PRTArtificial
SequenceSynthetic Polypeptide 486Ser Pro Ser Gln Val Gln Val Ala Asp Phe
Gly Val Ala Asp Leu Leu 1 5 10
15 Pro Pro Asp Asp Lys 20 4878PRTArtificial
SequenceSynthetic Polypeptide 487Val Ala Gln Val Ser Ile Thr Lys 1
5 48811PRTArtificial SequenceSynthetic Polypeptide
488Val Thr Ser Gly Asp Pro Glu Leu Pro Gln Val 1 5
10 4897PRTArtificial SequenceSynthetic Polypeptide 489Ala
Val Leu Gln Trp Thr Lys 1 5 49014PRTArtificial
SequenceSynthetic Polypeptide 490Leu Gly Ala Val Asp Glu Ser Leu Ser Glu
Glu Thr Gln Lys 1 5 10
4918PRTArtificial SequenceSynthetic Polypeptide 491Leu Leu Glu Ser Asp
Tyr Phe Arg 1 5 4927PRTArtificial
SequenceSynthetic Polypeptide 492Asn Leu Leu Gln Asn Ile His 1
5 49317PRTArtificial SequenceSynthetic Polypeptide 493Val
Leu Pro Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn 1
5 10 15 Lys 49410PRTArtificial
SequenceSynthetic Polypeptide 494Phe Pro Phe Phe Gln Tyr Ser Val Thr Lys
1 5 10 4958PRTArtificial
SequenceSynthetic Polypeptide 495Glu Ala Gln Asp Asp Leu Val Lys 1
5 4968PRTArtificial SequenceSynthetic Polypeptide
496Glu Leu Ser Glu Gln Ile Gln Arg 1 5
4979PRTArtificial SequenceSynthetic Polypeptide 497Ile Gln Val Trp His
Ala Glu His Arg 1 5 4987PRTArtificial
SequenceSynthetic Polypeptide 498Leu Gln Asp Tyr Glu Glu Lys 1
5 4998PRTArtificial SequenceSynthetic Polypeptide 499Ser Gly
Tyr Leu Ser Ser Glu Arg 1 5
50015PRTArtificial SequenceSynthetic Polypeptide 500Ala Asp Glu Pro Ser
Ser Glu Glu Ser Asp Leu Glu Ile Asp Lys 1 5
10 15 50110PRTArtificial SequenceSynthetic
Polypeptide 501Ala Ile Asp Leu Phe Thr Asp Ala Ile Lys 1 5
10 50213PRTArtificial SequenceSynthetic Polypeptide
502Ala Ile Glu Ile Asn Pro Asp Ser Ala Gln Pro Tyr Lys 1 5
10 5039PRTArtificial SequenceSynthetic
Polypeptide 503Leu Gln Lys Pro Asn Ala Ala Ile Arg 1 5
5046PRTArtificial SequenceSynthetic Polypeptide 504Tyr Gln
Ser Asn Pro Lys 1 5 50510PRTArtificial
SequenceSynthetic Polypeptide 505Gly Ile Asn Val Ala Leu Ala Asn Gly Lys
1 5 10 50622PRTArtificial
SequenceSynthetic Polypeptide 506Leu Val Val Ala Val Ala Val Phe Leu Leu
Thr Phe Tyr Val Ile Ser 1 5 10
15 Gln Val Phe Glu Ile Lys 20
5078PRTArtificial SequenceSynthetic Polypeptide 507Ser Ala Leu Asp Thr
Ala Ala Arg 1 5 5088PRTArtificial
SequenceSynthetic Polypeptide 508Ser Pro Phe Glu Gln His Ile Lys 1
5 5098PRTArtificial SequenceSynthetic Polypeptide
509Thr Gly Glu Val Leu Asp Thr Lys 1 5
51017PRTArtificial SequenceSynthetic Polypeptide 510Gly Asn Ala Gly Gln
Ser Asn Tyr Gly Phe Ala Asn Ser Ala Met Glu 1 5
10 15 Arg 51117PRTArtificial
SequenceSynthetic Polypeptide 511Leu Pro Glu Asp Pro Leu Leu Ser Gly Leu
Leu Asp Ser Pro Ala Leu 1 5 10
15 Lys 51211PRTArtificial SequenceSynthetic Polypeptide 512Leu
Gln Val Val Asp Gln Pro Leu Pro Val Arg 1 5
10 51313PRTArtificial SequenceSynthetic Polypeptide 513Met Val Val
Pro Gly Leu Asp Gly Ala Gln Ile Pro Arg 1 5
10 51411PRTArtificial SequenceSynthetic Polypeptide 514Ser
Glu Gly Val Val Ala Val Leu Leu Thr Lys 1 5
10 5159PRTArtificial SequenceSynthetic Polypeptide 515Val Leu Glu
Ala Leu Leu Pro Leu Lys 1 5
51610PRTArtificial SequenceSynthetic Polypeptide 516Gly Trp Leu Leu Leu
Gln Val Ser Ser Arg 1 5 10
5177PRTArtificial SequenceSynthetic Polypeptide 517His Leu Glu Glu Glu
Leu Lys 1 5 5189PRTArtificial SequenceSynthetic
Polypeptide 518Leu Val Tyr Asn Val Leu Tyr Tyr Arg 1 5
51911PRTArtificial SequenceSynthetic Polypeptide 519Val Phe
Thr Glu Gly Glu Pro Leu Ala Leu Arg 1 5
10 52011PRTArtificial SequenceSynthetic Polypeptide 520Tyr Thr Ser
Ala Gly Ile Ser Val Thr Val Lys 1 5 10
52119PRTArtificial SequenceSynthetic Polypeptide 521Ile Glu Glu Asn Gly
Tyr Asn Thr Tyr Ala Ser Phe Asn Trp Gln His 1 5
10 15 Asn Gly Arg 52210PRTArtificial
SequenceSynthetic Polypeptide 522Ser Tyr Asn His Leu Gln Gly Asp Val Arg
1 5 10 52310PRTArtificial
SequenceSynthetic Polypeptide 523Leu Glu Ser Asn Asn Tyr Asn Thr Tyr Arg
1 5 10 5248PRTArtificial
SequenceSynthetic Polypeptide 524Leu Gln Leu Gln Ala Glu Glu Arg 1
5 5257PRTArtificial SequenceSynthetic Polypeptide
525Asn Gly Gly Phe Phe Leu Arg 1 5
52615PRTArtificial SequenceSynthetic Polypeptide 526Glu Leu Ile Leu Glu
Asn His Tyr Asn Thr Tyr Ala Ser Ala Lys 1 5
10 15 5276PRTArtificial SequenceSynthetic Polypeptide
527Thr Gln Trp Tyr Leu Arg 1 5 52810PRTArtificial
SequenceSynthetic Polypeptide 528Thr Val Ala Val Gly Ile Val Ala Ile Lys
1 5 10 52913PRTArtificial
SequenceSynthetic Polypeptide 529Trp Ile Leu Thr Trp Ile Leu Pro Thr Leu
Leu Tyr Arg 1 5 10
53017PRTArtificial SequenceSynthetic Polypeptide 530Glu Gln Phe Glu Glu
Asn Trp Tyr Asn Thr Tyr Ser Ser Asn Leu Tyr 1 5
10 15 Lys 53117PRTArtificial
SequenceSynthetic Polypeptide 531Phe Gly Ile Leu Glu Phe Ile Ser Ile Ala
Val Gly Leu Val Ser Ile 1 5 10
15 Arg 53213PRTArtificial SequenceSynthetic Polypeptide 532Phe
Thr His Phe Leu Pro Arg Pro Val Asp Pro Asp Lys 1 5
10 5338PRTArtificial SequenceSynthetic Polypeptide
533Gly Glu Leu Tyr Gly Ser Glu Lys 1 5
53411PRTArtificial SequenceSynthetic Polypeptide 534Gly Pro Ala Val Thr
Asp Leu Asp His Leu Lys 1 5 10
5358PRTArtificial SequenceSynthetic Polypeptide 535Glu Ile Glu Val Leu
Tyr Ile Arg 1 5 5368PRTArtificial
SequenceSynthetic Polypeptide 536Gln Leu Val Glu Asp Leu Asp Arg 1
5 53711PRTArtificial SequenceSynthetic Polypeptide
537Thr Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys 1 5
10 53810PRTArtificial SequenceSynthetic Polypeptide 538Tyr
Gly Pro Asp Gly Leu Pro Tyr Leu Lys 1 5
10 53920PRTArtificial SequenceSynthetic Polypeptide 539Tyr Gln Ile Ser
Gln Pro Glu Val Tyr Val Ala Ala Pro Gly Glu Ser 1 5
10 15 Leu Glu Val Arg 20
54010PRTArtificial SequenceSynthetic Polypeptide 540Asp Gly Thr Gly Leu
Val Pro Ser Glu Arg 1 5 10
54122PRTArtificial SequenceSynthetic Polypeptide 541Leu Ser Ser Gly Glu
Gly Pro Thr Leu Ala Asn Val Ser Glu Leu Glu 1 5
10 15 Leu Pro Ala Asp Pro Lys 20
5429PRTArtificial SequenceSynthetic Polypeptide 542Thr Ala Gly
Ala Asn Thr Thr Asp Lys 1 5
54313PRTArtificial SequenceSynthetic Polypeptide 543Val Gly Pro Asp Gly
Thr Pro Tyr Val Thr Val Leu Lys 1 5 10
5448PRTArtificial SequenceSynthetic Polypeptide 544Glu Leu Glu
Ser Glu Val Asn Lys 1 5 54515PRTArtificial
SequenceSynthetic Polypeptide 545Leu His Val Gly Asn Tyr Asn Gly Thr Ala
Gly Asp Ala Leu Arg 1 5 10
15 54611PRTArtificial SequenceSynthetic Polypeptide 546Leu Gln Ala Asp
Asp Asn Gly Asp Pro Gly Arg 1 5 10
54718PRTArtificial SequenceSynthetic Polypeptide 547Asn Gly Leu Leu Leu
Pro Ser Thr Gly Ala Pro Gly Glu Val Gly Asp 1 5
10 15 Asn Arg 54814PRTArtificial
SequenceSynthetic Polypeptide 548Val Ala Asn Leu Thr Phe Val Val Asn Ser
Leu Asp Gly Lys 1 5 10
5498PRTArtificial SequenceSynthetic Polypeptide 549Glu Asp Phe Pro Ala
Ser Trp Arg 1 5 55014PRTArtificial
SequenceSynthetic Polypeptide 550Phe Gly Gln His Leu Ile Lys Pro Ser Val
Val Phe Leu Lys 1 5 10
55118PRTArtificial SequenceSynthetic Polypeptide 551Phe His Asp Leu Arg
Pro Asp Glu Val Ala Asp Leu Phe Gln Thr Thr 1 5
10 15 Gln Arg 55210PRTArtificial
SequenceSynthetic Polypeptide 552Asn Asp Ser Ile Tyr Glu Glu Leu Gln Lys
1 5 10 5537PRTArtificial
SequenceSynthetic Polypeptide 553Val Gly Thr Val Val Glu Lys 1
5 55416PRTArtificial SequenceSynthetic Polypeptide 554Gly
Gly Ser Thr Ser Tyr Gly Thr Gly Ser Glu Thr Glu Ser Pro Arg 1
5 10 15 55513PRTArtificial
SequenceSynthetic Polypeptide 555Gly Leu Ile Asp Glu Val Asn Gln Asp Phe
Thr Asn Arg 1 5 10
5568PRTArtificial SequenceSynthetic Polypeptide 556Asn Ser Leu Phe Glu
Tyr Gln Lys 1 5 5579PRTArtificial
SequenceSynthetic Polypeptide 557Thr Val Ile Gly Pro Asp Gly His Lys 1
5 5589PRTArtificial SequenceSynthetic
Polypeptide 558Val Gln His Ile Gln Leu Leu Gln Lys 1 5
55918PRTArtificial SequenceSynthetic Polypeptide 559His Thr
Ser Val Gln Thr Thr Ser Ser Gly Ser Gly Pro Phe Thr Asp 1 5
10 15 Val Arg 56019PRTArtificial
SequenceSynthetic Polypeptide 560Ser Ser Pro Val Val Ile Asp Ala Ser Thr
Ala Ile Asp Ala Pro Ser 1 5 10
15 Asn Leu Arg 56114PRTArtificial SequenceSynthetic
Polypeptide 561Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys 1
5 10 56215PRTArtificial
SequenceSynthetic Polypeptide 562Val Pro Gly Thr Ser Thr Ser Ala Thr Leu
Thr Gly Leu Thr Arg 1 5 10
15 56328PRTArtificial SequenceSynthetic Polypeptide 563Val Val Thr Pro
Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala Asn 1 5
10 15 Pro Asp Thr Gly Val Leu Thr Val Ser
Trp Glu Arg 20 25
56412PRTArtificial SequenceSynthetic Polypeptide 564Ala Glu Ala Gly Leu
Glu Thr Glu Ser Pro Val Arg 1 5 10
5656PRTArtificial SequenceSynthetic Polypeptide 565Ala Asn Tyr Trp Leu
Lys 1 5 56610PRTArtificial SequenceSynthetic
Polypeptide 566Asp Pro Leu Val Ile Glu Leu Gly Gln Lys 1 5
10 5678PRTArtificial SequenceSynthetic Polypeptide
567Ile Ile Asp Thr Ser Leu Thr Arg 1 5
56822PRTArtificial SequenceSynthetic Polypeptide 568Asp Ser Trp Val Phe
Gly Gly Ile Asp Pro Gln Ser Gly Ala Ala Val 1 5
10 15 Val His Glu Ile Val Arg 20
56917PRTArtificial SequenceSynthetic Polypeptide 569Gly Val Ile
Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val 1 5
10 15 Lys 57013PRTArtificial
SequenceSynthetic Polypeptide 570Leu Gly Ser Gly Asn Asp Phe Glu Val Phe
Phe Gln Arg 1 5 10
57115PRTArtificial SequenceSynthetic Polypeptide 571Ser Tyr Pro Asp Gly
Trp Asn Leu Pro Gly Gly Gly Val Gln Arg 1 5
10 15 57214PRTArtificial SequenceSynthetic
Polypeptide 572Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys 1
5 10 5737PRTArtificial
SequenceSynthetic Polypeptide 573Asp Val Ser Tyr Leu Tyr Arg 1
5 5748PRTArtificial SequenceSynthetic Polypeptide 574Glu Lys
Pro Gly Pro Glu Asp Lys 1 5
57510PRTArtificial SequenceSynthetic Polypeptide 575Gly Trp Asn Trp Thr
Ser Gly Phe Asn Lys 1 5 10
5766PRTArtificial SequenceSynthetic Polypeptide 576Val Ser Asn Tyr Ser
Arg 1 5 57727PRTArtificial SequenceSynthetic
Polypeptide 577Ala Tyr Glu Gln Val Met His Tyr Pro Gly Tyr Gly Ser Pro
Met Pro 1 5 10 15
Gly Ser Leu Ala Met Gly Pro Val Thr Asn Lys 20
25 57810PRTArtificial SequenceSynthetic Polypeptide 578Glu Ala
Ala Gly Ala Ala Gly Ser Gly Lys 1 5 10
57912PRTArtificial SequenceSynthetic Polypeptide 579Met His Ser Ala Ser
Ser Met Leu Gly Ala Val Lys 1 5 10
58019PRTArtificial SequenceSynthetic Polypeptide 580Met Leu Thr Leu Ser
Glu Ile Tyr Gln Trp Ile Met Asp Leu Phe Pro 1 5
10 15 Phe Tyr Arg 58125PRTArtificial
SequenceSynthetic Polypeptide 581Ser Tyr Thr His Ala Lys Pro Pro Tyr Ser
Tyr Ile Ser Leu Ile Thr 1 5 10
15 Met Ala Ile Gln Gln Ser Pro Asn Lys 20
25 58227PRTArtificial SequenceSynthetic Polypeptide 582Thr Gly
Leu Asp Ala Ser Pro Leu Ala Ala Asp Thr Ser Tyr Tyr Gln 1 5
10 15 Gly Val Tyr Ser Arg Pro Ile
Met Asn Ser Ser 20 25
5836PRTArtificial SequenceSynthetic Polypeptide 583Trp Gln Asn Ser Ile
Arg 1 5 58412PRTArtificial SequenceSynthetic
Polypeptide 584Ala Glu Tyr Leu Pro Pro Ser Val Ala Ser Ile Lys 1
5 10 5859PRTArtificial SequenceSynthetic
Polypeptide 585Ala Pro Ser Pro Leu Gly Pro Thr Arg 1 5
58612PRTArtificial SequenceSynthetic Polypeptide 586Glu Leu
Leu Ser Gly Ile Gly Asn Ile Ser Glu Arg 1 5
10 58713PRTArtificial SequenceSynthetic Polypeptide 587Glu Pro
Gly Ser Gln Pro Ala Gly Pro Ala Ser Leu Arg 1 5
10 58811PRTArtificial SequenceSynthetic Polypeptide
588Ser Ala Pro Gly Asp Pro Asn Ala Leu Val Lys 1 5
10 58910PRTArtificial SequenceSynthetic Polypeptide 589His
Thr Leu Gly Asp Ser Asp Asn Glu Ser 1 5
10 59011PRTArtificial SequenceSynthetic Polypeptide 590Asn Val Asn Gln
Ser Leu Leu Glu Leu His Lys 1 5 10
59113PRTArtificial SequenceSynthetic Polypeptide 591Gln Asn Tyr His Gln
Asp Ser Glu Ala Ala Ile Asn Arg 1 5 10
59210PRTArtificial SequenceSynthetic Polypeptide 592Tyr Phe Leu
His Gln Ser His Glu Glu Arg 1 5 10
5937PRTArtificial SequenceSynthetic Polypeptide 593Ala Leu Phe Gln Asp
Ile Lys 1 5 59413PRTArtificial SequenceSynthetic
Polypeptide 594Asp Asp Val Ala Leu Glu Gly Val Ser His Phe Phe Arg 1
5 10 5959PRTArtificial
SequenceSynthetic Polypeptide 595Lys Pro Ala Glu Asp Glu Trp Gly Lys 1
5 59615PRTArtificial SequenceSynthetic
Polypeptide 596Leu Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe Glu
Arg 1 5 10 15
59715PRTArtificial SequenceSynthetic Polypeptide 597Leu Asn Gln Ala Leu
Leu Asp Leu His Ala Leu Gly Ser Ala Arg 1 5
10 15 59810PRTArtificial SequenceSynthetic
Polypeptide 598Met Gly Asp His Leu Thr Asn Leu His Arg 1 5
10 59915PRTArtificial SequenceSynthetic Polypeptide
599Gly Ala Leu Gln Asn Ile Ile Pro Ala Ser Thr Gly Ala Ala Lys 1
5 10 15 60014PRTArtificial
SequenceSynthetic Polypeptide 600Leu Ile Ser Trp Tyr Asp Asn Glu Phe Gly
Tyr Ser Asn Arg 1 5 10
60114PRTArtificial SequenceSynthetic Polypeptide 601Leu Val Ile Asn Gly
Asn Pro Ile Thr Ile Phe Gln Glu Arg 1 5
10 60211PRTArtificial SequenceSynthetic Polypeptide
602Val Val Asp Leu Met Ala His Met Ala Ser Lys 1 5
10 60315PRTArtificial SequenceSynthetic Polypeptide 603Asp
Gly Leu Leu Pro Glu Asn Thr Phe Ile Val Gly Tyr Ala Arg 1 5
10 15 60411PRTArtificial
SequenceSynthetic Polypeptide 604Gly Gly Tyr Phe Asp Glu Phe Gly Ile Ile
Arg 1 5 10 60524PRTArtificial
SequenceSynthetic Polypeptide 605Ile Phe Thr Pro Leu Leu His Gln Ile Glu
Leu Glu Lys Pro Lys Pro 1 5 10
15 Ile Pro Tyr Ile Tyr Gly Ser Arg 20
6067PRTArtificial SequenceSynthetic Polypeptide 606Leu Pro Asp Ala
Tyr Glu Arg 1 5 60716PRTArtificial
SequenceSynthetic Polypeptide 607Asn Ser Tyr Val Ala Gly Gln Tyr Asp Asp
Ala Ala Ser Tyr Gln Arg 1 5 10
15 6088PRTArtificial SequenceSynthetic Polypeptide 608Ala Val
Leu His Val Ala Leu Arg 1 5
60921PRTArtificial SequenceSynthetic Polypeptide 609Phe Asn His Phe Ser
Leu Thr Leu Asn Thr Asn His Gly His Ile Leu 1 5
10 15 Val Asp Tyr Ser Lys 20
61017PRTArtificial SequenceSynthetic Polypeptide 610Thr Leu Ala Gln Leu
Asn Pro Glu Ser Ser Leu Phe Ile Ile Ala Ser 1 5
10 15 Lys 61130PRTArtificial
SequenceSynthetic Polypeptide 611Val Asp His Gln Thr Gly Pro Ile Val Trp
Gly Glu Pro Gly Thr Asn 1 5 10
15 Gly Gln His Ala Phe Tyr Gln Leu Ile His Gln Gly Thr Lys
20 25 30 61215PRTArtificial
SequenceSynthetic Polypeptide 612Val Phe Glu Gly Asn Arg Pro Thr Asn Ser
Ile Val Phe Thr Lys 1 5 10
15 61327PRTArtificial SequenceSynthetic Polypeptide 613Ala Ala Pro Pro
Ala Pro Asn Ala Pro Ala Ala Gly Glu Asp Thr Thr 1 5
10 15 Glu Thr Ala Pro Ala Pro Gly Thr Pro
Ala Arg 20 25 61419PRTArtificial
SequenceSynthetic Polypeptide 614Ala Leu Glu Ala Val Ala Ser Val Thr Pro
Thr Gly Pro Val Pro Asp 1 5 10
15 Pro Ala Arg 61510PRTArtificial SequenceSynthetic
Polypeptide 615Leu Val Gln Phe Glu Gln Glu Ile Glu Arg 1 5
10 61611PRTArtificial SequenceSynthetic Polypeptide
616Val Gly Asp Ser Ser Leu Leu Ile Phe Val Arg 1 5
10 61717PRTArtificial SequenceSynthetic Polypeptide 617Val
Ser Ser Pro Ser Pro Glu Leu Gly Thr Thr Pro Ala Ser Ile Phe 1
5 10 15 Arg 61820PRTArtificial
SequenceSynthetic Polypeptide 618Glu Ile Ile Leu Val Asp Asp Tyr Ser Asn
Asp Pro Glu Asp Gly Ala 1 5 10
15 Leu Leu Gly Lys 20 61910PRTArtificial
SequenceSynthetic Polypeptide 619Gly Gly Phe Asp Trp Asn Leu Val Phe Lys
1 5 10 62011PRTArtificial
SequenceSynthetic Polypeptide 620Asn Phe Tyr Tyr Ala Ala Val Pro Ser Ala
Arg 1 5 10 62117PRTArtificial
SequenceSynthetic Polypeptide 621Val Asp Leu Pro Ala Thr Ser Val Val Ile
Thr Phe His Asn Glu Ala 1 5 10
15 Arg 62211PRTArtificial SequenceSynthetic Polypeptide 622Trp
Tyr Leu Glu Asn Val Tyr Pro Glu Leu Arg 1 5
10 62312PRTArtificial SequenceSynthetic Polypeptide 623Asp Gly Glu
Ala Thr Leu Glu Val Asp Gly Thr Arg 1 5
10 62415PRTArtificial SequenceSynthetic Polypeptide 624Glu Val
Phe Glu Asn Asp Pro Glu Thr Asp Tyr Phe Tyr Pro Arg 1 5
10 15 62513PRTArtificial
SequenceSynthetic Polypeptide 625Gly Gln Ser Glu Val Ser Ala Ala Gln Leu
Gln Glu Arg 1 5 10
62612PRTArtificial SequenceSynthetic Polypeptide 626Ile Ala Val Ala Gly
Asp Leu Phe Gln Pro Glu Arg 1 5 10
62717PRTArtificial SequenceSynthetic Polypeptide 627Ser Trp Asn Trp Leu
Asn Gly Glu Asp Thr Thr Ile Gln Glu Thr Val 1 5
10 15 Lys 62817PRTArtificial
SequenceSynthetic Polypeptide 628Ala Pro Glu Pro His Val Glu Glu Asp Asp
Asp Asp Glu Leu Asp Ser 1 5 10
15 Lys 6297PRTArtificial SequenceSynthetic Polypeptide 629Asp
Ile Val Ser Gly Leu Lys 1 5 6309PRTArtificial
SequenceSynthetic Polypeptide 630Leu Asn Tyr Lys Pro Pro Pro Gln Lys 1
5 63113PRTArtificial SequenceSynthetic
Polypeptide 631Gln Asp His Leu Ser Trp Glu Trp Asn Leu Ser Ile Lys 1
5 10 6328PRTArtificial
SequenceSynthetic Polypeptide 632Ser Phe Phe Thr Asp Asp Asp Lys 1
5 63313PRTArtificial SequenceSynthetic Polypeptide
633Thr Leu Leu Gly Asp Gly Pro Val Val Thr Asp Pro Lys 1 5
10 63422PRTArtificial SequenceSynthetic
Polypeptide 634Ala Gln Pro Val Gln Val Ala Glu Gly Ser Glu Pro Asp Gly
Phe Trp 1 5 10 15
Glu Ala Leu Gly Gly Lys 20 6358PRTArtificial
SequenceSynthetic Polypeptide 635Glu Pro Gly Leu Gln Ile Trp Arg 1
5 63624PRTArtificial SequenceSynthetic Polypeptide
636Phe Asp Leu Val Pro Val Pro Thr Asn Leu Tyr Gly Asp Phe Phe Thr 1
5 10 15 Gly Asp Ala Tyr
Val Ile Leu Lys 20 6378PRTArtificial
SequenceSynthetic Polypeptide 637Thr Ala Ser Asp Phe Ile Thr Lys 1
5 63818PRTArtificial SequenceSynthetic Polypeptide
638Thr Pro Ser Ala Ala Tyr Leu Trp Val Gly Thr Gly Ala Ser Glu Ala 1
5 10 15 Glu Lys
6397PRTArtificial SequenceSynthetic Polypeptide 639Asp Tyr Glu Ile Leu
Phe Lys 1 5 64013PRTArtificial SequenceSynthetic
Polypeptide 640Asn Leu Asp Gly Ile Ser His Ala Pro Asn Ala Val Lys 1
5 10 6418PRTArtificial
SequenceSynthetic Polypeptide 641Tyr Leu Glu Ser Ala Gly Ala Arg 1
5 64212PRTArtificial SequenceSynthetic Polypeptide
642Tyr Pro Val Tyr Gly Val Gln Trp His Pro Glu Lys 1 5
10 6439PRTArtificial SequenceSynthetic Polypeptide
643Tyr Tyr Ile Ala Ala Ser Tyr Val Lys 1 5
64424PRTArtificial SequenceSynthetic Polypeptide 644Phe Leu Ala Glu Leu
Ala Tyr Asp Leu Asp Val Asp Asp Ala Pro Gly 1 5
10 15 Asn Ser Gln Gln Ala Thr Pro Lys
20 64519PRTArtificial SequenceSynthetic Polypeptide
645Phe Leu Ile Ile Gln Asn Ala Ala Val Phe Gln Glu Ala Phe Glu Ile 1
5 10 15 Val Val Arg
64612PRTArtificial SequenceSynthetic Polypeptide 646Gly Pro Glu Pro Val
Val Ser Gln Ile Ile Asp Lys 1 5 10
64720PRTArtificial SequenceSynthetic Polypeptide 647Ile Phe Leu Gln Ala
Leu Asn Leu Gly Ile Glu Val Ile Asn Thr Thr 1 5
10 15 Asp His Leu Lys 20
6489PRTArtificial SequenceSynthetic Polypeptide 648Asn Gln Phe Asn Leu
His Glu Leu Lys 1 5 64910PRTArtificial
SequenceSynthetic Polypeptide 649Glu Leu Trp Ala Ala Leu Asn Ala Trp Lys
1 5 10 65011PRTArtificial
SequenceSynthetic Polypeptide 650Ala Ser Gln Gly Pro Pro Ser Ala Ile Ser
Arg 1 5 10 65110PRTArtificial
SequenceSynthetic Polypeptide 651Glu Val Asn Tyr Glu Leu Val Thr Gly Lys
1 5 10 65214PRTArtificial
SequenceSynthetic Polypeptide 652Ile Leu Ser Glu Ser Leu Leu Thr Pro Ala
Glu Tyr Gln Lys 1 5 10
65322PRTArtificial SequenceSynthetic Polypeptide 653Thr Ala Leu Glu Gln
Glu Leu Gly Leu Ala Ala Tyr Phe Val Ser Asn 1 5
10 15 Glu Val Pro Leu Glu Lys 20
65413PRTArtificial SequenceSynthetic Polypeptide 654Thr Gly Ala
Tyr Leu Gln Phe Leu Ser Val Leu Ser Arg 1 5
10 65518PRTArtificial SequenceSynthetic Polypeptide 655Ala
Gln His Asn Asp Ser Glu Gln Thr Gln Ser Pro Gln Gln Pro Gly 1
5 10 15 Ser Arg
65618PRTArtificial SequenceSynthetic Polypeptide 656Ala Leu Gly Asn Gln
Gln Pro Ser Trp Asp Ser Glu Asp Ser Ser Asn 1 5
10 15 Phe Lys 65714PRTArtificial
SequenceSynthetic Polypeptide 657Ala Val Pro Leu Pro Ala Gly Gly Gly Thr
Val Leu Thr Lys 1 5 10
6588PRTArtificial SequenceSynthetic Polypeptide 658Leu Ser Ala Pro Gly
Ser Gln Arg 1 5 6599PRTArtificial
SequenceSynthetic Polypeptide 659Asn Leu Leu Gly Leu Ile Glu Ala Lys 1
5 6607PRTArtificial SequenceSynthetic
Polypeptide 660Asn Pro Gln Leu Asn Gln Gln 1 5
66118PRTArtificial SequenceSynthetic Polypeptide 661Gly Val Pro Gln Ile
Glu Val Thr Phe Glu Ile Asp Val Asn Gly Ile 1 5
10 15 Leu Arg 6628PRTArtificial
SequenceSynthetic Polypeptide 662Leu Thr Pro Glu Glu Ile Glu Arg 1
5 66318PRTArtificial SequenceSynthetic Polypeptide
663Leu Tyr Gly Ser Ala Gly Pro Pro Pro Thr Gly Glu Glu Asp Thr Ala 1
5 10 15 Glu Lys
66412PRTArtificial SequenceSynthetic Polypeptide 664Thr Trp Asn Asp Pro
Ser Val Gln Gln Asp Ile Lys 1 5 10
66510PRTArtificial SequenceSynthetic Polypeptide 665Val Tyr Glu Gly Glu
Arg Pro Leu Thr Lys 1 5 10
66611PRTArtificial SequenceSynthetic Polypeptide 666Ile Ile Ile Gln Glu
Ser Ala Leu Asp Tyr Arg 1 5 10
6678PRTArtificial SequenceSynthetic Polypeptide 667Leu Asp Pro Ala Leu
Gln Asp Lys 1 5 6687PRTArtificial
SequenceSynthetic Polypeptide 668Leu Ile Ala Gln Asp Tyr Lys 1
5 6697PRTArtificial SequenceSynthetic Polypeptide 669Asn Asp
Ile Asn Ile Leu Lys 1 5 67013PRTArtificial
SequenceSynthetic Polypeptide 670Val Ala Glu Leu Ser Ser Asp Asp Phe His
Leu Asp Arg 1 5 10
67118PRTArtificial SequenceSynthetic Polypeptide 671Ala Phe Leu Ala Ser
Pro Glu Tyr Val Asn Leu Pro Ile Asn Gly Asn 1 5
10 15 Gly Lys 67220PRTArtificial
SequenceSynthetic Polypeptide 672Ala Leu Pro Gly Gln Leu Lys Pro Phe Glu
Thr Leu Leu Ser Gln Asn 1 5 10
15 Gln Gly Gly Lys 20 67315PRTArtificial
SequenceSynthetic Polypeptide 673Glu Glu Val Val Thr Val Glu Thr Trp Gln
Glu Gly Ser Leu Lys 1 5 10
15 67416PRTArtificial SequenceSynthetic Polypeptide 674Phe Gln Asp Gly
Asp Leu Thr Leu Tyr Gln Ser Asn Thr Ile Leu Arg 1 5
10 15 67513PRTArtificial
SequenceSynthetic Polypeptide 675Tyr Ile Ser Leu Ile Tyr Thr Asn Tyr Glu
Ala Gly Lys 1 5 10
67630PRTArtificial SequenceSynthetic Polypeptide 676Ala Gly Val Gln Gln
Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val 1 5
10 15 Asn Thr Ala Phe Thr Val Val Ser Leu Phe
Val Val Glu Arg 20 25 30
67731PRTArtificial SequenceSynthetic Polypeptide 677Gln Pro Ile Leu Ile
Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser 1 5
10 15 Gly Ile Asn Ala Val Phe Tyr Tyr Ser Thr
Ser Ile Phe Glu Lys 20 25
30 67810PRTArtificial SequenceSynthetic Polypeptide 678Thr Phe Asp
Glu Ile Ala Ser Gly Phe Arg 1 5 10
67915PRTArtificial SequenceSynthetic Polypeptide 679Thr Pro Glu Glu Leu
Phe His Pro Leu Gly Ala Asp Ser Gln Val 1 5
10 15 68013PRTArtificial SequenceSynthetic
Polypeptide 680Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp Val His Arg 1
5 10 68111PRTArtificial
SequenceSynthetic Polypeptide 681Ala Phe Glu Gly Gln Ala His Gly Ala Asp
Arg 1 5 10 68231PRTArtificial
SequenceSynthetic Polypeptide 682Asp Ala Gly Val Gln Glu Pro Ile Tyr Ala
Thr Ile Gly Ala Gly Val 1 5 10
15 Val Asn Thr Ile Phe Thr Val Val Ser Leu Phe Leu Val Glu Arg
20 25 30
68313PRTArtificial SequenceSynthetic Polypeptide 683Asp Gly Val Met Glu
Met Asn Ser Ile Glu Pro Ala Lys 1 5 10
6846PRTArtificial SequenceSynthetic Polypeptide 684Phe Leu Leu
Ile Asn Arg 1 5 68515PRTArtificial SequenceSynthetic
Polypeptide 685Leu Trp Gly Thr Gln Asp Val Ser Gln Asp Ile Gln Glu Met
Lys 1 5 10 15
68630PRTArtificial SequenceSynthetic Polypeptide 686Gln Pro Ile Ile Ile
Ser Ile Val Leu Gln Leu Ser Gln Gln Leu Ser 1 5
10 15 Gly Ile Asn Ala Val Phe Tyr Tyr Ser Thr
Gly Ile Phe Lys 20 25 30
6879PRTArtificial SequenceSynthetic Polypeptide 687Gln Val Thr Val Leu
Glu Leu Phe Arg 1 5 6889PRTArtificial
SequenceSynthetic Polypeptide 688Ser Val Glu Met Leu Ile Leu Gly Arg 1
5 6897PRTArtificial SequenceSynthetic
Polypeptide 689Thr Phe Glu Asp Ile Thr Arg 1 5
69031PRTArtificial SequenceSynthetic Polypeptide 690Val Thr Pro Ala Leu
Ile Phe Ala Ile Thr Val Ala Thr Ile Gly Ser 1 5
10 15 Phe Gln Phe Gly Tyr Asn Thr Gly Val Ile
Asn Ala Pro Glu Lys 20 25
30 6919PRTArtificial SequenceSynthetic Polypeptide 691Ala Gly Leu
Gln Phe Pro Val Gly Arg 1 5
6927PRTArtificial SequenceSynthetic Polypeptide 692His Leu Gln Leu Ala
Ile Arg 1 5 6937PRTArtificial SequenceSynthetic
Polypeptide 693Asn Asp Glu Glu Leu Asn Lys 1 5
69429PRTArtificial SequenceSynthetic Polypeptide 694Val Gly Ala Gly Ala
Pro Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu 1 5
10 15 Thr Ala Glu Ile Leu Glu Leu Ala Gly Asn
Ala Ala Arg 20 25
69531PRTArtificial SequenceSynthetic Polypeptide 695Gly Ala Leu Tyr Thr
Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala 1 5
10 15 Gly Gln Ala Thr Thr Ala Tyr Phe Leu Tyr
Gln Gln Gln Gly Arg 20 25
30 6968PRTArtificial SequenceSynthetic Polypeptide 696Gly Ser Phe
Pro Glu Asn Leu Arg 1 5 69713PRTArtificial
SequenceSynthetic Polypeptide 697His Ser Leu Glu Gln Lys Pro Thr Asp Ala
Pro Pro Lys 1 5 10
69810PRTArtificial SequenceSynthetic Polypeptide 698Leu Pro Lys Pro Pro
Lys Pro Val Ser Lys 1 5 10
69914PRTArtificial SequenceSynthetic Polypeptide 699Leu Thr Val Thr Ser
Gln Asn Leu Gln Leu Glu Asn Leu Arg 1 5
10 70014PRTArtificial SequenceSynthetic Polypeptide
700Asp Tyr Glu Ala Trp Leu Gly Ile His Asp Val His Gly Arg 1
5 10 7018PRTArtificial
SequenceSynthetic Polypeptide 701Glu Ser Trp Val Leu Thr Ala Arg 1
5 70210PRTArtificial SequenceSynthetic Polypeptide
702His Ile Phe Trp Glu Pro Asp Ala Ser Lys 1 5
10 7038PRTArtificial SequenceSynthetic Polypeptide 703Val Val Asn
Gly Ile Pro Thr Arg 1 5 7048PRTArtificial
SequenceSynthetic Polypeptide 704Trp Asp His Gln Thr Pro His Arg 1
5 70515PRTArtificial SequenceSynthetic Polypeptide
705Glu Glu Glu Glu Gly Ile Ser Gln Glu Ser Ser Glu Glu Glu Gln 1
5 10 15 7068PRTArtificial
SequenceSynthetic Polypeptide 706Ser Ser Gln Pro Leu Ala Ser Lys 1
5 70710PRTArtificial SequenceSynthetic Polypeptide
707Phe Phe Ala Asp Leu Leu Asp Tyr Ile Lys 1 5
10 70814PRTArtificial SequenceSynthetic Polypeptide 708Phe Val Val
Gly Tyr Ala Leu Asp Tyr Asn Glu Tyr Phe Arg 1 5
10 70913PRTArtificial SequenceSynthetic
Polypeptide 709Asn Val Leu Ile Val Glu Asp Ile Ile Asp Thr Gly Lys 1
5 10 71016PRTArtificial
SequenceSynthetic Polypeptide 710Ser Val Gly Tyr Lys Pro Asp Phe Val Gly
Phe Glu Ile Pro Asp Lys 1 5 10
15 71113PRTArtificial SequenceSynthetic Polypeptide 711Val Ile
Gly Gly Asp Asp Leu Ser Thr Leu Thr Gly Lys 1 5
10 71218PRTArtificial SequenceSynthetic Polypeptide
712Glu Asp Phe Leu Asn Pro Asp Val Leu Asp Ile Phe Ile Ser Ser Val 1
5 10 15 Gln Lys
7139PRTArtificial SequenceSynthetic Polypeptide 713Phe Leu Ile Leu Leu
Gly Ser Pro Lys 1 5 7148PRTArtificial
SequenceSynthetic Polypeptide 714Leu Pro Tyr Pro Phe Ser Asn Lys 1
5 71510PRTArtificial SequenceSynthetic Polypeptide
715Ser Val Gln Leu Asn Gly Leu Thr Leu Lys 1 5
10 71614PRTArtificial SequenceSynthetic Polypeptide 716Tyr Leu Leu
Arg Pro Leu Gly Pro His Gly Leu Leu Ser Lys 1 5
10 7177PRTArtificial SequenceSynthetic Polypeptide
717Asp Tyr Ala Glu Val Gly Arg 1 5
71813PRTArtificial SequenceSynthetic Polypeptide 718Thr Glu Gly Asp Gly
Val Tyr Thr Leu Asn Asn Glu Lys 1 5 10
7199PRTArtificial SequenceSynthetic Polypeptide 719Val Gly Tyr
Val Ser Gly Trp Gly Arg 1 5
72010PRTArtificial SequenceSynthetic Polypeptide 720Val Thr Ser Ile Gln
Asp Trp Val Gln Lys 1 5 10
72116PRTArtificial SequenceSynthetic Polypeptide 721Val Val Leu His Pro
Asn Tyr Ser Gln Val Asp Ile Gly Leu Ile Lys 1 5
10 15 72211PRTArtificial SequenceSynthetic
Polypeptide 722Asp Asn Ser Thr Met Gly Tyr Met Ala Ala Lys 1
5 10 72315PRTArtificial SequenceSynthetic
Polypeptide 723His Leu Glu Ile Asn Pro Asp His Ser Ile Ile Glu Thr Leu
Arg 1 5 10 15
72413PRTArtificial SequenceSynthetic Polypeptide 724Ser Leu Thr Asn Asp
Trp Glu Asp His Leu Ala Val Lys 1 5 10
72513PRTArtificial SequenceSynthetic Polypeptide 725Thr Leu Thr
Ile Val Asp Thr Gly Ile Gly Met Thr Lys 1 5
10 7269PRTArtificial SequenceSynthetic Polypeptide 726Ala
Asp His Gly Glu Pro Ile Gly Arg 1 5
72727PRTArtificial SequenceSynthetic Polypeptide 727Asp Leu Val Val Leu
Leu Phe Glu Thr Ala Leu Leu Ser Ser Gly Phe 1 5
10 15 Ser Leu Glu Asp Pro Gln Thr His Ser Asn
Arg 20 25 72810PRTArtificial
SequenceSynthetic Polypeptide 728Ile Asp Ile Ile Pro Asn Pro Gln Glu Arg
1 5 10 72934PRTArtificial
SequenceSynthetic Polypeptide 729Leu Gly Leu Gly Ile Asp Glu Asp Glu Val
Ala Ala Glu Glu Pro Asn 1 5 10
15 Ala Ala Val Pro Asp Glu Ile Pro Pro Leu Glu Gly Asp Glu Asp
Ala 20 25 30 Ser
Arg 73015PRTArtificial SequenceSynthetic Polypeptide 730Asn Pro Asp Asp
Ile Thr Gln Glu Glu Tyr Gly Glu Phe Tyr Lys 1 5
10 15 73110PRTArtificial SequenceSynthetic
Polypeptide 731Ala Gln Leu Gly Gly Pro Glu Ala Ala Lys 1 5
10 7329PRTArtificial SequenceSynthetic Polypeptide
732Asp Gly Val Val Glu Ile Thr Gly Lys 1 5
7338PRTArtificial SequenceSynthetic Polypeptide 733Gly Pro Ser Trp Asp
Pro Phe Arg 1 5 73417PRTArtificial
SequenceSynthetic Polypeptide 734Leu Ala Thr Gln Ser Asn Glu Ile Thr Ile
Pro Val Thr Phe Glu Ser 1 5 10
15 Arg 73510PRTArtificial SequenceSynthetic Polypeptide 735Leu
Phe Asp Gln Ala Phe Gly Leu Pro Arg 1 5
10 7369PRTArtificial SequenceSynthetic Polypeptide 736Gln Asp Glu His
Gly Tyr Ile Ser Arg 1 5
73710PRTArtificial SequenceSynthetic Polypeptide 737Gln Leu Ser Ser Gly
Val Ser Glu Ile Arg 1 5 10
7387PRTArtificial SequenceSynthetic Polypeptide 738Val Pro Phe Ser Leu
Leu Arg 1 5 73916PRTArtificial SequenceSynthetic
Polypeptide 739Val Ser Leu Asp Val Asn His Phe Ala Pro Asp Glu Leu Thr
Val Lys 1 5 10 15
74030PRTArtificial SequenceSynthetic Polypeptide 740Tyr Thr Leu Pro Pro
Gly Val Asp Pro Thr Gln Val Ser Ser Ser Leu 1 5
10 15 Ser Pro Glu Gly Thr Leu Thr Val Glu Ala
Pro Met Pro Lys 20 25 30
74111PRTArtificial SequenceSynthetic Polypeptide 741Leu His Arg Pro Pro
Val Ile Val Leu Gln Arg 1 5 10
7428PRTArtificial SequenceSynthetic Polypeptide 742Leu Pro Val Leu Leu
Leu Gly Arg 1 5 74333PRTArtificial
SequenceSynthetic Polypeptide 743Ser Ser Glu Leu Arg Pro Gly Glu Phe Val
Val Ala Ile Gly Ser Pro 1 5 10
15 Phe Ser Leu Gln Asn Thr Val Thr Thr Gly Ile Val Ser Thr Thr
Gln 20 25 30 Arg
74413PRTArtificial SequenceSynthetic Polypeptide 744Val Thr Ala Gly Ile
Ser Phe Ala Ile Pro Ser Asp Lys 1 5 10
74510PRTArtificial SequenceSynthetic Polypeptide 745Tyr Asn Phe
Ile Ala Asp Val Val Glu Lys 1 5 10
7469PRTArtificial SequenceSynthetic Polypeptide 746Asp Phe Asn Pro Thr
Ala Thr Val Lys 1 5 74710PRTArtificial
SequenceSynthetic Polypeptide 747Phe Leu Leu Ser Glu Ser Gly Ser Gly Lys
1 5 10 74811PRTArtificial
SequenceSynthetic Polypeptide 748His Ile Asp Leu Val Glu Gly Asp Glu Gly
Arg 1 5 10 74911PRTArtificial
SequenceSynthetic Polypeptide 749Leu Val Asp Glu Tyr Ser Leu Asn Ala Gly
Lys 1 5 10 75015PRTArtificial
SequenceSynthetic Polypeptide 750Ser Ala Asn Leu Val Ala Ala Thr Leu Gly
Ala Ile Leu Asn Arg 1 5 10
15 7518PRTArtificial SequenceSynthetic Polypeptide 751His Pro Asp Trp
Pro Pro Asp Arg 1 5 75228PRTArtificial
SequenceSynthetic Polypeptide 752Asn Asp Gln Leu Ala Trp Leu Trp Ala Glu
Ser Thr Ala Leu Phe Pro 1 5 10
15 Ser Val Tyr Leu Asp Glu Thr Leu Ala Ser Ser Arg
20 25 75330PRTArtificial SequenceSynthetic
Polypeptide 753Gln Ala Ala Gly Gly Ala Ser Glu Ala Trp Ala Gly Ser His
Leu Thr 1 5 10 15
Ser Leu Leu Ala Leu Ala Ala Leu Ala Phe Thr Trp Thr Leu 20
25 30 75421PRTArtificial
SequenceSynthetic Polypeptide 754Thr Gln Glu Ser Ala Gly Leu Ala Val Ile
Asp Trp Glu Asp Trp Arg 1 5 10
15 Pro Val Trp Val Arg 20 75528PRTArtificial
SequenceSynthetic Polypeptide 755Val Pro Leu Asp Leu Asn Ala Phe Asp Val
Gln Ala Ser Pro Asn Glu 1 5 10
15 Gly Phe Val Asn Gln Asn Ile Thr Ile Phe Tyr Arg
20 25 75612PRTArtificial SequenceSynthetic
Polypeptide 756Phe Phe Gly Asp Ser Ala Ala Ser Met Ala Ile Lys 1
5 10 75712PRTArtificial SequenceSynthetic
Polypeptide 757Phe Pro Glu His Glu Leu Thr Phe Asp Pro Gln Arg 1
5 10 7589PRTArtificial SequenceSynthetic
Polypeptide 758Leu Ala Gly Leu Phe Asn Glu Gln Arg 1 5
75918PRTArtificial SequenceSynthetic Polypeptide 759Leu Gly
Asn Thr Ile Ser Ser Leu Phe Gly Gly Gly Thr Thr Pro Asp 1 5
10 15 Ala Lys 76012PRTArtificial
SequenceSynthetic Polypeptide 760Leu Pro Ala Thr Glu Lys Pro Val Leu Leu
Ser Lys 1 5 10
76116PRTArtificial SequenceSynthetic Polypeptide 761Val Ala Ile Val Lys
Pro Gly Val Pro Met Glu Ile Val Leu Asn Lys 1 5
10 15 7626PRTArtificial SequenceSynthetic
Polypeptide 762Ala Glu Val Leu Phe Arg 1 5
7636PRTArtificial SequenceSynthetic Polypeptide 763Glu Leu Ala Val Phe
Arg 1 5 7647PRTArtificial SequenceSynthetic
Polypeptide 764His Gly Leu Tyr Asn Leu Lys 1 5
7659PRTArtificial SequenceSynthetic Polypeptide 765Leu Ile Gln Gly Ala
Pro Thr Ile Arg 1 5 7666PRTArtificial
SequenceSynthetic Polypeptide 766Val Thr Glu Gln His Arg 1
5 76720PRTArtificial SequenceSynthetic Polypeptide 767Ala Tyr Leu
Leu Pro Ala Pro Pro Ala Pro Gly Asn Ala Ser Glu Ser 1 5
10 15 Glu Glu Asp Arg 20
7687PRTArtificial SequenceSynthetic Polypeptide 768Phe His Pro Leu His
Ser Lys 1 5 7698PRTArtificial SequenceSynthetic
Polypeptide 769Phe Leu Asn Val Leu Ser Pro Arg 1 5
77015PRTArtificial SequenceSynthetic Polypeptide 770Ser Ala Gly Ser
Val Glu Ser Pro Ser Val Ser Ser Thr His Arg 1 5
10 15 77111PRTArtificial SequenceSynthetic
Polypeptide 771Tyr Gly Gln Pro Leu Pro Gly Tyr Thr Thr Lys 1
5 10 77214PRTArtificial SequenceSynthetic
Polypeptide 772Ala Ser Val Ser Val Thr Ala Glu Asp Glu Gly Thr Gln Arg 1
5 10 77316PRTArtificial
SequenceSynthetic Polypeptide 773Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu
Ser Val Thr Val Thr Arg 1 5 10
15 77415PRTArtificial SequenceSynthetic Polypeptide 774Leu Asn
Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser Ala Lys 1 5
10 15 77511PRTArtificial
SequenceSynthetic Polypeptide 775Thr Phe Leu Thr Val Tyr Trp Thr Pro Glu
Arg 1 5 10 77614PRTArtificial
SequenceSynthetic Polypeptide 776Val Glu Leu Ala Pro Leu Pro Ser Trp Gln
Pro Val Gly Lys 1 5 10
7777PRTArtificial SequenceSynthetic Polypeptide 777Ala Asp Gln Glu Gly
Ala Arg 1 5 77823PRTArtificial SequenceSynthetic
Polypeptide 778Glu Glu Ser Thr Tyr Leu Pro Leu Thr Ser Met Gln Pro Thr
Glu Ala 1 5 10 15
Met Gly Glu Glu Pro Ser Arg 20 7798PRTArtificial
SequenceSynthetic Polypeptide 779Gly Asn Pro Tyr Pro Glu Leu Arg 1
5 7809PRTArtificial SequenceSynthetic Polypeptide
780Ile Ala Leu Glu Thr Ser Leu Ser Lys 1 5
78118PRTArtificial SequenceSynthetic Polypeptide 781Gln Pro Ala Val Glu
Glu Pro Ala Glu Val Thr Ala Thr Val Leu Ala 1 5
10 15 Ser Arg 78220PRTArtificial
SequenceSynthetic Polypeptide 782Thr Glu Leu Asp Met Gln Pro Gln Gly Leu
Gly Leu Phe Val Asn Thr 1 5 10
15 Ser Ala Pro Arg 20 78310PRTArtificial
SequenceSynthetic Polypeptide 783Thr Phe Val Leu Pro Val Thr Pro Pro Arg
1 5 10 78419PRTArtificial
SequenceSynthetic Polypeptide 784Val Glu Leu Ala Pro Leu Pro Pro Trp Gln
Pro Val Gly Gln Asn Phe 1 5 10
15 Thr Leu Arg 78530PRTArtificial SequenceSynthetic
Polypeptide 785Val Gln Val Thr Leu Asp Gly Val Pro Ala Ala Ala Pro Gly
Gln Pro 1 5 10 15
Ala Gln Leu Gln Leu Asn Ala Thr Glu Ser Asp Asp Gly Arg 20
25 30 7868PRTArtificial SequenceSynthetic
Polypeptide 786Ala Thr Asp Phe Val Ala Asp Arg 1 5
7879PRTArtificial SequenceSynthetic Polypeptide 787Asp Ile Phe Gln
Glu Ile Phe Asp Lys 1 5 7887PRTArtificial
SequenceSynthetic Polypeptide 788Ile Ile Trp Gln Phe Ile Lys 1
5 78911PRTArtificial SequenceSynthetic Polypeptide 789Leu
Ile Leu Pro His Val Asp Ile Gln Leu Lys 1 5
10 7909PRTArtificial SequenceSynthetic Polypeptide 790Tyr Phe Asp
Leu Gly Leu Pro Asn Arg 1 5
79116PRTArtificial SequenceSynthetic Polypeptide 791Gly Ile Tyr Ala Tyr
Gly Phe Glu Lys Pro Ser Ala Ile Gln Gln Arg 1 5
10 15 79214PRTArtificial SequenceSynthetic
Polypeptide 792Gly Tyr Asp Val Ile Ala Gln Ala Gln Ser Gly Thr Gly Lys 1
5 10 79315PRTArtificial
SequenceSynthetic Polypeptide 793Leu Gln Met Glu Ala Pro His Ile Ile Val
Gly Thr Pro Gly Arg 1 5 10
15 79413PRTArtificial SequenceSynthetic Polypeptide 794Met Phe Val Leu
Asp Glu Ala Asp Glu Met Leu Ser Arg 1 5
10 7957PRTArtificial SequenceSynthetic Polypeptide 795Val
Phe Asp Met Leu Asn Arg 1 5 79610PRTArtificial
SequenceSynthetic Polypeptide 796Val Leu Ile Thr Thr Asp Leu Leu Ala Arg
1 5 10 79710PRTArtificial
SequenceSynthetic Polypeptide 797Glu Gly Thr Glu Ala Ser Leu Gln Ile Arg
1 5 10 79810PRTArtificial
SequenceSynthetic Polypeptide 798Ile Ser Ser Leu Pro Thr Gln Leu Phe Lys
1 5 10 7998PRTArtificial
SequenceSynthetic Polypeptide 799Thr His Pro Gly Gly Glu Gln Lys 1
5 8008PRTArtificial SequenceSynthetic Polypeptide
800Tyr Gln Pro Pro Ser Thr Asn Lys 1 5
80111PRTArtificial SequenceSynthetic Polypeptide 801Leu Glu Pro Leu Val
Asn Asp Leu Thr Leu Arg 1 5 10
80212PRTArtificial SequenceSynthetic Polypeptide 802Leu Glu Thr Asn Glu
Phe Gln Gln Leu Gln Ser Lys 1 5 10
80312PRTArtificial SequenceSynthetic Polypeptide 803Asn Ile Gly Asp Leu
Leu Ser Ser Ser Ile Asp Arg 1 5 10
80411PRTArtificial SequenceSynthetic Polypeptide 804Ser Ser Gly Gly Gly
Gly Trp Ala Asp Pro Arg 1 5 10
80511PRTArtificial SequenceSynthetic Polypeptide 805Thr Val Thr Phe Ala
Asn Asp Leu Lys Pro Lys 1 5 10
80623PRTArtificial SequenceSynthetic Polypeptide 806Phe Ile Asp Asn Thr
Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn Leu 1 5
10 15 Glu Ser Asp Tyr Phe Gly Lys
20 8078PRTArtificial SequenceSynthetic Polypeptide 807Ser
Asp Ile Ile Phe Phe Gln Arg 1 5
8088PRTArtificial SequenceSynthetic Polypeptide 808Ser Val Pro Gly His
Asp Asn Lys 1 5 8098PRTArtificial
SequenceSynthetic Polypeptide 809Asp His Gln Glu Pro Asn Pro Lys 1
5 8109PRTArtificial SequenceSynthetic Polypeptide
810Asn Leu Leu Ala Phe Tyr Val Asp Arg 1 5
8118PRTArtificial SequenceSynthetic Polypeptide 811Gln Glu Ala Thr Asn
Ala Thr Arg 1 5 81214PRTArtificial
SequenceSynthetic Polypeptide 812Ser Leu Gly Glu Leu Asp Val Phe Leu Ala
Trp Ile Asn Lys 1 5 10
81317PRTArtificial SequenceSynthetic Polypeptide 813Val Ile His Asp Asn
Tyr Asp Gln Leu Glu Val His Ala Ala Ala Ile 1 5
10 15 Lys 81412PRTArtificial
SequenceSynthetic Polypeptide 814Glu Ala Ser Leu Ala Asp Asn Asn Thr Asp
Val Arg 1 5 10
81517PRTArtificial SequenceSynthetic Polypeptide 815Gln Val Leu Asn Phe
Thr Leu Glu Glu Val Leu Phe Pro Gln Ser Asp 1 5
10 15 Arg 81611PRTArtificial
SequenceSynthetic Polypeptide 816Ser Asn Phe Gln Gln Pro Tyr Ile Thr Asn
Arg 1 5 10 8177PRTArtificial
SequenceSynthetic Polypeptide 817Glu Glu Leu Thr Pro Gln Lys 1
5 81824PRTArtificial SequenceSynthetic Polypeptide 818Glu
Gly Tyr Leu Glu Thr Val Ala Ala Tyr Tyr Glu Glu Gln His Pro 1
5 10 15 Glu Leu Thr Pro Leu Leu
Glu Lys 20 81913PRTArtificial
SequenceSynthetic Polypeptide 819Leu Gln Thr Trp Trp His Gly Val Leu Ala
Trp Val Lys 1 5 10
82013PRTArtificial SequenceSynthetic Polypeptide 820Val Val Ala Leu Val
His Ala Val Gln Ala Leu Trp Lys 1 5 10
8216PRTArtificial SequenceSynthetic Polypeptide 821Ser Leu Glu
Glu Asn Lys 1 5 8226PRTArtificial SequenceSynthetic
Polypeptide 822Glu Asn Trp Val Gln Arg 1 5
8239PRTArtificial SequenceSynthetic Polypeptide 823Thr Tyr Ser Lys Pro
Phe His Pro Lys 1 5 8249PRTArtificial
SequenceSynthetic Polypeptide 824Glu Ala Thr Thr Asn Ala Pro Phe Arg 1
5 82513PRTArtificial SequenceSynthetic
Polypeptide 825Leu Glu Glu Ser Tyr Thr Leu Asn Ser Asp Leu Ala Arg 1
5 10 82621PRTArtificial
SequenceSynthetic Polypeptide 826Leu His Glu Trp Thr Lys Pro Glu Asn Leu
Asp Phe Ile Glu Val Asn 1 5 10
15 Val Ser Leu Pro Arg 20 82713PRTArtificial
SequenceSynthetic Polypeptide 827Thr Phe His Phe Asn Thr Val Glu Glu Val
His Ser Arg 1 5 10
82814PRTArtificial SequenceSynthetic Polypeptide 828Thr Tyr Asn Phe Leu
Pro Glu Phe Leu Val Ser Thr Gln Lys 1 5
10 82915PRTArtificial SequenceSynthetic Polypeptide
829Gly Asp Asp Thr Pro Leu His Leu Ala Ala Ser His Gly His Arg 1
5 10 15 8307PRTArtificial
SequenceSynthetic Polypeptide 830His Ser Gly Ile Asp Phe Lys 1
5 83111PRTArtificial SequenceSynthetic Polypeptide 831Leu
Asn Glu Asn His Ser Gly Glu Leu Trp Lys 1 5
10 8327PRTArtificial SequenceSynthetic Polypeptide 832Gln Leu Asn
Phe Leu Thr Lys 1 5 8339PRTArtificial
SequenceSynthetic Polypeptide 833Trp Gln Gly Asn Asp Ile Val Val Lys 1
5 8348PRTArtificial SequenceSynthetic
Polypeptide 834Ala Glu Val Trp Leu Phe Leu Lys 1 5
83510PRTArtificial SequenceSynthetic Polypeptide 835Glu Gly Ser Asp
Leu Ser Val Val Glu Arg 1 5 10
8369PRTArtificial SequenceSynthetic Polypeptide 836Gly His Ser Pro Phe
Ala Asn Leu Lys 1 5 83718PRTArtificial
SequenceSynthetic Polypeptide 837His Pro Gln Gly Ser Leu Asp Thr Gly Glu
Glu Ala Glu Glu Val Gly 1 5 10
15 Leu Lys 8388PRTArtificial SequenceSynthetic Polypeptide
838Ser Glu Leu Leu Leu Ser Glu Lys 1 5
83913PRTArtificial SequenceSynthetic Polypeptide 839Ala Leu Pro Gly Thr
Pro Val Ala Ser Ser Gln Pro Arg 1 5 10
84016PRTArtificial SequenceSynthetic Polypeptide 840Glu Val Pro
Leu Leu Gln Ser Leu Trp Leu Ala His Asn Glu Ile Arg 1 5
10 15 84110PRTArtificial
SequenceSynthetic Polypeptide 841Leu Pro Gly Leu Pro Glu Gly Ala Phe Arg
1 5 10 84227PRTArtificial
SequenceSynthetic Polypeptide 842Ser Leu Asp Leu Ser His Asn Leu Ile Ser
Asp Phe Ala Trp Ser Asp 1 5 10
15 Leu His Asn Leu Ser Ala Leu Gln Leu Leu Lys 20
25 84314PRTArtificial SequenceSynthetic
Polypeptide 843Thr Val Ala Ala Gly Ala Leu Ala Ser Leu Ser His Leu Lys 1
5 10 84419PRTArtificial
SequenceSynthetic Polypeptide 844Asp Leu Asp Gly Asn Gly Tyr Pro Asp Leu
Ile Val Gly Ser Phe Gly 1 5 10
15 Val Asp Lys 84518PRTArtificial SequenceSynthetic
Polypeptide 845Leu Leu Glu Ser Ser Leu Ser Ser Ser Glu Gly Glu Glu Pro
Val Glu 1 5 10 15
Tyr Lys 84610PRTArtificial SequenceSynthetic Polypeptide 846Ser Leu Gln
Trp Phe Gly Ala Thr Val Arg 1 5 10
84711PRTArtificial SequenceSynthetic Polypeptide 847Ser Ser Ala Ser Ser
Gly Pro Gln Ile Leu Lys 1 5 10
84814PRTArtificial SequenceSynthetic Polypeptide 848Val Thr Ala Pro Pro
Glu Ala Glu Tyr Ser Gly Leu Val Arg 1 5
10 84910PRTArtificial SequenceSynthetic Polypeptide
849Leu Phe Thr Ala Leu Phe Pro Phe Glu Lys 1 5
10 85013PRTArtificial SequenceSynthetic Polypeptide 850Ser Leu Pro
Ile Ser Leu Val Phe Leu Val Pro Val Arg 1 5
10 85112PRTArtificial SequenceSynthetic Polypeptide 851Ser
Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg 1 5
10 85210PRTArtificial SequenceSynthetic Polypeptide 852Val
Gln Ser Leu Val Leu Gly Ala Pro Arg 1 5
10 85310PRTArtificial SequenceSynthetic Polypeptide 853Tyr Val Ile Gly
Val Gly Asp Ala Phe Arg 1 5 10
85419PRTArtificial SequenceSynthetic Polypeptide 854Ala Leu Val Gln Thr
Glu Asp His Leu Leu Leu Phe Leu Gln Gln Leu 1 5
10 15 Ala Gly Lys 85513PRTArtificial
SequenceSynthetic Polypeptide 855Phe Asn Val Glu Asp Gly Glu Ile Val Gln
Gln Val Arg 1 5 10
85616PRTArtificial SequenceSynthetic Polypeptide 856His Leu Leu Ile Gly
Leu Pro Ser Gly Ala Ile Leu Ser Leu Pro Lys 1 5
10 15 85714PRTArtificial SequenceSynthetic
Polypeptide 857Leu Phe Gly Ile Glu Ser Ser Ser Gly Thr Ile Leu Trp Lys 1
5 10 85810PRTArtificial
SequenceSynthetic Polypeptide 858Val Leu Leu Leu Ile Asp Asp Glu Tyr Lys
1 5 10 8597PRTArtificial
SequenceSynthetic Polypeptide 859Asp Trp Ser His Tyr Phe Lys 1
5 86019PRTArtificial SequenceSynthetic Polypeptide 860Gly
Leu Gln Ala Gln Ile Ala Ser Ser Gly Leu Thr Val Glu Val Asp 1
5 10 15 Ala Pro Lys
8617PRTArtificial SequenceSynthetic Polypeptide 861Leu Ala Ser Tyr Leu
Asp Arg 1 5 86211PRTArtificial SequenceSynthetic
Polypeptide 862Leu Gln Leu Glu Thr Glu Ile Glu Ala Leu Lys 1
5 10 8639PRTArtificial SequenceSynthetic
Polypeptide 863Val Val Ser Glu Thr Asn Asp Thr Lys 1 5
86411PRTArtificial SequenceSynthetic Polypeptide 864Ala Pro
Ser Ile His Gly Gly Ser Gly Gly Arg 1 5
10 86523PRTArtificial SequenceSynthetic Polypeptide 865Phe Gly Ala
Gln Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile Glu 1 5
10 15 Ala Gln Leu Gly Asp Val Arg
20 8668PRTArtificial SequenceSynthetic Polypeptide
866Phe Gly Pro Gly Val Ala Phe Arg 1 5
86721PRTArtificial SequenceSynthetic Polypeptide 867Gly Gln Val Gly Gly
Gln Val Ser Val Glu Val Asp Ser Ala Pro Gly 1 5
10 15 Thr Asp Leu Ala Lys 20
86817PRTArtificial SequenceSynthetic Polypeptide 868Ser Leu Leu Glu Gly
Gln Glu Asp His Tyr Asn Asn Leu Ser Ala Ser 1 5
10 15 Lys 8698PRTArtificial SequenceSynthetic
Polypeptide 869Ile Ser Ser Ser Ser Phe Ser Arg 1 5
8709PRTArtificial SequenceSynthetic Polypeptide 870Leu Gln Ala Glu
Ile Glu Gly Leu Lys 1 5 8719PRTArtificial
SequenceSynthetic Polypeptide 871Ser Tyr Thr Ser Gly Pro Gly Ser Arg 1
5 8728PRTArtificial SequenceSynthetic
Polypeptide 872Trp Ser Leu Leu Gln Gln Gln Lys 1 5
87310PRTArtificial SequenceSynthetic Polypeptide 873Tyr Glu Glu Leu
Gln Ser Leu Ala Gly Lys 1 5 10
87420PRTArtificial SequenceSynthetic Polypeptide 874Ile Asn Ser Val Gly
Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val 1 5
10 15 His Asp Asp Val 20
87513PRTArtificial SequenceSynthetic Polypeptide 875Leu Val Val Gln Ser
Ser Ile Asp Ser Ser Ala Phe Lys 1 5 10
87610PRTArtificial SequenceSynthetic Polypeptide 876Gln Ala Thr
Leu Thr Ile Ser Ser Ala Arg 1 5 10
87710PRTArtificial SequenceSynthetic Polypeptide 877Thr Ser Ala Tyr Phe
Asn Phe Ala Phe Lys 1 5 10
8789PRTArtificial SequenceSynthetic Polypeptide 878Tyr Val Ser Glu Leu
His Leu Thr Arg 1 5 87910PRTArtificial
SequenceSynthetic Polypeptide 879Glu Val Glu Val Ile Gly Gly Ala Asp Lys
1 5 10 88018PRTArtificial
SequenceSynthetic Polypeptide 880Lys Pro Phe Gly Ala Ile Leu Asn Leu Val
Pro Leu Ala Glu Ser Val 1 5 10
15 Val Lys 88119PRTArtificial SequenceSynthetic Polypeptide
881Ile Leu Gln Leu Ile Leu Leu Ala Leu Ala Thr Gly Leu Val Gly Gly 1
5 10 15 Glu Thr Arg
8826PRTArtificial SequenceSynthetic Polypeptide 882Leu Pro His Thr Leu
Arg 1 5 88318PRTArtificial SequenceSynthetic
Polypeptide 883Thr Ala Thr Glu Ser Phe Pro His Pro Gly Phe Asn Asn Ser
Leu Pro 1 5 10 15
Asn Lys 88412PRTArtificial SequenceSynthetic Polypeptide 884Tyr Ile Val
His Leu Gly Gln His Asn Leu Gln Lys 1 5
10 8858PRTArtificial SequenceSynthetic Polypeptide 885Val Glu
Ala Gly Glu Gln Val Arg 1 5
88616PRTArtificial SequenceSynthetic Polypeptide 886Val Ser Gly Trp Gly
Thr Thr Thr Ser Pro Gln Val Asn Tyr Pro Lys 1 5
10 15 8876PRTArtificial SequenceSynthetic
Polypeptide 887Tyr Val Leu Trp Ile Arg 1 5
88810PRTArtificial SequenceSynthetic Polypeptide 888Gln Val Thr His Pro
Asn Tyr Asn Ser Arg 1 5 10
88912PRTArtificial SequenceSynthetic Polypeptide 889Val Leu Gly Ser Gly
Thr Trp Pro Ser Ala Pro Lys 1 5 10
89013PRTArtificial SequenceSynthetic Polypeptide 890Val Ser Gly Trp Gly
Thr Ile Ser Ser Pro Ile Ala Arg 1 5 10
89111PRTArtificial SequenceSynthetic Polypeptide 891Glu Ser Ser
Gln Glu Gln Ser Ser Val Val Arg 1 5 10
89212PRTArtificial SequenceSynthetic Polypeptide 892Leu Ser Glu Leu Ile
Gln Pro Leu Pro Leu Glu Arg 1 5 10
8937PRTArtificial SequenceSynthetic Polypeptide 893Tyr Thr Asn Trp Ile
Gln Lys 1 5 8948PRTArtificial SequenceSynthetic
Polypeptide 894Asp Phe Val Gln Pro Pro Thr Lys 1 5
89519PRTArtificial SequenceSynthetic Polypeptide 895Asp Ile Pro Thr
Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 1 5
10 15 Ile Thr Lys 89619PRTArtificial
SequenceSynthetic Polypeptide 896Gly His Gly Leu Gly His Gly His Glu Gln
Gln His Gly Leu Gly His 1 5 10
15 Gly His Lys 89718PRTArtificial SequenceSynthetic
Polypeptide 897Leu Asp Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp
His Gly 1 5 10 15
His Lys 89811PRTArtificial SequenceSynthetic Polypeptide 898Thr Val Gly
Ser Asp Thr Phe Tyr Ser Phe Lys 1 5 10
8998PRTArtificial SequenceSynthetic Polypeptide 899Ala Pro Ile Ile Ala
Val Thr Arg 1 5 90014PRTArtificial
SequenceSynthetic Polypeptide 900Asp Pro Val Gln Glu Ala Trp Ala Glu Asp
Val Asp Leu Arg 1 5 10
9019PRTArtificial SequenceSynthetic Polypeptide 901Gly Asp Tyr Pro Leu
Glu Ala Val Arg 1 5 90213PRTArtificial
SequenceSynthetic Polypeptide 902Ile Tyr Val Asp Asp Gly Leu Ile Ser Leu
Gln Val Lys 1 5 10
90311PRTArtificial SequenceSynthetic Polypeptide 903Leu Asp Ile Asp Ser
Pro Pro Ile Thr Ala Arg 1 5 10
90413PRTArtificial SequenceSynthetic Polypeptide 904Asp Ala Leu Glu Ser
Thr Leu Ala Glu Thr Glu Ala Arg 1 5 10
90515PRTArtificial SequenceSynthetic Polypeptide 905Leu Asn Val
Glu Val Asp Ala Ala Pro Pro Val Asp Leu Asn Arg 1 5
10 15 9069PRTArtificial SequenceSynthetic
Polypeptide 906Leu Pro Ser Leu Ser Pro Val Ala Arg 1 5
9079PRTArtificial SequenceSynthetic Polypeptide 907Leu Val
Val Glu Ile Asp Asn Ala Lys 1 5
9088PRTArtificial SequenceSynthetic Polypeptide 908Tyr Glu Thr Glu Val
Ser Leu Arg 1 5 90912PRTArtificial
SequenceSynthetic Polypeptide 909Asp Thr Glu Gln Thr Leu Tyr Gln Val Gln
Glu Arg 1 5 10
91010PRTArtificial SequenceSynthetic Polypeptide 910Ile Gln Gly Thr Leu
Gln Pro His Ala Arg 1 5 10
91111PRTArtificial SequenceSynthetic Polypeptide 911Ser Leu Ala Asp Val
Asp Ala Ile Leu Ala Arg 1 5 10
91226PRTArtificial SequenceSynthetic Polypeptide 912Thr Gly Gly Ser Ala
Gln Pro Glu Thr Pro Tyr Ser Gly Pro Gly Leu 1 5
10 15 Leu Ile Asp Ser Leu Val Leu Leu Pro Arg
20 25 91323PRTArtificial
SequenceSynthetic Polypeptide 913Val Leu Glu Leu Ser Ile Pro Ala Ser Ala
Glu Gln Ile Gln His Leu 1 5 10
15 Ala Gly Ala Ile Ala Glu Arg 20
9149PRTArtificial SequenceSynthetic Polypeptide 914Asp Gln Leu Ile Tyr
Asn Leu Leu Lys 1 5 9158PRTArtificial
SequenceSynthetic Polypeptide 915Phe Ile Ile Pro Asn Val Val Lys 1
5 91617PRTArtificial SequenceSynthetic Polypeptide
916Leu Leu Ile Val Ser Asn Pro Val Asp Ile Leu Thr Tyr Val Ala Trp 1
5 10 15 Lys
9179PRTArtificial SequenceSynthetic Polypeptide 917Leu Val Ile Ile Thr
Ala Gly Ala Arg 1 5 91810PRTArtificial
SequenceSynthetic Polypeptide 918Thr Leu His Pro Asp Leu Gly Thr Asp Lys
1 5 10 9199PRTArtificial
SequenceSynthetic Polypeptide 919Asp Tyr Ser Val Thr Ala Asn Ser Lys 1
5 9208PRTArtificial SequenceSynthetic
Polypeptide 920Phe Ile Ile Pro Gln Ile Val Lys 1 5
9219PRTArtificial SequenceSynthetic Polypeptide 921Gly Leu Thr Ser
Val Ile Asn Gln Lys 1 5
92216PRTArtificial SequenceSynthetic Polypeptide 922Leu Ile Ala Pro Val
Ala Glu Glu Glu Ala Thr Val Pro Asn Asn Lys 1 5
10 15 9236PRTArtificial SequenceSynthetic
Polypeptide 923Asn Val Asn Val Phe Lys 1 5
92410PRTArtificial SequenceSynthetic Polypeptide 924Asp Gly Gly Ala Trp
Gly Thr Glu Gln Arg 1 5 10
9258PRTArtificial SequenceSynthetic Polypeptide 925Gly Glu Val Ala Pro
Asp Ala Lys 1 5 9268PRTArtificial
SequenceSynthetic Polypeptide 926Leu Pro Asp Gly Tyr Glu Phe Lys 1
5 9278PRTArtificial SequenceSynthetic Polypeptide
927Ser Phe Val Leu Asn Leu Gly Lys 1 5
92811PRTArtificial SequenceSynthetic Polypeptide 928Gly Asn Asp Val Ala
Phe His Phe Asn Pro Arg 1 5 10
9297PRTArtificial SequenceSynthetic Polypeptide 929Ile Ala Leu Asp Phe
Gln Arg 1 5 93011PRTArtificial SequenceSynthetic
Polypeptide 930Ile Gln Val Leu Val Glu Pro Asp His Phe Lys 1
5 10 9317PRTArtificial SequenceSynthetic
Polypeptide 931Leu Asp Asn Asn Trp Gly Arg 1 5
93214PRTArtificial SequenceSynthetic Polypeptide 932Val Ala Val Asn Asp
Ala His Leu Leu Gln Tyr Asn His Arg 1 5
10 93321PRTArtificial SequenceSynthetic Polypeptide
933Phe Ala Val Asn Phe Gln Thr Gly Phe Ser Gly Asn Asp Ile Ala Phe 1
5 10 15 His Phe Asn Pro
Arg 20 9348PRTArtificial SequenceSynthetic Polypeptide
934Phe Asp Glu Asn Ala Val Val Arg 1 5
93513PRTArtificial SequenceSynthetic Polypeptide 935Asn Thr Gln Ile Asp
Asn Ser Trp Gly Ser Glu Glu Arg 1 5 10
93614PRTArtificial SequenceSynthetic Polypeptide 936Ser Ile Leu
Leu Ser Gly Thr Val Leu Pro Ser Ala Gln Arg 1 5
10 93714PRTArtificial SequenceSynthetic
Polypeptide 937Val Ala Val Asp Gly Gln His Leu Phe Glu Tyr Tyr His Arg 1
5 10 93812PRTArtificial
SequenceSynthetic Polypeptide 938Ala Ser His Glu Glu Val Glu Gly Leu Val
Glu Lys 1 5 10
93910PRTArtificial SequenceSynthetic Polypeptide 939Ala Val Asp Thr Trp
Ser Trp Gly Glu Arg 1 5 10
9409PRTArtificial SequenceSynthetic Polypeptide 940Ser Thr His Thr Leu
Asp Leu Ser Arg 1 5 9416PRTArtificial
SequenceSynthetic Polypeptide 941Val Glu Ile Phe Tyr Arg 1
5 94213PRTArtificial SequenceSynthetic Polypeptide 942Tyr Ser Ser
Asp Tyr Phe Gln Ala Pro Ser Asp Tyr Arg 1 5
10 9439PRTArtificial SequenceSynthetic Polypeptide 943Ala
Gln Leu Ala Pro Ser Ala Thr Lys 1 5
94416PRTArtificial SequenceSynthetic Polypeptide 944Leu Glu Glu Trp Leu
Ser His Val Val Gly Ala Val Tyr Ala Pro Lys 1 5
10 15 94513PRTArtificial SequenceSynthetic
Polypeptide 945Leu Asn Val Ala Leu Asp Val Gly Ile Pro Leu Pro Lys 1
5 10 94611PRTArtificial
SequenceSynthetic Polypeptide 946Ser Val Ala Gly Asp Ile Ile Asp Phe Pro
Lys 1 5 10 94724PRTArtificial
SequenceSynthetic Polypeptide 947Val Leu Asn Ile Asn Phe Ser Asn Ser Val
Leu Glu Ile Val Glu Asn 1 5 10
15 Ala Val Val Leu Thr Val Ala Ser 20
94813PRTArtificial SequenceSynthetic Polypeptide 948Gly Leu Leu Pro
Asn Leu Val Asp Asn Leu Val Asn Arg 1 5
10 94922PRTArtificial SequenceSynthetic Polypeptide 949Ile
Leu Asn Ile Asp Phe Ser Asn Ala Asp Ile Asp Val Leu Glu Asp 1
5 10 15 Leu Leu Val Leu Ser Ala
20 9508PRTArtificial SequenceSynthetic Polypeptide
950Ile Val Glu Leu Thr Leu Pro Arg 1 5
95114PRTArtificial SequenceSynthetic Polypeptide 951Leu Leu Pro Gly Val
Gly Val Tyr Leu Ser Leu Tyr Thr Arg 1 5
10 95212PRTArtificial SequenceSynthetic Polypeptide
952Tyr Gly Glu Ile Leu Glu Ser Glu Gly Ser Ile Arg 1 5
10 95321PRTArtificial SequenceSynthetic Polypeptide
953Asp Ala Gly Ile Glu Pro Gly Pro Asp Thr Tyr Leu Ala Leu Leu Asn 1
5 10 15 Ala Tyr Ala Glu
Lys 20 95410PRTArtificial SequenceSynthetic Polypeptide
954Asn Val Gln Gly Ile Ile Glu Ile Leu Lys 1 5
10 95514PRTArtificial SequenceSynthetic Polypeptide 955Ser Gly Gly
Leu Gly Gly Ser His Ala Leu Leu Leu Leu Arg 1 5
10 95611PRTArtificial SequenceSynthetic
Polypeptide 956Thr Val Leu Asp Gln Gln Gln Thr Pro Ser Arg 1
5 10 95717PRTArtificial SequenceSynthetic
Polypeptide 957Thr Val Gln Leu Thr Ser Ser Glu Leu Glu Ser Thr Leu Glu
Thr Leu 1 5 10 15
Lys 95814PRTArtificial SequenceSynthetic Polypeptide 958Ala Ala Leu Ser
Gly Ala Asn Val Leu Thr Leu Ile Glu Lys 1 5
10 95916PRTArtificial SequenceSynthetic Polypeptide
959Thr Val Leu Trp Pro Asn Gly Leu Ser Leu Asp Ile Pro Ala Gly Arg 1
5 10 15
96011PRTArtificial SequenceSynthetic Polypeptide 960Val Phe Phe Thr Asp
Tyr Gly Gln Ile Pro Lys 1 5 10
96118PRTArtificial SequenceSynthetic Polypeptide 961Leu Pro Ser Gly Leu
Pro Val Ser Leu Leu Thr Leu Tyr Leu Asp Asn 1 5
10 15 Asn Lys 96221PRTArtificial
SequenceSynthetic Polypeptide 962Asn Ile Pro Thr Val Asn Glu Asn Leu Glu
Asn Tyr Tyr Leu Glu Val 1 5 10
15 Asn Gln Leu Glu Lys 20 96310PRTArtificial
SequenceSynthetic Polypeptide 963Asn Asn Gln Ile Asp His Ile Asp Glu Lys
1 5 10 96411PRTArtificial
SequenceSynthetic Polypeptide 964Ser Leu Glu Asp Leu Gln Leu Thr His Asn
Lys 1 5 10 96514PRTArtificial
SequenceSynthetic Polypeptide 965Ser Leu Glu Tyr Leu Asp Leu Ser Phe Asn
Gln Ile Ala Arg 1 5 10
9667PRTArtificial SequenceSynthetic Polypeptide 966Asp Pro Glu Asp Ser
Gln Arg 1 5 9677PRTArtificial SequenceSynthetic
Polypeptide 967Thr Asp Glu Gly Asp Asn Arg 1 5
96810PRTArtificial SequenceSynthetic Polypeptide 968Val Trp Thr Asp Ala
Asn Leu Thr Ala Arg 1 5 10
96910PRTArtificial SequenceSynthetic Polypeptide 969Asn Trp Ala Pro Gly
Glu Pro Asn Asn Arg 1 5 10
9708PRTArtificial SequenceSynthetic Polypeptide 970Gln Pro Gln Asn Gly
Ser Val Arg 1 5 97110PRTArtificial
SequenceSynthetic Polypeptide 971Tyr Thr His Leu Val Ala Ile Gln Asn Lys
1 5 10 97212PRTArtificial
SequenceSynthetic Polypeptide 972Glu Val Ala Ala Trp Thr Tyr His Tyr Ser
Thr Lys 1 5 10 9738PRTArtificial
SequenceSynthetic Polypeptide 973Asn Glu Ile Asp Tyr Leu Asn Lys 1
5 97410PRTArtificial SequenceSynthetic Polypeptide
974Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys 1 5
10 97511PRTArtificial SequenceSynthetic Polypeptide 975His Trp Phe
Gln Ala Gly Tyr Ser Thr Ser Arg 1 5 10
97613PRTArtificial SequenceSynthetic Polypeptide 976Asn Gln Gly Thr Ser
Asp Phe Leu Pro Ser Arg Pro Arg 1 5 10
9777PRTArtificial SequenceSynthetic Polypeptide 977Thr Pro Ile
Leu Leu Ile Arg 1 5 97820PRTArtificial
SequenceSynthetic Polypeptide 978Val Ser Val Asn Pro Ser Tyr Leu Val Pro
Glu Ser Asp Tyr Thr Asn 1 5 10
15 Asn Val Val Arg 20 97932PRTArtificial
SequenceSynthetic Polypeptide 979Tyr Arg Pro Gly Tyr Gly Thr Gly Tyr Phe
Gln Tyr Gly Leu Pro Asp 1 5 10
15 Leu Val Ala Asp Pro Tyr Tyr Ile Gln Ala Ser Thr Tyr Val Gln
Lys 20 25 30
9809PRTArtificial SequenceSynthetic Polypeptide 980Gly Gly Pro Gln Gln
Pro His Asn Lys 1 5 9816PRTArtificial
SequenceSynthetic Polypeptide 981Leu Asn Leu Thr Ser Arg 1
5 98211PRTArtificial SequenceSynthetic Polypeptide 982Leu Thr Gly
Gly Ala Ala Gly His Gln Asp Arg 1 5 10
9839PRTArtificial SequenceSynthetic Polypeptide 983Ser Asn Ser Gly Gln
Tyr Pro Ala Lys 1 5 9846PRTArtificial
SequenceSynthetic Polypeptide 984Thr Tyr Phe Ser Pro Arg 1
5 98511PRTArtificial SequenceSynthetic Polypeptide 985Glu Ala Ala
Leu Leu Glu Glu Glu Glu Gly Val 1 5 10
9867PRTArtificial SequenceSynthetic Polypeptide 986Ile Ala Tyr Pro Ser
Leu Arg 1 5 98725PRTArtificial SequenceSynthetic
Polypeptide 987Gln Pro Asn Glu Gly Ser Ser Ser Gln Glu Glu Glu Gly Pro
Ser Thr 1 5 10 15
Ser Pro Asp Ala Glu Ser Leu Phe Arg 20 25
9887PRTArtificial SequenceSynthetic Polypeptide 988Val Leu Glu His Val
Val Arg 1 5 9898PRTArtificial SequenceSynthetic
Polypeptide 989Tyr Glu Phe Leu Trp Gly Pro Arg 1 5
99025PRTArtificial SequenceSynthetic Polypeptide 990Ala Pro Glu Pro
Ile Ser Thr Gln Ser His Ser Val Leu Ile Leu Phe 1 5
10 15 His Ser Asp Asn Ser Gly Glu Asn Arg
20 25 99115PRTArtificial SequenceSynthetic
Polypeptide 991Ala Pro Gly Glu Leu Glu His Gly Leu Ile Thr Phe Ser Thr
Arg 1 5 10 15
99211PRTArtificial SequenceSynthetic Polypeptide 992Asp Ser Asp Leu Leu
Ser Pro Ser Asp Phe Lys 1 5 10
99311PRTArtificial SequenceSynthetic Polypeptide 993Ser Asp Glu Asn Glu
Gln His Leu Gly Val Lys 1 5 10
99415PRTArtificial SequenceSynthetic Polypeptide 994Thr Gly Val Ile Thr
Ser Pro Asp Phe Pro Asn Pro Tyr Pro Lys 1 5
10 15 99510PRTArtificial SequenceSynthetic
Polypeptide 995Glu Ser Ala Phe Glu Phe Leu Ser Ser Ala 1 5
10 99610PRTArtificial SequenceSynthetic Polypeptide
996Gly Glu Phe Val Thr Thr Val Gln Gln Arg 1 5
10 9979PRTArtificial SequenceSynthetic Polypeptide 997Leu Gly Val
Thr Ala Asn Asp Val Lys 1 5
99820PRTArtificial SequenceSynthetic Polypeptide 998Asn Val Ile Ile Trp
Gly Asn His Ser Ser Thr Gln Tyr Pro Asp Val 1 5
10 15 Asn His Ala Lys 20
99926PRTArtificial SequenceSynthetic Polypeptide 999Val Leu Val Thr Gly
Ala Ala Gly Gln Ile Ala Tyr Ser Leu Leu Tyr 1 5
10 15 Ser Ile Gly Asn Gly Ser Val Phe Gly Lys
20 25 100022PRTArtificial
SequenceSynthetic Polypeptide 1000Leu Thr Leu Tyr Asp Ile Ala His Thr Pro
Gly Val Ala Ala Asp Leu 1 5 10
15 Ser His Ile Glu Thr Lys 20
100119PRTArtificial SequenceSynthetic Polypeptide 1001Val Ala Val Leu Gly
Ala Ser Gly Gly Ile Gly Gln Pro Leu Ser Leu 1 5
10 15 Leu Leu Lys 100214PRTArtificial
SequenceSynthetic Polypeptide 1002Val Asp Phe Pro Gln Asp Gln Leu Thr Ala
Leu Thr Gly Arg 1 5 10
100312PRTArtificial SequenceSynthetic Polypeptide 1003Val Asn Val Pro Val
Ile Gly Gly His Ala Gly Lys 1 5 10
10047PRTArtificial SequenceSynthetic Polypeptide 1004Val Ser Ser Phe
Glu Glu Lys 1 5 10057PRTArtificial
SequenceSynthetic Polypeptide 1005Ile Gly Gly Ala Gln Asn Arg 1
5 100614PRTArtificial SequenceSynthetic Polypeptide 1006His
Glu Val His Phe Leu His Glu Glu Ser Ile Leu Glu Arg 1 5
10 100719PRTArtificial SequenceSynthetic
Polypeptide 1007His Phe Thr Glu Asp Gly Asn Ile Leu Gln Leu Ala Asn Leu
Pro Asp 1 5 10 15
Leu Tyr Lys 100816PRTArtificial SequenceSynthetic Polypeptide 1008Leu Gln
Ser Phe Glu Asp Leu Ala Ser Ile Ser Thr Tyr Gly Phe Arg 1 5
10 15 100912PRTArtificial
SequenceSynthetic Polypeptide 1009Thr Leu Pro Asn Ala Ser Thr Val Asp Asn
Ile Arg 1 5 10
10109PRTArtificial SequenceSynthetic Polypeptide 1010Trp Thr Val Glu His
Ile Val Tyr Lys 1 5 101111PRTArtificial
SequenceSynthetic Polypeptide 1011Asp Gly Phe Phe Tyr Phe Phe His Gly Thr
Arg 1 5 10 101210PRTArtificial
SequenceSynthetic Polypeptide 1012Asp Ile Tyr Ser Ser Phe Gly Phe Pro Arg
1 5 10 101310PRTArtificial
SequenceSynthetic Polypeptide 1013Ile Glu Asn Tyr Thr Pro Asp Leu Pro Arg
1 5 10 101410PRTArtificial
SequenceSynthetic Polypeptide 1014Leu Thr Phe Asp Ala Ile Thr Thr Ile Arg
1 5 10 101514PRTArtificial
SequenceSynthetic Polypeptide 1015Ser Gln Asn Pro Val Gln Pro Ile Gly Pro
Gln Thr Pro Lys 1 5 10
101613PRTArtificial SequenceSynthetic Polypeptide 1016Phe Pro Val His Ala
Ala Leu Val Trp Gly Pro Glu Lys 1 5 10
101711PRTArtificial SequenceSynthetic Polypeptide 1017Phe Pro
Trp Gln Leu Val Gln Glu Gln Val Arg 1 5
10 101814PRTArtificial SequenceSynthetic Polypeptide 1018Gly Gly Gln
Leu Gln Pro Gly Tyr Pro Ala Leu Ala Ser Arg 1 5
10 101921PRTArtificial SequenceSynthetic
Polypeptide 1019Gly Val Pro Ser Glu Ile Asp Ala Ala Phe Gln Asp Ala Asp
Gly Tyr 1 5 10 15
Ala Tyr Phe Leu Arg 20 102017PRTArtificial
SequenceSynthetic Polypeptide 1020Val Trp Ser Asp Val Thr Pro Leu Thr Phe
Thr Glu Val His Glu Gly 1 5 10
15 Arg 102125PRTArtificial SequenceSynthetic Polypeptide
1021Phe Leu Leu Ile Leu Leu Leu Gln Ala Thr Ala Ser Gly Ala Leu Pro 1
5 10 15 Leu Asn Ser Ser
Thr Ser Leu Glu Lys 20 25
102210PRTArtificial SequenceSynthetic Polypeptide 1022Gly Ile Gln Ser Leu
Tyr Gly Asp Pro Lys 1 5 10
10238PRTArtificial SequenceSynthetic Polypeptide 1023Ile Asp Ala Val Phe
Tyr Ser Lys 1 5 102426PRTArtificial
SequenceSynthetic Polypeptide 1024Thr Ser Val Asn Leu Ile Ser Ser Leu Trp
Pro Thr Leu Pro Ser Gly 1 5 10
15 Ile Glu Ala Ala Tyr Glu Ile Glu Ala Arg 20
25 102519PRTArtificial SequenceSynthetic Polypeptide
1025Tyr Tyr Tyr Phe Phe Gln Gly Ser Asn Gln Phe Glu Tyr Asp Phe Leu 1
5 10 15 Leu Gln Arg
10268PRTArtificial SequenceSynthetic Polypeptide 1026Ala Val Asp Ser Glu
Tyr Pro Lys 1 5 10276PRTArtificial
SequenceSynthetic Polypeptide 1027Phe Asn Glu Glu Leu Arg 1
5 10289PRTArtificial SequenceSynthetic Polypeptide 1028Phe Tyr Gly
Leu Gln Val Thr Gly Lys 1 5
102915PRTArtificial SequenceSynthetic Polypeptide 1029His Trp Val Phe Asp
Glu Ala Ser Leu Glu Pro Gly Tyr Pro Lys 1 5
10 15 10309PRTArtificial SequenceSynthetic
Polypeptide 1030Val Trp Glu Ser Ala Thr Pro Leu Arg 1 5
103112PRTArtificial SequenceSynthetic Polypeptide 1031Ala
Phe Gln Val Trp Ser Asp Val Thr Pro Leu Arg 1 5
10 103212PRTArtificial SequenceSynthetic Polypeptide
1032Ile Asp Ala Val Tyr Glu Ala Pro Gln Glu Glu Lys 1 5
10 103319PRTArtificial SequenceSynthetic
Polypeptide 1033Ile Ile Gly Tyr Thr Pro Asp Leu Asp Pro Glu Thr Val Asp
Asp Ala 1 5 10 15
Phe Ala Arg 103429PRTArtificial SequenceSynthetic Polypeptide 1034Leu Ile
Ala Asp Ala Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val 1 5
10 15 Val Asp Leu Gln Gly Gly Gly
His Ser Tyr Phe Phe Lys 20 25
103512PRTArtificial SequenceSynthetic Polypeptide 1035Gln Asp Ile Val
Phe Asp Gly Ile Ala Gln Ile Arg 1 5 10
103629PRTArtificial SequenceSynthetic Polypeptide 1036Asp Ser Ile
Tyr Asn Ala Val Ser Ile Trp Ser Asn Val Thr Pro Leu 1 5
10 15 Ile Phe Gln Gln Val Gln Asn Gly
Asp Ala Asp Ile Lys 20 25
10376PRTArtificial SequenceSynthetic Polypeptide 1037His Thr Leu Thr Tyr
Arg 1 5 10388PRTArtificial SequenceSynthetic
Polypeptide 1038Ile Gln His Leu Tyr Gly Glu Lys 1 5
103911PRTArtificial SequenceSynthetic Polypeptide 1039Thr Phe Gln
Leu Ser Ala Asp Asp Ile Gln Arg 1 5 10
10409PRTArtificial SequenceSynthetic Polypeptide 1040Asp Leu Pro His
Ile Thr Val Asp Arg 1 5
10416PRTArtificial SequenceSynthetic Polypeptide 1041Ile Val Ser Tyr Thr
Arg 1 5 10427PRTArtificial SequenceSynthetic
Polypeptide 1042Leu Ser Gln Asp Asp Ile Lys 1 5
10438PRTArtificial SequenceSynthetic Polypeptide 1043Asn Ala Asn Ser Leu
Glu Ala Lys 1 5 104415PRTArtificial
SequenceSynthetic Polypeptide 1044Ala Phe Ala Leu Trp Ser Ala Val Thr Pro
Leu Thr Phe Thr Arg 1 5 10
15 10459PRTArtificial SequenceSynthetic Polypeptide 1045Ala Val Ile
Asp Asp Ala Phe Ala Arg 1 5
10469PRTArtificial SequenceSynthetic Polypeptide 1046Phe Gln Thr Phe Glu
Gly Asp Leu Lys 1 5 104715PRTArtificial
SequenceSynthetic Polypeptide 1047Leu Gly Leu Gly Ala Asp Val Ala Gln Val
Thr Gly Ala Leu Arg 1 5 10
15 104811PRTArtificial SequenceSynthetic Polypeptide 1048Ser Leu Gly
Pro Ala Leu Leu Leu Leu Gln Lys 1 5 10
10499PRTArtificial SequenceSynthetic Polypeptide 1049Glu Gln Ile Leu
Gly Asp Glu Ala Arg 1 5
105012PRTArtificial SequenceSynthetic Polypeptide 1050Ser Leu Ala Ala Ser
Ser Ser Phe Tyr Gly Gln Arg 1 5 10
105111PRTArtificial SequenceSynthetic Polypeptide 1051Thr Leu Pro Ser
Gly Leu Asp Asp Tyr Pro Arg 1 5 10
105218PRTArtificial SequenceSynthetic Polypeptide 1052Val Asp Pro Ala Leu
Phe Pro Pro Val Pro Leu Phe Thr Ala Val Pro 1 5
10 15 Ser Arg 10539PRTArtificial
SequenceSynthetic Polypeptide 1053Val Pro Pro Glu Phe Leu Val Gln Arg 1
5 105413PRTArtificial SequenceSynthetic
Polypeptide 1054Phe Leu His Gln Asp Ile Asp Ser Gly Gln Gly Ile Arg 1
5 10 105511PRTArtificial
SequenceSynthetic Polypeptide 1055Gly His Gln Ala Phe Asp Val Gly Gln Pro
Arg 1 5 10 105611PRTArtificial
SequenceSynthetic Polypeptide 1056Thr Tyr His Ser Val Gly Asp Ser Val Leu
Arg 1 5 10 105712PRTArtificial
SequenceSynthetic Polypeptide 1057Val Pro Ile Asp Gly Pro Pro Ile Asp Ile
Gly Arg 1 5 10
105811PRTArtificial SequenceSynthetic Polypeptide 1058Tyr Val Asp Gln Val
Leu Gln Leu Val Tyr Lys 1 5 10
105910PRTArtificial SequenceSynthetic Polypeptide 1059Ala Asp Gly Ala Leu
Thr Gln Glu Glu Lys 1 5 10
10609PRTArtificial SequenceSynthetic Polypeptide 1060Asp Phe Glu Ile Ile
Ser Asp Thr Lys 1 5 106116PRTArtificial
SequenceSynthetic Polypeptide 1061Gly Val Val Ala Glu Phe Asp Ser Pro Ala
Asn Leu Ile Ala Ala Arg 1 5 10
15 106215PRTArtificial SequenceSynthetic Polypeptide 1062Ile
Asp Gly Leu Asn Val Ala Asp Ile Gly Leu His Asp Leu Arg 1 5
10 15 106317PRTArtificial
SequenceSynthetic Polypeptide 1063Asn Val Asp Pro Asn Pro Tyr Pro Glu Thr
Ser Ala Gly Phe Leu Ser 1 5 10
15 Arg 106417PRTArtificial SequenceSynthetic Polypeptide
1064Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr 1
5 10 15 Lys
106511PRTArtificial SequenceSynthetic Polypeptide 1065Gln Gly Gly Phe Leu
Gly Leu Ser Asn Ile Lys 1 5 10
10669PRTArtificial SequenceSynthetic Polypeptide 1066Ser Ser Val Pro Ser
Ser Thr Glu Lys 1 5 106724PRTArtificial
SequenceSynthetic Polypeptide 1067Val Ser Ala Gly Asn Gly Gly Ser Ser Leu
Ser Tyr Thr Asn Pro Ala 1 5 10
15 Val Ala Ala Thr Ser Ala Asn Leu 20
10689PRTArtificial SequenceSynthetic Polypeptide 1068Tyr Val Pro Pro
Ser Ser Thr Asp Arg 1 5
106919PRTArtificial SequenceSynthetic Polypeptide 1069Ala Leu Phe Ser Ser
Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe 1 5
10 15 Leu Asp Lys 107011PRTArtificial
SequenceSynthetic Polypeptide 1070Asp Ser Leu Tyr Val Asn Gly Phe Asn Pro
Arg 1 5 10 10718PRTArtificial
SequenceSynthetic Polypeptide 1071Leu Thr Leu Leu Arg Pro Glu Lys 1
5 107211PRTArtificial SequenceSynthetic Polypeptide
1072Val Leu Gln Gly Leu Leu Thr Pro Leu Phe Arg 1 5
10 107319PRTArtificial SequenceSynthetic Polypeptide
1073Val Pro Thr Gly Thr Ile Thr Glu Val Ser Ser Thr Gly Val Asn Ser 1
5 10 15 Ser Ser Lys
107415PRTArtificial SequenceSynthetic Polypeptide 1074Phe Leu Asn Ser Asn
Ser Gly Leu Gln Gly Leu Gln Phe Tyr Arg 1 5
10 15 107510PRTArtificial SequenceSynthetic
Polypeptide 1075Ile Gly Leu Ala Ser Ala Leu Gln Pro Arg 1 5
10 107614PRTArtificial SequenceSynthetic Polypeptide
1076Asn Asp Val Val Phe Gln Pro Ile Ser Gly Glu Asp Val Arg 1
5 10 107712PRTArtificial
SequenceSynthetic Polypeptide 1077Ser Leu Glu Pro Phe Thr Leu Glu Ile Leu
Ala Arg 1 5 10
107812PRTArtificial SequenceSynthetic Polypeptide 1078Ser Thr Ala Ala Pro
Ile Pro Ile Leu Pro Glu Arg 1 5 10
107914PRTArtificial SequenceSynthetic Polypeptide 1079Ala Val Thr Leu
Ser Leu Asp Gly Gly Asp Thr Ala Ile Arg 1 5
10 108010PRTArtificial SequenceSynthetic Polypeptide
1080Leu Thr Asp Pro Asn Ser Ala Phe Ser Arg 1 5
10 108111PRTArtificial SequenceSynthetic Polypeptide 1081Leu Thr
Pro Leu Gln Phe Gly Asn Leu Gln Lys 1 5
10 108214PRTArtificial SequenceSynthetic Polypeptide 1082Ser Val Val
Gly Asp Ala Leu Glu Phe Gly Asn Ser Trp Lys 1 5
10 108313PRTArtificial SequenceSynthetic
Polypeptide 1083Thr Gly Leu Leu Val Glu Gln Ser Gly Asp Tyr Ile Lys 1
5 10 10849PRTArtificial
SequenceSynthetic Polypeptide 1084Trp Val Gly Asp Leu Pro Asn Gly Arg 1
5 108511PRTArtificial SequenceSynthetic
Polypeptide 1085Glu His Phe Gln Asp Asp Val Phe Asn Glu Lys 1
5 10 108616PRTArtificial SequenceSynthetic
Polypeptide 1086Gly Asp Leu Glu Glu Tyr Gly Gln Asp Leu Leu His Thr Val
Phe Lys 1 5 10 15
108721PRTArtificial SequenceSynthetic Polypeptide 1087Ser Thr Gln Ala Pro
Leu Ile Ile Arg Pro Asp Ser Gly Asn Pro Leu 1 5
10 15 Asp Thr Val Leu Lys 20
108810PRTArtificial SequenceSynthetic Polypeptide 1088Tyr Asp Gly His Leu
Pro Ile Glu Ile Lys 1 5 10
108915PRTArtificial SequenceSynthetic Polypeptide 1089Tyr Leu Leu Glu Thr
Ser Gly Asn Leu Asp Gly Leu Glu Tyr Lys 1 5
10 15 109011PRTArtificial SequenceSynthetic
Polypeptide 1090Ala Ser Ser Ser Phe Gln Ala Asn Gly Thr Lys 1
5 10 10919PRTArtificial SequenceSynthetic
Polypeptide 1091Phe Ala Ile Gln Tyr Gly Thr Gly Arg 1 5
109216PRTArtificial SequenceSynthetic Polypeptide 1092Gly
Ala Asp Leu Gly Trp Gly Glu Thr Ala Gln Ala Gln Phe Pro Gly 1
5 10 15 109319PRTArtificial
SequenceSynthetic Polypeptide 1093Leu Gly Ala Pro Ser Pro Gly Asp Lys Pro
Ile Phe Val Pro Leu Ser 1 5 10
15 Asn Tyr Arg 10949PRTArtificial SequenceSynthetic
Polypeptide 1094Val Asp Gly Ile Leu Ser Glu Asp Lys 1 5
109512PRTArtificial SequenceSynthetic Polypeptide 1095Ala
Glu Ala Leu Phe Asp Phe Thr Gly Asn Ser Lys 1 5
10 10968PRTArtificial SequenceSynthetic Polypeptide
1096Asp Ala Glu Gly Asp Leu Val Arg 1 5
109715PRTArtificial SequenceSynthetic Polypeptide 1097Asp Ile Ala Val Glu
Glu Asp Leu Ser Ser Thr Pro Leu Leu Lys 1 5
10 15 109812PRTArtificial SequenceSynthetic
Polypeptide 1098Gly Ala Thr Gly Ile Phe Pro Leu Ser Phe Val Lys 1
5 10 109911PRTArtificial
SequenceSynthetic Polypeptide 1099Ser Val Ser Pro Gln Gly Asn Ser Val Asp
Arg 1 5 10 110010PRTArtificial
SequenceSynthetic Polypeptide 1100Asp Arg Pro Phe Phe Ala Gly Leu Val Lys
1 5 10 11017PRTArtificial
SequenceSynthetic Polypeptide 1101Glu His Tyr Val Asp Leu Lys 1
5 110214PRTArtificial SequenceSynthetic Polypeptide 1102Asn
Ile Ile His Gly Ser Asp Ser Val Glu Ser Ala Glu Lys 1 5
10 110312PRTArtificial SequenceSynthetic
Polypeptide 1103Thr Phe Ile Ala Ile Lys Pro Asp Gly Val Gln Arg 1
5 10 11047PRTArtificial
SequenceSynthetic Polypeptide 1104Ala Ser Glu Glu His Leu Lys 1
5 110510PRTArtificial SequenceSynthetic Polypeptide 1105Asp
Arg Pro Phe Phe Pro Gly Leu Val Lys 1 5
10 110615PRTArtificial SequenceSynthetic Polypeptide 1106Glu Ile Ser Leu
Trp Phe Lys Pro Glu Glu Leu Val Asp Tyr Lys 1 5
10 15 110710PRTArtificial SequenceSynthetic
Polypeptide 1107Asn Ile Ile His Gly Ser Asp Ser Val Lys 1 5
10 11089PRTArtificial SequenceSynthetic Polypeptide
1108Phe Glu Ala Pro Leu Phe Asn Ala Arg 1 5
110917PRTArtificial SequenceSynthetic Polypeptide 1109Ile Leu Gln Asp
Ile Ala Ser Gly Ser His Pro Phe Ser Gln Val Leu 1 5
10 15 Lys 111019PRTArtificial
SequenceSynthetic Polypeptide 1110Leu Val Asn Gln Gln Leu Leu Ala Asp Pro
Leu Val Pro Pro Gln Leu 1 5 10
15 Thr Ile Lys 111116PRTArtificial SequenceSynthetic
Polypeptide 1111Asn Asp Gly Ala Ala Ile Leu Ala Ala Val Ser Ser Ile Ala
Gln Lys 1 5 10 15
111210PRTArtificial SequenceSynthetic Polypeptide 1112Ser Ala Thr Tyr Val
Asn Thr Glu Gly Arg 1 5 10
111318PRTArtificial SequenceSynthetic Polypeptide 1113Glu Pro Ala Val Ile
Gly Arg Pro Asp Phe Glu His Ala Val Glu Ala 1 5
10 15 Ser Lys 111413PRTArtificial
SequenceSynthetic Polypeptide 1114Gly Phe Thr Pro Val Val Asp Asp Pro Val
Thr Glu Arg 1 5 10
111510PRTArtificial SequenceSynthetic Polypeptide 1115Gly Asn Ala Val Leu
Gln Ser Gln Val Lys 1 5 10
111610PRTArtificial SequenceSynthetic Polypeptide 1116Asn Ile Gly Ala Phe
Ile Ser Glu Ala Lys 1 5 10
111719PRTArtificial SequenceSynthetic Polypeptide 1117Thr Asp Pro Gly Ser
Ile Phe Asp Leu Asp Pro Leu Glu Asp Asn Ile 1 5
10 15 Gln Ser Arg 111814PRTArtificial
SequenceSynthetic Polypeptide 1118Asp Ser Val Ser Asp Gly Phe Val Gln Glu
Asn Gln Pro Arg 1 5 10
111911PRTArtificial SequenceSynthetic Polypeptide 1119Asp Tyr Ser Pro Glu
Leu Ala Glu Leu Ile Arg 1 5 10
112010PRTArtificial SequenceSynthetic Polypeptide 1120Gly Ser Tyr Gly Glu
Val Thr Leu Val Lys 1 5 10
112113PRTArtificial SequenceSynthetic Polypeptide 1121Leu Leu Gly Ser Ser
Asp Ser Pro Ala Ser Ala Ser Arg 1 5 10
11228PRTArtificial SequenceSynthetic Polypeptide 1122Val Asp
Val Thr Ser Thr Gln Lys 1 5
11236PRTArtificial SequenceSynthetic Polypeptide 1123Ala Gly Asp Trp Trp
Lys 1 5 112415PRTArtificial SequenceSynthetic
Polypeptide 1124Asp Ser Tyr Phe Tyr Ala Val Ser Asp Leu Gln Val Gly Gly
Arg 1 5 10 15
112510PRTArtificial SequenceSynthetic Polypeptide 1125Phe Thr Val Asn Ile
Ile Ser Val Tyr Lys 1 5 10
112616PRTArtificial SequenceSynthetic Polypeptide 1126Leu His Thr Phe Gly
Asp Glu Asn Glu Asp Asp Ser Glu Leu Ala Arg 1 5
10 15 11278PRTArtificial SequenceSynthetic
Polypeptide 1127Ser Ser Leu Val Ile Gln Trp Arg 1 5
112819PRTArtificial SequenceSynthetic Polypeptide 1128Leu Val Gln
Leu Ala Gly Ala Pro Glu Pro Phe Glu Pro Ala Gln Pro 1 5
10 15 Asp Ala Tyr 112916PRTArtificial
SequenceSynthetic Polypeptide 1129Ser Asn Ala Thr Gln Leu Asp Gly Pro Ala
Gly Ala Leu Leu Leu Arg 1 5 10
15 11307PRTArtificial SequenceSynthetic Polypeptide 1130Glu
Leu Thr Ser Glu Leu Lys 1 5 11316PRTArtificial
SequenceSynthetic Polypeptide 1131Ile Thr Leu Tyr Gly Arg 1
5 113211PRTArtificial SequenceSynthetic Polypeptide 1132Ser Tyr Pro
Gly Leu Thr Ser Tyr Leu Val Arg 1 5 10
113315PRTArtificial SequenceSynthetic Polypeptide 1133Val Pro Leu Gln
Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 1 5
10 15 113413PRTArtificial SequenceSynthetic
Polypeptide 1134Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg 1
5 10 113514PRTArtificial
SequenceSynthetic Polypeptide 1135Gly Asp Gly Asp Val Ala Trp Gln His Thr
Gln Leu Phe Arg 1 5 10
11369PRTArtificial SequenceSynthetic Polypeptide 1136Ile Gly Asn Thr Ala
Phe Ser Thr Arg 1 5 113712PRTArtificial
SequenceSynthetic Polypeptide 1137Ile Ile Val Glu Leu Val Glu Phe Ile Ser
Pro Lys 1 5 10
113811PRTArtificial SequenceSynthetic Polypeptide 1138Leu Leu Leu Thr Tyr
Ala Asp Asn Ile Leu Arg 1 5 10
113927PRTArtificial SequenceSynthetic Polypeptide 1139Ser Ser Gln Gln Pro
Ala Ala Ser Thr Gln Leu Pro Thr Thr Pro Ser 1 5
10 15 Ser Asn Pro Ser Gly Leu Asn Gln His Thr
Arg 20 25 114014PRTArtificial
SequenceSynthetic Polypeptide 1140Ser Val Asp Pro Asp Ser Pro Ala Glu Ala
Ser Gly Leu Arg 1 5 10
114112PRTArtificial SequenceSynthetic Polypeptide 1141Glu Phe Pro Val Tyr
Leu Trp Gln Pro Phe Phe Arg 1 5 10
114213PRTArtificial SequenceSynthetic Polypeptide 1142Glu Val Asn Glu
Val Ser Gln Asn Phe Gln Thr Thr Lys 1 5
10 114323PRTArtificial SequenceSynthetic Polypeptide 1143Gly
Glu Ser Leu Ser Leu Pro Gly Pro Ser Pro Pro Pro Asp Gly Thr 1
5 10 15 Glu Gln Val Ile Ile Ser
Arg 20 114411PRTArtificial SequenceSynthetic
Polypeptide 1144Asn Asp Tyr Ala Val Glu Ser Tyr Glu Asn Lys 1
5 10 114514PRTArtificial SequenceSynthetic
Polypeptide 1145Val Leu Thr Ser Glu Asp Glu Tyr Asn Leu Leu Ser Asp Arg 1
5 10 11468PRTArtificial
SequenceSynthetic Polypeptide 1146Gly Tyr Phe Leu Phe Arg Pro Arg 1
5 114714PRTArtificial SequenceSynthetic Polypeptide
1147Val Asp Glu Glu Phe Gln Ser Pro Phe Ala Ser Gln Ser Arg 1
5 10 114829PRTArtificial
SequenceSynthetic Polypeptide 1148Glu Gly Asn Lys Pro Val Leu Phe Gln Gly
Asn Thr Asn Pro Thr Asp 1 5 10
15 Val Val Val Ala Val Phe Pro Lys Pro Leu Ile Thr Arg
20 25 114915PRTArtificial
SequenceSynthetic Polypeptide 1149Phe Val Ser Asp Tyr Glu Thr His Gly Ala
Gly Phe Ser Ile Arg 1 5 10
15 115013PRTArtificial SequenceSynthetic Polypeptide 1150Phe Val Thr
Ala Val Gly Thr Gln Gly Ala Ile Ser Lys 1 5
10 115121PRTArtificial SequenceSynthetic Polypeptide
1151Ile Glu Ser Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro His Ser Tyr 1
5 10 15 His Pro Ser Glu
Lys 20 115214PRTArtificial SequenceSynthetic Polypeptide
1152Ser Phe Glu Gly Asn Asn Asn Tyr Asp Thr Pro Glu Leu Arg 1
5 10 11536PRTArtificial
SequenceSynthetic Polypeptide 1153Glu Ala Ile Asn Phe Arg 1
5 115420PRTArtificial SequenceSynthetic Polypeptide 1154Ile Ile Ile
Leu Leu Gly Phe Leu Gly Ala Thr Leu Ser Ala Pro Leu 1 5
10 15 Ile Pro Gln Arg 20
11556PRTArtificial SequenceSynthetic Polypeptide 1155Ser Pro Gln Gln Thr
Arg 1 5 115617PRTArtificial SequenceSynthetic
Polypeptide 1156Ala Ile Pro Val Ala Gln Asp Leu Asn Ala Pro Ser Asp Trp
Asp Ser 1 5 10 15
Arg 115719PRTArtificial SequenceSynthetic Polypeptide 1157Asp Ser Tyr Glu
Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His 1 5
10 15 Ser His Lys 11589PRTArtificial
SequenceSynthetic Polypeptide 1158Gly Asp Ser Val Val Tyr Gly Leu Arg 1
5 115913PRTArtificial SequenceSynthetic
Polypeptide 1159Ile Ser His Glu Leu Asp Ser Ala Ser Ser Glu Val Asn 1
5 10 116016PRTArtificial
SequenceSynthetic Polypeptide 1160Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn
Pro Asp Pro Ser Gln Lys 1 5 10
15 11619PRTArtificial SequenceSynthetic Polypeptide 1161Asp
Gly Glu Ala Phe Leu Leu Thr Asn 1 5
116216PRTArtificial SequenceSynthetic Polypeptide 1162Gln Gly Val Leu Asp
Leu Pro Asn Asp Val Val Glu Gly Ser Ala Arg 1 5
10 15 116312PRTArtificial SequenceSynthetic
Polypeptide 1163Ser Asp Pro Leu Ala Phe Ile Thr Phe Ser Ala Lys 1
5 10 116417PRTArtificial
SequenceSynthetic Polypeptide 1164Ser Glu Val Thr Gln Ala Pro Gly Gln Tyr
Thr Val Asp Val Glu Gly 1 5 10
15 Arg 116511PRTArtificial SequenceSynthetic Polypeptide
1165Ser Phe Leu Val Glu Pro Glu Gly Ile Glu Lys 1 5
10 116614PRTArtificial SequenceSynthetic Polypeptide
1166Asp His Val Val Ser Asp Phe Ser Glu His Gly Ser Leu Lys 1
5 10 116713PRTArtificial
SequenceSynthetic Polypeptide 1167Phe Gly Leu Gly Ala Glu Val Gly Ile Ser
Thr Ser Arg 1 5 10
116812PRTArtificial SequenceSynthetic Polypeptide 1168Gly Pro Val Gly Leu
Glu Gly Leu Leu Thr Thr Lys 1 5 10
116910PRTArtificial SequenceSynthetic Polypeptide 1169His Glu Ile Leu
Leu Ser Gln Ser Val Arg 1 5 10
117016PRTArtificial SequenceSynthetic Polypeptide 1170Ile Leu His Leu Leu
Thr Gln Glu Ala Leu Ser Ile His Gly Val Lys 1 5
10 15 117110PRTArtificial SequenceSynthetic
Polypeptide 1171Asp Ile Pro His Trp Leu Asn Pro Thr Arg 1 5
10 117215PRTArtificial SequenceSynthetic Polypeptide
1172Glu Gln Val Asp Phe Gln His His Gln Leu Ala Glu Ala Phe Lys 1
5 10 15 117310PRTArtificial
SequenceSynthetic Polypeptide 1173Gly Tyr Ile Glu His Phe Ser Leu Trp Lys
1 5 10 117413PRTArtificial
SequenceSynthetic Polypeptide 1174Leu Asp Gly Ser Thr His Leu Asn Ile Phe
Phe Ala Lys 1 5 10
117516PRTArtificial SequenceSynthetic Polypeptide 1175Val Ser Phe Ser Ser
Pro Leu Val Ala Ile Ser Gly Val Ala Leu Arg 1 5
10 15 117610PRTArtificial SequenceSynthetic
Polypeptide 1176Ala Leu Glu Ser Glu Leu Gln Gln Leu Arg 1 5
10 117716PRTArtificial SequenceSynthetic Polypeptide
1177Glu Leu Pro Leu Ser Pro Ala Phe Phe Gly Glu Asp Gly Ile Phe Arg 1
5 10 15
117810PRTArtificial SequenceSynthetic Polypeptide 1178Glu Gln Glu Pro Glu
Leu Ser Phe Leu Lys 1 5 10
117910PRTArtificial SequenceSynthetic Polypeptide 1179Gly Leu Glu Glu Glu
Asn Ala Gln Leu Arg 1 5 10
118015PRTArtificial SequenceSynthetic Polypeptide 1180Gln Glu Gly Leu Thr
Phe Phe Gly Thr Glu Leu Ala Pro Val Arg 1 5
10 15 118111PRTArtificial SequenceSynthetic
Polypeptide 1181Ile Ala Asn Pro Val Glu Gly Ser Ser Gly Arg 1
5 10 118213PRTArtificial SequenceSynthetic
Polypeptide 1182Ile Ile Thr Leu Thr Gly Pro Thr Asn Ala Ile Phe Lys 1
5 10 11836PRTArtificial
SequenceSynthetic Polypeptide 1183Leu Asn Gln Val Ala Arg 1
5 11849PRTArtificial SequenceSynthetic Polypeptide 1184Gln Gly Ala
Asn Ile Asn Glu Ile Arg 1 5
118521PRTArtificial SequenceSynthetic Polypeptide 1185Gln Val Thr Ile Thr
Gly Ser Ala Ala Ser Ile Ser Leu Ala Gln Tyr 1 5
10 15 Leu Ile Asn Ala Arg 20
11868PRTArtificial SequenceSynthetic Polypeptide 1186Ala Phe Ala Met Ile
Ile Asp Lys 1 5 118720PRTArtificial
SequenceSynthetic Polypeptide 1187Glu Ser Thr Gly Ala Gln Val Gln Val Ala
Gly Asp Met Leu Pro Asn 1 5 10
15 Ser Thr Glu Arg 20 118823PRTArtificial
SequenceSynthetic Polypeptide 1188Gly Val Thr Ile Pro Tyr Arg Pro Lys Pro
Ser Ser Ser Pro Val Ile 1 5 10
15 Phe Ala Gly Gly Gln Asp Arg 20
118911PRTArtificial SequenceSynthetic Polypeptide 1189Ile Ala Asn Pro Val
Glu Gly Ser Thr Asp Arg 1 5 10
119013PRTArtificial SequenceSynthetic Polypeptide 1190Ile Ile Thr Leu Ala
Gly Pro Thr Asn Ala Ile Phe Lys 1 5 10
119131PRTArtificial SequenceSynthetic Polypeptide 1191Leu His
Gln Leu Ala Met Gln Gln Ser His Phe Pro Met Thr His Gly 1 5
10 15 Asn Thr Gly Phe Ser Gly Ile
Glu Ser Ser Ser Pro Glu Val Lys 20 25
30 119211PRTArtificial SequenceSynthetic Polypeptide
1192Leu Ser Ser Glu Thr Gly Gly Met Gly Ser Ser 1 5
10 119317PRTArtificial SequenceSynthetic Polypeptide
1193Met Asp Thr Gly Val Ile Glu Gly Gly Leu Asn Val Thr Leu Thr Ile 1
5 10 15 Arg
11948PRTArtificial SequenceSynthetic Polypeptide 1194Gln Met Ser Gly Ala
Gln Ile Lys 1 5 119521PRTArtificial
SequenceSynthetic Polypeptide 1195Gln Val Thr Ile Thr Gly Ser Ala Ala Ser
Ile Ser Leu Ala Gln Tyr 1 5 10
15 Leu Ile Asn Val Arg 20 119616PRTArtificial
SequenceSynthetic Polypeptide 1196Glu Gly Asp Ser Ile Thr Tyr Ala Ile Glu
Asn Gly Asp Pro Gln Arg 1 5 10
15 119715PRTArtificial SequenceSynthetic Polypeptide 1197Gly
Gly Pro Pro Ala Thr Ile Val Ala Ile Asp Glu Glu Ser Arg 1 5
10 15 119815PRTArtificial
SequenceSynthetic Polypeptide 1198Gly Thr Ala Gly Gly Pro Asp Pro Thr Ile
Glu Leu Ser Leu Lys 1 5 10
15 119913PRTArtificial SequenceSynthetic Polypeptide 1199Val Gly Ala
Val Leu Leu Asn Leu Gln Ala Thr Asp Arg 1 5
10 120014PRTArtificial SequenceSynthetic Polypeptide
1200Val Gln Ala Asp Ser Leu Glu Val Val Leu Ala Asn Leu Arg 1
5 10 12017PRTArtificial
SequenceSynthetic Polypeptide 1201Ile Glu Asp Glu Glu Gly Ser 1
5 12029PRTArtificial SequenceSynthetic Polypeptide 1202Leu
Ser Gln Thr Ser Asn Val Asp Lys 1 5
12038PRTArtificial SequenceSynthetic Polypeptide 1203Ser Glu Gly Phe Asp
Thr Tyr Arg 1 5 12047PRTArtificial
SequenceSynthetic Polypeptide 1204Tyr Leu Asn Phe Phe Thr Lys 1
5 12056PRTArtificial SequenceSynthetic Polypeptide 1205Tyr
Tyr Leu Ala Pro Lys 1 5 120626PRTArtificial
SequenceSynthetic Polypeptide 1206Phe Gly Leu Asn Thr Val Leu Thr Thr Asp
Asn Ser Asp Leu Phe Ile 1 5 10
15 Asn Ser Ile Gly Ile Val Pro Ser Val Arg 20
25 120718PRTArtificial SequenceSynthetic Polypeptide
1207Ile Ala Ile Ile Gly Ala Gly Ile Gly Gly Thr Ser Ala Ala Tyr Tyr 1
5 10 15 Leu Arg
12089PRTArtificial SequenceSynthetic Polypeptide 1208Ile Phe Ser Gln Glu
Thr Leu Thr Lys 1 5 12098PRTArtificial
SequenceSynthetic Polypeptide 1209Thr Leu Leu Glu Thr Leu Gln Lys 1
5 121013PRTArtificial SequenceSynthetic Polypeptide
1210Tyr Gln Ser His Asp Tyr Ala Phe Ser Ser Val Glu Lys 1 5
10 12118PRTArtificial SequenceSynthetic
Polypeptide 1211Ala His Gly Val His Ala Thr Lys 1 5
12128PRTArtificial SequenceSynthetic Polypeptide 1212Glu Glu Asp
Thr Gly Arg Pro Arg 1 5 121318PRTArtificial
SequenceSynthetic Polypeptide 1213Leu Leu Glu Ile Asp Ser Val Gly Ser Glu
Asp Ser Leu Asp Thr Ser 1 5 10
15 Leu Arg 12147PRTArtificial SequenceSynthetic Polypeptide
1214Ser Gln Ile His Ser Ile Arg 1 5
12158PRTArtificial SequenceSynthetic Polypeptide 1215Thr Val Ile Tyr Glu
Ile Pro Arg 1 5 12167PRTArtificial
SequenceSynthetic Polypeptide 1216Ser Phe Asp Asp Leu Gln Arg 1
5 121712PRTArtificial SequenceSynthetic Polypeptide 1217Ser
His Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg 1 5
10 12189PRTArtificial SequenceSynthetic Polypeptide
1218Ser Pro Gly Gly Ser Gln Glu Gln Arg 1 5
121912PRTArtificial SequenceSynthetic Polypeptide 1219Asp Thr Ser Ala
Thr Pro Gln Ser Ala Ser Ile Lys 1 5 10
12209PRTArtificial SequenceSynthetic Polypeptide 1220Gly Asn Gly
Tyr Val Gln Ser Pro Arg 1 5
12219PRTArtificial SequenceSynthetic Polypeptide 1221Leu Ala Asn Val Val
Phe Phe Pro Arg 1 5 122212PRTArtificial
SequenceSynthetic Polypeptide 1222Ser Asp Asp Tyr Phe Val Ala Lys Pro Gly
Phe Lys 1 5 10
122317PRTArtificial SequenceSynthetic Polypeptide 1223Tyr Asp Phe Val Glu
Val Glu Asp Ile Ser Glu Thr Ser Thr Ile Ile 1 5
10 15 Arg 12248PRTArtificial
SequenceSynthetic Polypeptide 1224Asp Pro Asn Ile Val Ile Ala Lys 1
5 122511PRTArtificial SequenceSynthetic Polypeptide
1225Glu Leu Ser Asp Phe Ile Ser Tyr Leu Gln Arg 1 5
10 122631PRTArtificial SequenceSynthetic Polypeptide
1226Phe Ala His Thr Asn Val Glu Ser Leu Val Asn Glu Tyr Asp Asp Asn 1
5 10 15 Gly Glu Gly Ile
Ile Leu Phe Arg Pro Ser His Leu Thr Asn Lys 20
25 30 122713PRTArtificial SequenceSynthetic
Polypeptide 1227Ser Glu Pro Ile Pro Glu Ser Asn Asp Gly Pro Val Lys 1
5 10 12288PRTArtificial
SequenceSynthetic Polypeptide 1228Thr Val Ala Tyr Thr Glu Gln Lys 1
5 122920PRTArtificial SequenceSynthetic Polypeptide
1229Glu Glu Asn Gly Val Leu Val Leu Asn Asp Ala Asn Phe Asp Asn Phe 1
5 10 15 Val Ala Asp Lys
20 123019PRTArtificial SequenceSynthetic Polypeptide 1230Glu
Val Ser Gln Pro Asp Trp Thr Pro Pro Pro Glu Val Thr Leu Val 1
5 10 15 Leu Thr Lys
123110PRTArtificial SequenceSynthetic Polypeptide 1231Phe Asp Val Ser Gly
Tyr Pro Thr Ile Lys 1 5 10
123211PRTArtificial SequenceSynthetic Polypeptide 1232Phe His His Thr Phe
Ser Thr Glu Ile Ala Lys 1 5 10
12338PRTArtificial SequenceSynthetic Polypeptide 1233Phe Ile Glu Glu His
Ala Thr Lys 1 5 123411PRTArtificial
SequenceSynthetic Polypeptide 1234Gly Glu Ser Pro Val Asp Tyr Asp Gly Gly
Arg 1 5 10 123517PRTArtificial
SequenceSynthetic Polypeptide 1235His His Ser Leu Gly Gly Gln Tyr Gly Val
Gln Gly Phe Pro Thr Ile 1 5 10
15 Lys 123614PRTArtificial SequenceSynthetic Polypeptide
1236Asn Leu Glu Pro Glu Trp Ala Ala Ala Ala Ser Glu Val Lys 1
5 10 123710PRTArtificial
SequenceSynthetic Polypeptide 1237Asn Arg Pro Glu Asp Tyr Gln Gly Gly Arg
1 5 10 12389PRTArtificial
SequenceSynthetic Polypeptide 1238Asn Ser Tyr Leu Glu Val Leu Leu Lys 1
5 123916PRTArtificial SequenceSynthetic
Polypeptide 1239Asp Gln Asn Phe Val Ile Leu Glu Phe Pro Val Glu Glu Gln
Asp Arg 1 5 10 15
124013PRTArtificial SequenceSynthetic Polypeptide 1240Glu Asp Thr Ile Val
Ser Gln Thr Gln Asp Phe Thr Lys 1 5 10
124114PRTArtificial SequenceSynthetic Polypeptide 1241Ser Glu
Leu Val Thr Val Thr Glu Ser Phe Ser Thr Pro Lys 1 5
10 124211PRTArtificial SequenceSynthetic
Polypeptide 1242Ser Thr Glu Ser Tyr Phe Ile Pro Glu Val Arg 1
5 10 124316PRTArtificial SequenceSynthetic
Polypeptide 1243Val Ile Ala Pro Val Asp Glu Val Gln Ile Ser Ile Leu Ser
Ser Lys 1 5 10 15
124412PRTArtificial SequenceSynthetic Polypeptide 1244Asp Thr Asp Thr Gly
Ala Leu Leu Phe Ile Gly Lys 1 5 10
124511PRTArtificial SequenceSynthetic Polypeptide 1245Glu Leu Leu Asp
Thr Val Thr Ala Pro Gln Lys 1 5 10
124612PRTArtificial SequenceSynthetic Polypeptide 1246Leu Gln Ser Leu Phe
Asp Ser Pro Asp Phe Ser Lys 1 5 10
12479PRTArtificial SequenceSynthetic Polypeptide 1247Leu Ser Tyr Glu
Gly Glu Val Thr Lys 1 5
124810PRTArtificial SequenceSynthetic Polypeptide 1248Thr Val Gln Ala Val
Leu Thr Val Pro Lys 1 5 10
12498PRTArtificial SequenceSynthetic Polypeptide 1249Ala Val Ser Asn Glu
Ile Val Arg 1 5 125012PRTArtificial
SequenceSynthetic Polypeptide 1250Phe Pro Thr Asp Gln Leu Thr Pro Asp Gln
Glu Arg 1 5 10
125110PRTArtificial SequenceSynthetic Polypeptide 1251Ile Ala Asn Val Phe
Thr Asn Ala Phe Arg 1 5 10
12527PRTArtificial SequenceSynthetic Polypeptide 1252Val Phe Phe Ala Ser
Trp Arg 1 5 125312PRTArtificial SequenceSynthetic
Polypeptide 1253Val Val Leu Glu Gly Gly Ile Asp Pro Ile Leu Arg 1
5 10 125422PRTArtificial
SequenceSynthetic Polypeptide 1254Leu Ser Leu Pro Leu Leu Leu Leu Leu Leu
Gly Ala Trp Ala Ile Pro 1 5 10
15 Gly Gly Leu Gly Asp Arg 20
12558PRTArtificial SequenceSynthetic Polypeptide 1255Asn Trp Gln Asp Tyr
Gly Val Arg 1 5 125614PRTArtificial
SequenceSynthetic Polypeptide 1256Ala Leu Pro Phe Trp Asn Glu Glu Ile Val
Pro Gln Ile Lys 1 5 10
125710PRTArtificial SequenceSynthetic Polypeptide 1257Ala Met Glu Ala Val
Ala Ala Gln Gly Lys 1 5 10
125818PRTArtificial SequenceSynthetic Polypeptide 1258Phe Ser Gly Trp Tyr
Asp Ala Asp Leu Ser Pro Ala Gly His Glu Glu 1 5
10 15 Ala Lys 125911PRTArtificial
SequenceSynthetic Polypeptide 1259His Gly Glu Ser Ala Trp Asn Leu Glu Asn
Arg 1 5 10 126018PRTArtificial
SequenceSynthetic Polypeptide 1260Asn Leu Lys Pro Ile Lys Pro Met Gln Phe
Leu Gly Asp Glu Glu Thr 1 5 10
15 Val Arg 126113PRTArtificial SequenceSynthetic Polypeptide
1261Ile His Thr Tyr Val Tyr Glu Phe Ile Tyr Leu Val Arg 1 5
10 126227PRTArtificial SequenceSynthetic
Polypeptide 1262Leu Asp Pro Ser Pro Phe Ile Ala Asp Phe Gln Thr Thr Ala
Glu Glu 1 5 10 15
Leu Gly Leu Leu Ser Ser Ser Pro Asn Leu Leu 20
25 126318PRTArtificial SequenceSynthetic Polypeptide 1263Val
Val Ser Glu Glu Thr Leu Leu Phe Gln Thr Glu Leu Tyr Phe Thr 1
5 10 15 Pro Arg
126411PRTArtificial SequenceSynthetic Polypeptide 1264Asp Ala Val Thr Thr
Thr Val Thr Gly Ala Lys 1 5 10
126511PRTArtificial SequenceSynthetic Polypeptide 1265Glu Val Ser Asp Ser
Leu Leu Thr Ser Ser Lys 1 5 10
126616PRTArtificial SequenceSynthetic Polypeptide 1266Leu Pro Ile Leu Asn
Gln Pro Ser Thr Gln Ile Val Ala Asn Ala Lys 1 5
10 15 126718PRTArtificial SequenceSynthetic
Polypeptide 1267Ser Glu Leu Leu Val Glu Gln Tyr Leu Pro Leu Thr Glu Glu
Glu Leu 1 5 10 15
Glu Lys 126814PRTArtificial SequenceSynthetic Polypeptide 1268Ser Val Val
Ser Gly Ser Ile Asn Thr Val Leu Gly Ser Arg 1 5
10 126915PRTArtificial SequenceSynthetic
Polypeptide 1269Asp Thr Val Ala Thr Gln Leu Ser Glu Ala Val Asp Ala Thr
Arg 1 5 10 15
127017PRTArtificial SequenceSynthetic Polypeptide 1270Ile Ala Thr Ser Leu
Asp Gly Phe Asp Val Ala Ser Val Gln Gln Gln 1 5
10 15 Arg 127114PRTArtificial
SequenceSynthetic Polypeptide 1271Leu Glu Glu Asn Leu Pro Ile Leu Gln Gln
Pro Thr Glu Lys 1 5 10
127218PRTArtificial SequenceSynthetic Polypeptide 1272Ser Glu Glu Trp Ala
Asp Asn His Leu Pro Leu Thr Asp Ala Glu Leu 1 5
10 15 Ala Arg 127316PRTArtificial
SequenceSynthetic Polypeptide 1273Thr Leu Thr Ala Ala Ala Val Ser Gly Ala
Gln Pro Ile Leu Ser Lys 1 5 10
15 127418PRTArtificial SequenceSynthetic Polypeptide 1274Ala
Gln Val Glu Glu Phe Leu Ala Gln His Gly Ser Glu Tyr Gln Ser 1
5 10 15 Val Lys
127515PRTArtificial SequenceSynthetic Polypeptide 1275Ile Phe Gln Asn Leu
Asp Gly Ala Leu Asp Glu Val Val Leu Lys 1 5
10 15 127612PRTArtificial SequenceSynthetic
Polypeptide 1276Leu Gln Leu Asn Tyr Leu Gly Asn Tyr Ile Pro Arg 1
5 10 127712PRTArtificial
SequenceSynthetic Polypeptide 1277Leu Thr His Tyr His Glu Gly Leu Pro Thr
Thr Arg 1 5 10
127818PRTArtificial SequenceSynthetic Polypeptide 1278Asn Leu Ala Tyr Asp
Thr Leu Pro Val Leu Ile His Gly Asn Gly Pro 1 5
10 15 Thr Lys 127914PRTArtificial
SequenceSynthetic Polypeptide 1279Ile Val Gly Pro Glu Glu Asn Leu Ser Gln
Ala Glu Ala Arg 1 5 10
128019PRTArtificial SequenceSynthetic Polypeptide 1280Ile Val Gln Gln Trp
Asn Leu Gln Asp Asn Asp Asp Asp Gln Leu Phe 1 5
10 15 Tyr Thr Lys 128111PRTArtificial
SequenceSynthetic Polypeptide 1281Leu Thr His Leu His Glu Gly Leu Pro Val
Lys 1 5 10 128217PRTArtificial
SequenceSynthetic Polypeptide 1282Leu Trp Ser Asn Phe Trp Gly Ala Leu Ser
Pro Asp Gly Tyr Tyr Ala 1 5 10
15 Arg 128312PRTArtificial SequenceSynthetic Polypeptide
1283Ser Glu Asp Tyr Val Asp Ile Val Gln Gly Asn Arg 1 5
10 12849PRTArtificial SequenceSynthetic
Polypeptide 1284Ile Gly Asn Phe Ser Thr Asp Ile Lys 1 5
12858PRTArtificial SequenceSynthetic Polypeptide 1285Ile
Ser Phe Asp Glu Phe Ile Lys 1 5
128619PRTArtificial SequenceSynthetic Polypeptide 1286Val Asp Thr Asp Gly
Asn Gly Tyr Ile Ser Phe Asn Glu Leu Asn Asp 1 5
10 15 Leu Phe Lys 12877PRTArtificial
SequenceSynthetic Polypeptide 1287Val Pro Val Asp Trp Asn Arg 1
5 128822PRTArtificial SequenceSynthetic Polypeptide 1288Tyr
Pro Ala Leu His Lys Pro Glu Asn Gln Asp Ile Asp Trp Gly Ala 1
5 10 15 Leu Glu Gly Glu Thr Arg
20 128911PRTArtificial SequenceSynthetic Polypeptide
1289Leu Asp Ile Thr Ala Glu Ile Leu Ala Val Arg 1 5
10 129014PRTArtificial SequenceSynthetic Polypeptide
1290Leu Gln Val Asn Thr Pro Leu Val Gly Ala Ser Leu Leu Arg 1
5 10 129110PRTArtificial
SequenceSynthetic Polypeptide 1291Leu Tyr Val Thr Ile Pro Leu Gly Ile Lys
1 5 10 129219PRTArtificial
SequenceSynthetic Polypeptide 1292Val Thr Asp Pro Gln Leu Leu Glu Leu Gly
Leu Val Gln Ser Pro Asp 1 5 10
15 Gly His Arg 129315PRTArtificial SequenceSynthetic
Polypeptide 1293Val Thr Ser Val Ile Pro Gly Leu Asn Asn Ile Ile Asp Ile
Lys 1 5 10 15
129415PRTArtificial SequenceSynthetic Polypeptide 1294Glu Leu Pro Val Pro
Ile Tyr Val Thr Gln Gly Glu Ala Gln Arg 1 5
10 15 129517PRTArtificial SequenceSynthetic
Polypeptide 1295Gly Pro Ser Gly Ala Glu Glu Ala Thr Val Glu Tyr Gly Val
Thr Ser 1 5 10 15
Arg 12969PRTArtificial SequenceSynthetic Polypeptide 1296Gly Pro Val Asp
Ala Val Thr Gly Lys 1 5
129715PRTArtificial SequenceSynthetic Polypeptide 1297Gln Leu Ala Gly Ser
Gln Pro Phe Ser Ser Glu Gly Leu Gly Arg 1 5
10 15 129824PRTArtificial SequenceSynthetic
Polypeptide 1298Ser Gln Pro Pro Gly Ile Ser Ser Gln His Phe Thr Tyr Gln
Asp Pro 1 5 10 15
Val Leu Leu Ser Leu Ser Pro Arg 20
12997PRTArtificial SequenceSynthetic Polypeptide 1299Phe Trp Val Asn Ile
Leu Lys 1 5 130016PRTArtificial SequenceSynthetic
Polypeptide 1300Leu Asn Thr Ile Gly His Tyr Glu Ile Ser Asn Gly Ser Thr
Ile Lys 1 5 10 15
13019PRTArtificial SequenceSynthetic Polypeptide 1301Asn Pro Gln Phe Val
Phe Asp Ile Lys 1 5 130211PRTArtificial
SequenceSynthetic Polypeptide 1302Gly Phe Glu Pro Gly Val Thr Asn Ile Leu
Lys 1 5 10 130312PRTArtificial
SequenceSynthetic Polypeptide 1303Ile Ile Asp Gly Val Pro Val Glu Ile Thr
Glu Lys 1 5 10
130418PRTArtificial SequenceSynthetic Polypeptide 1304Ile Ile His Gly Asn
Gln Ile Ala Thr Asn Gly Val Val His Val Ile 1 5
10 15 Asp Arg 130520PRTArtificial
SequenceSynthetic Polypeptide 1305Leu Leu Tyr Pro Ala Asp Thr Pro Val Gly
Asn Asp Gln Leu Leu Glu 1 5 10
15 Ile Leu Asn Lys 20 130623PRTArtificial
SequenceSynthetic Polypeptide 1306Val Leu Thr Gln Ile Gly Thr Ser Ile Gln
Asp Phe Ile Glu Ala Glu 1 5 10
15 Asp Asp Leu Ser Ser Phe Arg 20
130717PRTArtificial SequenceSynthetic Polypeptide 1307Asp Pro Tyr Gln Glu
Glu Glu Trp Pro Gln Gly Phe Gly Gln Leu Thr 1 5
10 15 Lys 130811PRTArtificial
SequenceSynthetic Polypeptide 1308Phe Leu Phe Gly Ile Tyr Gln Gln Ala Glu
Lys 1 5 10 13097PRTArtificial
SequenceSynthetic Polypeptide 1309Phe Val Thr Leu Leu Tyr Arg 1
5 13109PRTArtificial SequenceSynthetic Polypeptide 1310His
Val Ala Asp Gly Glu Asp His Ala 1 5
13118PRTArtificial SequenceSynthetic Polypeptide 1311Leu Thr Glu Pro Val
Val Pro Lys 1 5 131214PRTArtificial
SequenceSynthetic Polypeptide 1312Ala Asn Glu Gly Thr Val Gly Val Ser Ala
Ala Thr Glu Arg 1 5 10
13138PRTArtificial SequenceSynthetic Polypeptide 1313Asp Gln Ala Gln Glu
Thr Leu Lys 1 5 131414PRTArtificial
SequenceSynthetic Polypeptide 1314His Glu Thr His Gly Gly Glu Asp Val Ala
Val Phe Ser Lys 1 5 10
131511PRTArtificial SequenceSynthetic Polypeptide 1315Leu Asp Gly Leu Asp
Leu Val Asp Thr Trp Lys 1 5 10
13167PRTArtificial SequenceSynthetic Polypeptide 1316Phe Pro Asp Glu Asn
Phe Lys 1 5 131711PRTArtificial SequenceSynthetic
Polypeptide 1317Ile Glu Val Glu Lys Pro Phe Ala Ile Ala Lys 1
5 10 131813PRTArtificial SequenceSynthetic
Polypeptide 1318Thr Val Asp Asn Phe Val Ala Leu Ala Thr Gly Glu Lys 1
5 10 13198PRTArtificial
SequenceSynthetic Polypeptide 1319Val Ile Phe Gly Leu Phe Gly Lys 1
5 13206PRTArtificial SequenceSynthetic Polypeptide
1320Val Tyr Phe Asp Leu Arg 1 5 13218PRTArtificial
SequenceSynthetic Polypeptide 1321Ala Asp Glu Gly Ile Ser Phe Arg 1
5 132211PRTArtificial SequenceSynthetic Polypeptide
1322Ala Thr Ala Val Met Pro Asp Gly Gln Phe Lys 1 5
10 13238PRTArtificial SequenceSynthetic Polypeptide
1323Asp Ile Ser Leu Ser Asp Tyr Lys 1 5
13248PRTArtificial SequenceSynthetic Polypeptide 1324Gly Leu Phe Ile Ile
Asp Asp Lys 1 5 13259PRTArtificial
SequenceSynthetic Polypeptide 1325Ile Gly His Pro Ala Pro Asn Phe Lys 1
5 132610PRTArtificial SequenceSynthetic
Polypeptide 1326Leu Val Gln Ala Phe Gln Phe Thr Asp Lys 1 5
10 132716PRTArtificial SequenceSynthetic Polypeptide
1327Gln Gly Gly Leu Gly Pro Met Asn Ile Pro Leu Val Ser Asp Pro Lys 1
5 10 15
132811PRTArtificial SequenceSynthetic Polypeptide 1328Gln Ile Thr Val Asn
Asp Leu Pro Val Gly Arg 1 5 10
13297PRTArtificial SequenceSynthetic Polypeptide 1329Ser Val Asp Glu Thr
Leu Arg 1 5 133010PRTArtificial SequenceSynthetic
Polypeptide 1330Thr Ile Ala Gln Asp Tyr Gly Val Leu Lys 1 5
10 133114PRTArtificial SequenceSynthetic Polypeptide
1331Asp Tyr Gly Val Tyr Leu Glu Asp Ser Gly His Thr Leu Arg 1
5 10 133213PRTArtificial
SequenceSynthetic Polypeptide 1332Ile Pro Leu Leu Ser Asp Leu Thr His Gln
Ile Ser Lys 1 5 10
133319PRTArtificial SequenceSynthetic Polypeptide 1333Ile Ser Lys Pro Ala
Pro Tyr Trp Glu Gly Thr Ala Val Ile Asp Gly 1 5
10 15 Glu Phe Lys 133411PRTArtificial
SequenceSynthetic Polypeptide 1334Gln Ile Thr Leu Asn Asp Leu Pro Val Gly
Arg 1 5 10 133512PRTArtificial
SequenceSynthetic Polypeptide 1335Val Ser Val Ala Asp His Ser Leu His Leu
Ser Lys 1 5 10
133612PRTArtificial SequenceSynthetic Polypeptide 1336Asp Ser Pro Ser Val
Trp Ala Ala Val Pro Gly Lys 1 5 10
133714PRTArtificial SequenceSynthetic Polypeptide 1337Ser Ser Phe Tyr
Val Asn Gly Leu Thr Leu Gly Gly Gln Lys 1 5
10 133814PRTArtificial SequenceSynthetic Polypeptide
1338Ser Thr Gly Gly Ala Pro Thr Phe Asn Val Thr Val Thr Lys 1
5 10 133916PRTArtificial
SequenceSynthetic Polypeptide 1339Thr Phe Val Asn Ile Thr Pro Ala Glu Val
Gly Val Leu Val Gly Lys 1 5 10
15 13407PRTArtificial SequenceSynthetic Polypeptide 1340Ile
Glu Glu Tyr Ile Ser Lys 1 5 13418PRTArtificial
SequenceSynthetic Polypeptide 1341Ile Tyr Glu Tyr Val Glu Ser Arg 1
5 13429PRTArtificial SequenceSynthetic Polypeptide
1342Gln Thr Gln Val Asn Glu Ala Thr Lys 1 5
134311PRTArtificial SequenceSynthetic Polypeptide 1343Val Asp Ser Phe
His Glu Ser Thr Glu Gly Lys 1 5 10
134421PRTArtificial SequenceSynthetic Polypeptide 1344Val Ile Val Asp Ala
Asn Asn Leu Thr Val Glu Ile Glu Asn Glu Leu 1 5
10 15 Asn Ile Ile His Lys 20
134520PRTArtificial SequenceSynthetic Polypeptide 1345Ala Met Glu Val Asp
Glu Arg Pro Thr Glu Gln Tyr Ser Asp Ile Gly 1 5
10 15 Gly Leu Asp Lys 20
134612PRTArtificial SequenceSynthetic Polypeptide 1346Gly Val Leu Met Tyr
Gly Pro Pro Gly Thr Gly Lys 1 5 10
134716PRTArtificial SequenceSynthetic Polypeptide 1347Leu Ala Gly Pro
Gln Leu Val Gln Met Phe Ile Gly Asp Gly Ala Lys 1 5
10 15 134816PRTArtificial
SequenceSynthetic Polypeptide 1348Gln Ile Gln Glu Leu Val Glu Ala Ile Val
Leu Pro Met Asn His Lys 1 5 10
15 134910PRTArtificial SequenceSynthetic Polypeptide 1349Val
Asp Ile Leu Asp Pro Ala Leu Leu Arg 1 5
10 135010PRTArtificial SequenceSynthetic Polypeptide 1350Ala Val Gly Leu
Leu Thr Val Ile Ser Lys 1 5 10
135114PRTArtificial SequenceSynthetic Polypeptide 1351Ala Gly Tyr Leu Thr
Leu Tyr Gly Ile Glu Ala Leu Pro Arg 1 5
10 135212PRTArtificial SequenceSynthetic Polypeptide
1352Asp Pro Glu Ile Tyr Thr Asp Pro Glu Val Phe Lys 1 5
10 135314PRTArtificial SequenceSynthetic
Polypeptide 1353Glu Val Val Val Asp Leu Ala Met Pro Met Ala Asp Gly Arg 1
5 10 135423PRTArtificial
SequenceSynthetic Polypeptide 1354Gly Glu Leu Glu Ser Ile Leu Trp Gln Ala
Glu Gln Pro Val Ser Gln 1 5 10
15 Thr Thr Thr Leu Pro Gln Lys 20
135512PRTArtificial SequenceSynthetic Polypeptide 1355His Gly Asp Ile Phe
Thr Ile Leu Val Gly Gly Arg 1 5 10
135615PRTArtificial SequenceSynthetic Polypeptide 1356Ile Phe Asp Val
Gln Leu Pro His Tyr Ser Pro Ser Asp Glu Lys 1 5
10 15 135711PRTArtificial SequenceSynthetic
Polypeptide 1357Leu Leu Leu Phe Pro Phe Leu Ser Pro Gln Arg 1
5 10 135811PRTArtificial SequenceSynthetic
Polypeptide 1358Val His Ser Ala Asp Val Phe His Thr Phe Arg 1
5 10 135917PRTArtificial SequenceSynthetic
Polypeptide 1359Val Leu Asp Ser Thr Pro Val Leu Asp Ser Val Leu Ser Glu
Ser Leu 1 5 10 15
Arg 136015PRTArtificial SequenceSynthetic Polypeptide 1360Tyr Gly Phe Gly
Leu Met Gln Pro Glu His Asp Val Pro Val Arg 1 5
10 15 136113PRTArtificial SequenceSynthetic
Polypeptide 1361Phe Gly Ser Leu Leu Pro Ile His Pro Val Thr Ser Gly 1
5 10 136229PRTArtificial
SequenceSynthetic Polypeptide 1362Leu Asp Glu Glu Ala Glu Asn Leu Val Ala
Thr Val Val Pro Thr His 1 5 10
15 Leu Ala Ala Ala Val Pro Glu Val Ala Val Tyr Leu Lys
20 25 136322PRTArtificial
SequenceSynthetic Polypeptide 1363Thr Gly Pro Phe Ala Glu His Ser Asn Gln
Leu Trp Asn Ile Ser Ala 1 5 10
15 Val Pro Ser Trp Ser Lys 20
136410PRTArtificial SequenceSynthetic Polypeptide 1364Val Asp Asp Gln Ile
Ala Ile Val Phe Lys 1 5 10
136513PRTArtificial SequenceSynthetic Polypeptide 1365Trp Ile Asp Glu Thr
Pro Pro Val Asp Gln Pro Ser Arg 1 5 10
136611PRTArtificial SequenceSynthetic Polypeptide 1366Asp Leu
Gln Tyr Ser Thr Asp Tyr Thr Phe Lys 1 5
10 136716PRTArtificial SequenceSynthetic Polypeptide 1367Ser Glu Ala
Ala His Gln Gly Val Ile Thr Trp Asn Pro Pro Gln Arg 1 5
10 15 136812PRTArtificial
SequenceSynthetic Polypeptide 1368Thr Leu Ile Leu Asp Val Pro Pro Gly Val
Glu Lys 1 5 10
136911PRTArtificial SequenceSynthetic Polypeptide 1369Tyr Asp Leu Gln Asn
Leu Lys Pro Tyr Thr Lys 1 5 10
137011PRTArtificial SequenceSynthetic Polypeptide 1370Tyr Val Asp Ile Leu
Pro Tyr Asp Tyr Asn Arg 1 5 10
137126PRTArtificial SequenceSynthetic Polypeptide 1371Ala Gly Ser Pro Thr
Ala Pro Val His Asp Glu Ser Leu Val Gly Pro 1 5
10 15 Val Asp Pro Ser Ser Gly Gln Gln Ser Arg
20 25 137214PRTArtificial
SequenceSynthetic Polypeptide 1372Ala Val Ser Ile Ser Pro Thr Asn Val Ile
Leu Thr Trp Lys 1 5 10
137314PRTArtificial SequenceSynthetic Polypeptide 1373Thr Pro Ser Ser Thr
Gly Pro Ser Pro Val Phe Asp Ile Lys 1 5
10 137412PRTArtificial SequenceSynthetic Polypeptide
1374Val Ile Thr Glu Pro Ile Pro Val Ser Asp Leu Arg 1 5
10 137517PRTArtificial SequenceSynthetic
Polypeptide 1375Val Leu Leu Glu Ser Ile Gly Ser His Glu Glu Leu Thr Gln
Asp Ser 1 5 10 15
Arg 137612PRTArtificial SequenceSynthetic Polypeptide 1376Glu Gly Pro Pro
Ser Glu His Ser Gly Ile Ser Arg 1 5 10
137714PRTArtificial SequenceSynthetic Polypeptide 1377Glu Asn Ser
Ser Ser Gln Asp Pro Gln Thr Glu Gly Thr Arg 1 5
10 13789PRTArtificial SequenceSynthetic
Polypeptide 1378Gln Ala Glu Leu Thr Val Gln Val Lys 1 5
13797PRTArtificial SequenceSynthetic Polypeptide 1379Ser
Val Asp Ile Trp Leu Arg 1 5 138013PRTArtificial
SequenceSynthetic Polypeptide 1380Val Leu Ala Lys Pro Gln Asn Thr Ala Glu
Val Gln Lys 1 5 10
138110PRTArtificial SequenceSynthetic Polypeptide 1381Asp Asn Ile Asn Ile
Glu Glu Ala Ala Arg 1 5 10
138217PRTArtificial SequenceSynthetic Polypeptide 1382Ile Leu Val Asn His
Gln Ser Phe Pro Asn Glu Glu Asn Asp Val Asp 1 5
10 15 Lys 13837PRTArtificial
SequenceSynthetic Polypeptide 1383Leu Asp Gln Glu Thr Leu Arg 1
5 138417PRTArtificial SequenceSynthetic Polypeptide 1384Val
His Leu Pro Asn Gly Ser Pro Ile Pro Ala Val Leu Leu Ala Asn 1
5 10 15 Lys 138511PRTArtificial
SequenceSynthetic Polypeptide 1385Val Leu Val Ile Gly Glu Leu Gly Val Gly
Lys 1 5 10 138619PRTArtificial
SequenceSynthetic Polypeptide 1386Ala Glu Leu Asn Gln Ser Glu Glu Pro Glu
Ala Gly Glu Ser Ser Thr 1 5 10
15 Gly Gly Pro 13878PRTArtificial SequenceSynthetic
Polypeptide 1387Ile Gly Glu Pro Leu Val Leu Lys 1 5
138821PRTArtificial SequenceSynthetic Polypeptide 1388Val Leu Pro
Asn Gly Ser Leu Phe Leu Pro Ala Val Gly Ile Gln Asp 1 5
10 15 Glu Gly Ile Phe Arg
20 138915PRTArtificial SequenceSynthetic Polypeptide 1389Val Leu Ser
Pro Gln Gly Gly Gly Pro Trp Asp Ser Val Ala Arg 1 5
10 15 139024PRTArtificial SequenceSynthetic
Polypeptide 1390Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp Ser Ala
Ser Glu 1 5 10 15
Leu Thr Ala Gly Val Pro Asn Lys 20
139111PRTArtificial SequenceSynthetic Polypeptide 1391Phe Asn Val Trp Asp
Thr Ala Gly Gln Glu Lys 1 5 10
139211PRTArtificial SequenceSynthetic Polypeptide 1392Leu Val Leu Val Gly
Asp Gly Gly Thr Gly Lys 1 5 10
13937PRTArtificial SequenceSynthetic Polypeptide 1393Asn Val Pro Asn Trp
His Arg 1 5 139412PRTArtificial SequenceSynthetic
Polypeptide 1394Ala Ser Val Asp Glu Leu Phe Ala Glu Ile Val Arg 1
5 10 13958PRTArtificial
SequenceSynthetic Polypeptide 1395Glu Val Ser Tyr Gly Glu Gly Lys 1
5 139615PRTArtificial SequenceSynthetic Polypeptide
1396Ser Ala Leu Thr Val Gln Phe Val Thr Gly Ser Phe Ile Glu Lys 1
5 10 15 13977PRTArtificial
SequenceSynthetic Polypeptide 1397Val Asp Leu Glu Gly Glu Arg 1
5 139811PRTArtificial SequenceSynthetic Polypeptide 1398Val
Val Val Leu Gly Ser Gly Gly Val Gly Lys 1 5
10 139915PRTArtificial SequenceSynthetic Polypeptide 1399Ser Ala
Leu Thr Val Gln Phe Val Thr Gly Thr Phe Ile Glu Lys 1 5
10 15 14007PRTArtificial
SequenceSynthetic Polypeptide 1400Val Asp Leu Glu Pro Glu Arg 1
5 14019PRTArtificial SequenceSynthetic Polypeptide 1401Val
Pro Leu Ile Leu Val Gly Asn Lys 1 5
140214PRTArtificial SequenceSynthetic Polypeptide 1402Ala Gly Asp Gly Asp
Gly Trp Val Ser Leu Ala Glu Leu Arg 1 5
10 14039PRTArtificial SequenceSynthetic Polypeptide
1403Ala Trp Ile Ala His Thr Gln Gln Arg 1 5
140413PRTArtificial SequenceSynthetic Polypeptide 1404Asp Ile Val Ile
Ala Glu Thr Leu Glu Asp Leu Asp Arg 1 5
10 140513PRTArtificial SequenceSynthetic Polypeptide 1405Glu
Phe Asp Gln Leu Thr Pro Glu Glu Ser Gln Ala Arg 1 5
10 14067PRTArtificial SequenceSynthetic
Polypeptide 1406Val Gly Trp Glu Glu Leu Arg 1 5
14078PRTArtificial SequenceSynthetic Polypeptide 1407Val Phe Gln Phe Leu
Asn Ala Lys 1 5 14087PRTArtificial
SequenceSynthetic Polypeptide 1408Asp Val Asp Ala Val Asp Lys 1
5 140915PRTArtificial SequenceSynthetic Polypeptide 1409Glu
Leu Leu Gln Thr Glu Leu Ser Gly Phe Leu Asp Ala Gln Lys 1 5
10 15 141025PRTArtificial
SequenceSynthetic Polypeptide 1410Asp Gln Glu Val Asn Phe Gln Glu Tyr Val
Thr Phe Leu Gly Ala Leu 1 5 10
15 Ala Leu Ile Tyr Asn Glu Ala Leu Lys 20
25 14117PRTArtificial SequenceSynthetic Polypeptide 1411Glu Leu
Thr Ile Gly Ser Lys 1 5 14128PRTArtificial
SequenceSynthetic Polypeptide 1412Leu Gln Asp Ala Glu Ile Ala Arg 1
5 141313PRTArtificial SequenceSynthetic Polypeptide
1413Asp Pro Asn His Phe Arg Pro Ala Gly Leu Pro Glu Lys 1 5
10 14149PRTArtificial SequenceSynthetic
Polypeptide 1414Glu Ala Asn Tyr Ile Gly Ser Asp Lys 1 5
141520PRTArtificial SequenceSynthetic Polypeptide 1415Phe
Phe Gly His Gly Ala Glu Asp Ser Leu Ala Asp Gln Ala Ala Asn 1
5 10 15 Glu Trp Gly Arg
20 141614PRTArtificial SequenceSynthetic Polypeptide 1416Ser Phe Phe
Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala Arg 1 5
10 141716PRTArtificial SequenceSynthetic
Polypeptide 1417Phe Ser Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile
Asp Lys 1 5 10 15
14189PRTArtificial SequenceSynthetic Polypeptide 1418Leu Phe Thr Pro Glu
Glu Phe Phe Arg 1 5 14197PRTArtificial
SequenceSynthetic Polypeptide 1419Leu Val Ala Asn Leu Pro Lys 1
5 142034PRTArtificial SequenceSynthetic Polypeptide 1420Asp
Thr Gln Leu Leu Thr Ala Ile Pro Thr Ser Pro Glu Pro Thr Gly 1
5 10 15 Leu Glu Ala Thr Ala Ala
Ser Thr Ser Thr Leu Pro Ala Gly Glu Gly 20
25 30 Pro Lys 142117PRTArtificial
SequenceSynthetic Polypeptide 1421Glu Gly Glu Ala Val Val Leu Pro Glu Val
Glu Pro Gly Leu Thr Ala 1 5 10
15 Arg 14229PRTArtificial SequenceSynthetic Polypeptide
1422Glu Gln Glu Ala Thr Pro Arg Pro Arg 1 5
142329PRTArtificial SequenceSynthetic Polypeptide 1423Glu Thr Thr Gln
Leu Pro Thr Thr His Leu Ala Ser Thr Thr Thr Ala 1 5
10 15 Thr Thr Ala Gln Glu Pro Ala Thr Ser
His Pro His Arg 20 25
142412PRTArtificial SequenceSynthetic Polypeptide 1424Gln Ala Asn Gly Gly
Ala Tyr Gln Lys Pro Thr Lys 1 5 10
142513PRTArtificial SequenceSynthetic Polypeptide 1425Asp Ile Leu Gln
Leu Ile Gly Phe Ala Asn Leu Pro Arg 1 5
10 142611PRTArtificial SequenceSynthetic Polypeptide 1426Asp
Tyr Pro Asp Glu Val Leu Gln Phe Ala Arg 1 5
10 142711PRTArtificial SequenceSynthetic Polypeptide 1427Glu Val
Leu Trp Pro Pro Gln Pro Gly Gln Arg 1 5
10 142813PRTArtificial SequenceSynthetic Polypeptide 1428Leu Phe Leu
Gly Gly Leu Asp Ala Leu Tyr Ser Leu Arg 1 5
10 142924PRTArtificial SequenceSynthetic Polypeptide
1429Val Ile Ala Leu Gln Ala Gly Gly Ser Ala Glu Pro Glu Glu Val Val 1
5 10 15 Leu Glu Glu Leu
Gln Val Phe Lys 20 143012PRTArtificial
SequenceSynthetic Polypeptide 1430Leu Ala Tyr Val Tyr Gln Asn Asn Ile Tyr
Leu Lys 1 5 10
143125PRTArtificial SequenceSynthetic Polypeptide 1431Asn Val Asp Tyr Leu
Leu Ile His Gly Thr Ala Asp Asp Asn Val His 1 5
10 15 Phe Gln Asn Ser Ala Gln Ile Ala Lys
20 25 143211PRTArtificial SequenceSynthetic
Polypeptide 1432Gln Phe Val Tyr Leu Glu Ser Asp Tyr Ser Lys 1
5 10 143314PRTArtificial SequenceSynthetic
Polypeptide 1433Ser Val Phe Ala Val Asn Trp Ile Ser Tyr Leu Ala Ser Lys 1
5 10 14349PRTArtificial
SequenceSynthetic Polypeptide 1434Thr Gln Glu His Ile Glu Glu Ser Arg 1
5 14359PRTArtificial SequenceSynthetic
Polypeptide 1435Ala Val Leu Ser Ala Glu Gln Leu Arg 1 5
143613PRTArtificial SequenceSynthetic Polypeptide 1436Asp
Glu Glu Val His Ala Gly Leu Gly Glu Leu Leu Arg 1 5
10 143726PRTArtificial SequenceSynthetic
Polypeptide 1437Asp Gln Ala Val Glu Asn Ile Leu Val Ser Pro Val Val Val
Ala Ser 1 5 10 15
Ser Leu Gly Leu Val Ser Leu Gly Gly Lys 20
25 143812PRTArtificial SequenceSynthetic Polypeptide 1438Asp Thr Gln
Ser Gly Ser Leu Leu Phe Ile Gly Arg 1 5
10 143911PRTArtificial SequenceSynthetic Polypeptide 1439Gly Val
Val Glu Val Thr His Asp Leu Gln Lys 1 5
10 144021PRTArtificial SequenceSynthetic Polypeptide 1440Gly Pro Pro
Gly Leu Pro Ala His Leu Asp Glu Glu Leu Gln Ala Thr 1 5
10 15 Leu His Asp Phe Arg
20 14417PRTArtificial SequenceSynthetic Polypeptide 1441His Gln Ile
Leu Gln Thr Arg 1 5 144214PRTArtificial
SequenceSynthetic Polypeptide 1442Tyr Ser Asp Gly Thr Pro Val Asn Tyr Thr
Asn Trp Tyr Arg 1 5 10
14437PRTArtificial SequenceSynthetic Polypeptide 1443Val Pro Leu Pro Val
Asp Lys 1 5 144412PRTArtificial SequenceSynthetic
Polypeptide 1444Ala Gly Tyr Pro Leu Glu His Pro Phe Asp Phe Arg 1
5 10 144515PRTArtificial
SequenceSynthetic Polypeptide 1445Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser
Ala Val Leu Glu Lys 1 5 10
15 14466PRTArtificial SequenceSynthetic Polypeptide 1446Asp Phe Asp
Ile Tyr Arg 1 5 144718PRTArtificial SequenceSynthetic
Polypeptide 1447Gly Ile Phe Val Phe Gly Asn Pro Gln Leu Ser Val Ile Ala
Leu Gly 1 5 10 15
Ser Arg 144816PRTArtificial SequenceSynthetic Polypeptide 1448Thr Pro Glu
Ile Val Ala Pro Gln Ser Ala His Ala Ala Phe Asn Lys 1 5
10 15 144910PRTArtificial
SequenceSynthetic Polypeptide 1449Ala Tyr Glu Asp Glu Tyr Ser Tyr Phe Lys
1 5 10 145016PRTArtificial
SequenceSynthetic Polypeptide 1450Gly Gln Gly Tyr Asp Gly Tyr Asp Gly Gln
Asn Tyr Tyr His His Gln 1 5 10
15 145111PRTArtificial SequenceSynthetic Polypeptide 1451Ile
Glu Asp Ser Glu Glu Asn Gly Val Phe Lys 1 5
10 14528PRTArtificial SequenceSynthetic Polypeptide 1452Thr Thr
Ser Pro Pro Phe Gly Lys 1 5
145319PRTArtificial SequenceSynthetic Polypeptide 1453Thr Thr Thr Ser Pro
Asn Gly Gly Phe Glu Pro Thr Thr Pro Pro Gln 1 5
10 15 Val Tyr Arg 145426PRTArtificial
SequenceSynthetic Polypeptide 1454Ser Ser Gly Leu Phe Pro Phe Leu Val Leu
Leu Ala Leu Gly Thr Leu 1 5 10
15 Ala Pro Trp Ala Val Glu Gly Ser Gly Lys 20
25 14558PRTArtificial SequenceSynthetic Polypeptide
1455Asn Gln Gly Ser Gly Ala Gly Arg 1 5
145610PRTArtificial SequenceSynthetic Polypeptide 1456Val Ala Gln Leu Glu
Gln Val Tyr Ile Arg 1 5 10
14575PRTArtificial SequenceSynthetic Polypeptide 1457Asn Phe Phe Trp Lys
1 5 145814PRTArtificial SequenceSynthetic Polypeptide
1458Ala Ile Trp Asn Val Ile Asn Trp Glu Asn Val Thr Glu Arg 1
5 10 145925PRTArtificial
SequenceSynthetic Polypeptide 1459Phe Asn Gly Gly Gly His Ile Asn His Ser
Ile Phe Trp Thr Asn Leu 1 5 10
15 Ser Pro Asn Gly Gly Gly Glu Pro Lys 20
25 146014PRTArtificial SequenceSynthetic Polypeptide 1460Gly Asp
Val Thr Ala Gln Ile Ala Leu Gln Pro Ala Leu Lys 1 5
10 146120PRTArtificial SequenceSynthetic
Polypeptide 1461Leu Thr Ala Ala Ser Val Gly Val Gln Gly Ser Gly Trp Gly
Trp Leu 1 5 10 15
Gly Phe Asn Lys 20 14628PRTArtificial SequenceSynthetic
Polypeptide 1462Asn Val Arg Pro Asp Tyr Leu Lys 1 5
146311PRTArtificial SequenceSynthetic Polypeptide 1463Glu Asn Gln
Glu Val Ile Leu Glu Glu Val Arg 1 5 10
146415PRTArtificial SequenceSynthetic Polypeptide 1464Glu Ser Ala Pro
Gly Leu Ile Ile Ala Thr Gly Ser Val Gly Lys 1 5
10 15 146512PRTArtificial SequenceSynthetic
Polypeptide 1465Leu His Gly Gly Ser Ala Pro Leu Pro Gln Asp Arg 1
5 10 146610PRTArtificial
SequenceSynthetic Polypeptide 1466Gly Leu Val Leu Ser Gly Val Leu His Lys
1 5 10 146723PRTArtificial
SequenceSynthetic Polypeptide 1467Asn Leu Ile Pro Glu Gly Asn Ile Gly Ser
Asn Thr Thr Leu Val Leu 1 5 10
15 Val Asn Ala Ile Tyr Phe Lys 20
146816PRTArtificial SequenceSynthetic Polypeptide 1468Gln Tyr Thr Ser Phe
His Phe Ala Ser Leu Glu Asp Val Gln Ala Lys 1 5
10 15 14697PRTArtificial SequenceSynthetic
Polypeptide 1469Val Asp Leu His Leu Pro Arg 1 5
14707PRTArtificial SequenceSynthetic Polypeptide 1470Val Leu Glu Ile Pro
Tyr Lys 1 5 147114PRTArtificial SequenceSynthetic
Polypeptide 1471Asp Glu Leu Asn Ala Asp His Pro Phe Ile Tyr Ile Ile Arg 1
5 10 147221PRTArtificial
SequenceSynthetic Polypeptide 1472Asp Leu Thr Asp Gly His Phe Glu Asn Ile
Leu Ala Asp Asn Ser Val 1 5 10
15 Asn Asp Gln Thr Lys 20 147311PRTArtificial
SequenceSynthetic Polypeptide 1473Asp Val Glu Asp Glu Ser Thr Gly Leu Glu
Lys 1 5 10 147415PRTArtificial
SequenceSynthetic Polypeptide 1474Asp Val Pro Phe Gly Phe Gln Thr Val Thr
Ser Asp Val Asn Lys 1 5 10
15 147512PRTArtificial SequenceSynthetic Polypeptide 1475Ile Leu Val
Val Asn Ala Ala Tyr Phe Val Gly Lys 1 5
10 147612PRTArtificial SequenceSynthetic Polypeptide 1476Ala Phe
Ile Pro Pro Ala Pro Val Leu Pro Ser Arg 1 5
10 14777PRTArtificial SequenceSynthetic Polypeptide 1477Ala
Leu Pro Pro Ile Ala Arg 1 5 14788PRTArtificial
SequenceSynthetic Polypeptide 1478Trp Ser Gln Thr Ala Phe Pro Lys 1
5 14798PRTArtificial SequenceSynthetic Polypeptide
1479Tyr Ser Ile Thr Phe Thr Gly Lys 1 5
148010PRTArtificial SequenceSynthetic Polypeptide 1480Asp Glu Asp Asn Asn
Leu Leu Thr Glu Lys 1 5 10
14819PRTArtificial SequenceSynthetic Polypeptide 1481Asn Val Leu Val Thr
Leu Tyr Glu Arg 1 5 14828PRTArtificial
SequenceSynthetic Polypeptide 1482Glu Val Leu Asp Gln Val Glu Arg 1
5 148314PRTArtificial SequenceSynthetic Polypeptide
1483Gly Pro Ser Ala Ala Phe Ala Pro Ala Ala Ala Glu Pro Lys 1
5 10 148416PRTArtificial
SequenceSynthetic Polypeptide 1484Leu Phe Gly Gly Phe Asn Ser Ser Asp Thr
Val Thr Ser Pro Gln Arg 1 5 10
15 14859PRTArtificial SequenceSynthetic Polypeptide 1485Leu
Leu Leu Asn Ala Glu Asn Pro Arg 1 5
148615PRTArtificial SequenceSynthetic Polypeptide 1486Thr Gln Phe Asn Ser
Leu Gln Gln Leu Val Ala Tyr Tyr Ser Lys 1 5
10 15 148729PRTArtificial SequenceSynthetic
Polypeptide 1487Gly Thr Trp Asn Gly Pro Trp Val Ser Thr Glu Val Leu Ala
Ala Ala 1 5 10 15
Ile Gly Leu Val Ile Tyr Tyr Leu Ala Phe Ser Ala Lys 20
25 148819PRTArtificial SequenceSynthetic
Polypeptide 1488Asn Asn Glu Asp Ile Ser Ile Ile Pro Pro Leu Phe Thr Val
Ser Val 1 5 10 15
Asp His Arg 14896PRTArtificial SequenceSynthetic Polypeptide 1489Gln Phe
Pro Val Thr Arg 1 5 149010PRTArtificial
SequenceSynthetic Polypeptide 1490Ser Ala His Ala Gly Thr Tyr Glu Val Arg
1 5 10 149110PRTArtificial
SequenceSynthetic Polypeptide 1491Tyr Gln Val Ser Trp Ser Leu Asp His Lys
1 5 10 149217PRTArtificial
SequenceSynthetic Polypeptide 1492Phe Asn Gln Ala Gln Ser Gly Asn Ile Gln
Ser Thr Val Met Leu Asp 1 5 10
15 Lys 149316PRTArtificial SequenceSynthetic Polypeptide
1493Leu Leu Gly Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp Thr Arg 1
5 10 15
149413PRTArtificial SequenceSynthetic Polypeptide 1494Thr Glu Leu Ile Ser
Val Ser Glu Val His Pro Ser Arg 1 5 10
149513PRTArtificial SequenceSynthetic Polypeptide 1495Val Met
Ala Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys 1 5
10 149610PRTArtificial SequenceSynthetic Polypeptide
1496Tyr Thr Tyr Glu His Asp Pro Ile Thr Lys 1 5
10 149714PRTArtificial SequenceSynthetic Polypeptide 1497Ala Ile
Leu Ser Thr Lys Pro Pro Gly Thr Phe Leu Leu Arg 1 5
10 149821PRTArtificial SequenceSynthetic
Polypeptide 1498Glu Ser His Ala Thr Leu Val Phe His Asn Leu Leu Gly Glu
Ile Asp 1 5 10 15
Gln Gln Tyr Ser Arg 20 149916PRTArtificial
SequenceSynthetic Polypeptide 1499Leu Glu Asn Trp Ile Thr Ser Leu Ala Glu
Ser Gln Leu Gln Thr Arg 1 5 10
15 150026PRTArtificial SequenceSynthetic Polypeptide 1500Leu
Leu Gln Thr Ala Ala Thr Ala Ala Gln Gln Gly Gly Gln Ala Asn 1
5 10 15 His Pro Thr Ala Ala Val
Val Thr Glu Lys 20 25
150114PRTArtificial SequenceSynthetic Polypeptide 1501Val Val Glu Asn Leu
Gln Asp Asp Phe Asp Phe Asn Tyr Lys 1 5
10 15028PRTArtificial SequenceSynthetic Polypeptide
1502Ser Phe Leu Tyr Ser Ala Ala Lys 1 5
150311PRTArtificial SequenceSynthetic Polypeptide 1503Val Ala Ala Gln Asn
Ser Ala Glu Val Val Arg 1 5 10
150412PRTArtificial SequenceSynthetic Polypeptide 1504Glu Asn Asp Tyr Tyr
Thr Pro Thr Gly Glu Phe Arg 1 5 10
150515PRTArtificial SequenceSynthetic Polypeptide 1505Phe Glu Ser Val
Ile His Glu Phe Asp Pro Tyr Phe Asn Tyr Arg 1 5
10 15 15069PRTArtificial SequenceSynthetic
Polypeptide 1506Phe Leu Ala Glu Glu Gly Phe Tyr Lys 1 5
150711PRTArtificial SequenceSynthetic Polypeptide 1507Phe
Tyr Ser Leu Leu Asp Pro Ser Tyr Ala Lys 1 5
10 15087PRTArtificial SequenceSynthetic Polypeptide 1508Ile Ile
Phe Asp Asp Phe Arg 1 5 15099PRTArtificial
SequenceSynthetic Polypeptide 1509Ala Ala Glu Asp Tyr Gly Val Ile Lys 1
5 15108PRTArtificial SequenceSynthetic
Polypeptide 1510Leu Gly Phe Gln Val Trp Leu Lys 1 5
151114PRTArtificial SequenceSynthetic Polypeptide 1511Leu Val Asn
Ser Leu Tyr Pro Asp Gly Ser Lys Pro Val Lys 1 5
10 15126PRTArtificial SequenceSynthetic
Polypeptide 1512Asn Asp Gly His Tyr Arg 1 5
15137PRTArtificial SequenceSynthetic Polypeptide 1513Asn Gly Val Ile Leu
Ser Lys 1 5 15148PRTArtificial SequenceSynthetic
Polypeptide 1514Ala Gly Ser Glu Val Ile Ser Arg 1 5
151510PRTArtificial SequenceSynthetic Polypeptide 1515Ala Ser Ser
Thr Gln Gln Glu Ile Ser Arg 1 5 10
151611PRTArtificial SequenceSynthetic Polypeptide 1516Leu Gln Gly Glu Ala
Pro Gln Ser Ala Leu Arg 1 5 10
15179PRTArtificial SequenceSynthetic Polypeptide 1517Leu Ser Glu Glu Ile
Asp Gln Leu Arg 1 5 151812PRTArtificial
SequenceSynthetic Polypeptide 1518Tyr Gln Asp Val Tyr Val Glu Leu Ser His
Ile Lys 1 5 10
151915PRTArtificial SequenceSynthetic Polypeptide 1519Ala Val Phe Val Asp
Leu Glu Pro Thr Val Ile Asp Glu Val Arg 1 5
10 15 15209PRTArtificial SequenceSynthetic
Polypeptide 1520Glu Ile Ile Asp Leu Val Leu Asp Arg 1 5
152115PRTArtificial SequenceSynthetic Polypeptide 1521Ala
Ile Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg 1 5
10 15 152212PRTArtificial
SequenceSynthetic Polypeptide 1522Glu Val Asp Glu Gln Met Leu Asn Val Gln
Asn Lys 1 5 10
152310PRTArtificial SequenceSynthetic Polypeptide 1523Phe Pro Gly Gln Leu
Asn Ala Asp Leu Arg 1 5 10
152418PRTArtificial SequenceSynthetic Polypeptide 1524Gly His Tyr Thr Glu
Gly Ala Glu Leu Val Asp Ser Val Leu Asp Val 1 5
10 15 Val Arg 152510PRTArtificial
SequenceSynthetic Polypeptide 1525Ile Ser Glu Gln Phe Thr Ala Met Phe Arg
1 5 10 152610PRTArtificial
SequenceSynthetic Polypeptide 1526Leu Ala Val Asn Met Val Pro Phe Pro Arg
1 5 10 152714PRTArtificial
SequenceSynthetic Polypeptide 1527Leu His Phe Phe Met Pro Gly Phe Ala Pro
Leu Thr Ser Arg 1 5 10
152817PRTArtificial SequenceSynthetic Polypeptide 1528Met Ser Ala Thr Phe
Ile Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe 1 5
10 15 Lys 152914PRTArtificial
SequenceSynthetic Polypeptide 1529Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro
Asn Asn Val Lys 1 5 10
153026PRTArtificial SequenceSynthetic Polypeptide 1530Ser Gly Pro Phe Gly
Gln Ile Phe Arg Pro Asp Asn Phe Val Phe Gly 1 5
10 15 Gln Ser Gly Ala Gly Asn Asn Trp Ala Lys
20 25 153115PRTArtificial
SequenceSynthetic Polypeptide 1531Ala Leu Thr Val Pro Glu Leu Thr Gln Gln
Met Phe Asp Ala Lys 1 5 10
15 153212PRTArtificial SequenceSynthetic Polypeptide 1532Glu Val Asp
Glu Gln Met Leu Ala Ile Gln Ser Lys 1 5
10 153312PRTArtificial SequenceSynthetic Polypeptide 1533Ile Ser
Val Tyr Tyr Asn Glu Ala Ser Ser His Lys 1 5
10 153417PRTArtificial SequenceSynthetic Polypeptide 1534Met
Ser Ser Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe 1
5 10 15 Lys 15359PRTArtificial
SequenceSynthetic Polypeptide 1535Tyr Leu Thr Val Ala Thr Val Phe Arg 1
5 153612PRTArtificial SequenceSynthetic
Polypeptide 1536Ile Met Asn Thr Phe Ser Val Val Pro Ser Pro Lys 1
5 10 153717PRTArtificial
SequenceSynthetic Polypeptide 1537Met Ala Val Thr Phe Ile Gly Asn Ser Thr
Ala Ile Gln Glu Leu Phe 1 5 10
15 Lys 15389PRTArtificial SequenceSynthetic Polypeptide
1538Tyr Leu Thr Val Ala Ala Val Phe Arg 1 5
153911PRTArtificial SequenceSynthetic Polypeptide 1539Phe Ala Thr Glu
Ala Ala Ile Thr Ile Leu Arg 1 5 10
154011PRTArtificial SequenceSynthetic Polypeptide 1540Ile His Pro Thr Ser
Val Ile Ser Gly Tyr Arg 1 5 10
154112PRTArtificial SequenceSynthetic Polypeptide 1541Leu Gly Val Gln Val
Val Ile Thr Asp Pro Glu Lys 1 5 10
154210PRTArtificial SequenceSynthetic Polypeptide 1542Ser Ser Leu Gly
Pro Val Gly Leu Asp Lys 1 5 10
154315PRTArtificial SequenceSynthetic Polypeptide 1543Tyr Ile Asn Glu Asn
Leu Ile Val Asn Thr Asp Glu Leu Gly Arg 1 5
10 15 15448PRTArtificial SequenceSynthetic
Polypeptide 1544Ala Tyr Ile Leu Asn Leu Val Lys 1 5
154514PRTArtificial SequenceSynthetic Polypeptide 1545Gly Asp Val
Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Lys 1 5
10 154613PRTArtificial SequenceSynthetic
Polypeptide 1546Gly Ile His Pro Thr Ile Ile Ser Glu Ser Phe Gln Lys 1
5 10 15478PRTArtificial
SequenceSynthetic Polypeptide 1547Ile Asp Asp Val Val Asn Thr Arg 1
5 154813PRTArtificial SequenceSynthetic Polypeptide
1548Val Ile Asp Pro Ala Thr Ala Thr Ser Val Asp Leu Arg 1 5
10 154910PRTArtificial SequenceSynthetic
Polypeptide 1549Ala Val Asp Asp Gly Val Asn Thr Phe Lys 1 5
10 155010PRTArtificial SequenceSynthetic Polypeptide
1550Asp Ile Asp Glu Val Ser Ser Leu Leu Arg 1 5
10 155111PRTArtificial SequenceSynthetic Polypeptide 1551Leu Ala
Thr Asn Ala Ala Val Thr Val Leu Arg 1 5
10 155210PRTArtificial SequenceSynthetic Polypeptide 1552Leu Tyr Ala
Val His Gln Glu Gly Asn Lys 1 5 10
155314PRTArtificial SequenceSynthetic Polypeptide 1553Asn Val Gly Leu Asp
Ile Glu Ala Glu Val Pro Ala Val Lys 1 5
10 15549PRTArtificial SequenceSynthetic Polypeptide
1554Ala Leu Gln Phe Leu Glu Glu Val Lys 1 5
155513PRTArtificial SequenceSynthetic Polypeptide 1555Ala Gln Ala Ala
Leu Ala Val Asn Ile Ser Ala Ala Arg 1 5
10 155617PRTArtificial SequenceSynthetic Polypeptide 1556Ala
Gln Leu Gly Val Gln Ala Phe Ala Asp Ala Leu Leu Ile Ile Pro 1
5 10 15 Lys 155712PRTArtificial
SequenceSynthetic Polypeptide 1557Gly Ile Asp Pro Phe Ser Leu Asp Ala Leu
Ser Lys 1 5 10
15589PRTArtificial SequenceSynthetic Polypeptide 1558Gly Leu Val Leu Asp
His Gly Ala Arg 1 5 155913PRTArtificial
SequenceSynthetic Polypeptide 1559Gln Ala Asp Leu Tyr Ile Ser Glu Gly Leu
His Pro Arg 1 5 10
156010PRTArtificial SequenceSynthetic Polypeptide 1560Thr Glu Val Asn Ser
Gly Phe Phe Tyr Lys 1 5 10
156125PRTArtificial SequenceSynthetic Polypeptide 1561Val Ala Thr Ala Gln
Asp Asp Ile Thr Gly Asp Gly Thr Thr Ser Asn 1 5
10 15 Val Leu Ile Ile Gly Glu Leu Leu Lys
20 25 156221PRTArtificial SequenceSynthetic
Polypeptide 1562Val His Ala Glu Leu Ala Asp Val Leu Thr Glu Ala Val Val
Asp Ser 1 5 10 15
Ile Leu Ala Ile Lys 20 156316PRTArtificial
SequenceSynthetic Polypeptide 1563Val Leu Ala Gln Asn Ser Gly Phe Asp Leu
Gln Glu Thr Leu Val Lys 1 5 10
15 156413PRTArtificial SequenceSynthetic Polypeptide 1564His
Phe Asn Val Asn Thr Asp Tyr Gln Asn Pro Val Arg 1 5
10 156525PRTArtificial SequenceSynthetic
Polypeptide 1565Ser Glu Asp Glu Glu Asp Leu Gly Asn Ala Arg Pro Ser Ala
Pro Ser 1 5 10 15
Thr Leu Phe Asp Phe Leu Glu Ser Lys 20 25
156618PRTArtificial SequenceSynthetic Polypeptide 1566Ser Asn Ile Gly Thr
Glu Gly Gly Pro Pro Pro Phe Val Pro Phe Gly 1 5
10 15 Gln Lys 156710PRTArtificial
SequenceSynthetic Polypeptide 1567Ser Val Leu Glu Gly Ser Gly Leu Pro Arg
1 5 10 15689PRTArtificial
SequenceSynthetic Polypeptide 1568Thr Ala Ala Ile Ala Glu Val Ala Lys 1
5 156914PRTArtificial SequenceSynthetic
Polypeptide 1569Ala Val Asp Ile Pro Gly Leu Glu Ala Ala Thr Pro Tyr Arg 1
5 10 157016PRTArtificial
SequenceSynthetic Polypeptide 1570Gly Leu Glu Pro Gly Gln Glu Tyr Asn Val
Leu Leu Thr Ala Glu Lys 1 5 10
15 157125PRTArtificial SequenceSynthetic Polypeptide 1571Thr
Ala His Ile Ser Gly Leu Pro Pro Ser Thr Asp Phe Ile Val Tyr 1
5 10 15 Leu Ser Gly Leu Ala Pro
Ser Ile Arg 20 25 157223PRTArtificial
SequenceSynthetic Polypeptide 1572Thr Val Ser Gly Asn Thr Val Glu Tyr Ala
Leu Thr Asp Leu Glu Pro 1 5 10
15 Ala Thr Glu Tyr Thr Leu Arg 20
157316PRTArtificial SequenceSynthetic Polypeptide 1573Tyr Ala Pro Ile Ser
Gly Gly Asp His Ala Glu Val Asp Val Pro Lys 1 5
10 15 157416PRTArtificial SequenceSynthetic
Polypeptide 1574Asp Ala Gln Gly Gln Pro Gln Ala Val Pro Val Ser Gly Asp
Leu Arg 1 5 10 15
157523PRTArtificial SequenceSynthetic Polypeptide 1575Gly Phe Glu Glu Ser
Glu Pro Leu Thr Gly Phe Leu Thr Thr Val Pro 1 5
10 15 Asp Gly Pro Thr Gln Leu Arg
20 157618PRTArtificial SequenceSynthetic Polypeptide 1576Val
Pro Gly His Glu Asp Gly Val Thr Ile Ser Gly Leu Glu Pro Asp 1
5 10 15 His Lys
157721PRTArtificial SequenceSynthetic Polypeptide 1577Val Ser Tyr Gln Leu
Ala Asp Gly Gly Glu Pro Gln Ser Val Gln Val 1 5
10 15 Asp Gly Gln Ala Arg 20
15789PRTArtificial SequenceSynthetic Polypeptide 1578Tyr Glu Val Thr Val
Val Ser Val Arg 1 5 157912PRTArtificial
SequenceSynthetic Polypeptide 1579Gly Ile Leu Leu Tyr Gly Pro Pro Gly Thr
Gly Lys 1 5 10
158017PRTArtificial SequenceSynthetic Polypeptide 1580Gly Pro Glu Leu Leu
Thr Met Trp Phe Gly Glu Ser Glu Ala Asn Val 1 5
10 15 Arg 158113PRTArtificial
SequenceSynthetic Polypeptide 1581Ile Val Ser Gln Leu Leu Thr Leu Met Asp
Gly Leu Lys 1 5 10
158213PRTArtificial SequenceSynthetic Polypeptide 1582Leu Asp Gln Leu Ile
Tyr Ile Pro Leu Pro Asp Glu Lys 1 5 10
158320PRTArtificial SequenceSynthetic Polypeptide 1583Leu Ile
Val Asp Glu Ala Ile Asn Glu Asp Asn Ser Val Val Ser Leu 1 5
10 15 Ser Gln Pro Lys
20 15848PRTArtificial SequenceSynthetic Polypeptide 1584Met Asp Glu Leu
Gln Leu Phe Arg 1 5 158517PRTArtificial
SequenceSynthetic Polypeptide 1585Asn Ala Pro Ala Ile Ile Phe Ile Asp Glu
Leu Asp Ala Ile Ala Pro 1 5 10
15 Lys 158615PRTArtificial SequenceSynthetic Polypeptide
1586Val Ile Asn Gln Ile Leu Thr Glu Met Asp Gly Met Ser Thr Lys 1
5 10 15 158712PRTArtificial
SequenceSynthetic Polypeptide 1587Trp Ala Leu Ser Gln Ser Asn Pro Ser Ala
Leu Arg 1 5 10
158821PRTArtificial SequenceSynthetic Polypeptide 1588Gly Gly Thr Leu Ser
Thr Pro Gln Thr Gly Ser Glu Asn Asp Ala Leu 1 5
10 15 Tyr Glu Tyr Leu Arg 20
158912PRTArtificial SequenceSynthetic Polypeptide 1589Leu Asp Thr Leu Ala
Gln Glu Val Ala Leu Leu Lys 1 5 10
159014PRTArtificial SequenceSynthetic Polypeptide 1590Asn Trp Glu Thr
Glu Ile Thr Ala Gln Pro Asp Gly Gly Lys 1 5
10 159110PRTArtificial SequenceSynthetic Polypeptide
1591Asp Leu Ile Tyr Thr Leu Tyr Tyr Trp Lys 1 5
10 15928PRTArtificial SequenceSynthetic Polypeptide 1592Glu Asn
Ser Pro Leu Asn Val Ser 1 5
159321PRTArtificial SequenceSynthetic Polypeptide 1593Thr Ile Leu Glu Trp
Glu Pro Lys Pro Val Asn Gln Val Tyr Thr Val 1 5
10 15 Gln Ile Ser Thr Lys 20
159412PRTArtificial SequenceSynthetic Polypeptide 1594Thr Asn Thr Asn Glu
Phe Leu Ile Asp Val Asp Lys 1 5 10
15959PRTArtificial SequenceSynthetic Polypeptide 1595Val Asn Val Thr
Val Glu Asp Glu Arg 1 5
159615PRTArtificial SequenceSynthetic Polypeptide 1596Gly Phe Val Glu Pro
Asp His Tyr Val Val Val Gly Ala Gln Arg 1 5
10 15 159710PRTArtificial SequenceSynthetic
Polypeptide 1597Leu Thr Thr Asp Phe Gly Asn Ala Glu Lys 1 5
10 15988PRTArtificial SequenceSynthetic Polypeptide
1598Leu Thr Val Ser Asn Val Leu Lys 1 5
159916PRTArtificial SequenceSynthetic Polypeptide 1599Ser Ala Phe Ser Asn
Leu Phe Gly Gly Glu Pro Leu Ser Tyr Thr Arg 1 5
10 15 160014PRTArtificial SequenceSynthetic
Polypeptide 1600Ser Ser Gly Leu Pro Asn Ile Pro Val Gln Thr Ile Ser Arg 1
5 10 16019PRTArtificial
SequenceSynthetic Polypeptide 1601His Glu Lys Pro Ser Ala Leu Leu Lys 1
5 16029PRTArtificial SequenceSynthetic
Polypeptide 1602Asp Glu Leu Asn Gly Phe Phe Asn Lys 1 5
160315PRTArtificial SequenceSynthetic Polypeptide 1603His
Pro Lys Pro Ser Pro Phe Ile Gly Asn Leu Thr Phe Phe Arg 1 5
10 15 160416PRTArtificial
SequenceSynthetic Polypeptide 1604Gln Gln His Arg Pro Phe Thr Tyr Leu Pro
Phe Gly Ala Gly Pro Arg 1 5 10
15 160513PRTArtificial SequenceSynthetic Polypeptide 1605Gln
Val Leu Val Glu Asn Phe Ser Asn Phe Thr Asn Arg 1 5
10 160610PRTArtificial SequenceSynthetic
Polypeptide 1606Ser Val Ala Asp Ser Val Leu Phe Leu Arg 1 5
10 160717PRTArtificial SequenceSynthetic Polypeptide
1607His Glu Asn Thr Ser Ser Ser Pro Ile Gln Tyr Glu Phe Ser Leu Thr 1
5 10 15 Arg
160810PRTArtificial SequenceSynthetic Polypeptide 1608Val Leu Tyr Leu Ser
Ala Phe Thr Ser Lys 1 5 10
160915PRTArtificial SequenceSynthetic Polypeptide 1609Phe Val Gly Thr Pro
Glu Val Asn Gln Thr Thr Leu Tyr Gln Arg 1 5
10 15 161012PRTArtificial SequenceSynthetic
Polypeptide 1610Gly Phe Gln Ala Leu Gly Asp Ala Ala Asp Ile Arg 1
5 10 16119PRTArtificial
SequenceSynthetic Polypeptide 1611Ser Glu Glu Phe Leu Ile Ala Gly Lys 1
5 161212PRTArtificial SequenceSynthetic
Polypeptide 1612Glu Gly Pro Phe Gly Thr Leu Val Tyr Thr Ile Lys 1
5 10 16137PRTArtificial
SequenceSynthetic Polypeptide 1613Gly Trp Ala Pro Pro Asp Lys 1
5 16148PRTArtificial SequenceSynthetic Polypeptide 1614Ser
Ile Ile Asn Ala Thr Asp Pro 1 5
16158PRTArtificial SequenceSynthetic Polypeptide 1615Tyr Gln Tyr Leu Leu
Thr Gly Arg 1 5 161612PRTArtificial
SequenceSynthetic Polypeptide 1616Asp Gly Thr Ser Glu Asn Ser Pro Leu Ile
Gly Arg 1 5 10
161711PRTArtificial SequenceSynthetic Polypeptide 1617Ile Pro Asp Pro Leu
Val Ala Thr Gly Asn Lys 1 5 10
161812PRTArtificial SequenceSynthetic Polypeptide 1618Leu Asn Gly Thr Ile
Thr Thr Pro Gly Trp Pro Lys 1 5 10
161911PRTArtificial SequenceSynthetic Polypeptide 1619Val Pro Leu Gln
Phe Ser Gly Gln Asn Glu Lys 1 5 10
162015PRTArtificial SequenceSynthetic Polypeptide 1620Tyr Asp Tyr Val Glu
Ile Trp Ser Gly Leu Ser Ser Glu Ser Lys 1 5
10 15 162114PRTArtificial SequenceSynthetic
Polypeptide 1621Ala Ala Pro Phe Leu Thr Tyr Phe Gly Leu Phe Gln Val His 1
5 10 16228PRTArtificial
SequenceSynthetic Polypeptide 1622Ile Asn Ser Ser Ser Pro Leu Arg 1
5 162312PRTArtificial SequenceSynthetic Polypeptide
1623Leu Asp Leu Leu Val Asp Gly Val Leu Ala Leu Arg 1 5
10 16249PRTArtificial SequenceSynthetic
Polypeptide 1624Gln Ile Gly Glu Phe Ile Val Thr Arg 1 5
16258PRTArtificial SequenceSynthetic Polypeptide 1625Thr
Leu Pro Trp Ala His Leu Lys 1 5
162612PRTArtificial SequenceSynthetic Polypeptide 1626Asp Ile Thr Ser Asp
Ser Glu Asn Ser Asn Phe Arg 1 5 10
16277PRTArtificial SequenceSynthetic Polypeptide 1627Ile Gln Thr Ile
Ile Leu Lys 1 5 162811PRTArtificial
SequenceSynthetic Polypeptide 1628Asn Asp Asn Val Gln Asp Thr Ala Glu Gln
Lys 1 5 10 16297PRTArtificial
SequenceSynthetic Polypeptide 1629Asn Glu Ile Gln Ser Leu Val 1
5 163012PRTArtificial SequenceSynthetic Polypeptide 1630Ser
Val Asn Ala Gln Val Thr Asp Ile Asn Ser Lys 1 5
10 163129PRTArtificial SequenceSynthetic Polypeptide
1631Glu Leu Ala Ser Gln Pro Asp Val Asp Gly Phe Leu Val Gly Gly Ala 1
5 10 15 Ser Leu Lys Pro
Glu Phe Val Asp Ile Ile Asn Ala Lys 20 25
163212PRTArtificial SequenceSynthetic Polypeptide 1632Ser
Asn Val Ser Asp Ala Val Ala Gln Ser Thr Arg 1 5
10 163313PRTArtificial SequenceSynthetic Polypeptide
1633Thr Ala Thr Pro Gln Gln Ala Gln Glu Val His Glu Lys 1 5
10 16347PRTArtificial SequenceSynthetic
Polypeptide 1634Val Val Phe Glu Gln Thr Lys 1 5
163515PRTArtificial SequenceSynthetic Polypeptide 1635Val Val Leu Ala Tyr
Glu Pro Val Trp Ala Ile Gly Thr Gly Lys 1 5
10 15 163620PRTArtificial SequenceSynthetic
Polypeptide 1636Ala Asp Ala Val Thr Leu Asp Gly Gly Phe Ile Tyr Glu Ala
Gly Leu 1 5 10 15
Ala Pro Tyr Lys 20 163711PRTArtificial SequenceSynthetic
Polypeptide 1637Phe Gln Leu Phe Gly Ser Pro Ser Gly Gln Lys 1
5 10 163813PRTArtificial SequenceSynthetic
Polypeptide 1638Leu Arg Pro Val Ala Ala Glu Val Tyr Gly Thr Glu Arg 1
5 10 16399PRTArtificial
SequenceSynthetic Polypeptide 1639Val Pro Ser His Ala Val Val Ala Arg 1
5 16409PRTArtificial SequenceSynthetic
Polypeptide 1640Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg 1 5
16419PRTArtificial SequenceSynthetic Polypeptide 1641Phe
Gln Asp Leu Val Asp Ala Val Arg 1 5
164218PRTArtificial SequenceSynthetic Polypeptide 1642Phe Thr Gly Ser Gln
Pro Phe Gly Gln Gly Val Glu His Ala Thr Ala 1 5
10 15 Asn Lys 164312PRTArtificial
SequenceSynthetic Polypeptide 1643Phe Val Phe Gly Thr Thr Pro Glu Asp Ile
Leu Arg 1 5 10
16449PRTArtificial SequenceSynthetic Polypeptide 1644Gly Phe Leu Leu Leu
Ala Ser Leu Arg 1 5 164512PRTArtificial
SequenceSynthetic Polypeptide 1645Gly Thr Ser Gln Asn Asp Pro Asn Trp Val
Val Arg 1 5 10
164622PRTArtificial SequenceSynthetic Polypeptide 1646Thr Ser Glu Ser Gly
Glu Leu His Gly Leu Thr Thr Glu Glu Glu Phe 1 5
10 15 Val Glu Gly Ile Tyr Lys 20
16476PRTArtificial SequenceSynthetic Polypeptide 1647Val Glu Ile
Asp Thr Lys 1 5 164811PRTArtificial SequenceSynthetic
Polypeptide 1648Ala Leu Gln Glu Ala Leu Val Leu Ser Asp Arg 1
5 10 164917PRTArtificial SequenceSynthetic
Polypeptide 1649Glu Gln Glu Glu Leu Leu Ala Pro Ala Asp Gly Thr Val Glu
Leu Val 1 5 10 15
Arg 16507PRTArtificial SequenceSynthetic Polypeptide 1650Leu Ser Glu Ala
Asp Ile Arg 1 5 165112PRTArtificial
SequenceSynthetic Polypeptide 1651Thr Leu Val Gly Val Gly Ala Ser Leu Gly
Leu Arg 1 5 10
165213PRTArtificial SequenceSynthetic Polypeptide 1652Val Ala Ala Ala Leu
Asp Asp Gly Ser Ala Leu Gly Arg 1 5 10
16539PRTArtificial SequenceSynthetic Polypeptide 1653Asp Leu
Ser Gln Asn Phe Pro Thr Lys 1 5
16549PRTArtificial SequenceSynthetic Polypeptide 1654Phe Thr Ile Leu Asp
Ser Gln Gly Lys 1 5 165525PRTArtificial
SequenceSynthetic Polypeptide 1655Ile Ile Gly Pro Leu Glu Asp Ser Glu Leu
Phe Asn Gln Asp Asp Phe 1 5 10
15 His Leu Leu Glu Asn Ile Ile Leu Lys 20
25 165613PRTArtificial SequenceSynthetic Polypeptide 1656Leu Gly
Ile Glu Gly Leu Ser Leu His Asn Val Leu Lys 1 5
10 165717PRTArtificial SequenceSynthetic Polypeptide
1657Tyr Val Leu Glu Pro Glu Ile Ser Phe Thr Ser Asp Asn Ser Phe Ala 1
5 10 15 Lys
16589PRTArtificial SequenceSynthetic Polypeptide 1658Ala Asn Pro Gly Ala
Trp Ile Leu Arg 1 5 165919PRTArtificial
SequenceSynthetic Polypeptide 1659Phe Leu Gly Pro Leu Asp Glu Asp Phe Tyr
Ala Glu Asp Phe Tyr Leu 1 5 10
15 Leu Glu Lys 166011PRTArtificial SequenceSynthetic
Polypeptide 1660Ile Ile Phe Val Asp Ala Asp Gln Ile Val Arg 1
5 10 166114PRTArtificial SequenceSynthetic
Polypeptide 1661Ile Leu Phe Leu Asp Val Leu Phe Pro Leu Ala Val Asp Lys 1
5 10 166210PRTArtificial
SequenceSynthetic Polypeptide 1662Ile Asn Glu Glu Asn Thr Ala Ile Ser Arg
1 5 10 166310PRTArtificial
SequenceSynthetic Polypeptide 1663Gly Gly Thr Leu Thr Gln Tyr Glu Gly Lys
1 5 10 166412PRTArtificial
SequenceSynthetic Polypeptide 1664Gly Leu Pro Asp Asn Ile Ser Ser Val Leu
Asn Lys 1 5 10
166512PRTArtificial SequenceSynthetic Polypeptide 1665Gly Thr Val Ile Ile
Ile Ala Asn His Gly Asp Arg 1 5 10
166612PRTArtificial SequenceSynthetic Polypeptide 1666Ile Asp Ile Pro
Pro Gly Ala Val Leu Glu Asn Lys 1 5 10
166715PRTArtificial SequenceSynthetic Polypeptide 1667Ile Phe Asn
Thr Asn Asn Leu Trp Ile Ser Leu Ala Ala Val Lys 1 5
10 15 166814PRTArtificial SequenceSynthetic
Polypeptide 1668Ile Gln Arg Pro Pro Glu Asp Ser Ile Gln Pro Tyr Glu Lys 1
5 10 16699PRTArtificial
SequenceSynthetic Polypeptide 1669Leu Val Glu Ile Ala Gln Val Pro Lys 1
5 167018PRTArtificial SequenceSynthetic
Polypeptide 1670Asn Glu Asn Thr Phe Leu Asp Leu Thr Val Gln Gln Ile Glu
His Leu 1 5 10 15
Asn Lys 167112PRTArtificial SequenceSynthetic Polypeptide 1671Ser Phe Glu
Asn Ser Leu Gly Ile Asn Val Pro Arg 1 5
10 167220PRTArtificial SequenceSynthetic Polypeptide 1672Thr Leu
Asp Gly Gly Leu Asn Val Ile Gln Leu Glu Thr Ala Val Gly 1 5
10 15 Ala Ala Ile Lys
20 167313PRTArtificial SequenceSynthetic Polypeptide 1673Leu Trp Glu Glu
Gly Glu Glu Leu Glu Leu Val Glu Lys 1 5
10 16749PRTArtificial SequenceSynthetic Polypeptide 1674Leu
Trp Gly Gly Thr Leu Leu Trp Thr 1 5
167510PRTArtificial SequenceSynthetic Polypeptide 1675Leu Val Asp Thr Leu
Pro Gln Lys Pro Arg 1 5 10
167627PRTArtificial SequenceSynthetic Polypeptide 1676Val Ile Glu Thr Leu
Leu Met Asp Thr Pro Ser Ser Tyr Glu Ala Ala 1 5
10 15 Met Glu Leu Phe Ser Pro Asp Gln Asp Met
Arg 20 25 16778PRTArtificial
SequenceSynthetic Polypeptide 1677Ala Asp Asp Tyr Glu Gln Val Lys 1
5 167827PRTArtificial SequenceSynthetic Polypeptide
1678Leu His Leu Gln Ser Thr Asp Tyr Gly Asn Phe Leu Ala Asn Glu Ala 1
5 10 15 Ser Pro Leu Thr
Val Ser Val Ile Asp Asp Arg 20 25
167913PRTArtificial SequenceSynthetic Polypeptide 1679Leu Leu Phe Glu Gly
Ala Gly Ser Asn Pro Gly Asp Lys 1 5 10
168011PRTArtificial SequenceSynthetic Polypeptide 1680Leu Tyr
Pro Glu Gly Leu Ala Gln Leu Ala Arg 1 5
10 168110PRTArtificial SequenceSynthetic Polypeptide 1681Asn Val Ala
Asp Tyr Tyr Pro Glu Tyr Lys 1 5 10
168210PRTArtificial SequenceSynthetic Polypeptide 1682Leu Gln Ala Glu Thr
Glu Leu Ile Asn Arg 1 5 10
168313PRTArtificial SequenceSynthetic Polypeptide 1683Asn Asp Gln Asn Leu
Tyr Gln Val Phe Ile Asn Tyr Lys 1 5 10
168426PRTArtificial SequenceSynthetic Polypeptide 1684Gln Phe
Gln Leu Ser Ile Glu Asn Leu Asn Gln Pro Val Leu Leu Phe 1 5
10 15 Gly Arg Pro Gln Gly Asp Gly
Glu Ile Arg 20 25 168525PRTArtificial
SequenceSynthetic Polypeptide 1685Thr Pro Ile Ala Leu Ala Thr Gly Ile Arg
Pro Phe Pro Thr Glu Glu 1 5 10
15 Ser Ile Asn Asp Glu Asp Ile Tyr Lys 20
25 168616PRTArtificial SequenceSynthetic Polypeptide 1686Val Thr
Trp Asp Ser Ala Gln Val Phe Asp Leu Ala Gln Thr Leu Arg 1 5
10 15 16877PRTArtificial
SequenceSynthetic Polypeptide 1687Gln Leu Glu Leu Asn Glu Arg 1
5 16889PRTArtificial SequenceSynthetic Polypeptide 1688Ser
Trp Ser Val Tyr Val Gly Ala Arg 1 5
16897PRTArtificial SequenceSynthetic Polypeptide 1689Asp Leu Glu Glu Gln
Leu Arg 1 5 169031PRTArtificial SequenceSynthetic
Polypeptide 1690Glu Ala Pro Ala Ala Ala Ala Ala Phe Glu Ser Gly Leu Asp
Leu Ser 1 5 10 15
Asp Ala Glu Pro Asp Ala Gly Glu Ala Thr Ala Tyr Ala Ser Lys
20 25 30 16918PRTArtificial
SequenceSynthetic Polypeptide 1691Glu Gln Ala Asn Leu Asn Ser Arg 1
5 169212PRTArtificial SequenceSynthetic Polypeptide
1692Phe Ala Ala Ala His Tyr Asn Thr Glu Ile Leu Lys 1 5
10 16938PRTArtificial SequenceSynthetic
Polypeptide 1693Asn Gln Pro Leu Asn Pro Gly Lys 1 5
169410PRTArtificial SequenceSynthetic Polypeptide 1694Ala Ala Ser
Ser Leu Glu Glu Leu Leu Arg 1 5 10
16957PRTArtificial SequenceSynthetic Polypeptide 1695Asp Leu Ile Gln His
Pro Lys 1 5 169612PRTArtificial SequenceSynthetic
Polypeptide 1696Phe Ala Ala Thr Phe Tyr Asp Ile Glu Thr Leu Lys 1
5 10 169719PRTArtificial
SequenceSynthetic Polypeptide 1697Gln Leu Phe Glu Ile Ser Val Pro Leu Thr
Ser Val Pro Glu Leu Val 1 5 10
15 Pro Val Lys 16988PRTArtificial SequenceSynthetic
Polypeptide 1698Val Ile Asp Glu Glu Trp Gln Arg 1 5
169911PRTArtificial SequenceSynthetic Polypeptide 1699Ala Phe Pro
Ser Pro Glu Val Val Trp Leu Lys 1 5 10
170016PRTArtificial SequenceSynthetic Polypeptide 1700Ala Val Ser Ser
Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser Arg 1 5
10 15 170117PRTArtificial
SequenceSynthetic Polypeptide 1701Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr
Val Gln Gly Thr Ser Asp 1 5 10
15 Lys 170214PRTArtificial SequenceSynthetic Polypeptide
1702Leu Gly Asp Leu Leu Gln Ala Asn Val Gln Gln Asp Gly Lys 1
5 10 170311PRTArtificial
SequenceSynthetic Polypeptide 1703Asn Ile Leu Leu Ser Glu Asn Asn Val Val
Lys 1 5 10 170423PRTArtificial
SequenceSynthetic Polypeptide 1704Ala Thr Trp Leu Ser Leu Phe Ser Ser Glu
Glu Ser Asn Leu Gly Ala 1 5 10
15 Asn Asn Tyr Asp Asp Tyr Arg 20
17058PRTArtificial SequenceSynthetic Polypeptide 1705Ala Val Arg Pro Gly
Tyr Pro Lys 1 5 170614PRTArtificial
SequenceSynthetic Polypeptide 1706Asp Ser Trp Glu Asp Ile Phe Glu Leu Leu
Phe Trp Gly Arg 1 5 10
170715PRTArtificial SequenceSynthetic Polypeptide 1707Asp Val Trp Gly Ile
Glu Gly Pro Ile Asp Ala Ala Phe Thr Arg 1 5
10 15 170812PRTArtificial SequenceSynthetic
Polypeptide 1708Phe Glu Asp Gly Val Leu Asp Pro Asp Tyr Pro Arg 1
5 10 17099PRTArtificial
SequenceSynthetic Polypeptide 1709Ala Gly Asp Leu Gln Val Arg Pro Arg 1
5 171011PRTArtificial SequenceSynthetic
Polypeptide 1710Gln Ala Trp Val Ser Gln Gly Gly Gly Ala Lys 1
5 10 17119PRTArtificial SequenceSynthetic
Polypeptide 1711Val Asn Glu Leu Gly Arg Pro Ala Arg 1 5
17127PRTArtificial SequenceSynthetic Polypeptide 1712Glu
Asn Arg Pro Asp Ala Arg 1 5 171319PRTArtificial
SequenceSynthetic Polypeptide 1713Glu Ser Ala Phe Val His Ala Ile Ala Ser
Ala Gly Val Ala Phe Ala 1 5 10
15 Val Thr Arg 17149PRTArtificial SequenceSynthetic
Polypeptide 1714Gly Trp Val Glu Thr Leu Arg Pro Arg 1 5
17157PRTArtificial SequenceSynthetic Polypeptide 1715His
Gln Gly Ser Pro Gly Lys 1 5 17165PRTArtificial
SequenceSynthetic Polypeptide 1716Tyr Thr Tyr Phe Lys 1 5
171711PRTArtificial SequenceSynthetic Polypeptide 1717Gly Val Ala Ala Gly
Ser Ser Ser Ser Val Lys 1 5 10
17188PRTArtificial SequenceSynthetic Polypeptide 1718Ile His Thr His Gly
Val Phe Arg 1 5 171932PRTArtificial
SequenceSynthetic Polypeptide 1719Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp
Gly Thr Pro Ser Tyr Gly 1 5 10
15 His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
Lys 20 25 30
17206PRTArtificial SequenceSynthetic Polypeptide 1720Ser Asp Glu Leu Val
Arg 1 5 172118PRTArtificial SequenceSynthetic
Polypeptide 1721Tyr Gly Pro Phe Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser
Gly Gln 1 5 10 15
Ala Arg 172218PRTArtificial SequenceSynthetic Polypeptide 1722Asp Ile Val
Glu Tyr Tyr Asn Asp Ser Asn Gly Ser His Val Leu Gln 1 5
10 15 Gly Arg 17237PRTArtificial
SequenceSynthetic Polypeptide 1723Asp Tyr Ile Glu Phe Asn Lys 1
5 172416PRTArtificial SequenceSynthetic Polypeptide 1724Glu
Ile Pro Ala Trp Val Pro Phe Asp Pro Ala Ala Gln Ile Thr Lys 1
5 10 15 172510PRTArtificial
SequenceSynthetic Polypeptide 1725Trp Glu Ala Glu Pro Val Tyr Val Gln Arg
1 5 10 172612PRTArtificial
SequenceSynthetic Polypeptide 1726Tyr Ser Leu Thr Tyr Ile Tyr Thr Gly Leu
Ser Lys 1 5 10
172730PRTArtificial SequenceSynthetic Polypeptide 1727Leu Asp Gly Gln Ile
Ser Ser Ala Tyr Pro Ser Gln Glu Gly Gln Val 1 5
10 15 Leu Val Gly Ile Tyr Gly Gln Tyr Gln Leu
Leu Gly Ile Lys 20 25 30
172821PRTArtificial SequenceSynthetic Polypeptide 1728Leu Gly Ala Leu Gly
Gly Asn Thr Gln Glu Val Thr Leu Gln Pro Gly 1 5
10 15 Glu Tyr Ile Thr Lys 20
17299PRTArtificial SequenceSynthetic Polypeptide 1729Val Ser Val Gly Leu
Leu Leu Val Lys 1 5 173016PRTArtificial
SequenceSynthetic Polypeptide 1730Tyr Phe Ser Thr Thr Glu Asp Tyr Asp His
Glu Ile Thr Gly Leu Arg 1 5 10
15 17316PRTArtificial SequenceSynthetic Polypeptide 1731Tyr
Phe Tyr Phe Gly Lys 1 5
User Contributions:
Comment about this patent or add new information about this topic: